"component","regulator","date","condition","accelerated","withdrawn","first_in_class","note","context","stage_or_status","risk_stratification","demographics","ineligibility","prior_therapy","prior_therapy_negation","prior_therapy_setting","response_contingency","time_contingency","prior_biomarker","with","biomarker","biomarker_negation","study_yn","study","string","date_added"
"Abarelix","FDA","2003-11-25","Prostate cancer",FALSE,FALSE,TRUE,"","","Symptomatic","","men","","",NA,"","","","","","","",TRUE,"Koch et al. 2003","2003-11-25: Approved for palliative treatment of men with advanced symptomatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following: risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia. <i>(Based on Koch et al. 2003)</i>","2022-09-05"
"Abciximab","FDA","1994-12-22","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1994-12-22: Initial approval (label not available at Drugs @ FDA)","2022-09-05"
"Abemaciclib","EMA","2018-09-26","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","women","","",NA,"","","","","Aromatase inhibitor OR Fulvestrant","HR+ and HER2-","FALSE AND TRUE",NA,"","2018-09-26: Initial authorization as Verzenios for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.","2023-09-17"
"Abemaciclib","EMA","2018-09-26","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","women","","",NA,"","","","","Aromatase inhibitor OR Fulvestrant","HR+ and HER2-","FALSE AND TRUE",NA,"","2018-09-26: Initial authorization as Verzenios for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.","2023-09-17"
"Abemaciclib","EMA","2022-04-01","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","node-positive early","high risk of recurrence","","","",NA,"","","","","Endocrine therapy","HR+ and HER2-","FALSE AND TRUE",NA,"","2022-04-01: Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence.","2023-09-17"
"Abemaciclib","FDA","2017-09-28","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","women","","Antiestrogen","FALSE","","","","","Fulvestrant","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONARCH 2","2017-09-28: FDA approved in combination with <a href=""/wiki/Fulvestrant_(Faslodex)"" title=""Fulvestrant (Faslodex)"">fulvestrant</a> for women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with disease progression following endocrine therapy. <i>(Based on MONARCH 2)</i>","2022-09-05"
"Abemaciclib","FDA","2017-09-28","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","women and men","","Antiestrogen AND Chemotherapy","FALSE","Metastatic","","","","","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONARCH 1","2017-09-28: FDA approved as monotherapy for women and men with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. <i>(Based on MONARCH 1)</i>","2022-09-05"
"Abemaciclib","FDA","2018-02-26","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","",NA,"","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONARCH 3","2018-02-26: FDA approved in combination with an <a href=""/wiki/Category:Aromatase_inhibitors"" title=""Category:Aromatase inhibitors"">aromatase inhibitor</a> as initial endocrine-based therapy for postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on MONARCH 3)</i>","2022-09-05"
"Abemaciclib","FDA","2021-10-12","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","high risk of recurrence AND Ki-67 > 20%","adults","","Surgery","FALSE","","","","","Aromatase inhibitor OR Tamoxifen","HR+ and HER2-","FALSE AND TRUE",TRUE,"monarchE","2021-10-12: Approved with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a>, node-positive, early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence and a Ki-67 score of at least 20%, as determined by an FDA approved test. <i>(Based on monarchE)</i>","2023-01-03"
"Abemaciclib","FDA","2023-03-03","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","node-positive early","high risk of recurrence","adults","","",NA,"","","","","Tamoxifen|Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"monarchE","2023-03-03: Approved with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on monarchE; Ki-67 biomarker requirement removed)</i>","2023-03-15"
"Abemaciclib","HC","2019-04-05","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","0","FALSE","","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",NA,"","2019-04-05: Initial notice of compliance for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy.","2023-05-08"
"Abemaciclib","HC","2019-04-05","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","women","","Endocrine-based regimen","FALSE","","progression","","","Fulvestrant AND GnRH agonist, if premenopausal or perimenopausal","HR+ and HER2-","FALSE AND TRUE",NA,"","2019-04-05: Initial notice of compliance for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist.","2023-05-08"
"Abemaciclib","HC","2019-04-05","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","women","","endocrine-based regimen AND 1+ taxane-based regimen AND 1+ chemotherapy-based regimen","FALSE","1+ metastatic","progression","","","0","HR+ and HER2-","FALSE AND TRUE",NA,"","2019-04-05: Initial notice of compliance for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy regimen should have been administered in the metastatic setting, and at least one should have contained a taxane.","2023-05-08"
"Abemaciclib","HC","2022-01-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-01-12: New indication","2023-05-08"
"Abemaciclib","PMDA","2018-09-21","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable|Recurrent","","","","",NA,"","","","","","HR+ and HER2-","FALSE AND TRUE",NA,"","2018-09-21: Newly indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)negative inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Abemaciclib","PMDA","2021-12-24","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","high risk of recurrence","","","Surgery","FALSE","","","","","","HR+ and HER2-","FALSE AND TRUE",NA,"","2021-12-24: New indication and a new dosage for the postoperative adjuvant treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with a high risk of recurrence.","2023-06-16"
"Abiraterone","EMA","2011-09-05","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adult men","","Docetaxel-containing regimen",NA,"","progression","","","Predisone OR Prednisolone","","",TRUE,"COU-AA-301","2011-09-05: Initial marketing authorization as Zytiga. Zytiga is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. <i>(Based on COU-AA-301)</i>","2023-09-17"
"Abiraterone","EMA","2012-12-18","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adult men","asympotomatic or mildly symptomatic in whom chemotherapy is not yet clinically indicated","ADT",NA,"","Failure","","","","","",NA,"","2012-12-18: Extension of Indication to include new population for Zytiga in combination with prednisone or prednisolone for the treatment of metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.","2023-09-17"
"Abiraterone","EMA","2017-11-15","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","high risk","adult men","","0",NA,"","","","","ADT AND (Prednisone OR Prednisolone)","","",NA,"","2017-11-15: Extension of Indication to include treatment of newly diagnosed high risk metastatic hormone sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mHSCP) in adult men in combination with androgen deprivation therapy (ADT) for Zytiga plus prednisone or prednisolone.","2023-09-17"
"Abiraterone","FDA","2011-04-28","Prostate cancer",FALSE,FALSE,TRUE,"","Castrate-resistant","Metastatic","","","","Docetaxel","FALSE","","","","","","","",TRUE,"COU-AA-301","2011-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm"">FDA approved</a> to treat patients with late-stage (metastatic) castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a> who have received prior <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)""> docetaxel</a> (chemotherapy). <i>(Based on COU-AA-301)</i>","2022-09-05"
"Abiraterone","FDA","2012-12-10","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","men","","Chemotherapy","TRUE","","","","","","","",TRUE,"COU-AA-302","2012-12-10: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm"">FDA approved</a> to treat men with late-stage (metastatic) castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a> prior to receiving chemotherapy. <i>(Based on COU-AA-302)</i>","2022-09-05"
"Abiraterone","FDA","2018-02-07","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","High-risk","","","",NA,"","","","","Prednisone","","",TRUE,"LATITUDE","2018-02-07: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive"">FDA approved</a> in combination with <a href=""/wiki/Prednisone_(Sterapred)"" title=""Prednisone (Sterapred)"">prednisone</a> for metastatic high-risk castration-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (CSPC). <i>(Based on LATITUDE)</i>","2022-09-05"
"Abiraterone","HC","2011-07-27","Prostate cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Docetaxel-containing regimen","FALSE","","","","","Prednisone","","",NA,"","2011-07-27: Initial notice of compliance with prednisone for the treatment of metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (castration-resistant prostate cancer) in patients who have received prior chemotherapy containing docetaxel.","2023-05-08"
"Abiraterone","HC","2013-05-28","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Androgen deprivation therapy","FALSE","","Failure","","","Prednisone","","",NA,"","2013-05-28: New indication in combination with prednisone for the treatment of metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).","2023-05-08"
"Abiraterone","HC","2018-02-13","Prostate cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","High-risk","","","Optional ADT","FALSE","","","Up to 3 months","","Prednisone AND ADT","","",NA,"","2018-02-13: New indication in combination with prednisone and androgen depletion therapy (ADT) for the treatment of patients with newly diagnosed high-risk metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>, who may have received up to 3 months of prior ADT.","2023-05-08"
"Abiraterone","PMDA","2014-07-04","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","","","","","",NA,"","","","","","","",NA,"","2014-07-04: Initial approval for the treatment of castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Abiraterone","PMDA","2018-02-16","Prostate cancer",FALSE,FALSE,FALSE,"","","","High-risk","","","Endocrine therapy","TRUE","","","","","","","",NA,"","2018-02-16: New additional indication for the treatment of <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in patients with high-risk prognostic factors who have not received previous endocrine therapy.","2023-06-16"
"Acalabrutinib","EMA","2020-11-05","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","0",NA,"","","","","0|Obinutuzumab","","",NA,"","2020-11-05: Initial authorization as Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a>.","2023-09-17"
"Acalabrutinib","EMA","2020-11-05","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","0","","",NA,"","2020-11-05: Initial authorization as Calquence as monotherapy is indicated for the treatment of adult patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a> who have received at least one prior therapy.","2023-09-17"
"Acalabrutinib","FDA","2017-10-31","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","","","",TRUE,"ACE-LY-004","2017-10-31: Granted accelerated approval for treatment of adult patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> who have received at least one prior therapy. <i>(Based on ACE-LY-004)</i>","2022-09-05"
"Acalabrutinib","FDA","2019-11-21","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASCEND","2019-11-21: Approved for adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>. <i>(Based on ELEVATE TN and ASCEND)</i>","2022-09-05"
"Acalabrutinib","FDA","2019-11-21","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ELEVATE TN","2019-11-21: Approved for adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>. <i>(Based on ELEVATE TN and ASCEND)</i>","2022-09-05"
"Acalabrutinib","HC","2019-08-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-08-23: Initial notice of compliance","2023-06-15"
"Acalabrutinib","PMDA","2021-01-22","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-01-22: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia/small lymphocytic lymphoma</a>.","2023-06-16"
"Acetaminophen","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Acetazolamide","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Aclarubicin","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Acyclovir","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Adagrasib","EMA","2023-11-09","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"1+ SACT","progression","","","","KRAS p.G12C","",NA,"","2023-11-09: CHMP recommendation for conditional marketing authorisation - KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with KRAS G12C mutation and disease progression after at least one prior systemic therapy.","2024-01-06"
"Adagrasib","FDA","2022-12-12","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT","FALSE","","","","","","KRAS p.G12C","FALSE",TRUE,"KRYSTAL-1_NSCLC","2022-12-12: Granted accelerated approval for adult patients with <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">KRAS</a> <a href=""/wiki/Biomarkers#G12C"" title=""Biomarkers"">G12C-mutated</a> locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as determined by an FDA-approved test, who have received at least one prior systemic therapy. <i>(Based on KRYSTAL-1_NSCLC)</i>","2023-03-10"
"Adagrasib","FDA","2024-06-21","Colorectal cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","",NA,"fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy","","","","cetuximab","KRAS p.G12C","FALSE",TRUE,"KRYSTAL-1_CRC","2024-06-21: Granted accelerated approval in combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a>, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. <i>(Based on KRYSTAL-1_CRC)</i>","2024-09-06"
"ADAMTS13 recombinant","FDA","2023-11-09","Congenital thrombotic thrombocytopenic purpura",FALSE,FALSE,TRUE,"","","","","adults and pediatric","","",NA,"","","","","","","",NA,"","2023-11-09: Approved for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with <a href=""/wiki/Congenital_thrombotic_thrombocytopenic_purpura"" title=""Congenital thrombotic thrombocytopenic purpura"">congenital thrombotic thrombocytopenic purpura (cTTP)</a>.","2024-06-03"
"Afamitresgene autoleucel","FDA","2024-08-02","Synovial sarcoma",TRUE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"SPEARHEAD-1","2024-08-02: Granted accelerated approval for adults with unresectable or metastatic <a href=""/wiki/Synovial_sarcoma"" title=""Synovial sarcoma"">synovial sarcoma</a> who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. <i>(Based on SPEARHEAD-1)</i>","2024-12-02"
"Afatinib","EMA","2013-09-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","",NA,"EGFR TKI-na•ve","","","","0","activating EGFR mutation","FALSE",NA,"","2013-09-25: Initial marketing authorization as Giotrif as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naive adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with activating EGFR mutation(s).","2023-09-17"
"Afatinib","EMA","2016-03-31","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen",NA,"","progression","","","","","",NA,"","2016-03-31: Extension of indications to include patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">Non-small cell lung cancer (NSCLC) of squamous histology</a> progressing on or after platinum-based chemotherapy.","2023-09-17"
"Afatinib","FDA","2013-07-12","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"LUX-Lung 3","2013-07-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm"">Approved</a> for the <a href=""/wiki/Contexts#First-line_therapy"" title=""Contexts"">first-line treatment</a> of patients with <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 (L858R) substitution</a> mutations as detected by an FDA-approved test. <i>(Based on LUX-Lung 3)</i>","2022-09-05"
"Afatinib","FDA","2016-04-15","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",TRUE,"LUX-Lung 8","2016-04-15: Approved for treatment of patients with <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a>, <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous NSCLC</a> <a href=""/wiki/Contexts#Subsequent-line_therapy"" title=""Contexts"">progressing after</a> <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Based on LUX-Lung 8)</i>","2022-09-05"
"Afatinib","FDA","2018-01-12","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","non-resistant EGFRm","FALSE",TRUE,"LUX-Lung 2","2018-01-12: Approval expanded for a broadened indication in <a href=""/wiki/Contexts#First-line_therapy"" title=""Contexts"">first-line treatment</a> of patients with <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#Non-resistant"" title=""Biomarkers"">non-resistant</a> <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor</a> mutations as detected by an FDA-approved test. <i>(Based on LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6)</i>","2022-09-05"
"Afatinib","FDA","2018-01-12","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","non-resistant EGFRm","FALSE",TRUE,"LUX-Lung 3","2018-01-12: Approval expanded for a broadened indication in <a href=""/wiki/Contexts#First-line_therapy"" title=""Contexts"">first-line treatment</a> of patients with <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#Non-resistant"" title=""Biomarkers"">non-resistant</a> <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor</a> mutations as detected by an FDA-approved test. <i>(Based on LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6)</i>","2022-09-05"
"Afatinib","FDA","2018-01-12","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","non-resistant EGFRm","FALSE",TRUE,"LUX-Lung 6","2018-01-12: Approval expanded for a broadened indication in <a href=""/wiki/Contexts#First-line_therapy"" title=""Contexts"">first-line treatment</a> of patients with <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#Non-resistant"" title=""Biomarkers"">non-resistant</a> <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor</a> mutations as detected by an FDA-approved test. <i>(Based on LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6)</i>","2022-09-05"
"Afatinib","HC","2013-11-01","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","EGFR TKI","TRUE","","","","","0","Activating EGFR mutation","FALSE",NA,"","2013-11-01: Initial notice of compliance as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor-naive patients with metastatic (including cytologically proven pleural effusion) <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">adenocarcinoma of the lung</a> with activating EGFR mutation(s).","2023-05-08"
"Afatinib","HC","2016-08-25","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","Second-line","Locally advanced OR Metastatic","","","","1 SACT","FALSE","","","","","","","",NA,"","2016-08-25: New indication for second line treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">non-small cell lung cancer (NSCLC) of squamous histology</a>.","2023-05-08"
"Afatinib","HC","2018-09-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-20: Updated indication (unclear)","2023-05-08"
"Afatinib","PMDA","2014-01-17","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","EGFR mutation","FALSE",NA,"","2014-01-17: Initial approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with EGFR gene mutation.","2023-06-16"
"Aldesleukin","EMA","1989-07-03","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1989-07-03: EURD","2023-07-31"
"Aldesleukin","FDA","1992-05-05","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","","",TRUE,"Fyfe et al. 1995","1992-05-05: Initial approval for treatment of adults (&gt;18 years old) with metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>. <i>(Based on Fyfe et al. 1995)</i>","2022-09-05"
"Aldesleukin","FDA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","","",TRUE,"Atkins et al. 1999","Uncertain date: Approved for the treatment of adults with metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on Atkins et al. 1999)</i>","2022-09-05"
"Aldesleukin","PMDA","2021-06-23","Neuroblastoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","dinutuximab","","",NA,"","2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>.","2023-06-16"
"Alectinib","EMA","2017-02-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","Crizotinib","FALSE","","","","","0","ALK rearrangement","FALSE",NA,"","2017-02-16: Initial marketing authorization as Alecensa as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> previously treated with crizotinib.","2023-09-17"
"Alectinib","EMA","2017-12-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","","","adults","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2017-12-18: Extension of Indication for Alecensa (alectinib) to first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Prior treatment criteria removed)</i>","2023-09-17"
"Alectinib","FDA","2015-12-11","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","","","","","Crizotinib","FALSE","","","","","","ALK rearrangement","FALSE",TRUE,"NP28673","2015-12-11: Granted accelerated FDA approval for the treatment of patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to <a href=""/wiki/Crizotinib_(Xalkori)"" title=""Crizotinib (Xalkori)"">crizotinib</a>. <i>(Based on NP28761 and NP28673)</i>","2022-09-05"
"Alectinib","FDA","2015-12-11","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","","","","","Crizotinib","FALSE","","","","","","ALK rearrangement","FALSE",TRUE,"NP28761","2015-12-11: Granted accelerated FDA approval for the treatment of patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to <a href=""/wiki/Crizotinib_(Xalkori)"" title=""Crizotinib (Xalkori)"">crizotinib</a>. <i>(Based on NP28761 and NP28673)</i>","2022-09-05"
"Alectinib","FDA","2017-11-06","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"ALEX","2017-11-06: Granted regular FDA approval for treatment of patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> <a href=""/wiki/Contexts#Metastatic"" title=""Contexts"">metastatic</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as detected by an FDA-approved test. <i>(Converted to regular approval; prior crizotinib exposure requirement removed; based on ALEX)</i>","2022-09-05"
"Alectinib","FDA","2024-04-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","resection",NA,"","","","","","ALK rearrangement","",TRUE,"ALINA","2024-04-18: Approved for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as detected by an FDA-approved test. <i>(Based on ALINA)</i>","2024-06-03"
"Alectinib","HC","2016-09-28","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Crizotinib","FALSE","","Progression OR Intolerance","","","0","","",NA,"","2016-09-28: Initial notice of compliance with conditions as a monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to crizotinib.","2023-05-08"
"Alectinib","HC","2018-06-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","","","",NA,"","2018-06-11: New indication for the first-line treatment of patients with anaplastic lymphoma kinase-positive, locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-05-08"
"Alectinib","HC","2018-09-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Crizotinib","FALSE","","Progression OR Intolerance","","","","","",NA,"","2018-09-26: Conditions were met for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to crizotinib.","2023-05-08"
"Alectinib","PMDA","2014-07-04","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2014-07-04: Initial approval for the treatment of unresectable advanced/relapsed ALK fusion gene-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Alectinib","PMDA","2020-02-21","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2020-02-21: New indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">anaplastic large cell lymphoma</a>.","2023-06-16"
"Alemtuzumab","EMA","2001-07-06","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","fludarabine combination chemotherapy is not appropriate","",NA,"","","","","","","",NA,"","2001-07-06: Initial authorization for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">B-cell chronic lymphocytic leukaemia (B-CLL)</a> for whom fludarabine combination chemotherapy is not appropriate.","2023-05-08"
"Alemtuzumab","EMA","2012-08-08","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2012-08-08: Authorization withdrawn at the request of the manufacturer, for commercial reasons","2023-05-08"
"Alemtuzumab","FDA","2001-05-07","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","Alkylating agent AND Fludarabine","FALSE","","","","","","","",TRUE,"Keating et al. 2002","2001-05-07: Initial accelerated approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia</a> who have been treated with <a href=""/wiki/Regimen_classes#Alkylator-based_regimen"" title=""Regimen classes"">alkylating agents</a> and who have failed <a href=""/wiki/Regimen_classes#Fludarabine-based_regimen"" title=""Regimen classes""> fludarabine therapy</a>.<sup id=""cite_ref-6"" class=""reference""><a href=""#cite_note-6"">&#91;6&#93;</a> <i>(Based on Keating et al. 2002, Rai et al. 2002, and Lozanski et al. 2004)</i>","2022-09-05"
"Alemtuzumab","FDA","2001-05-07","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","Alkylating agent AND Fludarabine","FALSE","","","","","","","",TRUE,"Lozanski et al. 2004","2001-05-07: Initial accelerated approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia</a> who have been treated with <a href=""/wiki/Regimen_classes#Alkylator-based_regimen"" title=""Regimen classes"">alkylating agents</a> and who have failed <a href=""/wiki/Regimen_classes#Fludarabine-based_regimen"" title=""Regimen classes""> fludarabine therapy</a>.<sup id=""cite_ref-6"" class=""reference""><a href=""#cite_note-6"">&#91;6&#93;</a> <i>(Based on Keating et al. 2002, Rai et al. 2002, and Lozanski et al. 2004)</i>","2022-09-05"
"Alemtuzumab","FDA","2001-05-07","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","Alkylating agent AND Fludarabine","FALSE","","","","","","","",TRUE,"Rai et al. 2002","2001-05-07: Initial accelerated approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia</a> who have been treated with <a href=""/wiki/Regimen_classes#Alkylator-based_regimen"" title=""Regimen classes"">alkylating agents</a> and who have failed <a href=""/wiki/Regimen_classes#Fludarabine-based_regimen"" title=""Regimen classes""> fludarabine therapy</a>.<sup id=""cite_ref-6"" class=""reference""><a href=""#cite_note-6"">&#91;6&#93;</a> <i>(Based on Keating et al. 2002, Rai et al. 2002, and Lozanski et al. 2004)</i>","2022-09-05"
"Alemtuzumab","FDA","2007-09-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","0","","",TRUE,"CAM 307","2007-09-19: Converted to regular approval and indication expanded to include use as a single agent for treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia (B-CLL)</a> <i>(Based on CAM 307)</i>","2022-09-05"
"Alemtuzumab","FDA","2012-10-15","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-10: Genzyme withdraws drug from USA and EU (still available for B-CLL patients, however). See Lancet editorial.<sup id=""cite_ref-7"" class=""reference""><a href=""#cite_note-7"">&#91;7&#93;</a>","2023-05-08"
"Alemtuzumab","PMDA","2014-09-26","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2014-09-26: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a>.","2023-06-16"
"Alemtuzumab","PMDA","2020-12-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-12-25: New indication and a new dosage for a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.","2023-06-16"
"Alendronate","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Alitretinoin","FDA","1999-02-02","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","Cutaneous","","","","",NA,"","","","","","","",TRUE,"Bodsworth et al. 2001","1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-related Kaposi's sarcoma</a>. <i>(Based on Walmsley et al. 1999 and Bodsworth et al. 2001)</i>","2022-09-05"
"Alitretinoin","FDA","1999-02-02","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","Cutaneous","","","","",NA,"","","","","","","",TRUE,"Walmsley et al. 1999","1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-related Kaposi's sarcoma</a>. <i>(Based on Walmsley et al. 1999 and Bodsworth et al. 2001)</i>","2022-09-05"
"Alizapride","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"All-trans retinoic acid","EMA","1994-03-31","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1994-03-31: EURD","2023-07-31"
"All-trans retinoic acid","FDA","1995-11-22","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1995-11-22: Initial FDA approval","2022-09-05"
"All-trans retinoic acid","FDA","2004-07-19","Acute promyelocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","Anthracycline OR contraindication to Anthracycline","FALSE","","","","","","t(15;17)|PML-RARA","FALSE",NA,"","2004-07-19: FDA approved for the induction of remission in patients with <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">acute promyelocytic leukemia (APL)</a>, French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the <a href=""/wiki/Biomarkers#t(15;17)"" title=""Biomarkers"">t(15;17) translocation</a> and/or the presence of the <a href=""/wiki/Biomarkers#PML-RARA"" title=""Biomarkers"">PML/RARA gene</a> who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated.","2023-01-03"
"Allopurinol","FDA","1966-08-19","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1966-08-19: Initial approval","2022-09-05"
"Alpelisib","EMA","2020-07-27","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women OR men","","Endocrine monotherapy",NA,"","progression","","","Fulvestrant","HR+ and HER2- and PIK3CA mutated","FALSE AND TRUE AND FALSE",NA,"","2020-07-27: Initial authorization as Piqray in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.","2023-09-17"
"Alpelisib","FDA","2019-05-24","Breast cancer",FALSE,FALSE,TRUE,"","","Advanced OR Metastatic","","postmenopausal women OR men","","Endocrine-based regimen","FALSE","","","","","Fulvestrant","HR+ and HER2- and PIK3CA mutated","FALSE AND TRUE AND FALSE",TRUE,"SOLAR-1","2019-05-24: Approved in combination with fulvestrant for postmenopausal women, and men, with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a>, <a href=""/wiki/Biomarkers#PIK3CA"" title=""Biomarkers"">PIK3CA</a>-<a href=""/wiki/Biomarkers#SNV"" title=""Biomarkers"">mutated</a>, <a href=""/wiki/Contexts#Advanced_or_metastatic"" title=""Contexts"">advanced or metastatic</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as detected by an FDA-approved test <a href=""/wiki/Contexts#Subsequent-line_therapy"" title=""Contexts"">following progression</a> on or after an <a href=""/wiki/Regimen_classes#Endocrine-based_regimen"" title=""Regimen classes"">endocrine-based regimen</a>. <i>(Based on SOLAR-1)</i>","2022-09-05"
"Alpelisib","HC","2020-03-11","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women OR men","","Endocrine-based regimen","FALSE","","progression","","","Fulvestrant","HR+ and HER2- and PIK3CA mutated","FALSE AND TRUE AND FALSE",NA,"","2020-03-11: Initial notice of compliance in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> after disease progression following an endocrine-based regimen.","2023-05-08"
"Alprazolam","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Altretamine","EMA","1979-01-22","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1979-01-22: EURD","2023-07-31"
"Altretamine","FDA","1990-12-26","Ovarian cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent","","","","Cisplatin OR Alkylating agent-based regimen","FALSE","","","","","","","",NA,"","1990-12-26: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> following first-line therapy with a cisplatin and/or alkylating agent-based combination.","2022-09-05"
"Amifostine","FDA","1995-12-08","Ovarian cancer",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1995-12-08: indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a>.","2022-09-05"
"Aminocaproic acid","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Aminoglutethimide","FDA","1980-10-29","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1980-10-29: Initial approval","2022-09-05"
"Amivantamab","EMA","2021-12-09","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Advanced","","adults","","Platinum-based regimen",NA,"","failure","","","0","EGFR exon 20 insertion","FALSE",NA,"","2021-12-09: Initial conditional approval as Rybrevant as monotherapy for treatment of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.","2023-09-17"
"Amivantamab","FDA","2021-05-21","Non-small cell lung cancer",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen","FALSE","","","","","","EGFR exon 20 insertion","FALSE",TRUE,"CHRYSALIS","2021-05-21: Granted accelerated approval for adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_20"" title=""Biomarkers"">exon 20</a> <a href=""/wiki/Biomarkers#Insertion"" title=""Biomarkers"">insertion mutations</a>, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. <i>(Based on CHRYSALIS)</i>","2022-09-05"
"Amivantamab","FDA","2024-03-01","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen",NA,"","progression","","","","EGFR exon 20 insertion","",TRUE,"PAPILLON","2024-03-01: Converted to regular approval for adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. <i>(Based on PAPILLON)</i>","2024-06-03"
"Amivantamab","FDA","2024-03-01","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","Carboplatin AND Pemetrexed","EGFR exon 20 insertion","",TRUE,"PAPILLON","2024-03-01: Approved with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. <i>(Based on PAPILLON)</i>","2024-06-03"
"Amivantamab","FDA","2024-09-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"MARIPOSA-2","2024-09-19: Approved with carboplatin and pemetrexed for adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. <i>(Based on MARIPOSA-2)</i>","2024-12-02"
"Amivantamab","HC","2022-03-30","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen","FALSE","","progression","","","","EGFR exon 20 insertion","FALSE",NA,"","2022-03-30: Initial notice of compliance with conditions for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.","2023-05-08"
"Amoxicillin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ampicillin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Amrubicin","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Amrubicin","PMDA","2002-04-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2002-04-11: Initial approval for the treatment of <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> and <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Amrubicin","PMDA","2002-04-11","Small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2002-04-11: Initial approval for the treatment of <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> and <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Amsacrine","EMA","1982-04-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1982-04-23: EURD","2023-07-31"
"Amsacrine","HC","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Anagrelide","EMA","2004-11-15","Essential thrombocythemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2004-11-15: Initial approval as Xagrid for the reduction of elevated platelet counts in at-risk <a href=""/wiki/Essential_thrombocythemia"" title=""Essential thrombocythemia"">essential-thrombocythaemia (ET)</a> patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient is defined by one or more of the following features: 60 years of age or more; a platelet count 1000 x 10^9/l or more; or a history of thrombohaemorrhagic events.","2024-12-02"
"Anagrelide","PMDA","2014-09-26","Essential thrombocythemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-09-26: Initial approval for the treatment of <a href=""/wiki/Essential_thrombocythemia"" title=""Essential thrombocythemia"">essential thrombocythemia</a>.","2023-06-16"
"Anakinra","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Anastrozole","EMA","1995-08-11","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-08-11: EURD","2023-07-31"
"Anastrozole","FDA","1995-12-27","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women","","Tamoxifen","FALSE","","","","","","","",TRUE,"Buzdar et al. 1996","1995-12-27: Initial approval for treatment of advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with disease progression following tamoxifen therapy. <i>(Based on Buzdar et al. 1996 and Jonat et al. 1996)</i>","2022-09-05"
"Anastrozole","FDA","1995-12-27","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women","","Tamoxifen","FALSE","","","","","","","",TRUE,"Jonat et al. 1996","1995-12-27: Initial approval for treatment of advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with disease progression following tamoxifen therapy. <i>(Based on Buzdar et al. 1996 and Jonat et al. 1996)</i>","2022-09-05"
"Anastrozole","FDA","2002-09-05","Breast cancer",TRUE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery","FALSE","","","","","","HR+","FALSE",TRUE,"ATAC","2002-09-05: Accelerated approval for adjuvant treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on ATAC)</i>","2022-09-05"
"Anastrozole","FDA","2005-09-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery","FALSE","","","","","","HR+","FALSE",TRUE,"ATAC","2005-09-16: Converted to regular approval for adjuvant treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on ATAC)</i>","2022-09-05"
"Anastrozole","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","postmenopausal women","","0","FALSE","","","","","","HR+|HR unknown","FALSE",TRUE,"Arimidex Study Group 2000","Uncertain date: Approved for first-line treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on Arimidex Study Group 2000 and TARGET_Breast)</i>","2022-09-05"
"Anastrozole","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","postmenopausal women","","0","FALSE","","","","","","HR+|HR unknown","FALSE",TRUE,"TARGET_Breast","Uncertain date: Approved for first-line treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on Arimidex Study Group 2000 and TARGET_Breast)</i>","2022-09-05"
"Anastrozole","HC","2004-06-30","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-06-30: Initial notice of compliance with conditions","2023-05-08"
"Anastrozole","HC","2008-12-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-12-02: Conditions were met","2023-05-08"
"Ancestim","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Andexanet alfa","FDA","2018-05-04","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-05-04: Approved for patients treated with <a href=""/wiki/Rivaroxaban_(Xarelto)"" title=""Rivaroxaban (Xarelto)"">rivaroxaban</a> and <a href=""/wiki/Apixaban_(Eliquis)"" title=""Apixaban (Eliquis)"">apixaban</a>, when reversal of anticoagulation is necessary due to fatal or uncontrolled bleeding.","2023-07-31"
"Andexanet alfa","PMDA","2022-03-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-03-28: Newly indicated for the reversal of anticoagulant effect in life-threatening or uncontrolled bleeding in patients treated with a direct-acting factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban tosilate hydrate).","2023-06-16"
"Anlotinib","NMPA","2018-05-08","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","2+ SACT",NA,"","progression","","","","","",TRUE,"ALTER 0303","2018-05-08: Approved as a treatment for patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed after treatment with two or more lines of prior systemic chemotherapy. <i>(Based on ALTER 0303)</i>","2024-01-06"
"Anti-inhibitor coagulant complex","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Antithrombin III","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Antithymocyte globulin horse ATG","EMA","1981-11-17","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1981-11-17: EURD","2023-07-31"
"Antithymocyte globulin rabbit ATG","EMA","1984-04-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1984-04-16: EURD","2023-07-31"
"Apalutamide","EMA","2019-01-14","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","High-risk of developing metastases","adult men","","",NA,"","","","","","","",TRUE,"SPARTAN","2019-01-14: Initial marketing authorization as Erleada. Erleada is indicated in adult men for the treatment of non-metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (NM CRPC) who are at high risk of developing metastatic disease. <i>(Based on SPARTAN)</i>","2023-09-17"
"Apalutamide","EMA","2020-01-27","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","","","",NA,"","","","","ADT","","",TRUE,"TITAN_prostate","2020-01-27: Extension of Indication to include the treatment of metastatic hormone-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mHSPC) in combination with androgen deprivation therapy (ADT). <i>(Based on TITAN_prostate)</i>","2023-09-17"
"Apalutamide","FDA","2018-02-14","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","","","","",NA,"","","","","","","",TRUE,"SPARTAN","2018-02-14: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596768.htm"">FDA approved</a> for patients with non-metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (NM-CRPC). <i>(Based on SPARTAN)</i>","2022-09-05"
"Apalutamide","FDA","2019-09-17","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","","","",NA,"","","","","","","",TRUE,"TITAN_prostate","2019-09-17: Approved for patients with metastatic castration-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCSPC). <i>(Based on TITAN_prostate)</i>","2022-09-05"
"Apalutamide","HC","2018-07-03","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","High-risk of developing metastases","","","",NA,"","","","","","","",NA,"","2018-07-03: Initial notice of compliance for the treatment of patients with non-metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> at high risk of developing metastases.","2023-05-08"
"Apalutamide","HC","2019-12-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-12-12: New indication","2023-05-08"
"Apalutamide","PMDA","2019-03-26","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","","","","",NA,"","","","","","","",NA,"","2019-03-26: New approval for the treatment of non-metastatic, castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Apalutamide","PMDA","2020-05-29","Prostate cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",NA,"","2020-05-29: New indication for the treatment of metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Apatinib","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Apixaban","EMA","2011-05-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-05-18: Initial authorization","2023-05-08"
"Apixaban","FDA","2012-12-28","Atrial fibrillation",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-12-28: Approved to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.<sup id=""cite_ref-5"" class=""reference""><a href=""#cite_note-5"">&#91;5&#93;</a> <i>(Non-hematologic indication)</i>","2022-09-05"
"Apixaban","FDA","2014-03-13","Venous thromboembolism",FALSE,FALSE,FALSE,"","prophylaxis","","","","","Hip or knee replacement surgery","FALSE","","","","","","","",NA,"","2014-03-13: Approved for the prophylaxis of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE)</a>, in patients who have undergone hip or knee replacement surgery.","2022-09-05"
"Apixaban","FDA","2014-08-21","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","Anticoagulation","FALSE","","","","","","","",NA,"","2014-08-21: Approved for the treatment of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">DVT and PE</a>, and for the reduction in the risk of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">recurrent DVT and PE</a> following initial therapy.","2022-09-05"
"Apixaban","PMDA","2015-12-21","Venous thromboembolism",FALSE,FALSE,FALSE,"","Treatment|Prevention","","","","","",NA,"","","","","","","",NA,"","2015-12-21: New additional indication and a new dosage for the treatment and prevention of the recurrence of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">venous thromboembolism</a> (deep vein thrombosis and pulmonary thromboembolism).","2023-06-16"
"Aprepitant","EMA","2003-11-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2003-11-11: Initial authorization","2023-05-08"
"Aprepitant","FDA","2003-03-26","Nausea and vomiting",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2003-03-26: Approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose <a href=""/wiki/Cisplatin"" class=""mw-redirect"" title=""Cisplatin"">cisplatin</a>.","2022-09-05"
"Aprepitant","FDA","2005-10-28","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2005-10-28: Approved for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.","2022-09-05"
"Aprepitant","FDA","2006-06-30","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2006-06-30: Approved for the prevention of postoperative nausea and vomiting.","2022-09-05"
"Argatroban","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Aripiprazole","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Arsenic trioxide","EMA","2002-03-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",TRUE,"97-66","2002-03-05: Initial authorization <i>(Based on PLRXAS01 and 97-66)</i>","2023-09-17"
"Arsenic trioxide","EMA","2002-03-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",TRUE,"PLRXAS01","2002-03-05: Initial authorization <i>(Based on PLRXAS01 and 97-66)</i>","2023-09-17"
"Arsenic trioxide","EMA","2016-11-14","Acute promyelocytic leukemia",FALSE,FALSE,FALSE,"","Induction and Consolidation","","low-to-intermediate risk","adults","","0","FALSE","","","","","ATRA","t(15;17)|PML-RARA","FALSE",NA,"","2016-11-14: Extension of Indication to include induction of remission, and consolidation in adult patients with newly diagnosed low-to-intermediate risk <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">acute promyelocytic leukaemia (APL)</a> (white blood cell count, â‰¤ 10 x 103/Î¼l) in combination with all trans retinoic acid (ATRA), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-AcidReceptor-alpha (PML/RAR-alpha) gene.","2023-09-17"
"Arsenic trioxide","FDA","2000-09-25","Acute promyelocytic leukemia",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","Retinoid AND Anthracycline","FALSE","","","","","","t(15;17)|PML-RARA","FALSE",TRUE,"PLRXAS01","2000-09-25: Initial FDA approval for induction of remission and consolidation in patients with <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia""> acute promyelocytic leukemia (APL)</a> who are refractory to, or have relapsed from, <a href=""/wiki/Category:Retinoids"" title=""Category:Retinoids"">retinoid</a> and <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a> chemotherapy, and whose APL is characterized by the presence of the <a href=""/wiki/Biomarkers#t(15;17)"" title=""Biomarkers"">t(15;17) translocation</a> or <a href=""/wiki/Biomarkers#PML-RARA"" title=""Biomarkers"">PML/RAR-alpha gene expression</a>. <i>(Based on PLRXAS01)</i>","2022-09-05"
"Arsenic trioxide","FDA","2018-01-12","Acute promyelocytic leukemia",FALSE,FALSE,FALSE,"","","","Low-risk","adults","","0","FALSE","","","","","Tretinoin","t(15;17)|PML-RARA","FALSE",TRUE,"GIMEMA/DSIL APL0406","2018-01-12: Approved in combination with tretinoin for treatment of adults with newly-diagnosed low-risk <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">acute promyelocytic leukemia (APL)</a> whose APL is characterized by the presence of the <a href=""/wiki/Biomarkers#t(15;17)"" title=""Biomarkers"">t(15;17) translocation</a> or <a href=""/wiki/Biomarkers#PML-RARA"" title=""Biomarkers"">PML/RAR-alpha gene expression</a>. <i>(Based on GIMEMA/DSIL APL0406)</i>","2022-09-05"
"Asciminib","EMA","2022-08-25","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","adults","","2+ TKI",NA,"","","","","","Ph+","FALSE",TRUE,"ASCEMBL","2022-08-25: Initial authorization as Scemblix. Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukaemia</a> in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors. <i>(Based on ASCEMBL and CABL001X2101)</i>","2023-09-17"
"Asciminib","EMA","2022-08-25","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","adults","","2+ TKI",NA,"","","","","","Ph+","FALSE",TRUE,"CABL001X2101","2022-08-25: Initial authorization as Scemblix. Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukaemia</a> in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors. <i>(Based on ASCEMBL and CABL001X2101)</i>","2023-09-17"
"Asciminib","FDA","2021-10-29","Chronic myeloid leukemia",FALSE,FALSE,TRUE,"","","Chronic phase","","adults","","",NA,"","","","","","BCR-ABL1 p.T315I","FALSE",TRUE,"CABL001X2101","2021-10-29: Approved for adult patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a> in CP with the <a href=""/wiki/Biomarkers#T315I"" title=""Biomarkers"">T315I</a> mutation. <i>(Based on CABL001X2101)</i>","2022-09-21"
"Asciminib","FDA","2021-10-29","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase","","","","2+ TKI","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"ASCEMBL","2021-10-29: Granted accelerated approval for patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). <i>(Based on ASCEMBL)</i>","2022-09-21"
"Asciminib","FDA","2022-10-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-10-12: Converted to regular approval.","2023-05-08"
"Asciminib","FDA","2024-10-29","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"ASC4FIRST","2024-10-29: Granted accelerated approval for adult patients with newly diagnosed <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)</a> in chronic phase (CP). <i>(Based on ASC4FIRST)</i>","2024-12-02"
"Asciminib","HC","2022-06-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-06-22: Initial notice of compliance","2023-06-15"
"Asciminib","PMDA","2022-03-28","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","Resistance OR Intolerance","","","","","",NA,"","2022-03-28: Newly indicated for the treatment of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia</a> with resistance or intolerance to prior drug therapies.","2023-06-16"
"Ascorbic acid","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Asparaginase","FDA","1978-01-10","Acute lymphoblastic leukemia",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"CCG 101/143","1978-01-10: Initial approval for <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a>. <i>(Based on CCG 101/143)</i>","2022-09-05"
"Asparaginase","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",NA,"","2002-08-01 (oldest label available at Drugs @ FDA): indicated in the therapy of patients with <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a>. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. ELSPAR should not be used as the sole induction agent unless combination therapy is deemed inappropriate. ELSPAR is not recommended for maintenance therapy.","2023-05-20"
"Asparaginase Erwinia chrysanthemi","FDA","2011-11-18","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","Asparaginase","FALSE","","","","","Chemotherapy","","",TRUE,"COG AALL07P2","2011-11-18: Initial FDA approval as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia (ALL)</a> who have developed hypersensitivity to <a href=""/wiki/Asparaginase_(Elspar)"" title=""Asparaginase (Elspar)""> E. coli-derived asparaginase</a>. <i>(Based on COG AALL07P2)</i>","2022-09-05"
"Asparaginase Erwinia chrysanthemi","PMDA","2016-12-19","Acute leukemia",FALSE,FALSE,FALSE,"","","","","","","L-asparaginase","FALSE","","hypersensitivity","","","","","",NA,"","2016-12-19: Initial approval for the treatment of <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a> (including blast crisis of chronic leukemia) and <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> (only for patients who experienced hypersensitivity to L-asparaginase preparations).","2023-06-16"
"Asparaginase Erwinia chrysanthemi","PMDA","2016-12-19","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","L-asparaginase","FALSE","","hypersensitivity","","","","","",NA,"","2016-12-19: Initial approval for the treatment of <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a> (including blast crisis of chronic leukemia) and <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> (only for patients who experienced hypersensitivity to L-asparaginase preparations).","2023-06-16"
"Asparaginase erwinia chrysanthemi-rywn","EMA","2023-09-22","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults OR pediatric patients 1 month and older","","Asparaginase",NA,"","hypersensitivity","","","Chemotherapy","","",TRUE,"COG AALL1931","2023-09-22: Granted marketing authorization as Enrylaze. Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)</a> in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. <i>(Based on COG AALL1931)</i>","2023-11-07"
"Asparaginase erwinia chrysanthemi-rywn","FDA","2021-06-30","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults OR pediatric patients 1 month and older","","Asparaginase","FALSE","","","","","Chemotherapy","","",TRUE,"COG AALL1931","2021-06-30: Approved as a component of a multi-agent chemotherapeutic regimen for the treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL)</a> in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. <i>(Based on COG AALL1931)</i>","2022-09-05"
"Asparaginase erwinia chrysanthemi-rywn","FDA","2022-11-18","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"COG AALL1931","2022-11-18: Approved a new Monday-Wednesday-Friday dosing regimen. Under the new regimen, patients should receive 25 mg/m^2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m^2 intramuscularly on Friday afternoon. <i>(Based on COG AALL1931)</i>","2023-03-10"
"Aspirin","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Aspirin and dipyridamole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Atenolol","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Atezolizumab","EMA","2017-09-20","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen OR cisplatin-ineligible",NA,"","","","","0","","",TRUE,"IMvigor210 previously treated","2017-09-20: Initial marketing authorization as Tecentriq. Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> after prior platinum-containing chemotherapy or who are considered cisplatin ineligible. <i>(Based on IMvigor210 previously treated, IMvigor210 untreated, and IMvigor211)</i>","2023-09-17"
"Atezolizumab","EMA","2017-09-20","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen OR cisplatin-ineligible",NA,"","","","","0","","",TRUE,"IMvigor210 untreated","2017-09-20: Initial marketing authorization as Tecentriq. Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> after prior platinum-containing chemotherapy or who are considered cisplatin ineligible. <i>(Based on IMvigor210 previously treated, IMvigor210 untreated, and IMvigor211)</i>","2023-09-17"
"Atezolizumab","EMA","2017-09-20","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen OR cisplatin-ineligible",NA,"","","","","0","","",TRUE,"IMvigor211","2017-09-20: Initial marketing authorization as Tecentriq. Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> after prior platinum-containing chemotherapy or who are considered cisplatin ineligible. <i>(Based on IMvigor210 previously treated, IMvigor210 untreated, and IMvigor211)</i>","2023-09-17"
"Atezolizumab","EMA","2017-09-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Chemotherapy",NA,"","","","Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy","0","","",TRUE,"OAK","2017-09-20: Initial marketing authorization as Tecentriq. Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving Tecentriq. <i>(Based on OAK)</i>","2023-09-17"
"Atezolizumab","EMA","2018-07-02","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen OR cisplatin-ineligible",NA,"","","","","0","PD-L1 TPS at least 5%","",TRUE,"IMvigor130","2018-07-02: Indication revised as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> after prior platinum-containing chemotherapy or who are considered cisplatin ineligible and whose tumours have a PD-L1 expression at least 5%. <i>(Based on IMvigor130)</i>","2023-09-17"
"Atezolizumab","EMA","2019-03-05","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Bevacizumab AND Paclitaxel AND Carboplatin","","",TRUE,"IMpower150","2019-03-05: Extension of indication to include in combination with bevacizumab, paclitaxel and carboplatin the first-line treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>. <i>(Based on IMpower150)</i>","2023-09-17"
"Atezolizumab","EMA","2019-09-03","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Carboplatin AND nab-Paclitaxel","No EGFR mutations AND No ALK mutations","TRUE",NA,"","2019-09-03: Extension of indication to include Tecentriq, in combination with nab-paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSCLC)</a> who do not have EGFR mutant or ALK-positive NSCLC.","2023-09-17"
"Atezolizumab","EMA","2019-09-03","Small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Extensive-stage","","adults","","",NA,"","","","","Carboplatin AND Etoposide","","",NA,"","2019-09-03: Extension of Indication to include, in combination with carboplatin and etoposide, first-line treatment of adult patients with extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC).","2023-09-17"
"Atezolizumab","EMA","2020-10-27","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","0 SACT",NA,"","","","","Bevacizumab","","",TRUE,"GO30140","2020-10-27: Extension of indication to include, in combination with bevacizumab, the treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have not received prior systemic therapy. <i>(Based on IMbrave150 and GO30140)</i>","2023-09-17"
"Atezolizumab","EMA","2020-10-27","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","0 SACT",NA,"","","","","Bevacizumab","","",TRUE,"IMbrave150","2020-10-27: Extension of indication to include, in combination with bevacizumab, the treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have not received prior systemic therapy. <i>(Based on IMbrave150 and GO30140)</i>","2023-09-17"
"Atezolizumab","EMA","2021-04-30","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","","PD-L1+","",TRUE,"IMpower110","2021-04-30: Extension of indication to include the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumours express PD-L1. <i>(Based on IMpower110)</i>","2023-09-17"
"Atezolizumab","EMA","2022-06-07","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","adults","","Surgery AND Platinum-based regimen",NA,"","","","","0","PD-L1 TPS at least 50%","",TRUE,"IMpower010","2022-06-07: Extension of indication to include adjuvant treatment as monotherapy of <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on at least 50% of tumour cells (TC). <i>(Based on IMpower010)</i>","2023-09-17"
"Atezolizumab","FDA","2016-05-18","Urothelial carcinoma",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",TRUE,"IMvigor210 previously treated","2016-05-18: Granted accelerated approval for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> <i>(Based on IMvigor210 previously treated)</i>","2022-09-05"
"Atezolizumab","FDA","2016-05-18","Urothelial carcinoma",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","12 months","","","","",TRUE,"IMvigor210 previously treated","2016-05-18: Granted accelerated approval for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression within 12 months of neoadjuvant or adjuvant treatment with <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(Based on IMvigor210 previously treated)</i>","2022-09-05"
"Atezolizumab","FDA","2016-10-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","","","Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations","","","",TRUE,"OAK","2016-10-18: Approval expanded for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose disease progressed during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab. <i>(New disease entity; based on OAK)</i>","2022-09-05"
"Atezolizumab","FDA","2017-04-17","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","12 months","","","","",TRUE,"IMvigor210 untreated","2017-04-17: Granted accelerated approval for an expanded indication for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin-containing</a> chemotherapy, or have disease progression during or following any <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>, or within 12 months of neoadjuvant or adjuvant chemotherapy.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(No longer needs to be used after platinum-containing chemotherapy; based on IMvigor210 untreated)</i>","2022-09-05"
"Atezolizumab","FDA","2018-06-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Contraindication to Cisplatin","FALSE","","","","","","PD-L1 TIL at least 5%","FALSE",TRUE,"IMvigor130","2018-06-19: Label revised for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin-containing</a> therapy, and whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (PD-L1 stained tumor-infiltrating immune cells [IC] covering at least 5% of the tumor area), as determined by an FDA-approved test. <i>(Conditional approval dependent on PD-L1 expression; based on IMvigor130)</i>","2022-09-05"
"Atezolizumab","FDA","2018-06-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Contraindication to Platinum-based regimen","FALSE","","","","","","","",TRUE,"IMvigor130","2018-06-19: Label revised for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for any <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing therapy</a> regardless of PD-L1 status. <i>(Based on IMvigor130)</i>","2022-09-05"
"Atezolizumab","FDA","2018-12-06","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Bevacizumab AND Paclitaxel AND Carboplatin","no EGFR or ALK genomic tumor aberrations","TRUE",TRUE,"IMpower150","2018-12-06: Approved in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous, non-small cell lung cancer (NSq NSCLC)</a> with no EGFR or ALK genomic tumor aberrations. <i>(Approval extended to the first-line setting and restricted to non-squamous histology; based on IMpower150)</i>","2022-09-05"
"Atezolizumab","FDA","2019-03-08","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","",NA,"","","","","","TNBC|PD-L1 TIL at least 1%","FALSE",TRUE,"IMpassion130","2019-03-08: Granted accelerated approval in combination with <a href=""/wiki/Paclitaxel,_nanoparticle_albumin-bound_(Abraxane)"" title=""Paclitaxel, nanoparticle albumin-bound (Abraxane)"">paclitaxel protein-bound</a> for adult patients with unresectable locally advanced or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (TNBC) whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering at least 1% of the tumor area) <i>(New disease entity; based on IMpassion130)</i>","2022-09-05"
"Atezolizumab","FDA","2019-03-18","Small cell lung cancer",FALSE,FALSE,FALSE,"","","Extensive-stage","","adults","","0","FALSE","","","","","Carboplatin AND Etoposide","","",TRUE,"IMpower133","2019-03-18: Approved in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)""> carboplatin</a> and <a href=""/wiki/Etoposide_(Vepesid)"" title=""Etoposide (Vepesid)""> etoposide</a>, for the first-line treatment of adult patients with extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC). <i>(New disease entity; based on IMpower133)</i>","2022-09-05"
"Atezolizumab","FDA","2019-12-03","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","0","FALSE","","","","","Paclitaxel, nanoparticle albumin-bound AND Carboplatin","no EGFR or ALK genomic tumor aberrations","TRUE",TRUE,"IMpower130","2019-12-03: Approved in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSCLC)</a> with no EGFR or ALK genomic tumor aberrations. <i>(Approval extended to three-drug combination; based on IMpower130)</i>","2022-09-05"
"Atezolizumab","FDA","2020-05-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","0","","(PD-L1 TPS at least 50%|PD-L1 TIL at least 10%) and no EGFR or ALK genomic tumor aberrations","FALSE",TRUE,"IMpower110","2020-05-18: Approved for the first-line treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have high <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expression</a> (PD-L1 stained at least 50% of tumor cells [TC at least 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering at least 10% of the tumor area [IC at least 10%]), with no EGFR or ALK genomic tumor aberrations. <i>(Approval extended to protein expression-specific monotherapy; non-squamous restriction removed; based on IMpower110)</i>","2023-01-03"
"Atezolizumab","FDA","2020-05-29","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","SACT","TRUE","","","","","Bevacizumab","","",TRUE,"IMbrave150","2020-05-29: Approved in combination with <a href=""/wiki/Bevacizumab_(Avastin)"" title=""Bevacizumab (Avastin)"">bevacizumab</a> for patients with unresectable or metastatic <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> who have not received prior systemic therapy. <i>(New disease entity; based on IMbrave150)</i>","2022-09-05"
"Atezolizumab","FDA","2020-07-30","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Cobimetinib AND Vemurafenib","BRAF p.V600","FALSE",TRUE,"IMspire150","2020-07-30: Approved in combination with cobimetinib and vemurafenib for patients with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600</a> mutation-positive unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(New disease entity; based on IMspire150)</i>","2022-09-05"
"Atezolizumab","FDA","2021-04-13","Urothelial carcinoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"IMvigor211","2021-04-13: Accelerated approval for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> withdrawn. <i>(Based on IMvigor211)</i>","2022-09-21"
"Atezolizumab","FDA","2021-04-13","Urothelial carcinoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"IMvigor211","2021-04-13: Accelerated approval for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression within 12 months of neoadjuvant or adjuvant treatment with <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> withdrawn. <i>(Based on IMvigor211)</i>","2022-09-21"
"Atezolizumab","FDA","2021-10-06","Breast cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","TNBC","FALSE",TRUE,"IMpassion131","2021-10-06: Accelerated approval in combination with <a href=""/wiki/Paclitaxel,_nanoparticle_albumin-bound_(Abraxane)"" title=""Paclitaxel, nanoparticle albumin-bound (Abraxane)"">paclitaxel protein-bound</a> for adult patients with unresectable locally advanced or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (TNBC) whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering at least 1% of the tumor area) withdrawn. <i>(Based on IMpassion131)</i>","2022-09-21"
"Atezolizumab","FDA","2021-10-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage II to IIIA","","","","Surgery AND Platinum-based regimen","FALSE","","","","","","PD-L1 TPS at least 1%","FALSE",TRUE,"IMpower010","2021-10-15: Approved for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expression</a> on at least 1% of tumor cells. <i>(Based on IMpower010)</i>","2023-01-03"
"Atezolizumab","FDA","2022-12-02","Urothelial carcinoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"IMvigor130","2022-12-02: All indications for <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> withdrawn at the request of the manufacturer. <i>(Based on IMvigor130)</i>","2023-05-08"
"Atezolizumab","FDA","2022-12-09","Alveolar soft part sarcoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults AND pediatric patients 2 years and older","","",NA,"","","","","","","",TRUE,"Study ML39345","2022-12-09: Approved for adult and pediatric patients 2 years of age and older with unresectable or metastatic <a href=""/wiki/Alveolar_soft_part_sarcoma"" title=""Alveolar soft part sarcoma"">alveolar soft part sarcoma (ASPS)</a>. <i>(Based on Study ML39345)</i>","2023-03-10"
"Atezolizumab","HC","2017-04-12","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",NA,"","2017-04-12: Initial notice of compliance with conditions to treat patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> that have received prior platinum based chemotherapy.","2023-05-08"
"Atezolizumab","HC","2018-04-06","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen","FALSE","","progression","","Patients with EGFR or ALK genomic tumor aberrations should have disease progression on a therapy for these aberrations","","","",NA,"","2018-04-06: New indication for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with progression on or after platinum-based chemotherapy (patients with epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK] tumour aberrations should also have disease progression on a therapy for those aberrations prior to receiving atezolizumab).","2023-05-08"
"Atezolizumab","HC","2019-05-24","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","SACT","TRUE","Metastatic","","","","Bevacizumab AND Paclitaxel AND Carboplatin","no EGFR or ALK genomic tumor aberrations","TRUE",NA,"","2019-05-24: New indication in combination with bevacizumab, carboplatin, and paclitaxel for the treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer</a>, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous non-small cell lung cancer.","2023-05-08"
"Atezolizumab","HC","2019-08-08","Small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Extensive-stage","","","","0","FALSE","","","","","Carboplatin AND Etoposide","","",NA,"","2019-08-08: New indication in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC).","2023-05-08"
"Atezolizumab","HC","2020-04-02","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","0","FALSE","","","","","Carboplatin AND nab-Paclitaxel","no EGFR or ALK genomic tumor aberrations","TRUE",NA,"","2020-04-02: New indication in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous-non-small cell lung cancer (NSCLC)</a> who do not have EGFR or ALK genomic tumour aberrations.","2023-05-08"
"Atezolizumab","HC","2020-08-10","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","First-line","Unresectable OR Metastatic","","adults","","",NA,"","","","","Bevacizumab","","",NA,"","2020-08-10: New indication, in combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> who require systemic therapy.","2023-05-08"
"Atezolizumab","HC","2021-03-01","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","0","(PD-L1 TPS at least 50%|PD-L1 TIL at least 10%) AND EGFR or ALK genomic tumor aberrations","FALSE AND TRUE",NA,"","2021-03-01: New indication as monotherapy for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> whose tumours have high PD-L1 expression (PD-L1 stained at least 50% of tumour cells [TCs] or PD-L1 stained tumour-infiltrating immune cells [ICs] covering at least 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","2023-05-08"
"Atezolizumab","HC","2021-03-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-03-05: Conditions met","2023-05-08"
"Atezolizumab","HC","2022-01-14","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage II to IIIA","","adults","","Surgery AND Platinum-based regimen","FALSE","","complete resection AND no progression","","","0","PD-L1 TPS at least 50%","FALSE",NA,"","2022-01-14: New indication as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> whose tumours have PD-L1 expression on at least 50% of tumour cells (TCs).","2023-05-08"
"Atezolizumab","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Atezolizumab","PMDA","2018-01-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2018-01-19: New approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Atezolizumab","PMDA","2019-08-22","Small cell lung cancer",FALSE,FALSE,FALSE,"","","Extensive-stage","","","","",NA,"","","","","","","",NA,"","2019-08-22: New indication and a new dosage for the treatment of extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small-cell lung cancer</a>.","2023-06-16"
"Atezolizumab","PMDA","2019-09-20","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable|Recurrent","","","","",NA,"","","","","","PD-L1+ and HR- and HER2-","FALSE",NA,"","2019-09-20: New indication and a new dosage in an additional dosage form indicated for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Atezolizumab","PMDA","2020-09-25","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2020-09-25: New indication and a new dosage for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a>.","2023-06-16"
"Atezolizumab","PMDA","2022-05-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","PD-L1+","FALSE",NA,"","2022-05-26: New indication and a new dosage for the postoperative adjuvant treatment for PD-L1-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Atezolizumab and hyaluronidase","FDA","2024-09-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","","","","","","","","","",TRUE,"IMscin001","2024-09-12: Initial approval for all the adult indications as the intravenous formulation of atezolizumab. <i>(Based on IMscin001)</i>","2024-12-02"
"Atovaquone","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Atropine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Aumolertinib","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Avapritinib","EMA","2020-09-24","Gastrointestinal stromal tumor",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","0","PDGFRA p.D842V","",TRUE,"NAVIGATOR","2020-09-24: Initial conditional authorization as Ayvakyt. Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumours (GIST)</a> harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. <i>(Based on NAVIGATOR)</i>","2023-09-17"
"Avapritinib","EMA","2022-03-24","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","","adults","","1+ SACT",NA,"","","","","0","","",TRUE,"EXPLORER","2022-03-24: Ayvakyt is indicated as monotherapy for the treatment of adult patients with aggressive <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a> (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. <i>(Based on EXPLORER and PATHFINDER)</i>","2024-01-06"
"Avapritinib","EMA","2022-03-24","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","","adults","","1+ SACT",NA,"","","","","0","","",TRUE,"PATHFINDER","2022-03-24: Ayvakyt is indicated as monotherapy for the treatment of adult patients with aggressive <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a> (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. <i>(Based on EXPLORER and PATHFINDER)</i>","2024-01-06"
"Avapritinib","EMA","2023-11-09","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","","adults","","symptomatic treatment",NA,"","moderate to severe symptoms inadequately controlled","","","","","",NA,"","2023-11-09: CHMP recommendation - Ayvakyt is indicated for the treatment of adult patients with indolent <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a> (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.","2024-01-06"
"Avapritinib","FDA","2020-01-09","Gastrointestinal stromal tumor",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","","PDGFRA exon 18 mutations|PDGFRA p.D842V","FALSE",TRUE,"NAVIGATOR","2020-01-09: Initial approval for adults with unresectable or metastatic <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor (GIST)</a> harboring a <a href=""/wiki/Biomarkers#PDGFRA"" title=""Biomarkers"">platelet-derived growth factor receptor alpha (PDGFRA)</a> <a href=""/wiki/Biomarkers#Exon_18"" title=""Biomarkers"">exon 18</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>, including <a href=""/wiki/Biomarkers#D842V"" title=""Biomarkers"">D842V mutations</a>. <i>(Based on NAVIGATOR)</i>","2022-09-05"
"Avapritinib","FDA","2021-06-16","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"","","","","","","",TRUE,"EXPLORER","2021-06-16: Approved for adult patients with advanced <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a> (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). <i>(Based on EXPLORER and PATHFINDER)</i>","2022-09-05"
"Avapritinib","FDA","2021-06-16","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"","","","","","","",TRUE,"PATHFINDER","2021-06-16: Approved for adult patients with advanced <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a> (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). <i>(Based on EXPLORER and PATHFINDER)</i>","2022-09-05"
"Avapritinib","FDA","2023-05-22","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","indolent","adults","","",NA,"","","","","","","",TRUE,"PIONEER","2023-05-22: Approved for the treatment of adults with indolent <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">systemic mastocytosis</a>. <i>(Based on PIONEER)</i>","2023-07-31"
"Avatrombopag","EMA","2019-06-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-06-20: Initial authorization as Doptelet","2023-05-08"
"Avatrombopag","EMA","Uncertain date","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","","","adults","","other treatments",NA,"","refractory","","","","","",NA,"","Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).","2023-05-20"
"Avatrombopag","EMA","Uncertain date","Thrombocytopenia in liver disease",FALSE,FALSE,FALSE,"","","Chronic liver disease","scheduled to undergo an invasive procedure","adults","","",NA,"","","","","","","",NA,"","Uncertain date: Doptelet is indicated for the treatment of severe <a href=""/wiki/Thrombocytopenia_in_liver_disease"" title=""Thrombocytopenia in liver disease"">thrombocytopenia in adult patients with chronic liver disease</a> who are scheduled to undergo an invasive procedure.","2023-05-20"
"Avatrombopag","EMA","Uncertain date","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","chronic","","adults","","other treatments","FALSE","","refractory","","","","","",NA,"","Uncertain date: Doptelet is indicated for the treatment of primary chronic <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">immune thrombocytopenia (ITP)</a> in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).","2023-07-31"
"Avatrombopag","FDA","2018-05-21","Thrombocytopenia in liver disease",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2018-05-21: Approved for <a href=""/wiki/Thrombocytopenia_in_liver_disease"" title=""Thrombocytopenia in liver disease"">thrombocytopenia in adults with chronic liver disease</a> scheduled to undergo a procedure.","2022-09-05"
"Avelumab","EMA","2017-09-18","Merkel cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","0","","",TRUE,"JAVELIN Merkel 200","2017-09-18: Initial marketing authorization as Bavencio. Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma (MCC)</a>. <i>(Based on JAVELIN Merkel 200)</i>","2023-09-17"
"Avelumab","EMA","2019-10-24","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","","","adults","","",NA,"","","","","Avelumab AND Axitinib","","",NA,"","2019-10-24: Extension of indication to include first-line combination treatment with avelumab and axitinib in adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> (aRCC).","2023-09-17"
"Avelumab","EMA","2021-01-21","Urothelial carcinoma",FALSE,FALSE,FALSE,"","First-line maintenance","Locally advanced OR Metastatic","","adults","","Platinum-based regimen",NA,"","progression-free","","","0","","",NA,"","2021-01-21: Extension of indication to include a new indication for Bavencio in the treatment as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> who are progression-free following platinum based chemotherapy.","2023-09-17"
"Avelumab","FDA","2017-03-23","Merkel cell carcinoma",TRUE,FALSE,FALSE,"","","Metastatic","","12 years and older","","",NA,"","","","","","","",TRUE,"JAVELIN Merkel 200","2017-03-23: Initial <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm547965.htm"">accelerated approval</a> for the treatment of patients 12 years and older with metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma (MCC)</a>. <i>(Based on JAVELIN Merkel 200)</i>","2022-09-05"
"Avelumab","FDA","2017-05-09","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen OR Platinum-based regimen, with progression within 12 months","FALSE","","","","","","","",TRUE,"JAVELIN Solid Tumor","2017-05-09: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm557162.htm"">Granted accelerated approval</a> for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> whose disease progressed during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> or within 12 months of neoadjuvant or adjuvant <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(Based on JAVELIN Solid Tumor)</i>","2022-09-05"
"Avelumab","FDA","2019-05-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","Axitinib","","",TRUE,"JAVELIN Renal 101","2019-05-14: Approved in combination with <a href=""/wiki/Axitinib_(Inlyta)"" title=""Axitinib (Inlyta)"">axitinib</a> for first-line treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on JAVELIN Renal 101)</i>","2022-09-05"
"Avelumab","FDA","2020-06-30","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","without progression","","","","","",TRUE,"JAVELIN Bladder 100","2020-06-30: Full approval for maintenance treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> that has not progressed with first-line platinum-containing chemotherapy. <i>(Converted to regular approval; expanded to maintenance setting; based on JAVELIN Bladder 100)</i>","2022-09-05"
"Avelumab","HC","2017-12-18","Merkel cell carcinoma",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","1+","FALSE","","","","","","","",NA,"","2017-12-18: Initial notice of compliance with conditions for the treatment of metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel Cell Carcinoma (MCC)</a> in previously treated adults.","2023-05-08"
"Avelumab","HC","2018-05-04","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",NA,"","2018-05-04: Notice of compliance with conditions for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.","2023-05-08"
"Avelumab","HC","2019-05-14","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",NA,"","2019-05-14: Conditions were met for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.","2023-05-08"
"Avelumab","HC","2019-11-06","Merkel cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","","",NA,"","2019-11-06: New indication for the treatment of adult patients with metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma (MCC)</a>","2023-05-08"
"Avelumab","HC","2020-12-10","Urothelial carcinoma",FALSE,FALSE,FALSE,"","First-line maintenance","Unresectable locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","not progressed","","","","","",NA,"","2020-12-10: New indication for the maintenance treatment of patients with unresectable locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> whose disease has not progressed following first-line platinum-based chemotherapy.","2023-05-08"
"Avelumab","HC","2021-01-13","Merkel cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","1+","FALSE","","","","","","","",NA,"","2021-01-13: Conditions were met for the treatment of metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel Cell Carcinoma (MCC)</a> in previously treated adults.","2023-05-08"
"Avelumab","PMDA","2017-09-27","Merkel cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2017-09-27: New approval for the treatment of unresectable <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma</a>.","2023-06-16"
"Avelumab","PMDA","2019-12-20","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2019-12-20: New indication and a new dosage for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Avelumab","PMDA","2021-02-24","Urothelial carcinoma",FALSE,FALSE,FALSE,"","Maintenance","Unresectable","","","","Chemotherapy","FALSE","","","","","","","",NA,"","2021-02-24: New indication for the maintenance therapy of unresectable <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> in patients who have received chemotherapy.","2023-06-16"
"Axatilimab","FDA","2024-08-14","Graft versus host disease",FALSE,FALSE,TRUE,"","","chronic","","adults and pediatric patients 40 kg or more","","2+ systemic treatments",NA,"","","","","","","",TRUE,"AGAVE-201","2024-08-14: Initial approval for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. <i>(Based on AGAVE-201)</i>","2024-09-06"
"Axicabtagene ciloleucel","EMA","2018-08-23","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","","","",TRUE,"ZUMA-1","2018-08-23: Initial marketing authorization as Yescarta. Yescarta is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a>, after two or more lines of systemic therapy. <i>(Based on ZUMA-1)</i>","2023-09-17"
"Axicabtagene ciloleucel","EMA","2018-08-23","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","","","",TRUE,"ZUMA-1","2018-08-23: Initial marketing authorization as Yescarta. Yescarta is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a>, after two or more lines of systemic therapy. <i>(Based on ZUMA-1)</i>","2023-09-17"
"Axicabtagene ciloleucel","EMA","2022-06-21","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","3+ SACT",NA,"","","","","","","",NA,"","2022-06-21: Extension of indication to include the treatment of adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> after three or more lines of systemic therapy.","2023-09-17"
"Axicabtagene ciloleucel","EMA","2022-10-14","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",NA,"","2022-10-14: Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a>.","2023-09-17"
"Axicabtagene ciloleucel","EMA","2022-10-14","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",NA,"","2022-10-14: Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a>.","2023-09-17"
"Axicabtagene ciloleucel","FDA","2017-10-18","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"ZUMA-1","2017-10-18: Granted initial approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. NOT indicated for the treatment of patients with primary central nervous system lymphoma. <i>(Based on ZUMA-1)</i>","2022-09-05"
"Axicabtagene ciloleucel","FDA","2017-10-18","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"ZUMA-1","2017-10-18: Granted initial approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. NOT indicated for the treatment of patients with primary central nervous system lymphoma. <i>(Based on ZUMA-1)</i>","2022-09-05"
"Axicabtagene ciloleucel","FDA","2017-10-18","Transformed lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"ZUMA-1","2017-10-18: Granted initial approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. NOT indicated for the treatment of patients with primary central nervous system lymphoma. <i>(Based on ZUMA-1)</i>","2022-09-05"
"Axicabtagene ciloleucel","FDA","2021-03-05","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"ZUMA-5","2021-03-05: Granted accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> after two or more lines of systemic therapy. <i>(Based on ZUMA-5)</i>","2022-09-05"
"Axicabtagene ciloleucel","FDA","2022-04-01","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","Refractory to first-line chemoimmunotherapy OR relapse within 12 months of first-line chemoimmunotherapy","FALSE","","","","","","","",TRUE,"ZUMA-7","2022-04-01: Approved for adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">large B-cell lymphoma (LBCL)</a> that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. <i>(Based on ZUMA-7)</i>","2022-09-05"
"Axicabtagene ciloleucel","HC","2019-02-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-02-13: Initial notice of compliance","2023-06-15"
"Axicabtagene ciloleucel","HC","2022-09-29","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",NA,"","2022-09-29: Notice of compliance with conditions for the treatment of adult patients with relapsed or refractory grade <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">1, 2 or 3a follicular lymphoma (FL)</a> after two or more lines of systemic therapy.","2023-05-08"
"Axicabtagene ciloleucel","PMDA","2021-01-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-01-22: Initial approval","2023-06-15"
"Axitinib","EMA","2012-09-03","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","sunitinib|cytokine",NA,"","failure","","","","","",TRUE,"AXIS","2012-09-03: Initial marketing authorization as Inlyta. Inlyta is indicated for the treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> after failure of prior treatment with sunitinib or a cytokine. <i>(Based on AXIS)</i>","2023-09-17"
"Axitinib","EMA","Uncertain date","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","advanced","","adults","","sunitinib|cytokine","FALSE","","failure","","","","","",NA,"","Uncertain date: Inlyta is indicated for the treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> after failure of prior treatment with sunitinib or a cytokine.","2023-05-08"
"Axitinib","FDA","2012-01-27","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","1 SACT","FALSE","","","","","","","",TRUE,"AXIS","2012-01-27: Initial approval for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a> after failure of one prior systemic therapy. <i>(Based on AXIS)</i>","2022-09-05"
"Axitinib","FDA","2019-05-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","Avelumab","","",TRUE,"JAVELIN Renal 101","2019-05-14: Approved in combination with <a href=""/wiki/Avelumab_(Bavencio)"" title=""Avelumab (Bavencio)"">avelumab</a> for first-line treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Approval extended to first-line setting, in combination; based on JAVELIN Renal 101)</i>","2022-09-05"
"Axitinib","FDA","2020-06-04","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","Pembrolizumab","","",TRUE,"KEYNOTE-426","2020-06-04: Approved in combination with pembrolizumab, for the first-line treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">RCC</a>. <i>(Based on KEYNOTE-426)</i>","2022-09-05"
"Axitinib","HC","2012-07-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-07-12: Initial notice of compliance","2023-07-31"
"Axitinib","HC","Uncertain date","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","SACT","TRUE","Metastatic","","","","Pembrolizumab","","",NA,"","Uncertain date: in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> with no prior systemic therapy for metastatic RCC.","2023-07-31"
"Axitinib","HC","Uncertain date","Clear cell renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","sunitinib|cytokine","FALSE","","failure","","","","","",NA,"","Uncertain date: Indicated for the treatment of patients with metastatic <a href=""/wiki/Clear_cell_renal_cell_carcinoma"" title=""Clear cell renal cell carcinoma"">renal cell carcinoma (RCC) of clear cell histology</a> after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib.","2023-07-31"
"Axitinib","PMDA","2012-06-29","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2012-06-29: Initial approval for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Azacitidine","EMA","2008-12-17","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","20-30% marrow blasts","intermediate-2 and high-risk","adults","HSCT-ineligible","",NA,"","","","","","","",TRUE,"AZA-001","2008-12-17: Initial authorization as Vidaza. Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: intermediate-2 and high-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> according to the International Prognostic Scoring System (IPSS), <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukaemia (CMML)</a> with 10-29% marrow blasts without myeloproliferative disorder, and <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> with 20-30% blasts. <i>(Based on AZA-001)</i>","2023-09-17"
"Azacitidine","EMA","2008-12-17","Chronic myelomonocytic leukemia",FALSE,FALSE,FALSE,"","","10-29% marrow blasts without myeloproliferative disorder","intermediate-2 and high-risk","adults","HSCT-ineligible","",NA,"","","","","","","",TRUE,"AZA-001","2008-12-17: Initial authorization as Vidaza. Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: intermediate-2 and high-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> according to the International Prognostic Scoring System (IPSS), <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukaemia (CMML)</a> with 10-29% marrow blasts without myeloproliferative disorder, and <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> with 20-30% blasts. <i>(Based on AZA-001)</i>","2023-09-17"
"Azacitidine","EMA","2008-12-17","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","intermediate-2 and high-risk","adults","not eligible for haematopoietic stem cell transplantation","",NA,"","","","","","","",TRUE,"AZA-001","2008-12-17: Initial authorization as Vidaza. Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: intermediate-2 and high-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> according to the International Prognostic Scoring System (IPSS), <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukaemia (CMML)</a> with 10-29% marrow blasts without myeloproliferative disorder, and <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> with 20-30% blasts. <i>(Based on AZA-001)</i>","2023-09-17"
"Azacitidine","EMA","2015-10-28","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","",">30% marrow blasts","","adults aged 65 years or older","HSCT-ineligible","",NA,"","","","","","","",TRUE,"AZA-AML-001","2015-10-28: Extension of indication to add treatment of adult patients aged 65 years or older who are not eligible for HSCT with <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">AML</a> with &gt;30% marrow blasts according to the WHO classification. <i>(Based on AZA-AML-001)</i>","2023-09-17"
"Azacitidine","FDA","2004-05-19","Chronic myelomonocytic leukemia",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"CALGB 9221","2004-05-19: Initial approval for treatment of patients with the following <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a> subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia""> chronic myelomonocytic leukemia</a>. <i>(Based on CALGB 9221)</i>","2022-09-05"
"Azacitidine","FDA","2004-05-19","Myelodysplastic syndrome",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"CALGB 9221","2004-05-19: Initial approval for treatment of patients with the following <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a> subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia""> chronic myelomonocytic leukemia</a>. <i>(Based on CALGB 9221)</i>","2022-09-05"
"Azacitidine","FDA","2008-08-20","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"AZA-001","2008-08-20: Approval for <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a> updated to include overall survival benefit from AZA-001 study. <i>(Based on AZA-001)</i>","2022-09-05"
"Azacitidine","FDA","2022-05-20","Juvenile myelomonocytic leukemia",FALSE,FALSE,FALSE,"","","","","pediatric","","0","FALSE","","","","","","","",TRUE,"AZA-JMML-001","2022-05-20: Approved for pediatric patients with newly diagnosed <a href=""/wiki/Juvenile_myelomonocytic_leukemia"" title=""Juvenile myelomonocytic leukemia"">juvenile myelomonocytic leukemia (JMML)</a>. <i>(Based on AZA-JMML-001)</i>","2022-09-05"
"Azacitidine","HC","2009-10-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-10-23: Initial notice of compliance","2023-07-31"
"Azacitidine","PMDA","2011-01-21","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-01-21: Initial approval for the treatment of <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a>.","2023-06-16"
"Azacitidine","PMDA","2021-03-23","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-03-23: New indication for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Azacitidine oral","EMA","2021-06-17","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Maintenance","","","adults","transplant-ineligible OR choosing not to proceed with HSCT","",NA,"","CR OR CRi after induction +/- consolidation","","","","","",TRUE,"QUAZAR AML-001","2021-06-17: Initial authorization as maintenance therapy in adult patients with <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT). <i>(Based on QUAZAR AML-001)</i>","2023-05-08"
"Azacitidine oral","FDA","2020-09-01","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Maintenance","","","","not able to complete intensive curative therapy","Chemotherapy","FALSE","","CR OR CRi after induction","","","","","",TRUE,"QUAZAR AML-001","2020-09-01: Approved for continued treatment of patients with <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a> who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. <i>(Based on QUAZAR AML-001)</i>","2022-09-05"
"Azathioprine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"BCG vaccine","EMA","1988-03-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1988-03-02: EURD","2023-07-31"
"BCG vaccine","FDA","1990-05-22","Bladder cancer",FALSE,FALSE,TRUE,"","","","","","","Transurethral resection","FALSE","","","","","","","",TRUE,"SWOG 8216","1990-05-22: Initial approval for the prophylaxis of primary or recurrent stage Ta and/or T1 <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">papillary tumors</a> following transurethral resection (TUR). <i>(Based on SWOG 8216 and SWOG 8507)</i>","2022-09-05"
"BCG vaccine","FDA","1990-05-22","Bladder cancer",FALSE,FALSE,TRUE,"","","","","","","Transurethral resection","FALSE","","","","","","","",TRUE,"SWOG 8507","1990-05-22: Initial approval for the prophylaxis of primary or recurrent stage Ta and/or T1 <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">papillary tumors</a> following transurethral resection (TUR). <i>(Based on SWOG 8216 and SWOG 8507)</i>","2022-09-05"
"BCG vaccine","FDA","1990-05-22","Bladder CIS",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1990-05-22: Initial approval for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder","2022-09-05"
"BCG vaccine","HC","1994-09-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1994-09-08: Initial notice of compliance","2023-07-31"
"Belantamab mafodotin","EMA","2020-08-25","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","adults","","4+ including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent","FALSE","","progression","","","0","","",TRUE,"DREAMM-2","2020-08-25: Initial conditional approval as monotherapy for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. <i>(Based on DREAMM-2)</i>","2023-05-08"
"Belantamab mafodotin","FDA","2020-08-05","Multiple myeloma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","4+ including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent","FALSE","","","","","","","",TRUE,"DREAMM-2","2020-08-05: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. <i>(Based on DREAMM-2)</i>","2022-09-05"
"Belantamab mafodotin","FDA","2023-02-06","NONE",TRUE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"DREAMM-3","2023-02-06: Accelerated approval withdrawn. <i>(Based on DREAMM-3)</i>","2023-05-08"
"Belinostat","FDA","2014-07-03","Peripheral T-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"BELIEF","2014-07-03: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm"">FDA accelerated approval</a> for the treatment of patients with relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma""> peripheral T-cell lymphoma (PTCL)</a>. <i>(Based on BELIEF)</i>","2022-09-05"
"Belotecan","KFDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Belumosudil","FDA","2021-07-16","Graft versus host disease",FALSE,FALSE,TRUE,"","","","","adults AND pediatric patients 12 years and older","","2+ systemic treatments","FALSE","","failure","","","","","",TRUE,"ROCKstar","2021-07-16: Approved for adult and pediatric patients 12 years and older with chronic <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">graft-versus-host disease</a> (chronic GVHD) after failure of at least two prior lines of systemic therapy. <i>(Based on ROCKstar)</i>","2022-09-05"
"Belzutifan","FDA","2021-08-13","Pancreatic NET",FALSE,FALSE,TRUE,"","not requiring immediate surgery","","","adults","","",NA,"","","","","","","",TRUE,"MK-6482-004","2021-08-13: Approved for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>, <a href=""/w/index.php?title=CNS_hemangioblastomaandaction=editandredlink=1"" class=""new"" title=""CNS hemangioblastoma (page does not exist)"">central nervous system (CNS) hemangioblastomas</a>, or <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumors (pNET)</a>, not requiring immediate surgery. <i>(Based on MK-6482-004)</i>","2022-09-05"
"Belzutifan","FDA","2021-08-13","Renal cell carcinoma",FALSE,FALSE,FALSE,"","not requiring immediate surgery","","","adults","","",NA,"","","","","","","",TRUE,"MK-6482-004","2021-08-13: Approved for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>, <a href=""/w/index.php?title=CNS_hemangioblastomaandaction=editandredlink=1"" class=""new"" title=""CNS hemangioblastoma (page does not exist)"">central nervous system (CNS) hemangioblastomas</a>, or <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumors (pNET)</a>, not requiring immediate surgery. <i>(Based on MK-6482-004)</i>","2022-09-05"
"Belzutifan","FDA","2023-12-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","(anti-PD-1 antibody OR anti-PD-L1 antibody) AND VEGF TKI",NA,"","","","","","","",TRUE,"LITESPARK-005","2023-12-14: Approved for patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). <i>(Based on LITESPARK-005)</i>","2024-01-06"
"Bendamustine","EMA","2010-07-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-07-07: EURD","2023-07-31"
"Bendamustine","FDA","2008-03-20","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Knauf et al. 2009","2008-03-20: Initial approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a>. <i>(Based on Knauf et al. 2009)</i>","2022-09-05"
"Bendamustine","FDA","2008-10-31","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","Rituximab-containing regimen","FALSE","","progression","during or within 6 months","","","","",TRUE,"SDX-105-01 part 2","2008-10-31: Approved for the treatment of patients with <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">indolent B-cell non-Hodgkin's lymphoma (NHL)</a> that progressed during or within 6 months of treatment with <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)""> rituximab</a> or a <a href=""/wiki/Regimen_classes#Rituximab-containing_regimen"" title=""Regimen classes"">rituximab-containing regimen</a>. <i>(New disease entity; based on SDX-105-01 part 2)</i>","2023-05-08"
"Bendamustine","FDA","2015-12-07","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Knauf et al. 2009","2015-12-07: Approved for <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(Based on Knauf et al. 2009)</i>","2022-09-05"
"Bendamustine","FDA","2015-12-07","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","Rituximab","FALSE","","progression","during or within 6 months","","","","",TRUE,"SDX-105-01 part 2","2015-12-07: Approved for <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">indolent B-cell non-Hodgkin lymphoma (NHL)</a> that has progressed during or within six months of treatment with <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">rituximab</a> or a <a href=""/wiki/Regimen_classes#Rituximab-containing_regimen"" title=""Regimen classes"">rituximab-containing regimen</a>. <i>(Based on SDX-105-01 part 2)</i>","2022-09-05"
"Bendamustine","HC","2012-08-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-08-24: Initial notice of compliance","2023-07-31"
"Bendamustine","PMDA","2010-10-27","Indolent lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2010-10-27: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">indolent B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Bendamustine","PMDA","2010-10-27","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2010-10-27: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">indolent B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Bendamustine","PMDA","2016-08-26","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-08-26: New additional indication and a new dosage for the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a>.","2023-06-16"
"Bendamustine","PMDA","2016-09-28","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-09-28: New additional indication, dosage, and dosage form for the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a>.","2023-06-16"
"Bendamustine","PMDA","2016-12-19","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-12-19: revised indication and a new dosage for the treatment of <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Bendamustine","PMDA","2016-12-19","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-12-19: revised indication and a new dosage for the treatment of <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Bendamustine","PMDA","2019-03-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-03-26: indicated for the treatment prior to tumor-specific T-cell infusion therapy.","2023-06-16"
"Bendamustine","PMDA","2021-03-23","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-03-23: New indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>.","2023-06-16"
"Benralizumab","","","",FALSE,FALSE,TRUE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Betrixaban","FDA","2017-06-23","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2017-06-23: FDA approved for the prophylaxis of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">venous thromboembolism (VTE)</a> in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.","2022-09-05"
"Bevacizumab","EMA","2005-01-12","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","(Fluorouracil AND Leuvorin) OR (Fluorouracil AND Leucovorin AND Irinotecan)","","",TRUE,"AVF0780g","2005-01-12: Initial market authorization as Avastin in combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum. <i>(Based on AVF2107g and AVF0780g)</i>","2023-09-17"
"Bevacizumab","EMA","2005-01-12","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","(Fluorouracil AND Leuvorin) OR (Fluorouracil AND Leucovorin AND Irinotecan)","","",TRUE,"AVF2107g","2005-01-12: Initial market authorization as Avastin in combination with intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum. <i>(Based on AVF2107g and AVF0780g)</i>","2023-09-17"
"Bevacizumab","EMA","2011-12-19","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line","Advanced (FIGO stages III B, III C and IV)","","","","",NA,"","","","","Carboplatin AND Palictaxel","","",NA,"","2011-12-19: Extension of indication to include the use of Avastin, in combination with carboplatin and paclitaxel for the front-line treatment of advanced (FIGO stages III B, III C and IV) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>.","2023-09-17"
"Bevacizumab","EMA","2014-07-31","Ovarian cancer",FALSE,FALSE,FALSE,"","","Platinum-resistant recurrent","","adults","","0-2 chemotherapy-based regimens AND (bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents)","TRUE AND FALSE","","","","","Paclitaxel OR Pegylated liposomal doxorubicin OR Topotecan","","",NA,"","2014-07-31: Extension of indication to include Avastin in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adult patients with platinum-resistant recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.","2023-09-17"
"Bevacizumab","EMA","2015-03-30","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","adults","","",NA,"","","","","(Cisplatin AND Paclitaxel) OR (Paclitaxel AND Topotecan)","","",NA,"","2015-03-30: Extension of Indication to include treatment of adult patients with persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">carcinoma of the cervix</a> for Bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan.","2023-09-17"
"Bevacizumab","EMA","2016-06-02","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","Unresectable advanced OR Metastatic OR Recurrent","","","","",NA,"","","","","Erlotinib","EGFR activating mutations","FALSE",NA,"","2016-06-02: Extension of indication to include the combination of bevacizumab with erlotinib for the first line treatment of patients with unresectable advanced, metastatic or recurrent <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSCLC)</a> with Epidermal Growth Factor Receptor (EGFR) activating mutations.","2023-09-17"
"Bevacizumab","EMA","2017-06-02","Ovarian cancer",FALSE,FALSE,FALSE,"","First recurrence","Platinum-sensitive","","adults","","bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents","FALSE","","","","","Carboplatin AND Palictaxel","","",NA,"","2017-06-02: Extension of indication to include the use of Avastin in combination with paclitaxel and carboplatin for the for treatment of adult patients with first recurrence of platinum-sensitive <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.","2023-09-17"
"Bevacizumab","FDA","2004-02-26","Colon cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","0","FALSE","","","","","5-FU-based regimen","","",TRUE,"AVF2107g","<b>2004-02-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/125085ltr.pdf"">Initial FDA approval</a></b>, in combination with intravenous <a href=""/wiki/Regimen_classes#5-FU-based_regimen"" title=""Regimen classes"">5-fluorouracil-based chemotherapy</a>...for first- line treatment of patients with metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(Based on AVF2107g)</i>","2023-01-03"
"Bevacizumab","FDA","2004-02-26","Rectal cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","0","FALSE","","","","","5-FU-based regimen","","",TRUE,"AVF2107g","<b>2004-02-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/125085ltr.pdf"">Initial FDA approval</a></b>, in combination with intravenous <a href=""/wiki/Regimen_classes#5-FU-based_regimen"" title=""Regimen classes"">5-fluorouracil-based chemotherapy</a>...for first- line treatment of patients with metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(Based on AVF2107g)</i>","2023-01-03"
"Bevacizumab","FDA","2006-06-20","Colon cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1","FALSE","","","","","","","",TRUE,"ECOG E3200","2006-06-20: Approved for second-line treatment of metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(New treatment setting without explicit requirement for combination therapy; based on ECOG E3200 and TRC-301)</i>","2022-09-05"
"Bevacizumab","FDA","2006-06-20","Rectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1","FALSE","","","","","","","",TRUE,"ECOG E3200","2006-06-20: Approved for second-line treatment of metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(New treatment setting without explicit requirement for combination therapy; based on ECOG E3200 and TRC-301)</i>","2022-09-05"
"Bevacizumab","FDA","2006-06-20","Colon cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1","FALSE","","","","","","","",TRUE,"TRC-301","2006-06-20: Approved for second-line treatment of metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(New treatment setting without explicit requirement for combination therapy; based on ECOG E3200 and TRC-301)</i>","2022-09-05"
"Bevacizumab","FDA","2006-06-20","Rectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1","FALSE","","","","","","","",TRUE,"TRC-301","2006-06-20: Approved for second-line treatment of metastatic carcinoma of the <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon</a> or <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectum</a>. <i>(New treatment setting without explicit requirement for combination therapy; based on ECOG E3200 and TRC-301)</i>","2022-09-05"
"Bevacizumab","FDA","2006-10-11","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Recurrent OR Metastatic","","","","0","FALSE","","","","","Carboplatin AND Palictaxel","","",TRUE,"AVAil","2006-10-11: Approved for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous""><b>non-squamous</b>, non-small cell lung cancer</a>, with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)"">carboplatin</a> and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. <i>(New disease entity; based on ECOG E4599 and AVAil)</i>","2022-09-05"
"Bevacizumab","FDA","2006-10-11","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Recurrent OR Metastatic","","","","0","FALSE","","","","","Carboplatin AND Palictaxel","","",TRUE,"ECOG E4599","2006-10-11: Approved for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous""><b>non-squamous</b>, non-small cell lung cancer</a>, with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)"">carboplatin</a> and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. <i>(New disease entity; based on ECOG E4599 and AVAil)</i>","2022-09-05"
"Bevacizumab","FDA","2008-02-22","Breast cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Chemotherapy","TRUE","Metastatic","","","","","","",TRUE,"ECOG E2100","2008-02-22: Granted accelerated approval for use in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> for the treatment of patients who have not received chemotherapy for metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">HER2 negative breast cancer</a>. <i>(New disease entity; based on ECOG E2100)</i>","2022-09-05"
"Bevacizumab","FDA","2009-05-05","Glioblastoma",TRUE,FALSE,FALSE,"","Progressive","","","","","1+","FALSE","","","","","0","","",TRUE,"AVF3708g","2009-05-05: Granted accelerated approval as a single agent for patients with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, with progressive disease following prior therapy. <i>(Based on NCI 06-C-0064E and AVF3708g)</i>","2022-09-05"
"Bevacizumab","FDA","2009-05-05","Glioblastoma",TRUE,FALSE,FALSE,"","Progressive","","","","","1+","FALSE","","","","","0","","",TRUE,"NCI 06-C-0064E","2009-05-05: Granted accelerated approval as a single agent for patients with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, with progressive disease following prior therapy. <i>(Based on NCI 06-C-0064E and AVF3708g)</i>","2022-09-05"
"Bevacizumab","FDA","2009-07-31","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Interferon alfa","","",TRUE,"AVOREN","2009-07-31: Approved in combination with interferon alfa for the treatment of patients with metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>. <i>(Based on AVOREN)</i>","2022-09-05"
"Bevacizumab","FDA","2011-11-18","Breast cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"AVADO","2011-11-18: Accelerated approval for metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">HER2 negative breast cancer</a> withdrawn. <i>(Based on AVADO and RIBBON-1)</i>","2022-09-05"
"Bevacizumab","FDA","2011-11-18","Breast cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"RIBBON-1","2011-11-18: Accelerated approval for metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">HER2 negative breast cancer</a> withdrawn. <i>(Based on AVADO and RIBBON-1)</i>","2022-09-05"
"Bevacizumab","FDA","2013-01-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Bevacizumab-containing regimen","FALSE","","","","","Fluoropyrimidine AND Irinotecan OR Fluoropyrimidine AND Oxaliplatin","","",TRUE,"ML18147","2013-01-23: Approved for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) whose disease has progressed on a first-line <a href=""/wiki/Regimen_classes#Bevacizumab-containing_regimen"" title=""Regimen classes"">bevacizumab-containing regimen</a>. <i>(Based on ML18147)</i>","2022-09-05"
"Bevacizumab","FDA","2014-08-14","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","","","",NA,"","","","","Paclitaxel AND Cisplatin OR Palictaxel AND Topotecan","","",TRUE,"GOG 240","2014-08-14: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm410128.htm"">Approved</a> for treatment of <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> and <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin</a> or <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> and <a href=""/wiki/Topotecan_(Hycamtin)"" title=""Topotecan (Hycamtin)"">topotecan</a> in persistent, recurrent, or metastatic disease. <i>(Based on GOG 240)</i>","2022-09-05"
"Bevacizumab","FDA","2014-11-14","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","Platinum-based regimen","FALSE","","Platinum-resistant","","","Paclitaxel OR Pegylated liposomal doxorubicin OR Topotecan","","",TRUE,"AURELIA","2014-11-14: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm423159.htm"">Approved</a> for treatment of platinum-resistant recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube or primary peritoneal cancer</a>, in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a>, <a href=""/wiki/Pegylated_liposomal_doxorubicin_(Doxil)"" title=""Pegylated liposomal doxorubicin (Doxil)"">pegylated liposomal doxorubicin</a> or <a href=""/wiki/Topotecan_(Hycamtin)"" title=""Topotecan (Hycamtin)"">topotecan</a>. <i>(Based on AURELIA)</i>","2022-09-05"
"Bevacizumab","FDA","2016-12-06","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","Platinum-based regimen","FALSE","","Platinum-sensitive","","","Carboplatin AND Paclitaxel OR Carboplatin AND Gemcitabine","","",TRUE,"NRG/GOG-0213","2016-12-06: Approved for recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> that is platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent. <i>(Based on NRG/GOG-0213 and OCEANS)</i>","2022-09-05"
"Bevacizumab","FDA","2016-12-06","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","Platinum-based regimen","FALSE","","Platinum-sensitive","","","Carboplatin AND Paclitaxel OR Carboplatin AND Gemcitabine","","",TRUE,"OCEANS","2016-12-06: Approved for recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> that is platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent. <i>(Based on NRG/GOG-0213 and OCEANS)</i>","2022-09-05"
"Bevacizumab","FDA","2017-12-05","Glioblastoma",FALSE,FALSE,FALSE,"","Progressive","","","","","1+","FALSE","","","","","","","",TRUE,"EORTC 26101","2017-12-05: Converted to regular approval for patients with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a> with progressive disease following prior therapy. <i>(Based on EORTC 26101)</i>","2022-09-05"
"Bevacizumab","FDA","2018-06-13","Ovarian cancer",FALSE,FALSE,FALSE,"","","Stage III to IV","","","","Surgery","FALSE","","","","","Carboplatin AND Palictaxel","","",TRUE,"GOG-0218","2018-06-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-bevacizumab-combination-chemotherapy-ovarian-cancer"">FDA approved</a> for patients with <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)"">carboplatin</a> and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a>, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. <i>(Indication expanded to first-line setting; based on GOG-0218)</i>","2022-09-05"
"Bevacizumab","FDA","2020-05-29","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","SACT","TRUE","","","","","Atezolizumab","","",TRUE,"IMbrave150","2020-05-29: Approved in combination with <a href=""/wiki/Atezolizumab_(Tecentriq)"" title=""Atezolizumab (Tecentriq)"">atezolizumab</a> for patients with unresectable or metastatic <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> who have not received prior systemic therapy. <i>(Based on IMbrave150)</i>","2022-09-05"
"Bevacizumab","HC","2005-09-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2005-09-09: Initial notice of compliance.","2023-07-31"
"Bevacizumab","HC","2011-11-25","Breast cancer",FALSE,TRUE,FALSE,"","","Metastatic","","ECOG PS 0-1","","",NA,"","","","","Paclitaxel","HER2-","TRUE",NA,"","2011-11-25: Avastin used in combination with paclitaxel is indicated for the treatment of patients with metastatic HER2-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> and who are ECOG Class 0-1, has been suspended.","2023-05-08"
"Bevacizumab","HC","2018-05-23","Glioblastoma",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2018-05-23: Avastin, as a single agent, for the treatment of patients with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma (GBM)</a> after relapse or disease progression, following prior therapy, has been withdrawn.","2023-05-08"
"Bevacizumab","PMDA","2007-04-18","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2007-04-18: Initial approval for the treatment of unresectable advanced/relapsed <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Bevacizumab","PMDA","2009-09-18","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","Not suited for curative resection","",NA,"","","","","CapeOx","","",NA,"","2009-09-18: New additional indication for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> not suited for curative resection.","2023-06-16"
"Bevacizumab","PMDA","2009-11-06","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2009-11-06: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer</a>.","2023-06-16"
"Bevacizumab","PMDA","2011-09-26","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2011-09-26: New additional indication and a new dosage for the treatment of unresectable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Bevacizumab","PMDA","2013-06-14","High-grade glioma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-06-14: New additional indication and a new dosage for the treatment of <a href=""/wiki/Category:High-grade_gliomas"" title=""Category:High-grade gliomas"">malignant glioma</a>.","2023-06-16"
"Bevacizumab","PMDA","2013-11-22","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-11-22: New additional indication for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a>.","2023-06-16"
"Bevacizumab","PMDA","2016-05-23","Cervical cancer",FALSE,FALSE,FALSE,"","","Advanced or Recurrent","","","","",NA,"","","","","","","",NA,"","2016-05-23: New additional indication for the treatment of advanced or recurrent <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>.","2023-06-16"
"Bevacizumab","PMDA","2020-09-25","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2020-09-25: New indication and a new dosage for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a>.","2023-06-16"
"Bevacizumab-adcd","FDA","2022-09-28","Cervical cancer",FALSE,FALSE,FALSE,"","","persistent, recurrent, or metastatic","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-adcd","FDA","2022-09-28","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-adcd","FDA","2022-09-28","Glioblastoma",FALSE,FALSE,FALSE,"","","Recurrent","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-adcd","FDA","2022-09-28","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-adcd","FDA","2022-09-28","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-adcd","FDA","2022-09-28","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"CT-P16 3.1","2022-09-28: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, recurrent or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer (NSCLC)</a>, recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, and <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>. <i>(Based on CT-P16 3.1)</i>","2023-01-03"
"Bevacizumab-awwb","FDA","2017-09-14","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Recurrent OR Metastatic","","","","0","FALSE","","","","","Carboplatin AND Palictaxel","","",TRUE,"MAPLE","2017-09-14: Approved for the treatment of patients with <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous""><b>non-squamous</b> non-small cell lung cancer</a>, in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)"">carboplatin</a> and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. <i>(Based on MAPLE)</i>","2022-09-05"
"Bevacizumab-awwb","FDA","2017-09-14","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","","","",NA,"","","","","(Cisplatin AND Paclitaxel) OR (Paclitaxel AND Topotecan)","","",NA,"","2017-09-14: Approved for the treatment of patients with <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> that is persistent, recurrent, or metastatic disease, in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> and <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin</a> or <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)"">paclitaxel</a> and <a href=""/wiki/Topotecan_(Hycamtin)"" title=""Topotecan (Hycamtin)"">topotecan</a>.","2022-09-05"
"Bevacizumab-awwb","FDA","2017-09-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Interferon alfa","","",NA,"","2017-09-14: Approved for the treatment of patients with metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, in combination with <a href=""/wiki/Category:Interferon_alfas"" title=""Category:Interferon alfas"">interferon alfa</a>.","2022-09-05"
"Bevacizumab-awwb","FDA","2017-09-14","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0 or 1","FALSE","","","","","Fluorouracil-based chemotherapy","","",NA,"","2017-09-14: Approved for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with intravenous <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">5-fluorouracil</a>-based chemotherapy for first- or second-line treatment.","2023-01-03"
"Bevacizumab-awwb","FDA","2017-09-14","Glioblastoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","progression","","","","","",NA,"","2017-09-14: Approved for the treatment of patients with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a> with progressive disease following prior therapy, based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with bevacizumab products.","2022-09-05"
"Bevacizumab-awwb","FDA","2017-09-14","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Bevacizumab-containing regimen","FALSE","","progression","","","Fluoropyrimidine AND Irinotecan OR Fluoropyrimidine AND Oxaliplatin","","",NA,"","2017-09-14: Approved for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line <a href=""/wiki/Regimen_classes#Bevacizumab-containing_regimen"" title=""Regimen classes"">bevacizumab product-containing regimen</a>.","2022-09-05"
"Bevacizumab-bvzr","FDA","2019-06-28","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"REFLECTIONS B7391003","2019-06-28: Approved <i>(Based on REFLECTIONS B7391003)</i>","2022-09-05"
"Bevacizumab-maly","FDA","2022-04-13","Glioblastoma",FALSE,FALSE,FALSE,"","","Recurrent","","adults","","",NA,"","","","","","","",NA,"","2022-04-13: Approved for recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a> in adults.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","","","",NA,"","","","","Paclitaxel AND Cisplatin OR Palictaxel AND Topotecan","","",NA,"","2022-04-13: Approved for persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line|Second-line","Metastatic","","","","",NA,"","","","","Fluorouracil-based chemotherapy","","",NA,"","2022-04-13: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","","","","","",NA,"","","","","Carboplatin AND Palictaxel","","",TRUE,"STELLA","2022-04-13: Approved for first-line <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer</a>, in combination with carboplatin and paclitaxel. <i>(Based on STELLA)</i>","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-04-13: Alymsys is not indicated for adjuvant treatment of colon cancer.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Paclitaxel","","",NA,"","2022-04-13: Approved for <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, in combination with paclitaxel.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Interferon alfa","","",NA,"","2022-04-13: Approved for metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> in combination with interferon alfa.","2023-07-31"
"Bevacizumab-maly","FDA","2022-04-13","Colorectal cancer",FALSE,FALSE,FALSE,"","Second-line","Metastatic","","","","Bevacizumab-containing regimen","FALSE","First-line","progression","","","Fluoropyrimidine AND Irinotecan OR Fluoropyrimidine AND Oxaliplatin","","",NA,"","2022-04-13: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.","2023-07-31"
"Bevacizumab-tnjn","FDA","2023-12-06","Glioblastoma",FALSE,FALSE,FALSE,"","","Recurrent","","adults","","",NA,"","","","","","","",NA,"","2023-12-06: Approved for recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a> in adults.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line|Second-line","Metastatic","","","","",NA,"","","","","Fluorouracil-based chemotherapy","","",NA,"","2023-12-06: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Colorectal cancer",FALSE,FALSE,FALSE,"","Second-line","Metastatic","","","","Bevacizumab-containing regimen",NA,"","progression","","","(Fluoropyrimidine AND Irinotecan) OR (Fluoropyrimidine AND Oxaliplatin)","","",NA,"","2023-12-06: Approved for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","","","","","",NA,"","","","","Carboplatin AND Palictaxel","","",NA,"","2023-12-06: Approved for first-line <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer</a>, in combination with carboplatin and paclitaxel.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Interferon alfa","","",NA,"","2023-12-06: Approved for metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> in combination with interferon alfa.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Cervical cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Paclitaxel AND Cisplatin OR Palictaxel AND Topotecan","","",NA,"","2023-12-06: Approved for <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.","2024-09-06"
"Bevacizumab-tnjn","FDA","2023-12-06","Ovarian cancer",FALSE,FALSE,FALSE,"","","Platinum-resistant recurrent","","","","0-2 chemotherapy-based regimens",NA,"","","","","Paclitaxel OR Pegylated liposomal doxorubicin OR Topotecan","","",NA,"","2023-12-06: Approved for <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.","2024-09-06"
"Bexarotene","EMA","2001-03-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-03-29: Initial authorization","2023-05-08"
"Bexarotene","FDA","1999-12-29","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","Refractory","","","","","1+ SACT","FALSE","","","","","","","",TRUE,"Duvic et al. 2001a","1999-12-29: Initial approval for the treatment of cutaneous manifestations of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a> in patients who are refractory to at least one prior systemic therapy. <i>(Based on Duvic et al. 2001a and Duvic et al. 2001b)</i>","2022-09-05"
"Bexarotene","FDA","1999-12-29","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","Refractory","","","","","1+ SACT","FALSE","","","","","","","",TRUE,"Duvic et al. 2001b","1999-12-29: Initial approval for the treatment of cutaneous manifestations of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a> in patients who are refractory to at least one prior systemic therapy. <i>(Based on Duvic et al. 2001a and Duvic et al. 2001b)</i>","2022-09-05"
"Bexarotene","PMDA","2016-01-22","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-01-22: Initial approval for the treatment of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Bicalutamide","EMA","1995-02-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-02-28: EURD","2023-07-31"
"Bicalutamide","FDA","1995-10-04","Prostate cancer",TRUE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","GnRH agonist","","",TRUE,"Schellhammer et al. 1995","1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on Schellhammer et al. 1995)</i>","2022-09-05"
"Bicalutamide","FDA","1997-12-12","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","GnRH agonist","","",TRUE,"Schellhammer et al. 1995","1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on Schellhammer et al. 1995)</i>","2022-09-21"
"Bicalutamide","HC","1995-11-02","Prostate cancer",FALSE,FALSE,FALSE,"","","Metastatic (Stage D2)","","","","",NA,"","","","","LHRH analog|Surgical castration","","",NA,"","1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-07-31"
"Binimetinib","EMA","2018-09-20","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Encorafenib","BRAF p.V600","",TRUE,"COLUMBUS","2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation. <i>(Based on COLUMBUS and LOGIC-2)</i>","2023-09-17"
"Binimetinib","EMA","2018-09-20","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Encorafenib","BRAF p.V600","",TRUE,"LOGIC-2","2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation. <i>(Based on COLUMBUS and LOGIC-2)</i>","2023-09-17"
"Binimetinib","EMA","2020-04-30","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","1+ SACT","FALSE","","","","","Cetuximab","BRAF p.V600E","FALSE",NA,"","2020-04-30: Extension of indication to include encorafenib in combination with cetuximab, for the treatment of adult patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> with a BRAF V600E mutation, who have received prior systemic therapy.","2023-09-17"
"Binimetinib","FDA","2018-06-27","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Encorafenib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COLUMBUS","2018-06-27: Initial FDA approval in combination with <a href=""/wiki/Encorafenib_(Braftovi)"" title=""Encorafenib (Braftovi)"">Encorafenib (Braftovi)</a> for patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutation</a>, as detected by an FDA-approved test. <i>(Based on COLUMBUS)</i>","2022-09-05"
"Binimetinib","FDA","2023-10-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","Encorafenib","BRAF p.V600E","FALSE",TRUE,"PHAROS","2023-10-11: Approved with <a href=""/wiki/Encorafenib_(Braftovi)"" title=""Encorafenib (Braftovi)"">Encorafenib (Braftovi)</a> for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a BRAF V600E mutation, as detected by an FDA-approved test. <i>(Based on PHAROS)</i>","2023-11-07"
"Binimetinib","HC","2021-03-02","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Encorafenib","BRAF p.V600","FALSE",NA,"","2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation, as detected by a validated test.","2023-05-08"
"Binimetinib","PMDA","2019-01-08","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2019-01-08: New approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with BRAF gene mutation.","2023-06-16"
"Binimetinib","PMDA","2020-11-27","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable|Advanced|Recurrent","","","","Chemotherapy","FALSE","","progression","","","","BRAF mutation","FALSE",NA,"","2020-11-27: New indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Bismuth subcitrate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Bismuth subsalicylate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Bivalirudin","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Bleomycin","EMA","1970-03-18","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1970-03-18: EURD","2023-07-31"
"Bleomycin","FDA","1973-07-31","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1973-07-31: Initial approval","2022-09-05"
"Bleomycin","FDA","Uncertain date","Cervical cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Head and neck cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Penile cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Testicular cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Bleomycin","FDA","Uncertain date","Vulvar cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-03-21 (oldest label available at Drugs @ FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); <a href=""/wiki/Penile_cancer"" title=""Penile cancer"">penis</a>; <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervix</a>; <a href=""/wiki/Vulvar_cancer"" title=""Vulvar cancer"">vulva</a>; <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>; <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphoma</a>; <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a> (including embryonal cell, choriocarcinoma, and teratocarcinoma). <i>(No supporting studies are cited)</i>","2023-05-20"
"Blinatumomab","EMA","2015-11-23","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","Ph-","TRUE",TRUE,"MT103-206","2015-11-23: Initial authorization as Blincyto. Blincyto is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-precursor acute lymphoblastic leukaemia (ALL)</a>. <i>(Based on MT103-211 and MT103-206)</i>","2023-09-17"
"Blinatumomab","EMA","2015-11-23","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","Ph-","TRUE",TRUE,"MT103-211","2015-11-23: Initial authorization as Blincyto. Blincyto is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-precursor acute lymphoblastic leukaemia (ALL)</a>. <i>(Based on MT103-211 and MT103-206)</i>","2023-09-17"
"Blinatumomab","EMA","2019-01-18","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","CR1 or CR2 with MRD greater than or equal to 0.1%","","","0","Ph- AND CD19+","",NA,"","2019-01-18: Extension of indication to include the treatment of adults with Philadelphia chromosome-negative CD19 positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B precursor ALL</a> in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for BLINCYTO monotherapy.","2023-09-17"
"Blinatumomab","EMA","2020-12-22","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","alternative treatment","2+ TKIs",NA,"","failure","","","","Ph+ AND CD19+","",NA,"","2020-12-22: To modify the approved therapeutic indication to include the treatment of Philadelphia chromosome positive CD19 positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukaemia (ALL)</a> in adult patients with relapsed or refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment.","2023-09-17"
"Blinatumomab","EMA","2021-06-24","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","consolidation","First relapse","high-risk","pediatric 1 year of age or older","","",NA,"","","","","0","Ph- AND CD19+","",NA,"","2021-06-24: Extension of indication to include the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-precursor ALL</a> as part of the consolidation therapy.","2023-09-17"
"Blinatumomab","FDA","2014-12-03","B-cell acute lymphoblastic leukemia",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","Ph-","TRUE",TRUE,"MT103-211","2014-12-03: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425597.htm"">Granted FDA accelerated approval</a> for the treatment of <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia""> B-cell precursor acute lymphoblastic leukemia</a> (R/R ALL). <i>(Based on MT103-211)</i>","2022-09-05"
"Blinatumomab","FDA","2017-07-11","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","","",NA,"","","","","","","",TRUE,"ALCANTARA","2017-07-11: Granted FDA regular approval for the treatment of relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in adults and children. <i>(Based on TOWER, MT103-205, and ALCANTARA)</i>","2022-09-05"
"Blinatumomab","FDA","2017-07-11","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","","",NA,"","","","","","","",TRUE,"MT103-205","2017-07-11: Granted FDA regular approval for the treatment of relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in adults and children. <i>(Based on TOWER, MT103-205, and ALCANTARA)</i>","2022-09-05"
"Blinatumomab","FDA","2017-07-11","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","","",NA,"","","","","","","",TRUE,"TOWER","2017-07-11: Granted FDA regular approval for the treatment of relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in adults and children. <i>(Based on TOWER, MT103-205, and ALCANTARA)</i>","2022-09-05"
"Blinatumomab","FDA","2018-03-29","B-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%","","adults and pediatric","","",NA,"","","","","","","",TRUE,"BLAST","2018-03-29: Granted FDA accelerated approval for the treatment of adult and pediatric patients with <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. <i>(Based on BLAST)</i>","2022-09-05"
"Blinatumomab","FDA","2023-06-21","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","First or second CR","","","adults and pediatric","","",NA,"1 to 2","MRD greater than or equal to 0.1%","","","","CD19+","FALSE",TRUE,"Amgen 20120215","2023-06-21: Converted to regular approval for the treatment of adult and pediatric patients with CD19-positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in first or second complete remission with measurable residual disease (MRD) greater than or equal to 0.1%. <i>(Based on COG AALL1331 and Amgen 20120215)</i>","2023-07-31"
"Blinatumomab","FDA","2023-06-21","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","First or second CR","","","adults and pediatric","","",NA,"1 to 2","MRD greater than or equal to 0.1%","","","","CD19+","FALSE",TRUE,"COG AALL1331","2023-06-21: Converted to regular approval for the treatment of adult and pediatric patients with CD19-positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> in first or second complete remission with measurable residual disease (MRD) greater than or equal to 0.1%. <i>(Based on COG AALL1331 and Amgen 20120215)</i>","2023-07-31"
"Blinatumomab","FDA","2024-06-14","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","consolidation","","","adults AND pediatric patients 1 month and older","","",NA,"","","","","","CD19+","FALSE",TRUE,"ECOG-ACRIN E1910","2024-06-14: Approved for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia</a> (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy. <i>(Based on ECOG-ACRIN E1910)</i>","2024-09-06"
"Blinatumomab","HC","2015-12-22","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-12-22: Initial notice of compliance with conditions","2023-05-08"
"Blinatumomab","HC","2017-04-28","B-cell acute lymphoblastic leukemia pediatric",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","pediatric","","",NA,"","","","","","Ph-","TRUE",NA,"","2017-04-28: Notice of compliance with conditions for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia,_pediatric"" title=""B-cell acute lymphoblastic leukemia, pediatric"">B-cell precursor ALL</a>.","2023-05-08"
"Blinatumomab","HC","2017-11-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-11-16: Conditions were met","2023-05-08"
"Blinatumomab","HC","2019-12-19","B-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%","","","","",NA,"","","","","","Ph- AND CD19+","TRUE AND FALSE",NA,"","2019-12-19: Notice of compliance with conditions for the treatment of patients with Philadelphia chromosome-negative CD19 positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-precursor acute lymphoblastic leukemia (ALL)</a> in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.","2023-05-08"
"Blinatumomab","PMDA","2018-09-21","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2018-09-21: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell acute lymphoblastic leukemia</a>.","2023-06-16"
"Borofalan-10B","PMDA","2020-03-25","Head and neck cancer",FALSE,FALSE,FALSE,"","","Locally unresectable recurrent|Unresectable advanced","","","","",NA,"","","","","","","",NA,"","2020-03-25: Newly indicated for the treatment of locally unresectable recurrent or unresectable advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>.","2023-07-31"
"Bortezomib","EMA","2004-04-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-04-26: Initial marketing authorization as Velcade.","2023-11-07"
"Bortezomib","EMA","2013-07-31","Multiple myeloma",FALSE,FALSE,FALSE,"","Induction","","","adults","eligible for high dose chemotherapy with haematopoietic stem cell transplantation","0",NA,"","","","","Dexamethasone","","",NA,"","2013-07-31: Velcade in combination with dexamethasone is indicated for the induction treatment of adult patients with previously untreated <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.","2023-09-17"
"Bortezomib","EMA","2013-07-31","Multiple myeloma",FALSE,FALSE,FALSE,"","Induction","","","adults","eligible for high dose chemotherapy with haematopoietic stem cell transplantation","0",NA,"","","","","Dexamethasone AND Thalidomide","","",NA,"","2013-07-31: Velcade in combination with dexamethasone and thalidomide is indicated for the induction treatment of adult patients with previously untreated <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.","2023-09-17"
"Bortezomib","EMA","2013-12-18","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or progressive","","","","1+",NA,"","","","","Pegylated liposomal doxorubicin","","",NA,"","2013-12-18: Extension of indication for Velcade in combination with pegylated liposomal doxorubicin in patients with relapsed and /or progressive <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 1 prior therapy.","2023-09-17"
"Bortezomib","EMA","2013-12-18","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or progressive","","","","1+",NA,"","","","","Dexamethasone","","",NA,"","2013-12-18: Extension of indication for Velcade in combination with dexamethasone in patients with relapsed and /or progressive <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 1 prior therapy.","2023-09-17"
"Bortezomib","EMA","2015-01-30","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","0",NA,"","","","","Rituximab AND Cyclophosphamide AND Doxorubicin AND Prednisone","","",NA,"","2015-01-30: Extension of indication for the use of VELCADE in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-09-17"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","progressive","","adults","","1+ including auto HSCT unless ineligible","FALSE","","","","","0","","",NA,"","Uncertain date: Velcade as monotherapy is indicated for the treatment of adult patients with progressive <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.","2023-09-09"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","progressive","","adults","","1+ including auto HSCT unless ineligible","FALSE","","","","","Pegylated liposomal doxorubicin","","",NA,"","Uncertain date: Velcade in combination with pegylated liposomal doxorubicin is indicated for the treatment of adult patients with progressive <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.","2023-09-09"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","progressive","","adults","","1+ including auto HSCT unless ineligible","FALSE","","","","","Dexamethasone","","",NA,"","Uncertain date: Velcade in combination with dexamethasone is indicated for the treatment of adult patients with progressive <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.","2023-09-09"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","Induction","","","adults","eligible for high dose chemotherapy with haematopoietic stem cell transplantation","0","FALSE","","","","","Dexamethasone","","",NA,"","Uncertain date: Velcade in combination with dexamethasone is indicated for the induction treatment of adult patients with previously untreated <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.","2023-09-09"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","Induction","","","adults","eligible for high dose chemotherapy with haematopoietic stem cell transplantation","0","FALSE","","","","","Dexamethasone AND Thalidomide","","",NA,"","Uncertain date: Velcade in combination with dexamethasone and thalidomide is indicated for the induction treatment of adult patients with previously untreated <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.","2023-09-09"
"Bortezomib","EMA","Uncertain date","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","not eligible for autologous HSCT","0","FALSE","","","","","Rituximab AND Cyclophosphamide AND Doxorubicin AND Prednisone","","",NA,"","Uncertain date: Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a> who are unsuitable for haematopoietic stem cell transplantation.","2023-07-31"
"Bortezomib","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","not eligible for autologous HSCT","0","FALSE","","","","","Melphalan AND Prednisone","","",NA,"","Uncertain date: Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.","2023-07-31"
"Bortezomib","FDA","2003-05-13","Multiple myeloma",TRUE,FALSE,TRUE,"","","","","","","2+","FALSE","","progression","","","","","",TRUE,"SUMMIT","2003-05-13: Initial <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021602lbl.pdf"">accelerated approval</a> for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma""> multiple myeloma</a> patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. <i>(Based on SUMMIT)</i>","2022-09-05"
"Bortezomib","FDA","2005-03-25","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"APEX","2005-03-25: Converted to regular approval for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma""> multiple myeloma</a> patients who have received at least 1 prior therapy. <i>(Based on APEX)</i>","2022-09-05"
"Bortezomib","FDA","2006-12-08","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"PINNACLE","2006-12-08: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094929.htm"">Approved</a> for the treatment of patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma""> mantle cell lymphoma</a> who have received at least one prior therapy. <i>(New disease entity; based on PINNACLE)</i>","2022-09-05"
"Bortezomib","FDA","2008-06-23","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"VISTA","2008-06-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm"">Approved</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>. <i>(previously was only approved for patients who had received prior therapy; based on VISTA)</i>","2022-09-05"
"Bortezomib","FDA","2012-01-23","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"MMY-3021","2012-01-23: Approved for subcutaneous administration of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>. <i>(Based on MMY-3021)</i>","2022-09-05"
"Bortezomib","FDA","2014-08-11","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","Bortezomib","FALSE","","","","","","","",TRUE,"RETRIEVE","2014-08-11: Approved for retreatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>. <i>(Based on RETRIEVE)</i>","2022-09-05"
"Bortezomib","FDA","2014-10-08","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"LYM-3002","2014-10-08: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021602Orig1s040ltr.pdf"">Approved</a> for treatment of patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma""> mantle cell lymphoma</a>. <i>(including first-line therapy for untreated patients; previously was only approved for patients who had received at least one prior treatment; based on LYM-3002)</i>","2022-09-05"
"Bortezomib","HC","2005-01-27","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2005-01-27: Initial notice of compliance with conditions","2023-05-08"
"Bortezomib","HC","2007-09-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-09-11: Conditions were met","2023-05-08"
"Bortezomib","PMDA","2006-10-20","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2006-10-20: Initial approval for treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Bortezomib","PMDA","2011-09-16","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-09-16: New indication and a new dosage for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Bortezomib","PMDA","2012-12-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-12-21: New route of administration indicated for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Bortezomib","PMDA","2015-06-26","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-06-26: New additional indication and a new dosage for the treatment of patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Bortezomib","PMDA","2018-03-23","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-03-23: New additional indication and a new dosage indicated for the treatment of <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinemia</a> and lymphoplasmacytic lymphoma.","2023-06-16"
"Bortezomib","PMDA","2021-08-25","Light-chain (AL) amyloidosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-08-25: New indication and a new dosage for the treatment of <a href=""/wiki/Light-chain_(AL)_amyloidosis"" title=""Light-chain (AL) amyloidosis"">systemic AL amyloidosis</a>.","2023-06-16"
"Bosutinib","EMA","2013-03-27","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","imatinib, nilotinib and dasatinib are not considered appropriate treatment options","1+ TKI",NA,"","","","","","Ph+","",TRUE,"Study 200","2013-03-27: Initial authorization as Bosulif. Bosulif is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukaemia</a> (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. <i>(Based on Study 200)</i>","2023-09-17"
"Bosutinib","EMA","2018-04-23","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","0",NA,"","","","","","","",TRUE,"BFORE","2018-04-23: Extension of Indication to include treatment of adult patients with newly diagnosed Philadelphia Chromosome positive (Ph+) Chronic Phase (CP) <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">Chronic Myelogenous Leukaemia (CML)</a>. <i>(Based on BFORE)</i>","2023-09-17"
"Bosutinib","FDA","2012-09-04","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","1+","FALSE","","Resistance OR Intolerance","","","","BCR-ABL1","FALSE",TRUE,"Study 200","2012-09-04: Initial approval for the treatment of adult patients with chronic, accelerated, or blast phase <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> with resistance or intolerance to prior therapy. <i>(Based on Study 200)</i>","2022-09-05"
"Bosutinib","FDA","2017-12-19","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase","","","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"BFORE","2017-12-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml"">Accelerated approval</a> for treatment of patients with newly-diagnosed chronic phase (CP) <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive (Ph+)</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a>. <i>(Based on BFORE)</i>","2022-09-05"
"Bosutinib","FDA","2021-05-14","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"BFORE","2021-05-14: Converted to regular approval. <i>(Based on BFORE)</i>","2022-09-05"
"Bosutinib","FDA","2023-09-26","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","chronic phase","","","pediatric 1 year of age or older","","0|1+","FALSE","","NA|resistant or intolerant","","","","Ph+","FALSE",TRUE,"BCHILD","2023-09-26: Approved for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> that is newly diagnosed (ND) or resistant or intolerant (R/I) to prior therapy. <i>(Based on BCHILD)</i>","2023-11-07"
"Bosutinib","HC","2014-03-07","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","Subsequent treatment with imatinib, nilotinib, and dasatinib is not clinically appropriate","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","1+ TKI","FALSE","","Resistance OR Intolerance","","","","BCR-ABL1","FALSE",NA,"","2014-03-07: Initial notice of compliance with conditions for the treatment of chronic, accelerated, or blast phase <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a> in adult patients with resistance or intolerance to prior tyrosine kinase inhibitor therapy, and for whom subsequent treatment with imatinib, nilotinib, and dasatinib is not clinically appropriate.","2023-05-08"
"Bosutinib","HC","2017-08-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-08-02: Conditions were met","2023-05-08"
"Bosutinib","PMDA","2014-09-26","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","Resistance OR Intolerance","","","","","",NA,"","2014-09-26: Initial approval for the treatment of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia</a> with resistance or intolerance to prior drug therapies.","2023-06-16"
"Bosutinib","PMDA","2020-06-29","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","","","0","FALSE","","","","","","","",NA,"","2020-06-29: New indication and a new dosage for the treatment of newly-diagnosed chronic phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a>.","2023-06-16"
"Brentuximab vedotin","EMA","2012-10-25","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","Autologous HSCT",NA,"","","","","","CD30+","FALSE",TRUE,"SG035-0003","2012-10-25: Initial authorization as Adcetris. Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin lymphoma (HL)</a> following autologous stem cell transplant (ASCT). <i>(Based on SG035-0003)</i>","2023-09-17"
"Brentuximab vedotin","EMA","2012-10-25","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",TRUE,"SG035-0004","2012-10-25: Initial authorization as Adcetris. Adcetris is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">systemic anaplastic large cell lymphoma (sALCL)</a>. <i>(Based on SG035-0004)</i>","2023-09-17"
"Brentuximab vedotin","EMA","2012-10-25","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","ASCT or multi-agent chemotherapy is not a treatment option","2+",NA,"","","","","","CD30+","FALSE",TRUE,"SG035-0003","2012-10-25: Initial authorization as Adcetris. Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin lymphoma (HL)</a> following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. <i>(Based on SG035-0003)</i>","2023-09-17"
"Brentuximab vedotin","EMA","2016-06-24","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","increased risk of relapse or progression","adults","","Autologous HSCT",NA,"","","","","","","",NA,"","2016-06-24: Extension of Indication to include the treatment of adult patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin Lymphoma (HL)</a> at increased risk of relapse or progression following autologous stem cell transplantation (ASCT).","2023-09-17"
"Brentuximab vedotin","EMA","2017-12-15","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","require systemic therapy","","adults","","",NA,"","","","","","CD30+","",TRUE,"ALCANZA","2017-12-15: Extension of indication for the treatment of adult patients with CD30+ <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma (CTCL)</a> who require systemic therapy. <i>(Based on ALCANZA)</i>","2023-09-17"
"Brentuximab vedotin","EMA","2019-02-06","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","First-line","Stage IV","","adults","","",NA,"","","","","Doxorubicin AND Vincristine AND Dacarbazine","CD30+","FALSE",TRUE,"ECHELON-1","2019-02-06: Extension of the existing Hodgkin lymphoma (HL) indication to include the frontline treatment of adult patients with CD30+ Stage IV <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin lymphoma (HL)</a> in combination with doxorubicin, vinblastine and dacarbazine (AVD). <i>(Based on ECHELON-1)</i>","2023-09-17"
"Brentuximab vedotin","EMA","2020-05-12","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","0",NA,"","","","","Cyclophosphamide AND Doxorubicin AND Prednisone","CD30+","",NA,"","2020-05-12: Extension of indication to include in combination with cyclophosphamide, doxorubicin, and prednisone treatment of adults with previously untreated CD30+ <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">sALCL</a>.","2023-09-17"
"Brentuximab vedotin","FDA","2011-08-19","Classical Hodgkin lymphoma",TRUE,FALSE,TRUE,"","","","","","","Autologous HSCT OR 2+ Multi-agent chemotherapy regimens in non-transplant candidates","FALSE","","","","","","","",TRUE,"SG035-0003","2011-08-19: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm#accelerated"">accelerated approval</a> for treatment of patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin lymphoma</a> after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. <i>(Based on SG035-0003)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2011-08-19","Anaplastic large cell lymphoma",TRUE,FALSE,TRUE,"","","","","","","1+ Multi-agent chemotherapy regimen","FALSE","","","","","","","",TRUE,"SG035-0004","2011-08-19: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm#accelerated"">accelerated approval</a> for treatment of patients with <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma""> systemic anaplastic large cell lymphoma (sALCL)</a> after failure of at least one prior multi-agent chemotherapy regimen. <i>(Based on SG035-0004)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2015-08-17","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","High risk of relapse or progression","","","Autologous HSCT","FALSE","","","","","","","",TRUE,"AETHERA","2015-08-17: Converted to full approval for the post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation treatment of patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (HL)</a> at high risk of relapse or progression. <i>(new treatment context added; based on AETHERA)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2017-11-09","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","1+ SACT","FALSE","","","","","","CD30+","FALSE",TRUE,"ALCANZA","2017-11-09: Regular approval for the treatment of adult patients with <a href=""/wiki/Biomarkers#CD30"" title=""Biomarkers"">CD30</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a> <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (MF)</a> who have received prior systemic therapy. <i>(Based on ALCANZA)</i>","2023-03-10"
"Brentuximab vedotin","FDA","2017-11-09","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ALCANZA","2017-11-09: Regular approval for the treatment of adult patients with <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">primary cutaneous anaplastic large cell lymphoma (pcALCL)</a>. <i>(New disease indication; based on ALCANZA)</i>","2023-03-10"
"Brentuximab vedotin","FDA","2018-03-20","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Stage III to IV","","adults","","0","FALSE","","","","","Chemotherapy","","",TRUE,"ECHELON-1","2018-03-20: Approved to treat adult patients with previously untreated stage III or IV <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> in combination with chemotherapy. <i>(New treatment context; based on ECHELON-1)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2018-11-16","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Chemotherapy","CD30+","FALSE",TRUE,"ECHELON-2","2018-11-16: Approved in combination with chemotherapy for previously untreated <a href=""/wiki/Biomarkers#CD30"" title=""Biomarkers"">CD30</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a> <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphomas (PTCL)</a>, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. <i>(New disease indication; based on ECHELON-2)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2018-11-16","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Chemotherapy","","",TRUE,"ECHELON-2","2018-11-16: Approved in combination with chemotherapy for previously untreated <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">systemic anaplastic large cell lymphoma (sALCL)</a>. <i>(New treatment context; based on ECHELON-2)</i>","2022-09-05"
"Brentuximab vedotin","FDA","2022-11-10","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","high risk","pediatric patients 2 years and older","","0","FALSE","","","","","Doxorubicin AND Vincristine AND Etoposide AND Prednisone AND Cyclophosphamide","","",TRUE,"COG AHOD1331","2022-11-10: Approved in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a>. <i>(Based on COG AHOD1331)</i>","2022-11-22"
"Brentuximab vedotin","HC","2013-02-01","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-02-01: Initial notice of compliance with conditions","2023-05-08"
"Brentuximab vedotin","HC","2020-05-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-05-12: Conditions were met","2023-05-08"
"Brentuximab vedotin","PMDA","2014-01-17","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD30+","FALSE",NA,"","2014-01-17: Initial approval for the treatment of relapsed or refractory CD30-positive <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's lymphoma</a> and <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">anaplastic large cell lymphoma</a>.","2023-06-16"
"Brentuximab vedotin","PMDA","2018-09-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-21: New indication and a new dosage for the treatment of CD30-positive <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's lymphoma</a>.","2023-06-16"
"Brentuximab vedotin","PMDA","2019-12-20","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","CD30+","FALSE",NA,"","2019-12-20: New indication and a new dosage for the treatment of CD30-positive <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>.","2023-06-16"
"Brentuximab vedotin","PMDA","2023-11-24","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Refractory","","","","",NA,"","","","","","CD30+","FALSE",NA,"","2023-11-24: New indication and a new dosage for the treatment of relapsed or refractory CD30-positive <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2024-06-03"
"Brexucabtagene autoleucel","EMA","2020-12-14","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-12-14: Initial conditional authorization.","2023-05-08"
"Brexucabtagene autoleucel","FDA","2020-07-24","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",TRUE,"ZUMA-2","2020-07-24: Granted accelerated approval for the treatment of adult patients with relapsed/refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>. <i>(Based on ZUMA-2)</i>","2022-09-05"
"Brexucabtagene autoleucel","FDA","2021-10-01","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",TRUE,"ZUMA-3","2021-10-01: Approved for adult patients with relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a>. <i>(Based on ZUMA-3)</i>","2022-09-05"
"Brigatinib","EMA","2018-11-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","Crizotinib",NA,"","","","","0","ALK rearrangement","",TRUE,"ALTA","2018-11-22: Initial authorization as Alunbrig. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> previously treated with crizotinib. <i>(Based on ALTA)</i>","2023-09-17"
"Brigatinib","EMA","2020-04-01","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Advanced","","adults","","ALK inhibitor","TRUE","","","","","","ALK rearrangement","",TRUE,"ALTA-1L","2020-04-01: Extension of indication to include first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> previously not treated with an ALK inhibitor. <i>(Based on ALTA-1L)</i>","2023-09-17"
"Brigatinib","FDA","2017-04-28","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Crizotinib","FALSE","","","","","","ALK rearrangement","FALSE",TRUE,"ALTA","2017-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm"">Accelerated approval</a> for the treatment of patients with metastatic <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to <a href=""/wiki/Crizotinib_(Xalkori)"" title=""Crizotinib (Xalkori)"">crizotinib</a>. <i>(Based on ALTA)</i>","2022-09-05"
"Brigatinib","FDA","2020-05-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"ALTA-1L","2020-05-22: Full approval for adult patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Converted to regular approval and prior treatment requirement removed); based on ALTA-1L)</i>","2022-09-05"
"Brigatinib","HC","2018-07-26","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","","","adults","","Crizotinib","FALSE","","Progression OR Intolerance","","","0","ALK rearrangement","FALSE",NA,"","2018-07-26: Initial notice of compliance with conditions as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).","2023-05-08"
"Brigatinib","HC","2021-03-03","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","adults","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2021-03-03: New indication for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>.","2023-05-08"
"Brigatinib","HC","2022-07-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-07-20: Conditions were met","2023-05-08"
"Brigatinib","PMDA","2021-01-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2021-01-22: Newly indicated for the treatment of unresectable advanced/recurrent anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Buserelin","EMA","1984-08-16","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1984-08-16: EURD","2023-07-31"
"Busulfan","EMA","2003-07-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2003-07-09: EURD","2023-07-31"
"Busulfan","FDA","1954-06-26","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1954-06-26: Initial FDA approval","2022-09-05"
"Busulfan","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-01-23 (oldest label available at Drugs @ FDA): indicated for the palliative treatment of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia</a>. <i>(No supporting studies are cited)</i>","2023-05-20"
"Busulfan","PMDA","2020-03-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-03-25: New indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem-cell transplantation.","2023-06-16"
"Cabazitaxel","EMA","2011-03-17","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Docetaxel-containing regimen",NA,"","","","","Prednisone OR Prednisolone","","",TRUE,"TROPIC","2011-03-17: Initial marketing authorization as Jevtana. Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> previously treated with a docetaxel-containing regimen. <i>(Based on TROPIC)</i>","2023-09-17"
"Cabazitaxel","FDA","2010-06-17","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Docetaxel-containing regimen","FALSE","","","","","Prednisone","","",TRUE,"TROPIC","2010-06-17: Initial approval in combination with <a href=""/wiki/Prednisone_(Sterapred)"" title=""Prednisone (Sterapred)""> prednisone</a> for treatment of patients with hormone-refractory metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a> previously treated with a <a href=""/wiki/Regimen_classes#Docetaxel-containing_regimen"" title=""Regimen classes""> docetaxel-containing treatment regimen</a>. <i>(Based on TROPIC)</i>","2022-09-05"
"Cabazitaxel","FDA","2017-09-14","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Docetaxel-containing regimen","FALSE","","","","","Prednisone","","",TRUE,"PROSELICA","2017-09-14: Approved at a lower dose (20 mg/m^2 every 3 weeks) in combination with <a href=""/wiki/Prednisone_(Sterapred)"" title=""Prednisone (Sterapred)""> prednisone</a> for the treatment of patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> previously treated with a <a href=""/wiki/Regimen_classes#Docetaxel-containing_regimen"" title=""Regimen classes""> docetaxel-containing treatment regimen</a>. <i>(Based on PROSELICA)</i>","2022-09-05"
"Cabazitaxel","FDA","2020-12-18","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Docetaxel-containing regimen","FALSE","","","","","Prednisone","","",TRUE,"CARD","2020-12-18: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> previously treated with a <a href=""/wiki/Regimen_classes#Docetaxel-containing_regimen"" title=""Regimen classes""> docetaxel-containing treatment regimen</a>. <i>(Based on CARD)</i>","2022-09-05"
"Cabazitaxel","HC","2011-06-06","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Docetaxel-containing regimen","FALSE","","","","","","","",NA,"","2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> previously treated with a docetaxel containing regimen.","2023-05-20"
"Cabazitaxel","PMDA","2014-07-04","Prostate cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-07-04: Initial approval for the treatment of <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Cabozantinib","EMA","2014-03-21","Thyroid cancer medullary",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","",NA,"","progression","","","","","",TRUE,"EXAM","2014-03-21: Initial authorization as Cometriq. Cometriq is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid carcinoma</a>. <i>(Based on EXAM)</i>","2023-09-17"
"Cabozantinib","EMA","2016-09-09","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","VEGFR inhibitor therapy",NA,"","","","","","","",TRUE,"METEOR","2016-09-09: Initial authorization as Cabometyx. Cabometyx is indicated for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. <i>(Based on METEOR)</i>","2023-09-17"
"Cabozantinib","EMA","2018-05-08","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","Intermediate-risk OR Poor-risk","adults","","0",NA,"","","","","","","",NA,"","2018-05-08: Extension of indication to include for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> the â€˜treatment-naive adults with intermediate or poor risk' for CABOMETYX.","2023-09-17"
"Cabozantinib","EMA","2018-11-12","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","adults","","Sorafenib",NA,"","","","","0","","",NA,"","2018-11-12: Extension of indication to add Cabometyx as monotherapy for the treatment of <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> in adults who have previously been treated with sorafenib.","2023-09-17"
"Cabozantinib","EMA","2021-03-26","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Nivolumab","","",NA,"","2021-03-26: Extension of indication to include in combination with nivolumab first line treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> for CABOMETYX.","2023-09-17"
"Cabozantinib","EMA","2022-04-29","NONE",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","Iodine-131 AND 1+ SACT",NA,"","progression","","","0","","",NA,"","2022-04-29: Extension of indication to include monotherapy treatment of adults and adolescent patients aged 12 years and older, with locally advanced or metastatic <a href=""/wiki/Differentiated_thyroid_cancer"" class=""mw-redirect"" title=""Differentiated thyroid cancer"">differentiated thyroid carcinoma (DTC)</a>, refractory to radioactive iodine (RAI) who have progressed during or after prior systemic therapy for CABOMETYX.","2024-12-02"
"Cabozantinib","EMA","2022-04-29","NONE",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","1+ SACT",NA,"","progression","","","0","","",NA,"","2022-04-29: Extension of indication to include monotherapy treatment of adults and adolescent patients aged 12 years and older, with locally advanced or metastatic <a href=""/wiki/Differentiated_thyroid_cancer"" class=""mw-redirect"" title=""Differentiated thyroid cancer"">differentiated thyroid carcinoma (DTC)</a>, not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy for CABOMETYX.","2024-12-02"
"Cabozantinib","FDA","2012-11-29","Thyroid cancer medullary",FALSE,FALSE,FALSE,"","Progressive","Metastatic","","","","",NA,"","","","","","","",TRUE,"EXAM","2012-11-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm"">Initial approval</a> (as Cometriq) for treatment of progressive metastatic <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary""> medullary thyroid cancer (MTC)</a>. <i>(Based on EXAM)</i>","2022-09-05"
"Cabozantinib","FDA","2016-04-25","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","VEGFR inhibitor therapy","FALSE","","","","","","","",TRUE,"METEOR","2016-04-25: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm"">Approved</a> (as Cabometyx) for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> in patients who have received prior <a href=""/wiki/Category:VEGFR_inhibitors"" title=""Category:VEGFR inhibitors"">anti-angiogenic therapy</a>. <i>(New disease entity; based on METEOR)</i>","2022-09-05"
"Cabozantinib","FDA","2017-12-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"CABOSUN","2017-12-19: Granted FDA regular approval for treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Converted to regular approval; no longer requires prior treatment; based on CABOSUN)</i>","2022-09-05"
"Cabozantinib","FDA","2019-01-14","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","","","",TRUE,"CELESTIAL","2019-01-14: Approved for patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with <a href=""/wiki/Sorafenib_(Nexavar)"" title=""Sorafenib (Nexavar)"">sorafenib</a>. <i>(New disease entity; based on CELESTIAL)</i>","2022-09-05"
"Cabozantinib","FDA","2021-09-17","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","VEGFR inhibitor therapy AND (Contraindication to Iodine-131 OR Iodine-131)","FALSE","","","","","","","",TRUE,"COSMIC-311","2021-09-17: Approved for adult and pediatric patients 12 years of age and older with locally advanced or metastatic <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated thyroid cancer (DTC)</a> that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine. <i>(Based on COSMIC-311)</i>","2022-09-05"
"Cabozantinib","HC","2018-09-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","VEGFR inhibitor therapy","FALSE","","","","","","","",NA,"","2018-09-14: Initial notice of compliance for the treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> who have received prior vascular endothelial growth factor (VEGF)-targeted therapy.","2023-05-08"
"Cabozantinib","HC","2019-10-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-10-10: New indication","2023-05-08"
"Cabozantinib","HC","2019-11-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-11-08: New indication","2023-05-08"
"Cabozantinib","HC","2021-10-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-10-12: New indication","2023-05-08"
"Cabozantinib","HC","2022-04-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-04-28: New indication","2023-05-08"
"Cabozantinib","PMDA","2020-03-25","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2020-03-25: Initial approval for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Cabozantinib","PMDA","2020-11-27","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2020-11-27: New indication for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Cadonilimab","NMPA","2022-06-29","Cervical cancer",FALSE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"COMPASSION-13","2022-06-29: Initial approval for use in patients with relapsed or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> (r/mCC) who have progressed on or after platinum-based chemotherapy. <i>(Based on COMPASSION-13)</i>","2024-12-02"
"Cadonilimab","NMPA","2024-09-30","Gastric cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"COMPASSION-15","2024-09-30: Approved in combination with fluoropyrimidine and platinum-based chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (G/GEJ) adenocarcinoma. <i>(Based on COMPASSION-15)</i>","2024-12-02"
"Calaspargase","FDA","2018-12-20","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","pediatric and young adults aged 1 month to 21 years","","",NA,"","","","","Multi-agent chemotherapy","","",TRUE,"COG AALL07P4","2018-12-20: Initial approval as a component of a multi-agent chemotherapeutic regimen for <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia (ALL)</a> in pediatric and young adult patients age 1 month to 21 years. <i>(Based on COG AALL07P4)</i>","2022-09-05"
"Calcium phosphate rinse","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Camrelizumab","NMPA","2019-05-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-05-29: Initial approval","2023-09-09"
"Camrelizumab","NMPA","2021-06-17","Nasopharyngeal carcinoma",FALSE,FALSE,FALSE,"","First-line","Recurrent OR Metastatic","","","","",NA,"","","","","Cisplatin AND Gemcitabine","","",TRUE,"CAPTAIN-1st","2021-06-17: Approved combined with gemcitabine and cisplatin (GP) as a first-line treatment for the patients with recurrent or metastatic <a href=""/wiki/Nasopharyngeal_carcinoma"" title=""Nasopharyngeal carcinoma"">nasopharyngeal carcinoma (NPC)</a>. <i>(Based on CAPTAIN-1st)</i>","2024-02-01"
"Cangrelor","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Capecitabine","EMA","1998-04-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-04-30: EURD","2023-07-31"
"Capecitabine","EMA","2001-02-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-02-02: Initial market authorization as Xeloda.","2023-05-08"
"Capecitabine","FDA","1998-04-30","Breast cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","(Paclitaxel AND Anthracycline-based regimen) OR (Paclitaxel AND Contraindication to Anthracycline)","FALSE","","","","","","","",TRUE,"SO14697","1998-04-30: Initial accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> resistant to both <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> and an <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing chemotherapy regimen</a> or resistant to <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m^2 of <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a> or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing adjuvant regimen</a>. <i>(Based on SO14697)</i>","2022-09-05"
"Capecitabine","FDA","2001-04-30","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","","",TRUE,"SO14695","2001-04-30: New indication as first-line treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer""> colorectal carcinoma</a> when treatment with <a href=""/wiki/Category:Fluoropyrimidines"" title=""Category:Fluoropyrimidines"">fluoropyrimidine</a> therapy alone is preferred. <i>(Based on SO14695 and SO14796)</i>","2022-09-05"
"Capecitabine","FDA","2001-09-07","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Anthracycline-based regimen","FALSE","","failure","","","Docetaxel","","",TRUE,"SO14999","2001-09-07: Converted to regular approval in combination with <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)""> docetaxel</a> is indicated for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> after failure of prior <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline containing chemotherapy</a>. <i>(Based on SO14999)</i>","2022-09-05"
"Capecitabine","FDA","2005-06-15","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Dukes' C","","","","Surgery","FALSE","","complete resection","","","0","","",TRUE,"X-ACT","2005-06-15: New indication as a single agent for adjuvant treatment in patients with Dukes' C <a href=""/wiki/Colon_cancer"" title=""Colon cancer""> colon cancer</a> who have undergone complete resection of the primary tumor when treatment with <a href=""/wiki/Category:Fluoropyrimidines"" title=""Category:Fluoropyrimidines"">fluoropyrimidine</a> therapy alone is preferred. <i>(Based on X-ACT)</i>","2022-09-05"
"Capecitabine","FDA","2022-12-14","Pancreatic cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","adults","","Surgery","FALSE","","","","","chemotherapy","","",TRUE,"ESPAC-4","2022-12-14: Project Renewal new indication for adjuvant treatment of adults with <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a> as a component of a combination chemotherapy regimen. <i>(Based on ESPAC-4)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Esophageal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Chemotherapy","","",TRUE,"REAL-2","2022-12-14: Project Renewal new indication for treatment of adults with unresectable or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a>, <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal</a>, or <a href=""/w/index.php?title=Gastroesophageal_junction_cancerandaction=editandredlink=1"" class=""new"" title=""Gastroesophageal junction cancer (page does not exist)"">gastroesophageal junction cancer</a> as a component of a combination chemotherapy regimen. <i>(Based on REAL-2)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Chemotherapy","","",TRUE,"REAL-2","2022-12-14: Project Renewal new indication for treatment of adults with unresectable or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a>, <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal</a>, or <a href=""/w/index.php?title=Gastroesophageal_junction_cancerandaction=editandredlink=1"" class=""new"" title=""Gastroesophageal junction cancer (page does not exist)"">gastroesophageal junction cancer</a> as a component of a combination chemotherapy regimen. <i>(Based on REAL-2)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Rectal cancer",FALSE,FALSE,FALSE,"","Perioperative","Locally advanced","","adults","","",NA,"","","","","chemoradiotherapy","","",TRUE,"Rektum-III","2022-12-14: Project Renewal new indication as perioperative treatment of adults with locally advanced <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectal cancer</a> as a component of chemoradiotherapy. <i>(Based on Rektum-III)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","0","FALSE","Metastatic","","","","SACT","HER2+","FALSE",TRUE,"ToGA","2022-12-14: Project Renewal new indication for treatment of adults with HER2-overexpressing metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or <a href=""/w/index.php?title=Gastroesophageal_junction_adenocarcinomaandaction=editandredlink=1"" class=""new"" title=""Gastroesophageal junction adenocarcinoma (page does not exist)"">gastroesophageal junction adenocarcinoma</a> who have not received prior treatment for metastatic disease as a component of a combination regimen. <i>(Based on ToGA)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","Anthracycline- or taxane-containing chemotherapy not indicated","",NA,"","","","","0","","",TRUE,"SO14697","2022-12-14: Project Renewal revision for treatment of patients with advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. <i>(Based on SO14697)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","chemotherapy","","",TRUE,"NO16966","2022-12-14: Project Renewal new indication as treatment of patients with unresectable or metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> as a component of a combination chemotherapy regimen. <i>(Based on NO16966)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","0","","",TRUE,"SO14695","2022-12-14: Project Renewal revision as treatment of patients with unresectable or metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> as a single agent. <i>(Based on SO14695 and SO14796)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","0","","",TRUE,"SO14796","2022-12-14: Project Renewal revision as treatment of patients with unresectable or metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> as a single agent. <i>(Based on SO14695 and SO14796)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Anthracycline-based regimen","FALSE","","progression","","","Docetaxel","","",TRUE,"SO14999","2022-12-14: Project Renewal revision for treatment of patients with advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. <i>(Based on SO14999)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage III","","","","",NA,"","","","","0","","",TRUE,"X-ACT","2022-12-14: Project Renewal revision as adjuvant treatment of patients with Stage III <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a> as a single agent. <i>(Based on X-ACT)</i>","2023-03-10"
"Capecitabine","FDA","2022-12-14","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage III","","","","Surgery","FALSE","","","","","chemotherapy","","",TRUE,"XELOXA","2022-12-14: Project Renewal new indication as adjuvant treatment of patients with Stage III <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a> as a component of a combination chemotherapy regimen. <i>(Based on XELOXA)</i>","2023-03-10"
"Capecitabine","HC","1998-08-31","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-08-31: Initial notice of compliance","2023-07-31"
"Capecitabine","HC","2000-07-17","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","0","","",NA,"","2000-07-17: Indicated as monotherapy for the first-line treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-07-31"
"Capecitabine","HC","2001-12-28","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Anthracycline-based regimen","FALSE","","failure","","","Docetaxel","","",NA,"","2001-12-28: New indication in combination with docetaxel for the treatment of patients with advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> after failure of prior anthracycline containing chemotherapy.","2023-07-31"
"Capecitabine","HC","2005-12-07","Colon cancer",TRUE,FALSE,FALSE,"","Adjuvant","Stage III (Dukes' stage C)","","","","",NA,"","","","","0","","",NA,"","2005-12-07: Indicated with conditions as monotherapy for the adjuvant treatment of patients with stage III (Dukes' stage C) <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>.","2023-07-31"
"Capecitabine","HC","2008-10-23","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage III (Dukes' stage C)","","","","",NA,"","","","","0","","",NA,"","2008-10-23: Conditions were met as monotherapy for the adjuvant treatment of patients with stage III (Dukes' stage C) <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>.","2023-07-31"
"Capecitabine","HC","2009-12-03","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Irinotecan-based regimen","FALSE","","failure","","","Oxaliplatin","","",NA,"","2009-12-03: In combination with oxaliplatin is indicated for the treatment of metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> following failure of irinotecan-containing combination chemotherapy.","2023-07-31"
"Capecitabine","HC","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Anthracycline-based regimen","FALSE","","failure","","","Docetaxel","","",NA,"","Uncertain date: Indicated in combination with docetaxel for the treatment of patients with advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> after failure of prior anthracycline containing chemotherapy.","2023-07-31"
"Capecitabine","HC","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Standard therapy including a taxane, unless therapy with a taxane is clinically contraindicated","FALSE","","failure","","","0","","",NA,"","Uncertain date: Indicated as monotherapy for the treatment of advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> after failure of standard therapy including a taxane, unless therapy with a taxane is clinically contraindicated.","2023-07-31"
"Capecitabine","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Capecitabine","PMDA","2007-12-12","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2007-12-12: New indication and dosage for use as a postoperative adjuvant chemotherapy of <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>.","2023-06-16"
"Capecitabine","PMDA","2009-09-18","Colorectal cancer",FALSE,FALSE,FALSE,"","","Advanced or Recurrent","","","Not suited for curative resection","",NA,"","","","","CapeOx","","",NA,"","2009-09-18: New additional indication for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> not suited for curative resection.","2023-06-16"
"Capecitabine","PMDA","2011-02-23","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2011-02-23: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Capecitabine","PMDA","2015-11-20","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-11-20: Revised indication for the treatment of <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Capecitabine","PMDA","2016-08-26","Rectal cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2016-08-26: New additional indication and a new dosage for adjuvant chemotherapy for <a href=""/wiki/Rectal_cancer"" title=""Rectal cancer"">rectal cancer</a>.","2023-06-16"
"Capivasertib","FDA","2023-11-16","Breast cancer",FALSE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","Endocrine-based regimen",NA,"Metastatic","progression","","","Fulvestrant","HR+ AND HER2- AND PIK3CA/AKT1/PTEN-alterations","",TRUE,"CAPItello-291","2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting. <i>(Based on CAPItello-291)</i>","2024-01-06"
"Capivasertib","FDA","2023-11-16","Breast cancer",FALSE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","Therapy",NA,"Adjuvant","recurrence","on or within 12 months of completion","","Fulvestrant","HR+ AND HER2- AND PIK3CA/AKT1/PTEN-alterations","",TRUE,"CAPItello-291","2023-11-16: Approved with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following recurrence on or within 12 months of completing adjuvant therapy. <i>(Based on CAPItello-291)</i>","2024-01-06"
"Caplacizumab","EMA","2018-08-30","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-08-30: Initial authorization","2023-05-08"
"Caplacizumab","FDA","2019-02-06","Acquired thrombotic thrombocytopenic purpura",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Plasma exchange AND Immunosuppressive therapy","","",NA,"","2019-02-06: Initial approval for adult patients with <a href=""/wiki/Acquired_thrombotic_thrombocytopenic_purpura"" title=""Acquired thrombotic thrombocytopenic purpura"">acquired thrombotic thrombocytopenic purpura (aTTP)</a>, in combination with plasma exchange and immunosuppressive therapy.","2022-09-05"
"Caplacizumab","PMDA","2022-09-26","Acquired thrombotic thrombocytopenic purpura",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-09-26: A drug with a new active ingredient indicated for the treatment of <a href=""/wiki/Acquired_thrombotic_thrombocytopenic_purpura"" title=""Acquired thrombotic thrombocytopenic purpura"">acquired thrombotic thrombocytopenic purpura</a>.","2023-06-16"
"Capmatinib","EMA","2022-06-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"Immunotherapy|Platinum-based chemotherapy","","","","0","MET exon 14 skipping alteration","FALSE",TRUE,"GEOMETRY mono-1","2022-06-20: Initial authorization as Tabrecta. Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. <i>(Based on GEOMETRY mono-1)</i>","2023-09-17"
"Capmatinib","FDA","2020-05-06","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",TRUE,"GEOMETRY mono-1","2020-05-06: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer"">FDA accelerated approval</a> for the treatment of adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have a mutation that leads to <a href=""/wiki/Biomarkers#MET"" title=""Biomarkers"">mesenchymal-epithelial transition (MET)</a> <a href=""/wiki/Biomarkers#Exon_14"" title=""Biomarkers"">exon 14</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">skipping</a> as detected by an FDA-approved test. <i>(Based on GEOMETRY mono-1)</i>","2022-09-05"
"Capmatinib","FDA","2022-08-10","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",TRUE,"GEOMETRY mono-1","2022-08-10: Regular approval for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have a mutation leading to <a href=""/wiki/Biomarkers#MET"" title=""Biomarkers"">mesenchymal-epithelial transition (MET)</a> <a href=""/wiki/Biomarkers#Exon_14"" title=""Biomarkers"">exon 14</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">skipping</a>. <i>(Based on GEOMETRY mono-1)</i>","2022-09-05"
"Capmatinib","HC","2022-05-26","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",NA,"","2022-05-26: Initial notice of compliance with conditions for the treatment of adult patients with locally advanced unresectable or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.","2023-05-08"
"Capmatinib","PMDA","2020-06-29","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",NA,"","2020-06-29: Newly indicated for the treatment of unresectable advanced or recurrent MET exon 14 (METex14) skipping mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Carboplatin","EMA","1986-01-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1986-01-23: EURD","2023-07-31"
"Carboplatin","FDA","1989-03-03","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","1+, including Cisplatin","FALSE","","","","","","","",TRUE,"Swenerton et al. 1992","1989-03-03: Initial approval as palliative treatment of patients with <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian carcinoma</a> recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. <i>(Based on SWOG 8412 and Swenerton et al. 1992)</i>","2022-09-05"
"Carboplatin","FDA","1989-03-03","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","1+, including Cisplatin","FALSE","","","","","","","",TRUE,"SWOG 8412","1989-03-03: Initial approval as palliative treatment of patients with <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian carcinoma</a> recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. <i>(Based on SWOG 8412 and Swenerton et al. 1992)</i>","2022-09-05"
"Carboplatin","PMDA","2011-11-25","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-11-25: New additional indication and new dosages for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Carfilzomib","EMA","2015-11-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",TRUE,"ASPIRE","2015-11-19: Initial authorization as Kyprolis in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy. <i>(Based on ASPIRE)</i>","2023-05-08"
"Carfilzomib","EMA","2016-06-29","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"1+","","","","(Lenalidomide AND Dexamethasone) OR Dexamethasone","","",NA,"","2016-06-29: Extension of Indication to include new indication for Kyprolis to be used with either lenalidomide and dexamethasone or dexamethasone alone for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy.","2024-06-03"
"Carfilzomib","EMA","2020-12-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-12-17: Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone.","2024-06-03"
"Carfilzomib","FDA","2012-07-20","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","","","2+, including Bortezomib AND Immunomodulator","FALSE","","progression","within 60 days of completion of the last therapy","","","","",TRUE,"PX-171-003-A1","2012-07-20: Received accelerated approval for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least two prior therapies including <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> and an <a href=""/wiki/Category:Immunomodulatory_drugs_(IMiDs)"" title=""Category:Immunomodulatory drugs (IMiDs)"">immunomodulatory agent</a> and have demonstrated disease progression on or within 60 days of completion of the last therapy. <i>(Based on PX-171-003-A1)</i>","2022-09-05"
"Carfilzomib","FDA","2015-07-24","Multiple myeloma",TRUE,FALSE,FALSE,"","Relapsed","","","","","1 to 3","FALSE","","","","","Lenalidomide AND Dexamethasone","","",TRUE,"ASPIRE","2015-07-24: Accelerated approval in combination with <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)"">lenalidomide</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a> for the treatment of patients with relapsed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three prior lines of therapy. <i>(Based on ASPIRE)</i>","2022-09-05"
"Carfilzomib","FDA","2016-01-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","1 to 3","FALSE","","","","","Dexamethasone OR (Lenalidomide AND Dexamethasone)","","",TRUE,"ARROW_MM","2016-01-21: Full approval in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three lines of therapy. <i>(Based on ENDEAVOR and ARROW_MM)</i>","2022-09-05"
"Carfilzomib","FDA","2016-01-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","1 to 3","FALSE","","","","","Dexamethasone OR (Lenalidomide AND Dexamethasone)","","",TRUE,"ENDEAVOR","2016-01-21: Full approval in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three lines of therapy. <i>(Based on ENDEAVOR and ARROW_MM)</i>","2022-09-05"
"Carfilzomib","FDA","2016-01-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","1+","FALSE","","","","","0","","",TRUE,"PX-171-004 bortezomib-naive","2016-01-21: Full approval as a single agent for the treatment of patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one or more lines of therapy. <i>(Based on PX-171-004 bortezomib-naive and PX-171-007)</i>","2022-09-05"
"Carfilzomib","FDA","2016-01-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","1+","FALSE","","","","","0","","",TRUE,"PX-171-007","2016-01-21: Full approval as a single agent for the treatment of patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one or more lines of therapy. <i>(Based on PX-171-004 bortezomib-naive and PX-171-007)</i>","2022-09-05"
"Carfilzomib","FDA","2020-08-20","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1 to 3","FALSE","","","","","Daratumumab AND Dexamethasone","","",TRUE,"CANDOR","2020-08-20: Approved in combination with <a href=""/wiki/Daratumumab_(Darzalex)"" title=""Daratumumab (Darzalex)"">daratumumab</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a> for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three lines of therapy. <i>(Based on CANDOR and EQUULEUS_cfz)</i>","2022-09-05"
"Carfilzomib","FDA","2020-08-20","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1 to 3","FALSE","","","","","Daratumumab AND Dexamethasone","","",TRUE,"EQUULEUS_cfz","2020-08-20: Approved in combination with <a href=""/wiki/Daratumumab_(Darzalex)"" title=""Daratumumab (Darzalex)"">daratumumab</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a> for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three lines of therapy. <i>(Based on CANDOR and EQUULEUS_cfz)</i>","2022-09-05"
"Carfilzomib","HC","2016-01-15","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-01-15: Initial notice of compliance","2023-06-15"
"Carfilzomib","PMDA","2016-07-04","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2016-07-04: New approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Carmustine","EMA","1974-04-23","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1974-04-23: EURD","2023-07-31"
"Carmustine","FDA","1977-03-07","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1977-03-07: Initial FDA approval","2022-09-05"
"Carmustine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","other approved anticancer drugs","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's Disease</a> as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. <i>(No supporting studies are cited)</i>","2023-05-20"
"Carmustine","FDA","Uncertain date","CNS cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. <i>(No supporting studies are cited)</i>","2023-05-20"
"Carmustine","FDA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","Palliative","","","","","",NA,"","","","","Prednisone","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in combination with prednisone. <i>(No supporting studies are cited)</i>","2023-05-20"
"Carmustine","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","other approved anticancer drugs","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">Non-Hodgkin's lymphomas</a> as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. <i>(No supporting studies are cited)</i>","2023-05-20"
"Carmustine","FDA","Uncertain date","CNS cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, brainstem glioma, <a href=""/wiki/Medulloblastoma"" title=""Medulloblastoma"">medulloblastoma</a>, <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">astrocytoma</a>, <a href=""/w/index.php?title=Ependymomaandaction=editandredlink=1"" class=""new"" title=""Ependymoma (page does not exist)"">ependymoma</a>, and <a href=""/wiki/CNS_carcinoma"" title=""CNS carcinoma"">metastatic brain tumors</a>. <i>(No supporting studies are cited)</i>","2024-12-02"
"Carmustine","FDA","Uncertain date","Glioblastoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, brainstem glioma, <a href=""/wiki/Medulloblastoma"" title=""Medulloblastoma"">medulloblastoma</a>, <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">astrocytoma</a>, <a href=""/w/index.php?title=Ependymomaandaction=editandredlink=1"" class=""new"" title=""Ependymoma (page does not exist)"">ependymoma</a>, and <a href=""/wiki/CNS_carcinoma"" title=""CNS carcinoma"">metastatic brain tumors</a>. <i>(No supporting studies are cited)</i>","2024-12-02"
"Carmustine","FDA","Uncertain date","Medulloblastoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, brainstem glioma, <a href=""/wiki/Medulloblastoma"" title=""Medulloblastoma"">medulloblastoma</a>, <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">astrocytoma</a>, <a href=""/w/index.php?title=Ependymomaandaction=editandredlink=1"" class=""new"" title=""Ependymoma (page does not exist)"">ependymoma</a>, and <a href=""/wiki/CNS_carcinoma"" title=""CNS carcinoma"">metastatic brain tumors</a>. <i>(No supporting studies are cited)</i>","2024-12-02"
"Carmustine","FDA","Uncertain date","Anaplastic glioma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, brainstem glioma, <a href=""/wiki/Medulloblastoma"" title=""Medulloblastoma"">medulloblastoma</a>, <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">astrocytoma</a>, <a href=""/w/index.php?title=Ependymomaandaction=editandredlink=1"" class=""new"" title=""Ependymoma (page does not exist)"">ependymoma</a>, and <a href=""/wiki/CNS_carcinoma"" title=""CNS carcinoma"">metastatic brain tumors</a>. <i>(No supporting studies are cited)</i>","2024-12-02"
"Carmustine","FDA","Uncertain date","CNS carcinoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a>: <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma</a>, brainstem glioma, <a href=""/wiki/Medulloblastoma"" title=""Medulloblastoma"">medulloblastoma</a>, <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">astrocytoma</a>, <a href=""/w/index.php?title=Ependymomaandaction=editandredlink=1"" class=""new"" title=""Ependymoma (page does not exist)"">ependymoma</a>, and <a href=""/wiki/CNS_carcinoma"" title=""CNS carcinoma"">metastatic brain tumors</a>. <i>(No supporting studies are cited)</i>","2024-12-02"
"Carmustine wafer polifeprosan 20","EMA","1996-09-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-09-23: EURD","2023-07-31"
"Carmustine wafer polifeprosan 20","FDA","1996-09-23","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1996-09-23: Initial FDA approval","2022-09-05"
"Carmustine wafer polifeprosan 20","FDA","Uncertain date","Glioblastoma",FALSE,FALSE,FALSE,"","Recurrent","","","","","",NA,"Surgery","","","","","","",NA,"","2003-02-25 (oldest label available at Drugs @ FDA): indicated for recurrent <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma multiforme</a> patients as an adjunct to surgery","2023-05-20"
"Carmustine wafer polifeprosan 20","FDA","Uncertain date","High-grade glioma",FALSE,FALSE,FALSE,"","First-line","","","","","",NA,"Surgery AND Radiotherapy","","","","","","",NA,"","2003-02-25 (oldest label available at Drugs @ FDA): indicated for newly diagnosed <a href=""/wiki/Category:High-grade_gliomas"" title=""Category:High-grade gliomas"">high-grade malignant glioma</a> patients as an adjunct to surgery and radiation","2023-05-20"
"Carmustine wafer polifeprosan 20","PMDA","2012-09-28","High-grade glioma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-09-28: Initial approval for the treatment of <a href=""/wiki/Category:High-grade_gliomas"" title=""Category:High-grade gliomas"">malignant glioma</a>.","2023-06-16"
"Caspofungin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Catumaxomab","EMA","2009-04-20","Carcinoma",FALSE,FALSE,TRUE,"","","","","adults","standard therapy available or feasible","",NA,"","","","","","EpCAM+","",NA,"","2009-04-20: Initial authorization for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.","2023-05-08"
"Catumaxomab","EMA","2017-06-02","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2017-06-02: Approval withdrawn at request of the manufacturer, for commercial reasons","2023-05-08"
"Cefixime","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Celecoxib","FDA","1998-12-31","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-12-31: Initial approval","2023-07-31"
"Cemiplimab","EMA","2019-06-28","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-06-28: Initial conditional authorization as Libtayo.","2023-11-07"
"Cemiplimab","EMA","2023-05-27","Cervical cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","adults","","Platinum-based regimen",NA,"","progression","","","0","","",TRUE,"EMPOWER-Cervical 1","2023-05-27: LIBTAYO as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> and disease progression on or after platinum-based chemotherapy. <i>(Based on EMPOWER-Cervical 1)</i>","2023-09-17"
"Cemiplimab","EMA","2023-05-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Platinum-based regimen","PD-L1 TPS at least 1% and No (EGFR OR ALK OR ROS1 aberrations)","",NA,"","2023-05-27: LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> expressing PD-L1 (in at least 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have metastatic NSCLC.","2023-09-17"
"Cemiplimab","EMA","2023-05-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced","","adults","not candidates for definitive chemoradiation","",NA,"","","","","Platinum-based regimen","PD-L1 TPS at least 1% and No (EGFR OR ALK OR ROS1 aberrations)","",NA,"","2023-05-27: LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> expressing PD-L1 (in at least 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation.","2023-09-17"
"Cemiplimab","FDA","2018-09-28","Cutaneous squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","","not candidate for curative surgery or curative radiation","",NA,"","","","","","","",TRUE,"R2810-ONC-1423","2018-09-28: Approved for patients with locally advanced <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">CSCC</a> who are not candidates for curative surgery or curative radiation. <i>(Based on R2810-ONC-1423 and R2810-ONC-1540)</i>","2022-11-22"
"Cemiplimab","FDA","2018-09-28","Cutaneous squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","","not candidate for curative surgery or curative radiation","",NA,"","","","","","","",TRUE,"R2810-ONC-1540","2018-09-28: Approved for patients with locally advanced <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">CSCC</a> who are not candidates for curative surgery or curative radiation. <i>(Based on R2810-ONC-1423 and R2810-ONC-1540)</i>","2022-11-22"
"Cemiplimab","FDA","2018-09-28","Cutaneous squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"R2810-ONC-1423","2018-09-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0"">Approved</a> for patients with metastatic <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">cutaneous squamous cell carcinoma (CSCC)</a>. <i>(Based on R2810-ONC-1423 and R2810-ONC-1540)</i>","2022-11-22"
"Cemiplimab","FDA","2018-09-28","Cutaneous squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"R2810-ONC-1540","2018-09-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0"">Approved</a> for patients with metastatic <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">cutaneous squamous cell carcinoma (CSCC)</a>. <i>(Based on R2810-ONC-1423 and R2810-ONC-1540)</i>","2022-11-22"
"Cemiplimab","FDA","2021-02-09","Cutaneous basal cell carcinoma",TRUE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Hedgehog pathway inhibitor or Contraindication to Hedgehog pathway inhibitor","","",TRUE,"R2810-ONC-1620","2021-02-09: Accelerated approval for patients with metastatic <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">BCC</a> (mBCC) previously treated with a HHI or for whom a HHI is not appropriate. <i>(New disease entity; based on R2810-ONC-1620)</i>","2022-09-05"
"Cemiplimab","FDA","2021-02-09","Cutaneous basal cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","","","",NA,"","","","","Hedgehog pathway inhibitor or Contraindication to Hedgehog pathway inhibitor","","",TRUE,"R2810-ONC-1620","2021-02-09: Approved for patients with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma</a> (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate. <i>(New disease entity; based on R2810-ONC-1620)</i>","2022-09-05"
"Cemiplimab","FDA","2021-02-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","","PD-L1 TPS at least 50% and No (EGFR OR ALK OR ROS1 aberrations)","FALSE",TRUE,"EMPOWER-Lung 1","2021-02-22: Approved for the first-line treatment of patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expression</a> (Tumor Proportion Score [TPS] &gt; 50%) as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations. <i>(New disease entity; based on EMPOWER-Lung 1)</i>","2022-11-22"
"Cemiplimab","FDA","2022-11-08","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"","","","","Platinum-based regimen","No (EGFR OR ALK OR ROS1 aberrations)","TRUE",TRUE,"EMPOWER-Lung 3 part 2","2022-11-08: Approved in combination with platinum-based chemotherapy for adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with no EGFR, ALK, or ROS1 aberrations. <i>(Based on EMPOWER-Lung 3 part 2)</i>","2022-11-22"
"Cemiplimab","HC","2019-04-10","Cutaneous squamous cell carcinoma",TRUE,FALSE,FALSE,"","not candidate for curative surgery or curative radiation","Locally advanced OR Metastatic","","adults","","",NA,"","","","","","","",NA,"","2019-04-10: Initial notice of compliance with conditions for the treatment of adult patients with metastatic or locally advanced <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">cutaneous squamous cell carcinoma</a> who are not candidates for curative surgery or curative radiation.","2023-05-08"
"Cemiplimab","PMDA","2022-12-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-12-23: Initial approval","2023-06-15"
"Cephalexin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ceritinib","EMA","2015-05-06","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-05-06: Initial marketing authorization as Zykadia.","2023-05-08"
"Ceritinib","FDA","2014-04-29","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","","","","","Crizotinib","FALSE","","","","","","ALK rearrangement","FALSE",TRUE,"ASCEND-1","2014-04-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://web.archive.org/web/20170213201352/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm"">Accelerated approval</a> for the treatment of patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or are intolerant to <a href=""/wiki/Crizotinib_(Xalkori)"" title=""Crizotinib (Xalkori)""> crizotinib</a>. <i>(Based on ASCEND-1)</i>","2022-09-05"
"Ceritinib","FDA","2017-05-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"ASCEND-4","2017-05-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm"">Granted regular FDA approval</a> for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> as detected by an FDA-approved test. <i>(Based on ASCEND-4)</i>","2022-09-05"
"Ceritinib","HC","2015-03-27","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Crizotinib","FALSE","","Progression OR Intolerance","","","0","ALK rearranged","FALSE",NA,"","2015-03-27: Initial notice of compliance with conditions as monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have progressed on or who were intolerant to crizotinib.","2023-05-08"
"Ceritinib","HC","2018-06-06","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","0","FALSE","","","","","","","",NA,"","2018-06-06: New indication for previously untreated adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-05-08"
"Ceritinib","PMDA","2016-03-28","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Crizotinib","FALSE","","Resistance OR Intolerance","","","","ALK rearrangement","FALSE",NA,"","2016-03-28: Initial approval for the treatment of unresectable advanced/relapsed anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with resistance or intolerance to crizotinib.","2023-06-16"
"Ceritinib","PMDA","2017-09-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2017-09-22: Revised indication for the treatment of unresectable advanced/relapsed ALK fusion gene-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Cetirizine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cetuximab","EMA","2004-06-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-06-29: Initial authorization","2023-05-08"
"Cetuximab","FDA","2004-02-12","Colorectal cancer",TRUE,FALSE,TRUE,"","","Metastatic","","","","Irinotecan-based regimen","FALSE","","","","","0","EGFR+","FALSE",TRUE,"BOND","2004-02-12: Initial accelerated FDA approval as a single agent for the treatment of <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a>, metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma</a> in patients who are intolerant to <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-based chemotherapy</a>. <i>(Based on BOND)</i>","2022-09-05"
"Cetuximab","FDA","2004-02-12","Colorectal cancer",TRUE,FALSE,TRUE,"","","Metastatic","","","","Irinotecan-based regimen","FALSE","","","","","Irinotecan","EGFR+","FALSE",TRUE,"Saltz et al. 2004","2004-02-12: Initial accelerated FDA approval in combination with <a href=""/wiki/Irinotecan_(Camptosar)"" title=""Irinotecan (Camptosar)""> irinotecan</a> for the treatment of <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a>, metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma</a> in patients who are refractory to <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-based chemotherapy</a>. <i>(Based on Saltz et al. 2004)</i>","2022-09-05"
"Cetuximab","FDA","2006-03-01","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","0","","",TRUE,"EMR 62202-016","2006-03-01: Indication expanded as a single agent for the treatment of patients with recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> for whom prior <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based therapy</a> has failed. <i>(Based on EMR 62202-016)</i>","2022-09-05"
"Cetuximab","FDA","2006-03-01","Head and neck cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Regionally advanced","","","","",NA,"","","","","Radiotherapy","","",TRUE,"IMCL-9815","2006-03-01: Indication expanded in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a>. <i>(New disease entity; based on IMCL-9815)</i>","2022-09-05"
"Cetuximab","FDA","2007-10-02","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Irinotecan-based regimen AND Oxaliplatin-based regimen","FALSE","","failure","","","","EGFR+","FALSE",TRUE,"NCIC-CTG CO.17","2007-10-02: Granted regular approval for the treatment of patients with <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a> metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) after failure of both <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-</a> and <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin-based</a> chemotherapy regimens. <i>(Approval changed from accelerated to regular; based on NCIC-CTG CO.17)</i>","2022-09-05"
"Cetuximab","FDA","2011-11-07","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent locoregional OR Metastatic","","","","",NA,"","","","","Platinum agent AND Fluorouracil","","",TRUE,"EXTREME","2011-11-07: Indication changed for the treatment of recurrent locoregional disease or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a> in combination with <a href=""/wiki/Category:Platinum_agents"" title=""Category:Platinum agents"">platinum</a>-based therapy with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">5-FU</a>. <i>(Based on EXTREME)</i>","2022-09-05"
"Cetuximab","FDA","2011-11-07","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-11-07: Retrospective subset analyses of metastatic or advanced colorectal cancer trials have not shown a treatment benefit for Erbitux in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Erbitux is not recommended for the treatment of colorectal cancer with these mutations. <i>(New recommendation dependent on KRAS mutant status)</i>","2022-09-05"
"Cetuximab","FDA","2012-07-06","Colon cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","FOLFIRI","KRAS and EGFR+","TRUE AND FALSE",TRUE,"CRYSTAL","2012-07-06: FDA indication changed for the treatment of <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">K-Ras</a> mutation-negative (<a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a>), <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a>, metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> as determined by FDA-approved test, <a href=""/wiki/Colon_cancer#FOLFIRI_&_Cetuximab"" title=""Colon cancer"">in combination with FOLFIRI</a> for first-line treatment."" <i>(New requirement dependent on KRAS mutant status; based on CRYSTAL)</i>","2022-09-05"
"Cetuximab","FDA","2012-07-06","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","FOLFIRI","KRAS and EGFR+","TRUE AND FALSE",TRUE,"CRYSTAL","2012-07-06: FDA indication changed for the treatment of <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">K-Ras</a> mutation-negative (<a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a>), <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">expressing</a>, metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> as determined by FDA-approved test, <a href=""/wiki/Colon_cancer#FOLFIRI_&_Cetuximab"" title=""Colon cancer"">in combination with FOLFIRI</a> for first-line treatment."" <i>(New requirement dependent on KRAS mutant status; based on CRYSTAL)</i>","2022-09-05"
"Cetuximab","FDA","2021-09-24","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","Encorafenib","BRAF p.V600E","FALSE",TRUE,"BEACON CRC","2021-09-24: Approved in combination with encorafenib for the treatment of adult patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a>. <i>(Based on BEACON CRC)</i>","2022-09-05"
"Cetuximab","HC","2005-09-09","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"Irinotecan-based regimen","Intolerance","","","0","EGFR+","FALSE",NA,"","2005-09-09: Initial notice of compliance administered as a single agent, is indicated for the treatment of EGFR-expressing metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma</a> in patients who are intolerant to irinotecan-based chemotherapy.","2023-05-20"
"Cetuximab","HC","2005-09-09","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"Other Irinotecan-based regimen","Refractory","","","Irinotecan","EGFR+","FALSE",NA,"","2005-09-09: Initial notice of compliance in combination with a chemotherapy medicine, irinotecan, is indicated for the treatment of EGFR-expressing metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma (CRC)</a> in patients who are refractory to other irinotecan-based chemotherapy regimens.","2023-05-20"
"Cetuximab","HC","2008-09-11","Head and neck cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Regionally advanced","","","","",NA,"","","","","Radiotherapy","","",NA,"","2008-09-11: New indication in combination with radiation therapy for the initial treatment of locally or regionally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a>.","2023-05-20"
"Cetuximab","HC","2010-02-03","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-02-03: New indication (unknown details)","2023-05-20"
"Cetuximab","HC","2012-12-20","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","FOLFIRI","EGFR+ AND KRAS","FALSE AND TRUE",NA,"","2012-12-20: New indication for the treatment of EGFR-expressing K-ras wild-type metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma</a> (mCRC) in combination with FOLFIRI (irinoteca, 5-fluorouracil, leucovorin) for first-line treatment.","2023-05-20"
"Cetuximab","PMDA","2008-07-16","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","EGFR+","FALSE",NA,"","2008-07-16: Initial approval for the treatment of EGFR-expressing, unresectable and advanced/recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinomas</a>.","2023-06-16"
"Cetuximab","PMDA","2012-12-21","Head and neck cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-12-21: New additional indication for the treatment of <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>.","2023-06-16"
"Cetuximab","PMDA","2019-09-20","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","RAS","TRUE",NA,"","2019-09-20: New indication for the treatment of unresectable, advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colon or rectal cancer</a> with wild-type RAS.","2023-06-16"
"Chidamide","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Chidamide","PMDA","2021-06-23","Adult T-cell leukemia-lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-06-23: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Adult_T-cell_leukemia-lymphoma"" title=""Adult T-cell leukemia-lymphoma"">adult T-cell leukemia-lymphoma</a>.","2023-06-16"
"Chidamide","PMDA","2021-11-25","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-11-25: New indication for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>.","2023-06-16"
"Chlorambucil","EMA","1956-09-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1956-09-14: EURD","2023-07-31"
"Chlorambucil","FDA","1957-03-18","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1957-03-18: Initial FDA approval","2022-09-05"
"Chlorambucil","FDA","Uncertain date","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-11-13 (oldest label available at Drugs @ FDA): indicated in the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphatic (lymphocytic) leukemia</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease</a>. It is not curative in any of these disorders but may produce clinically useful palliation. <i>(No supporting studies are cited)</i>","2023-05-08"
"Chlorambucil","FDA","Uncertain date","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-11-13 (oldest label available at Drugs @ FDA): indicated in the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphatic (lymphocytic) leukemia</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease</a>. It is not curative in any of these disorders but may produce clinically useful palliation. <i>(No supporting studies are cited)</i>","2023-05-08"
"Chlorpheniramine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cilostazol","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ciltacabtagene autoleucel","EMA","2022-05-25","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-05-25: Initial conditional authorization","2023-05-08"
"Ciltacabtagene autoleucel","FDA","2022-02-28","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","4+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","","","","","","",TRUE,"CARTITUDE-1","2022-02-28: Approved for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. <i>(Based on CARTITUDE-1)</i>","2022-09-05"
"Ciltacabtagene autoleucel","HC","2023-02-09","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","adults","","3+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","Refractory","","","","","","",NA,"","2023-02-09: Initial notice of compliance with conditions for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.","2023-05-08"
"Ciltacabtagene autoleucel","PMDA","2022-02-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-02-26: Initial approval","2023-06-15"
"Cimetidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ciprofloxacin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cisplatin","EMA","1978-12-19","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1978-12-19: EURD","2023-07-31"
"Cisplatin","FDA","1978-12-19","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1978-12-19: Initial FDA approval","2022-09-05"
"Cisplatin","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Approved surgery and/or radiotherapy","FALSE","","","","","other approved anticancer drugs","","",TRUE,"Wiernik et al. 1992a","2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian tumors</a> who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. <i>(Based on Wiernik et al. 1992a)</i>","2023-09-09"
"Cisplatin","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Standard therapy not including cisplatin","FALSE","","","","","0","","",TRUE,"Wiernik et al. 1992a","2010-09-02 (oldest label available at Drugs @ FDA): PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian tumors</a> refractory to standard chemotherapy who have not previously received PLATINOL therapy. <i>(Based on Wiernik et al. 1992a)</i>","2023-09-09"
"Cisplatin","FDA","Uncertain date","Bladder cancer",FALSE,FALSE,FALSE,"","","no longer amenable to local treatments","","","","",NA,"","","","","0","","",FALSE,"","2010-09-02 (oldest label available at Drugs @ FDA): Indicated as a single agent for patients with transitional cell <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">bladder cancer</a> which is no longer amenable to local treatments, such as surgery and/or radiotherapy. <i>(No supporting studies are cited)</i>","2023-05-08"
"Cisplatin","FDA","Uncertain date","Testicular cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"Surgery|Radiotherapy","","","","Chemotherapy","","",FALSE,"","2010-09-02 (oldest label available at Drugs @ FDA): Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular tumors</a> who have already received appropriate surgical and/or radiotherapeutic procedures. <i>(No supporting studies are cited)</i>","2023-05-08"
"Cisplatin","PMDA","2012-02-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-02-22: New additional indication and a new dosage for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer</a>.","2023-06-16"
"Cladribine","EMA","1993-02-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1993-02-26: EURD","2023-07-31"
"Cladribine","FDA","1993-02-26","Hairy cell leukemia",FALSE,FALSE,FALSE,"","","Active","","","","",NA,"","","","","","","",TRUE,"Saven et al. 1998","1993-02-26: Initial FDA approval for treatment of active <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a>. <i>(Based on Saven et al. 1998)</i>","2022-09-05"
"Clarithromycin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Clemastine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Clodronate","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Clofarabine","EMA","2006-05-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-05-29: Initial authorization as Evoltra","2023-05-08"
"Clofarabine","FDA","2004-12-28","Acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","Pediatric aged 1 to 21 years","","2+","FALSE","","","","","","","",TRUE,"CLO212","2004-12-28: Accelerated approval for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia</a> after at least two prior regimens. <i>(Based on Jeha et al. 2003 and CLO212)</i>","2022-09-05"
"Clofarabine","FDA","2004-12-28","Acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","Pediatric aged 1 to 21 years","","2+","FALSE","","","","","","","",TRUE,"Jeha et al. 2003","2004-12-28: Accelerated approval for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia</a> after at least two prior regimens. <i>(Based on Jeha et al. 2003 and CLO212)</i>","2022-09-05"
"Clofarabine","FDA","2022-07-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-07-18: Converted to regular approval","2023-05-08"
"Clofarabine","HC","2009-07-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-07-16: Initial notice of compliance","2023-07-31"
"Clofarabine","PMDA","2013-03-25","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2013-03-25: Initial approval for the treatment of recurrent or refractory <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia</a>.","2023-06-16"
"Clonazepam","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Clopidogrel","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cobimetinib","EMA","2015-11-20","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Vemurafenib","BRAF p.V600","FALSE",NA,"","2015-11-20: Initial authorization in combination with vemurafenib for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2023-05-08"
"Cobimetinib","FDA","2015-11-10","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Vemurafenib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"coBRIM","2015-11-10: Approved for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutation</a>, in combination with <a href=""/wiki/Vemurafenib_(Zelboraf)"" title=""Vemurafenib (Zelboraf)""> vemurafenib</a>. <i>(Based on coBRIM)</i>","2022-09-05"
"Cobimetinib","FDA","2022-11-01","Erdheim-Chester disease",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"MSK 15-216","2022-11-01: Approved for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include <a href=""/wiki/Erdheim-Chester_disease"" title=""Erdheim-Chester disease"">Erdheim-Chester disease</a>, <a href=""/wiki/Rosai-Dorfman-Destombes_disease"" title=""Rosai-Dorfman-Destombes disease"">Rosai-Dorfman disease</a>, and <a href=""/wiki/Langerhans_cell_histiocytosis"" title=""Langerhans cell histiocytosis"">Langerhans cell histiocytosis</a>. <i>(Based on MSK 15-216)</i>","2023-03-10"
"Cobimetinib","FDA","2022-11-01","Langerhans cell histiocytosis",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"MSK 15-216","2022-11-01: Approved for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include <a href=""/wiki/Erdheim-Chester_disease"" title=""Erdheim-Chester disease"">Erdheim-Chester disease</a>, <a href=""/wiki/Rosai-Dorfman-Destombes_disease"" title=""Rosai-Dorfman-Destombes disease"">Rosai-Dorfman disease</a>, and <a href=""/wiki/Langerhans_cell_histiocytosis"" title=""Langerhans cell histiocytosis"">Langerhans cell histiocytosis</a>. <i>(Based on MSK 15-216)</i>","2023-03-10"
"Cobimetinib","FDA","2022-11-01","Rosai-Dorfman-Destombes disease",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"MSK 15-216","2022-11-01: Approved for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include <a href=""/wiki/Erdheim-Chester_disease"" title=""Erdheim-Chester disease"">Erdheim-Chester disease</a>, <a href=""/wiki/Rosai-Dorfman-Destombes_disease"" title=""Rosai-Dorfman-Destombes disease"">Rosai-Dorfman disease</a>, and <a href=""/wiki/Langerhans_cell_histiocytosis"" title=""Langerhans cell histiocytosis"">Langerhans cell histiocytosis</a>. <i>(Based on MSK 15-216)</i>","2023-03-10"
"Cobimetinib","HC","2016-02-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-02-22: Initial notice of compliance","2023-05-08"
"Colchicine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Copanlisib","FDA","2017-09-14","Follicular lymphoma",TRUE,FALSE,FALSE,"","Relapsed","","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"CHRONOS-1","2017-09-14: Granted accelerated approval for the treatment of adult patients with relapsed <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> who have received at least two prior systemic therapies. <i>(Based on CHRONOS-1)</i>","2022-09-05"
"Copanlisib","FDA","2024-03-18","Follicular lymphoma",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"CHRONOS-4","2024-03-18: Accelerated approval for the treatment of adult patients with relapsed <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> who have received at least two prior systemic therapies withdrawn. <i>(Based on CHRONOS-4)</i>","2024-06-03"
"Cortisone","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Crizanlizumab","EMA","2020-10-28","Sickle cell anemia",TRUE,FALSE,FALSE,"","","","","adults AND pediatric patients 16 years and older","","",NA,"","","","","","","",TRUE,"SUSTAIN","2020-10-28: Initial conditional authorization for preventing painful crises in patients with <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell disease</a> aged 16 years and older. <i>(Based on SUSTAIN)</i>","2023-05-08"
"Crizanlizumab","FDA","2019-11-15","Sickle cell anemia",FALSE,FALSE,TRUE,"","","","","adults AND pediatric patients 16 years and older","","",NA,"","","","","","","",TRUE,"SUSTAIN","2019-11-15: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell disease</a>. <i>(Based on SUSTAIN)</i>","2022-09-05"
"Crizotinib","EMA","2012-10-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-10-23: Initial marketing authorization as Xalkori.","2023-05-08"
"Crizotinib","EMA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for first line treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non small cell lung cancer (NSCLC)</a>.","2024-12-02"
"Crizotinib","EMA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non small cell lung cancer (NSCLC)</a>.","2024-12-02"
"Crizotinib","EMA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for treatment of adults with ROS1 positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non small cell lung cancer (NSCLC)</a>.","2024-12-02"
"Crizotinib","EMA","Uncertain date","Anaplastic large cell lymphoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for treatment of paediatric patients (age 1 up to 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive <a href=""/wiki/Anaplastic_large_cell_lymphoma"" title=""Anaplastic large cell lymphoma"">anaplastic large cell lymphoma (ALCL)</a>.","2024-12-02"
"Crizotinib","EMA","Uncertain date","Inflammatory myofibroblastic tumor",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for treatment of paediatric patients (age 1 up to 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable <a href=""/wiki/Inflammatory_myofibroblastic_tumor"" title=""Inflammatory myofibroblastic tumor"">inflammatory myofibroblastic tumour (IMT)</a>.","2024-12-02"
"Crizotinib","FDA","2011-08-26","Non-small cell lung cancer",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"PROFILE 1001 ALK","2011-08-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm"">Initial accelerated approval</a> for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> that is <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Based on PROFILE 1001 ALK)</i>","2022-09-05"
"Crizotinib","FDA","2013-11-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"PROFILE 1005","2013-11-20: Converted to full approval for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Indication removed from locally advanced setting; based on PROFILE 1005, PROFILE 1007, PROFILE 1014)</i>","2022-09-05"
"Crizotinib","FDA","2013-11-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"PROFILE 1007","2013-11-20: Converted to full approval for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Indication removed from locally advanced setting; based on PROFILE 1005, PROFILE 1007, PROFILE 1014)</i>","2022-09-05"
"Crizotinib","FDA","2013-11-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"PROFILE 1014","2013-11-20: Converted to full approval for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Indication removed from locally advanced setting; based on PROFILE 1005, PROFILE 1007, PROFILE 1014)</i>","2022-09-05"
"Crizotinib","FDA","2016-03-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ROS1 rearrangement","FALSE",TRUE,"PROFILE 1001 ROS1","2016-03-11: Approved for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ROS1"" title=""Biomarkers"">ROS1</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(New mutation-specific indication; based on PROFILE 1001 ROS1)</i>","2022-09-05"
"Crizotinib","FDA","2021-01-14","Anaplastic large cell lymphoma pediatric",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","pediatric and young adults aged 1 year and older","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"COG ADVL0912","2021-01-14: Approved for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic <a href=""/wiki/Anaplastic_large_cell_lymphoma,_pediatric"" title=""Anaplastic large cell lymphoma, pediatric"">anaplastic large cell lymphoma (ALCL)</a> that is <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">ALK</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(New disease entity; based on COG ADVL0912)</i>","2022-09-05"
"Crizotinib","FDA","2022-07-14","Inflammatory myofibroblastic tumor",FALSE,FALSE,FALSE,"","","","","adults AND pediatric patients 1 year and older","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"COG ADVL0912","2022-07-14: Approved for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Inflammatory_myofibroblastic_tumor"" title=""Inflammatory myofibroblastic tumor"">myofibroblastic tumors (IMT)</a>. <i>(New disease entity; based on COG ADVL0912 and PROFILE 1013)</i>","2022-09-05"
"Crizotinib","FDA","2022-07-14","Inflammatory myofibroblastic tumor",FALSE,FALSE,FALSE,"","","","","adults AND pediatric patients 1 year and older","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"PROFILE 1013","2022-07-14: Approved for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Inflammatory_myofibroblastic_tumor"" title=""Inflammatory myofibroblastic tumor"">myofibroblastic tumors (IMT)</a>. <i>(New disease entity; based on COG ADVL0912 and PROFILE 1013)</i>","2022-09-05"
"Crizotinib","HC","2012-04-25","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","",NA,"","","","","0","ALK rearrangement","FALSE",NA,"","2012-04-25: Initial notice of compliance with conditions as monotherapy for use in patients with ALK-positive advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>.","2023-05-08"
"Crizotinib","HC","2015-11-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-11-18: Conditions were met","2023-05-08"
"Crizotinib","HC","2017-08-28","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","ROS1 rearrangement","FALSE",NA,"","2017-08-28: New indication for patients with ROS-1 positive advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>.","2023-05-08"
"Crizotinib","PMDA","2012-03-30","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2012-03-30: Initial approval for the treatment of unresectable advanced/relapsed ALK fusion gene-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Crizotinib","PMDA","2017-05-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ROS1 rearrangement","FALSE",NA,"","2017-05-18: New additional indication for the treatment of unresectable advanced/relapsed ROS1 fusion gene-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Cyanocobalamin","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cyclophosphamide","EMA","1958-10-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1958-10-13: EURD","2023-07-31"
"Cyclophosphamide","FDA","1959-11-16","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1959-11-16: initial FDA approval","2022-09-05"
"Cyclophosphamide","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Burkitt lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Neuroblastoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2023-05-08"
"Cyclophosphamide","FDA","Uncertain date","Retinoblastoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2012-03-31 (oldest label available at Drugs @ FDA): Approved for <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphomas</a> (Stages III and IV of the Ann Arbor staging system), <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>, <a href=""/wiki/Burkitt_lymphoma"" title=""Burkitt lymphoma"">Burkitt lymphoma</a>; <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, leukemias: <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic lymphocytic leukemia</a>, <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic granulocytic leukemia</a> (it is usually ineffective in acute blastic crisis), <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myelogenous and monocytic leukemia</a>, <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic (stem-cell) leukemia</a> in children (cyclophosphamide given during remission is effective in prolonging its duration); <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced disease); <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (disseminated disease); <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">adenocarcinoma of ovary</a>; <a href=""/wiki/Retinoblastoma"" title=""Retinoblastoma"">retinoblastoma</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast</a> <i>(No supporting studies are cited)</i>","2024-12-02"
"Cyclophosphamide","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Cyclophosphamide","PMDA","2013-03-25","Pheochromocytoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indication and a new dosage for the treatment of <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a>.","2023-06-16"
"Cyclophosphamide","PMDA","2015-06-26","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-06-26: revised indication and a new dosage for the relief of symptoms of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a>.","2023-06-16"
"Cyclophosphamide","PMDA","2019-03-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.","2023-06-16"
"Cyclophosphamide","PMDA","2021-08-21","Light-chain (AL) amyloidosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-08-21: New indication and a new dosage for the treatment of <a href=""/wiki/Light-chain_(AL)_amyloidosis"" title=""Light-chain (AL) amyloidosis"">systemic AL amyloidosis</a>.","2023-06-16"
"Cyclosporine","PMDA","2017-08-25","Aplastic anemia",FALSE,FALSE,FALSE,"","","Not severe","","","","",NA,"","","","","","","",NA,"","2017-08-25: Revised indication and a new dosage for the treatment of <a href=""/wiki/Aplastic_anemia"" title=""Aplastic anemia"">aplastic anemia</a> which is not severe.","2023-06-16"
"Cyproterone acetate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Cytarabine","EMA","2001-07-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-07-11: EURD","2023-07-31"
"Cytarabine","FDA","1969-06-17","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1969-06-17: initial FDA approval","2022-09-05"
"Cytarabine","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","1998-10-15 (oldest label available at Drugs @ FDA): indicated in the treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a> and the blast phase of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelocytic leukemia</a>. <i>(No supporting studies are cited)</i>","2023-07-31"
"Cytarabine","FDA","Uncertain date","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Induction","","","","","",NA,"","","","","other approved anticancer drugs","","",FALSE,"","1998-10-15 (oldest label available at Drugs @ FDA): indicated in combination with other approved anticancer drugs for remission induction in <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute nonlymphocytic leukemia</a> of adults and pediatric patients. <i>(No supporting studies are cited)</i>","2023-07-31"
"Cytarabine","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","1998-10-15 (oldest label available at Drugs @ FDA): indicated in the treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a> and the blast phase of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelocytic leukemia</a>. <i>(No supporting studies are cited)</i>","2023-07-31"
"Cytarabine","FDA","Uncertain date","CNS leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","1998-10-15 (oldest label available at Drugs @ FDA): Intrathecal administration is indicated in the prophylaxis and treatment of <a href=""/wiki/CNS_leukemia"" title=""CNS leukemia"">meningeal leukemia</a>. <i>(No supporting studies are cited)</i>","2023-07-31"
"Cytarabine","PMDA","2019-03-26","Cellular therapy conditioning regimens",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-03-26: New indication for the <a href=""/wiki/Cellular_therapy_conditioning_regimens"" title=""Cellular therapy conditioning regimens"">treatment prior to tumor-specific T-cell infusion therapy</a>.","2023-06-16"
"Cytarabine","PMDA","2023-05-25","Acute leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-05-25: New indication and a new dosage for the treatment of <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>.","2024-06-03"
"Cytarabine and daunorubicin liposomal","EMA","2018-08-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-08-23: Initial authorization","2023-05-08"
"Cytarabine and daunorubicin liposomal","FDA","2017-08-03","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","0","FALSE","","","","","","","",TRUE,"CLTR0310-301","2017-08-03: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm"">Granted FDA regular approval</a> for the treatment of adults with newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">therapy-related AML (t-AML)</a> or <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">AML with myelodysplasia-related changes (AML-MRC)</a>, two types of AML having a poor prognosis. <i>(Based on CLTR0310-301)</i>","2022-09-05"
"Cytarabine liposomal","EMA","2001-07-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-07-11: Initial authorization as DepoCyte","2023-05-08"
"Cytarabine liposomal","EMA","2018-07-10","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2018-07-10: Withdrawn on request from the manufacturer, for commercial reasons","2023-05-08"
"Cytarabine liposomal","FDA","1999-04-01","CNS lymphoma",TRUE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Glantz et al. 1999","1999-04-01: Initial accelerated approval for intrathecal treatment of <a href=""/wiki/CNS_lymphoma"" title=""CNS lymphoma"">lymphomatous meningitis</a>. <i>(Based on Glantz et al. 1999)</i>","2022-09-05"
"Cytarabine liposomal","FDA","2007-04-19","CNS lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-04-19: Converted to regular approval for intrathecal treatment of <a href=""/wiki/CNS_lymphoma"" title=""CNS lymphoma"">lymphomatous meningitis</a>.","2022-09-05"
"Cytarabine liposomal","FDA","Uncertain date","CNS lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-08-11 (oldest label available at Drugs @ FDA): indicated for the intrathecal treatment of <a href=""/wiki/CNS_lymphoma"" title=""CNS lymphoma"">lymphomatous meningitis</a>.","2023-05-08"
"Cytomegalovirus Immune Globulin","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dabigatran","EMA","2008-03-17","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-03-17: Initial authorization","2023-05-08"
"Dabrafenib","EMA","2013-08-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-08-26: Initial marketing authorization as Tafinlar.","2023-05-08"
"Dabrafenib","EMA","2023-09-14","High-grade glioma pediatric",FALSE,FALSE,FALSE,"","","","","pediatric aged 1 year and older","","1+ radiotherapy|1+ chemotherapy",NA,"","","","","Trametinib","BRAF p.V600E","",NA,"","2023-09-14: CHMP recommends authorization at Finlee. Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/High-grade_glioma,_pediatric"" title=""High-grade glioma, pediatric"">high-grade glioma (HGG)</a> with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.","2023-11-07"
"Dabrafenib","EMA","2023-09-14","Low-grade glioma pediatric",FALSE,FALSE,FALSE,"","","require systemic therapy","","pediatric aged 1 year and older","","",NA,"","","","","Trametinib","BRAF p.V600E","",NA,"","2023-09-14: CHMP recommends authorization at Finlee. Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">low-grade glioma (LGG)</a> with a BRAF V600E mutation who require systemic therapy.","2023-11-07"
"Dabrafenib","EMA","2023-11-15","Low-grade glioma pediatric",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2023-11-15: Approved as Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">low-grade glioma (LGG)</a> with a BRAF V600E mutation who require systemic therapy.","2024-12-02"
"Dabrafenib","EMA","2023-11-15","High-grade glioma pediatric",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2023-11-15: Approved as Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/High-grade_glioma,_pediatric"" title=""High-grade glioma, pediatric"">high-grade glioma (HGG)</a> with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.","2024-12-02"
"Dabrafenib","EMA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved as monotherapy for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2024-12-02"
"Dabrafenib","EMA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved in combination with trametinib for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2024-12-02"
"Dabrafenib","EMA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved in combination with trametinib for the adjuvant treatment of adult patients with Stage III <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation, following complete resection.","2024-12-02"
"Dabrafenib","EMA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved in combination with trametinib for the treatment of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with a BRAF V600 mutation.","2024-12-02"
"Dabrafenib","FDA","2013-05-29","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"BREAK-3","2013-05-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm"">FDA approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BREAK-3 and BREAK-MB)</i>","2022-09-05"
"Dabrafenib","FDA","2013-05-29","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"BREAK-MB","2013-05-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm"">FDA approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BREAK-3 and BREAK-MB)</i>","2022-09-05"
"Dabrafenib","FDA","2014-01-10","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-d","2014-01-10: Accelerated approval together with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on COMBI-d, COMBI-v, and COMBI-MB)</i>","2022-09-05"
"Dabrafenib","FDA","2014-01-10","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-MB","2014-01-10: Accelerated approval together with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on COMBI-d, COMBI-v, and COMBI-MB)</i>","2022-09-05"
"Dabrafenib","FDA","2014-01-10","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-v","2014-01-10: Accelerated approval together with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on COMBI-d, COMBI-v, and COMBI-MB)</i>","2022-09-05"
"Dabrafenib","FDA","2017-06-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E","FALSE",TRUE,"BRF113928 previously treated","2017-06-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm"">FDA approved</a> in combination with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BRF113928 previously treated and BRF113928 untreated)</i>","2022-09-05"
"Dabrafenib","FDA","2017-06-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E","FALSE",TRUE,"BRF113928 untreated","2017-06-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm"">FDA approved</a> in combination with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BRF113928 previously treated and BRF113928 untreated)</i>","2022-09-05"
"Dabrafenib","FDA","2018-04-30","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Involvement of lymph nodes","","","","Surgery","FALSE","","complete resection","","","Trametinib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-AD","2018-04-30: Regular FDA approval with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> in combination for the adjuvant treatment of patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a>, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. <i>(Based on COMBI-AD)</i>","2022-09-05"
"Dabrafenib","FDA","2018-05-04","Thyroid cancer",FALSE,FALSE,FALSE,"","no satisfactory locoregional treatment options","Locally advanced OR Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600E","FALSE",TRUE,"ROAR","2018-05-04: FDA approval with <a href=""/wiki/Trametinib_(Mekinist)"" title=""Trametinib (Mekinist)"">Trametinib (Mekinist)</a> in combination for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">anaplastic thyroid cancer (ATC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> and with no satisfactory locoregional treatment options. <i>(Based on ROAR)</i>","2022-09-05"
"Dabrafenib","FDA","2023-03-16","Low-grade glioma pediatric",FALSE,FALSE,FALSE,"","require systemic therapy","","","pediatric aged 1 year and older","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"TADPOLE","2023-03-16: FDA approved for pediatric patients 1 year of age and older with <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">low-grade glioma (LGG)</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> who require systemic therapy. <i>(Based on TADPOLE)</i>","2023-03-29"
"Dabrafenib","HC","2013-07-16","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","0","BRAF p.V600","FALSE",NA,"","2013-07-16: Initial notice of compliance as a monotherapy for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2023-05-08"
"Dabrafenib","HC","2015-03-06","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600","FALSE",NA,"","2015-03-06: New indication with conditions in combination with trametinib for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2023-05-08"
"Dabrafenib","HC","2016-06-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-06-01: Conditions were met.","2023-05-08"
"Dabrafenib","HC","2017-05-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","SACT","FALSE","","progression","","","Trametinib","BRAF p.V600","FALSE",NA,"","2017-05-16: New indication in combination with trametinib for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a BRAF V600 mutation whose disease has progressed following systemic therapy.","2023-05-08"
"Dabrafenib","HC","2018-05-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Trametinib","BRAF p.V600","FALSE",NA,"","2018-05-18: Expanded indication in combination with trametinib for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a BRAF V600 mutation.","2023-05-08"
"Dabrafenib","HC","2018-09-21","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage III","","","","Surgery","FALSE","","resection","","","Trametinib","BRAF p.V600","FALSE",NA,"","2018-09-21: New indication in combination with trametinib for the adjuvant treatment of patients with Stage III <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation following resection.","2023-05-08"
"Dabrafenib","PMDA","2016-03-28","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2016-03-28: Initial approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with BRAF mutation.","2023-06-16"
"Dabrafenib","PMDA","2018-03-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2018-03-23: New additional indication and a new dosage indicated for the treatment of unresectable advanced or recurrent BRAF mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Dabrafenib","PMDA","2018-07-02","Melanoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2018-07-02: New additional indication and a new dosage indicated for the treatment of BRAF mutation-positive <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Dabrafenib","PMDA","2023-11-24","Malignant solid neoplasm BRAF-mutated",FALSE,FALSE,FALSE,"","","Advanced or Recurrent","","","","standard therapy",NA,"","refractory or intolerant","","","","BRAF mutation","",NA,"","2023-11-24: New indication and a new dosage for the treatment of advanced or recurrent <a href=""/wiki/Malignant_solid_neoplasm,_BRAF-mutated"" title=""Malignant solid neoplasm, BRAF-mutated"">BRAF mutation-positive solid tumor</a> (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies.","2024-06-03"
"Dabrafenib","PMDA","2023-11-24","Hairy cell leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","BRAF mutation","",NA,"","2023-11-24: New indication and a new dosage for the treatment of relapsed or refractory BRAF mutation-positive <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a>.","2024-06-03"
"Dacarbazine","EMA","1978-02-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1978-02-01: EURD","2023-07-31"
"Dacarbazine","FDA","1975-05-27","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1975-05-27: Initial FDA approval","2022-09-05"
"Dacarbazine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","1","FALSE","","","","","Other effective agents","","",FALSE,"","Uncertain date: Indicated for <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a> as a second-line therapy when used in combination with other effective agents. <i>(No supporting studies are cited)</i>","2022-12-02"
"Dacarbazine","FDA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: indicated in the treatment of metastatic malignant <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(No supporting studies are cited)</i>","2022-12-02"
"Dacarbazine","PMDA","2013-03-25","Pheochromocytoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indication and a new dosage for the treatment of <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a>.","2023-06-16"
"Dacomitinib","EMA","2019-04-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-04-02: Initial authorization","2023-05-08"
"Dacomitinib","EMA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","","EGFR mutation","FALSE",NA,"","Uncertain date: Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non small cell lung cancer (NSCLC)</a> with epidermal growth factor receptor (EGFR) activating mutations.","2023-05-20"
"Dacomitinib","FDA","2018-09-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"ARCHER 1050","2018-09-27: Initial approval for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 L858R substitution</a> mutations. <i>(Based on ARCHER 1050)</i>","2022-09-05"
"Dacomitinib","HC","2019-02-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Unresectable locally advanced OR Metastatic","","adults","","",NA,"","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",NA,"","2019-02-26: Initial notice of compliance for the first-line treatment of adult patients with unresectable locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.","2023-06-15"
"Dacomitinib","HC","2022-06-09","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-06-09: Drug withdrawn","2023-07-31"
"Dacomitinib","PMDA","2019-01-08","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","EGFR mutation","FALSE",NA,"","2019-01-08: New approval for the treatment of inoperable or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with EGFR gene mutation.","2023-06-16"
"Dactinomycin","EMA","1963-07-01","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1963-07-01: EURD","2023-07-31"
"Dactinomycin","FDA","1964-12-10","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1964-12-10: Initial FDA approval","2022-09-05"
"Dactinomycin","FDA","Uncertain date","Rhabdomyosarcoma",FALSE,FALSE,FALSE,"","","","","pediatric","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"IRS-III","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of childhood <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>. <i>(Based on IRS-III)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Testicular cancer",FALSE,FALSE,FALSE,"","","Metastatic","Nonseminomatous","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"Bosl et al. 1986","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of metastatic, nonseminomatous <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a>. <i>(Based on Bosl et al. 1986 and Vugrin et al. 1981)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Ewing sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"ET-1","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of <a href=""/wiki/Ewing_sarcoma"" title=""Ewing sarcoma"">Ewing sarcoma</a>. <i>(Based on ET-1)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Gestational trophoblastic neoplasia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",TRUE,"Newlands et al. 1991","2009-03-13 (oldest label available at Drugs @ FDA): Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of <a href=""/wiki/Gestational_trophoblastic_neoplasia"" title=""Gestational trophoblastic neoplasia"">gestational trophoblastic neoplasia</a>. <i>(Based on Osathanondh et al. 1975 and Newlands et al. 1991)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Wilms tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"NWTS-1","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms tumor</a>. <i>(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Wilms tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"NWTS-2","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms tumor</a>. <i>(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Wilms tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"NWTS-3","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms tumor</a>. <i>(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Wilms tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"NWTS-4","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms tumor</a>. <i>(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Gestational trophoblastic neoplasia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",TRUE,"Osathanondh et al. 1975","2009-03-13 (oldest label available at Drugs @ FDA): Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of <a href=""/wiki/Gestational_trophoblastic_neoplasia"" title=""Gestational trophoblastic neoplasia"">gestational trophoblastic neoplasia</a>. <i>(Based on Osathanondh et al. 1975 and Newlands et al. 1991)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Testicular cancer",FALSE,FALSE,FALSE,"","","Metastatic","Nonseminomatous","","","",NA,"","","","","Chemotherapy OR Multi-modality treatment","","",TRUE,"Vugrin et al. 1981","2009-03-13 (oldest label available at Drugs @ FDA): Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of metastatic, nonseminomatous <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a>. <i>(Based on Bosl et al. 1986 and Vugrin et al. 1981)</i>","2023-05-08"
"Dactinomycin","FDA","Uncertain date","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","Locally recurrent OR Locoregional","","","","",NA,"","","","","","","",NA,"","2009-03-13 (oldest label available at Drugs @ FDA): Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid malignancies</a>.","2023-05-08"
"Dalteparin","FDA","1994-12-22","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1994-12-22: Initial approval for the prophylaxis of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT)</a>, which may lead to pulmonary embolism (PE) in patients undergoing hip replacement surgery.","2022-09-05"
"Dalteparin","FDA","2019-05-16","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2019-05-16: Approved to reduce the recurrence of symptomatic <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">venous thromboembolism (VTE)</a> in pediatric patients 1 month of age and older.","2022-09-05"
"Dalteparin","FDA","Uncertain date","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Subsequently approved for prophylaxis of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT)</a> in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness and extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months.","2023-05-08"
"Danaparoid","FDA","2001-06-26","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2001-06-26: Initial approval","2022-09-05"
"Danazol","FDA","1976-06-21","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1976-06-21: Initial FDA approval","2022-09-05"
"Dapsone","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Daratumumab","EMA","2016-05-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-05-20: Initial authorization","2023-05-08"
"Daratumumab","FDA","2015-11-16","Multiple myeloma",TRUE,FALSE,TRUE,"","","","","","","3+, including a proteasome inhibitor and an IMiD","FALSE","","","","","","","",TRUE,"GEN501 part 2","2015-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least three prior lines of therapy including a <a href=""/wiki/Category:Proteasome_inhibitors"" title=""Category:Proteasome inhibitors""> proteasome inhibitor (PI)</a> and an <a href=""/wiki/Category:Immunomodulatory_drugs_(IMiDs)"" title=""Category:Immunomodulatory drugs (IMiDs)""> immunomodulatory agent</a>. <i>(Based on GEN501 part 2 and SIRIUS)</i>","2023-03-10"
"Daratumumab","FDA","2015-11-16","Multiple myeloma",TRUE,FALSE,TRUE,"","","","","","","Proteasome inhibitor and an IMiD","FALSE","","double-refractory","","","","","",TRUE,"GEN501 part 2","2015-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are double-refractory to a PI and an immunomodulatory agent. <i>(Based on GEN501 part 2 and SIRIUS)</i>","2023-03-10"
"Daratumumab","FDA","2015-11-16","Multiple myeloma",TRUE,FALSE,TRUE,"","","","","","","3+, including a proteasome inhibitor and an IMiD","FALSE","","","","","","","",TRUE,"SIRIUS","2015-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least three prior lines of therapy including a <a href=""/wiki/Category:Proteasome_inhibitors"" title=""Category:Proteasome inhibitors""> proteasome inhibitor (PI)</a> and an <a href=""/wiki/Category:Immunomodulatory_drugs_(IMiDs)"" title=""Category:Immunomodulatory drugs (IMiDs)""> immunomodulatory agent</a>. <i>(Based on GEN501 part 2 and SIRIUS)</i>","2023-03-10"
"Daratumumab","FDA","2015-11-16","Multiple myeloma",TRUE,FALSE,TRUE,"","","","","","","Proteasome inhibitor and an IMiD","FALSE","","double-refractory","","","","","",TRUE,"SIRIUS","2015-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472904.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are double-refractory to a PI and an immunomodulatory agent. <i>(Based on GEN501 part 2 and SIRIUS)</i>","2023-03-10"
"Daratumumab","FDA","2016-11-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","(Lenalidomide AND Dexamethasone) OR (Bortezomib AND Dexamethasone)","","",TRUE,"CASTOR","2016-11-21: Full approval in combination with <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)"">lenalidomide</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a>, or <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a>, for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy. <i>(Label extended to second-line setting; based on CASTOR and POLLUX)</i>","2022-09-05"
"Daratumumab","FDA","2016-11-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","(Lenalidomide AND Dexamethasone) OR (Bortezomib AND Dexamethasone)","","",TRUE,"POLLUX","2016-11-21: Full approval in combination with <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)"">lenalidomide</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a>, or <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a>, for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy. <i>(Label extended to second-line setting; based on CASTOR and POLLUX)</i>","2022-09-05"
"Daratumumab","FDA","2017-06-16","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","2+, including Lenalidomide AND Proteasome inhibitor","FALSE","","","","","Pomalidomide AND Dexamethasone","","",TRUE,"EQUULEUS_pom","2017-06-16: Approved in combination with pomalidomide and dexamethasone for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. <i>(Based on EQUULEUS_pom)</i>","2022-09-05"
"Daratumumab","FDA","2018-05-07","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","Ineligible for autologous HSCT","0","FALSE","","","","","Bortezomib AND Melphalan AND Prednisone","","",TRUE,"ALCYONE","2018-05-07: Approved in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are ineligible for autologous stem cell transplant. <i>(Based on ALCYONE)</i>","2022-09-05"
"Daratumumab","FDA","2019-06-27","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","Ineligible for autologous HSCT","0","FALSE","","","","","Lenalidomide AND Dexamethasone","","",TRUE,"MAIA","2019-06-27: Approved in combination with lenalidomide and dexamethasone for patients with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are ineligible for autologous stem cell transplant. <i>(Label extended to first-line transplant-ineligible setting; based on MAIA)</i>","2022-09-05"
"Daratumumab","FDA","2019-09-26","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","eligible for autologous HSCT","0","FALSE","","","","","Bortezomib AND Thalidomide AND Dexamethasone","","",TRUE,"CASSIOPEIA part 1","2019-09-26: Approved for adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). <i>(Label extended to first-line transplant-eligible setting; based on CASSIOPEIA part 1)</i>","2022-09-05"
"Daratumumab","FDA","2020-08-20","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1 to 3","FALSE","","","","","Carfilzomib AND Dexamethasone","","",TRUE,"CANDOR","2020-08-20: Approved in combination with <a href=""/wiki/Carfilzomib_(Kyprolis)"" title=""Carfilzomib (Kyprolis)"">carfilzomib</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a> for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three lines of therapy. <i>(Based on CANDOR)</i>","2022-09-05"
"Daratumumab","HC","2016-06-29","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-06-29: Initial notice of compliance with conditions","2023-05-08"
"Daratumumab","HC","2018-10-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-10-10: Conditions were met","2023-05-08"
"Daratumumab","PMDA","2017-09-27","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-09-27: New approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Daratumumab","PMDA","2019-08-22","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2019-08-22: New indication and a new dosage for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Daratumumab and hyaluronidase","FDA","2020-05-01","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"COLUMBA","2020-05-01: Approved for adult patients with newly diagnosed or relapsed/refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. <i>(Based on COLUMBA)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2020-05-01","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"COLUMBA","2020-05-01: Approved for adult patients with newly diagnosed or relapsed/refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. <i>(Based on COLUMBA)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2020-05-01","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"PLEIADES","2020-05-01: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma"">Approved</a> for adult patients with newly diagnosed or relapsed/refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. <i>(Based on PLEIADES)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2020-05-01","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"PLEIADES","2020-05-01: Approved for adult patients with newly diagnosed or relapsed/refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. <i>(Based on PLEIADES)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2021-01-15","Light-chain (AL) amyloidosis",TRUE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Bortezomib AND Cyclophosphamide AND Dexamethasone","","",TRUE,"ANDROMEDA","2021-01-15: Accelerated approval in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed <a href=""/wiki/Light-chain_(AL)_amyloidosis"" title=""Light-chain (AL) amyloidosis"">light-chain (AL) amyloidosis</a>. <i>(New disease entity; based on ANDROMEDA)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2021-07-09","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","1+, including Lenalidomide AND Proteasome inhibitor","FALSE","","","","","Pomalidomide AND Dexamethasone","","",TRUE,"APOLLO","2021-07-09: Approved in combination with pomalidomide and dexamethasone for adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. <i>(Based on APOLLO)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2021-11-30","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1 to 3","FALSE","","","","","","","",TRUE,"PLEIADES","2021-11-30: Approved for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received 1 to 3 prior lines of therapy. <i>(Based on PLEIADES)</i>","2022-09-05"
"Daratumumab and hyaluronidase","FDA","2024-07-30","Multiple myeloma",FALSE,FALSE,FALSE,"","Induction AND Consolidation","","","","eligible for auto HSCT","",NA,"0","","","","Bortezomib AND Lenalidomide AND Dexamethasone","","",TRUE,"PERSEUS","2024-07-30: Approved in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in patients with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are eligible for autologous stem cell transplant (ASCT). <i>(Based on PERSEUS)</i>","2024-09-06"
"Daratumumab and vorhyaluronidase","PMDA","2021-03-23","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-03-23: Newly indicated for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-07-31"
"Daratumumab and vorhyaluronidase","PMDA","2021-08-25","Light-chain (AL) amyloidosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-08-25: New indication and a new dosage for the treatment of <a href=""/wiki/Light-chain_(AL)_amyloidosis"" title=""Light-chain (AL) amyloidosis"">systemic AL amyloidosis</a>.","2023-11-07"
"Darbepoetin alfa","PMDA","2014-12-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-12-18: New additional indication and a new dosage for the treatment of anemia due to myelodysplastic syndrome.","2023-06-16"
"Darinaparsin","PMDA","2022-06-20","Peripheral T-cell lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"SP-02","2022-06-20: A drug with a new active ingredient indicated for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>. <i>(Based on SP-02)</i>","2023-07-31"
"Darolutamide","EMA","2020-03-27","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","at risk of developing metastatic disease","adult men","","",NA,"","","","","","","",TRUE,"ARAMIS","2020-03-27: Initial authorization as Nubeqa. Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (nmCRPC) who are at risk of developing metastatic disease. <i>(Based on ARAMIS)</i>","2023-09-17"
"Darolutamide","EMA","2023-03-20","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","","","",NA,"","","","","Docetaxel AND ADT","","",TRUE,"ARASENS","2023-03-20: Additional indication for metastatic hormone sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mHSPC) in combination with docetaxel and androgen deprivation therapy. <i>(Based on ARASENS)</i>","2023-05-08"
"Darolutamide","EMA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","Risk of developing metastatic disease","men","","",NA,"","","","","","","",NA,"","Uncertain date: Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (nmCRPC) who are at risk of developing metastatic disease.","2023-05-08"
"Darolutamide","FDA","2019-07-30","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","","","","",NA,"","","","","","","",TRUE,"ARAMIS","2019-07-30: Initial approval for non-metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on ARAMIS)</i>","2022-09-05"
"Darolutamide","FDA","2022-08-05","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","adults","","",NA,"","","","","Docetaxel","","",TRUE,"ARASENS","2022-08-05: Approved in combination with docetaxel for adult patients with metastatic hormone-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mHSPC). <i>(Based on ARASENS)</i>","2022-09-05"
"Darolutamide","HC","2020-02-20","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","","","","",NA,"","","","","","","",NA,"","2020-02-20: Notice of compliance for the treatment of patients with non-metastatic castration resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (nmCRPC).","2023-05-20"
"Darolutamide","HC","2022-09-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-09-29: New indication (details unknown)","2023-05-20"
"Darolutamide","PMDA","2020-01-23","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","","","","",NA,"","","","","","","",NA,"","2020-01-23: Newly indicated for the treatment of non-metastatic, castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Dasatinib","EMA","2006-11-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-11-20: Initial authorization","2023-05-08"
"Dasatinib","FDA","2006-06-28","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","1+, including Imatinib","FALSE","","","","","","","",TRUE,"CA180-013","2006-06-28: Initial accelerated approval for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia</a> with resistance or intolerance to prior therapy including <a href=""/wiki/Imatinib_(Gleevec)"" title=""Imatinib (Gleevec)""> imatinib</a>. <i>(Based on CA180-013)</i>","2022-09-21"
"Dasatinib","FDA","2006-06-28","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"START-L","2006-06-28: Initial approval for the treatment of adults with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers""> Philadelphia chromosome-positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a> with resistance or intolerance to prior therapy. <i>(Based on START-L)</i>","2022-09-05"
"Dasatinib","FDA","2007-11-08","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase","","adults","","1+, including Imatinib","FALSE","","","","","","","",TRUE,"CA180-034","2007-11-08: New accelerated approval for the treatment of adults with chronic phase (CP) <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> with resistance or intolerance to prior therapy, including imatinib mesylate. The new dosing regimen is 100 mg taken orally once daily. <i>(New dosing instruction; based on CA180-034)</i>","2022-09-21"
"Dasatinib","FDA","2009-05-21","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","1+, including Imatinib","FALSE","","","","","","","",TRUE,"CA180-035","2009-05-21: Converted to regular approval for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia</a> with resistance or intolerance to prior therapy including <a href=""/wiki/Imatinib_(Gleevec)"" title=""Imatinib (Gleevec)""> imatinib</a>. <i>(Based on CA180-035)</i>","2022-09-21"
"Dasatinib","FDA","2010-10-28","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase","","adults","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"DASISION","2010-10-28: Accelerated approval for newly diagnosed adults with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive (Ph+)</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia (CML)</a> in chronic phase. <i>(Approval expanded to the first-line setting; based on DASISION)</i>","2022-09-21"
"Dasatinib","FDA","2015-08-12","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","adults","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"DASISION","2015-08-12: Converted to regular approval for newly diagnosed adults with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive (Ph+)</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia (CML)</a> in chronic phase. <i>(Based on DASISION)</i>","2022-09-21"
"Dasatinib","FDA","2017-11-10","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","pediatric","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"CA180-018","2017-11-10: New indication for the treatment of pediatric patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> in chronic phase. <i>(Approval expanded to include the pediatric population; based on CA180-018 and CA180-226)</i>","2022-09-21"
"Dasatinib","FDA","2017-11-10","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","pediatric","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"CA180-226","2017-11-10: New indication for the treatment of pediatric patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> in chronic phase. <i>(Approval expanded to include the pediatric population; based on CA180-018 and CA180-226)</i>","2022-09-21"
"Dasatinib","FDA","2018-12-21","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","pediatric aged 1 year and older","","0","FALSE","","","","","Chemotherapy","BCR-ABL1","FALSE",TRUE,"COG AALL1122","2018-12-21: Approved for pediatric patients 1 year of age and older with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">ALL</a> in combination with chemotherapy. <i>(Based on COG AALL1122)</i>","2022-09-05"
"Dasatinib","HC","2007-03-26","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-03-26: Initial notice of compliance with conditions","2023-05-08"
"Dasatinib","HC","2009-11-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-11-19: Conditions were met","2023-05-08"
"Dasatinib","PMDA","2009-01-21","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","Ph+","FALSE",NA,"","2009-01-21: Initial approval for the treatment of recurrent or refractory Philadelphia chromosome-positive <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>.","2023-06-16"
"Dasatinib","PMDA","2009-01-21","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","Imatinib","FALSE","","Resistance","","","","","",NA,"","2009-01-21: Initial approval for the treatment of imatinib-resistant <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia</a>.","2023-06-16"
"Dasatinib","PMDA","2011-06-16","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-06-16: New additional indication and a new dosage for the treatment of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelocytic leukemia</a>.","2023-06-16"
"Daunorubicin","EMA","1966-06-08","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1966-06-08: EURD","2023-07-31"
"Daunorubicin","FDA","1979-12-19","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1979-12-19: Initial FDA approval","2022-09-05"
"Daunorubicin","FDA","Uncertain date","Acute nonlymphocytic leukemia",FALSE,FALSE,FALSE,"","Induction","","","adults","","",NA,"","","","","other approved anticancer drugs","","",TRUE,"Yates et al. 1973","Uncertain date: Approved in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults. <i>(Based on Yates et al. 1973, possibly others)</i>","2022-09-05"
"Daunorubicin","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults and pediatric","","",NA,"","","","","","","",TRUE,"ALGB 6801","Uncertain date: Approved for remission induction in <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a> of children and adults. <i>(Based on ALGB 6801 and CALGB 7612)</i>","2022-09-05"
"Daunorubicin","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","adults and pediatric","","",NA,"","","","","","","",TRUE,"CALGB 7612","Uncertain date: Approved for remission induction in <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a> of children and adults. <i>(Based on ALGB 6801 and CALGB 7612)</i>","2022-09-05"
"Daunorubicin liposomal","FDA","1996-04-08","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","","","",TRUE,"Gill et al. 1996","1996-04-08: Initial FDA approval as a first-line cytotoxic therapy for the treatment of advanced, HIV-associated <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">Kaposi's sarcoma (KS)</a>. <i>(Based on Gill et al. 1996)</i>","2022-09-05"
"Decitabine","EMA","2012-09-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-09-20: Initial authorization","2023-05-08"
"Decitabine","EMA","Uncertain date","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","First-line","","","","not candidate for standard induction chemotherapy","",NA,"","","","","","","",NA,"","Uncertain date: Indicated for treatment of adult patients with newly diagnosed de novo or secondary <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a>, according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.","2023-05-20"
"Decitabine","FDA","2006-05-02","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"D-0007","2006-05-02: Initial approval for treatment of patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome""> myelodysplastic syndromes (MDS)</a> including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. <i>(Based on D-0007)</i>","2022-09-05"
"Decitabine and cedazuridine","EMA","2023-09-19","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","ineligible for standard induction chemotherapy","0",NA,"","","","","0","","",NA,"","2023-09-19: Initial marketing authorization as Inaqovi. Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> who are ineligible for standard induction chemotherapy.","2023-11-07"
"Decitabine and cedazuridine","FDA","2020-07-07","Chronic myelomonocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASCERTAIN","2020-07-07: Initial approval for adult patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukemia [CMML]</a>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. <i>(Based on ASTX727-01-B and ASCERTAIN)</i>","2022-09-05"
"Decitabine and cedazuridine","FDA","2020-07-07","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASCERTAIN","2020-07-07: Initial approval for adult patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukemia [CMML]</a>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. <i>(Based on ASTX727-01-B and ASCERTAIN)</i>","2022-09-05"
"Decitabine and cedazuridine","FDA","2020-07-07","Chronic myelomonocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASTX727-01-B","2020-07-07: Initial approval for adult patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukemia [CMML]</a>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. <i>(Based on ASTX727-01-B and ASCERTAIN)</i>","2022-09-05"
"Decitabine and cedazuridine","FDA","2020-07-07","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASTX727-01-B","2020-07-07: Initial approval for adult patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and <a href=""/wiki/Chronic_myelomonocytic_leukemia"" title=""Chronic myelomonocytic leukemia"">chronic myelomonocytic leukemia [CMML]</a>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. <i>(Based on ASTX727-01-B and ASCERTAIN)</i>","2022-09-05"
"Deferasirox","FDA","2015-03-30","Chronic iron overload",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.","2023-07-31"
"Deferasirox","FDA","2015-03-30","Chronic iron overload",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.","2023-07-31"
"Deferiprone","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Deferoxamine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Defibrotide","EMA","2013-10-18","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-10-18: Initial authorization","2023-05-08"
"Defibrotide","EMA","Uncertain date","Hepatic veno-occlusive disease",FALSE,FALSE,FALSE,"","","severe","","adults AND pediatric patients 1 month and older","","",NA,"","","","","","","",NA,"","Uncertain date: Defitelio is indicated for the treatment of severe <a href=""/wiki/Hepatic_veno-occlusive_disease"" title=""Hepatic veno-occlusive disease"">hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS)</a> in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.","2023-05-08"
"Defibrotide","FDA","2016-03-30","Hepatic veno-occlusive disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-03-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm493278.htm"">FDA approved</a> for the treatment of adult and pediatric patients with <a href=""/wiki/Hepatic_veno-occlusive_disease"" title=""Hepatic veno-occlusive disease"">hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome</a>, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).","2022-09-05"
"Defibrotide","PMDA","2019-06-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-06-18: Newly indicated for the treatment of <a href=""/wiki/Hepatic_veno-occlusive_disease"" title=""Hepatic veno-occlusive disease"">sinusoidal obstruction syndrome (SOS) /hepatic veno-occlusive disease (VOD)</a>.","2023-06-16"
"Degarelix","EMA","2009-02-17","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Advanced","","adult men","","",NA,"","","","","","","",NA,"","2009-02-17: Initial authorization as Firmagon. Firmagon is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-09-17"
"Degarelix","EMA","2021-10-19","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Localized OR Locally advanced","high-risk","","","",NA,"","","","","Radiotherapy","","",NA,"","2021-10-19: Extension of indication to include treatment of high-risk localized and locally advanced hormone dependent <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in combination with radiotherapy.","2023-09-17"
"Degarelix","EMA","2021-10-19","Prostate cancer",FALSE,FALSE,FALSE,"","Neoadjuvant castrate-sensitive","Localized OR Locally advanced","high-risk","","","",NA,"","","","","","","",NA,"","2021-10-19: Extension of indication to include treatment as neo-adjuvant prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-09-17"
"Degarelix","FDA","2008-12-24","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"CS21","2008-12-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129207.htm"">Approved</a> for treatment of patients with advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on CS21)</i>","2022-09-05"
"Degarelix","HC","2009-11-16","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Advanced","","","","",NA,"","","","","","","",NA,"","2009-11-16: Initial notice of compliance for testosterone suppression in patients with advanced hormone-dependent <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in whom androgen deprivation is warranted.","2023-05-20"
"Degarelix","PMDA","2012-06-29","Prostate cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-06-29: Initial approval for the treatment of <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Denileukin diftitox","FDA","1999-02-05","Cutaneous T-cell lymphoma",TRUE,FALSE,TRUE,"","","Persistent OR Recurrent","","","","",NA,"","","","","","CD25+","FALSE",TRUE,"L4389-10","1999-02-05: Initial accelerated approval for the treatment of patients with persistent or recurrent <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a> whose malignant cells <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> the <a href=""/wiki/Biomarkers#CD25"" title=""Biomarkers"">CD25</a> component of the IL-2 receptor. <i>(Based on L4389-10)</i>","2022-09-05"
"Denileukin diftitox","FDA","2008-10-15","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent","","","","",NA,"","","","","","CD25+","FALSE",TRUE,"L4389-11","2008-10-15: Converted to regular approval for the treatment of patients with persistent or recurrent <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a> whose malignant cells <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> the <a href=""/wiki/Biomarkers#CD25"" title=""Biomarkers"">CD25</a> component of the IL-2 receptor. <i>(Based on L4389-11)</i>","2022-09-05"
"Denileukin diftitox","PMDA","2021-03-23","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-03-23: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a> and relapsed or refractory <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Denileukin diftitox","PMDA","2021-03-23","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-03-23: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a> and relapsed or refractory <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Denosumab","EMA","2010-05-26","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-05-26: Initial authorization as Prolia","2023-05-08"
"Denosumab","EMA","2011-07-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-07-13: Initial authorization as Xgeva","2023-05-08"
"Denosumab","FDA","2010-06-01","Osteoporosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2010-06-01: Approved (as Prolia) for treatment of postmenopausal women with osteoporosis at high risk for fracture.<sup id=""cite_ref-7"" class=""reference""><a href=""#cite_note-7"">&#91;7&#93;</a>","2022-09-05"
"Denosumab","FDA","2010-11-18","Skeletal metastases from solid tumors",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2010-11-18: Approved for prevention of skeletal-related events in patients with bone metastases from solid tumors.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a>","2022-09-05"
"Denosumab","FDA","2013-06-13","Giant-cell tumor of bone",FALSE,FALSE,FALSE,"","Unresectable OR Surgical resection is likely to result in severe morbidity","","","adults AND skeletally mature adolescents","","",NA,"","","","","","","",TRUE,"Amgen 20040215","2013-06-13: Approved for treatment of adults and skeletally mature adolescents with <a href=""/wiki/Giant-cell_tumor_of_bone"" title=""Giant-cell tumor of bone""> giant cell tumor of bone</a> that is unresectable or where surgical resection is likely to result in severe morbidity. <i>(Based on Amgen 20040215 and Amgen 20062004)</i>","2022-09-05"
"Denosumab","FDA","2013-06-13","Giant-cell tumor of bone",FALSE,FALSE,FALSE,"","Unresectable OR Surgical resection is likely to result in severe morbidity","","","adults AND skeletally mature adolescents","","",NA,"","","","","","","",TRUE,"Amgen 20062004","2013-06-13: Approved for treatment of adults and skeletally mature adolescents with <a href=""/wiki/Giant-cell_tumor_of_bone"" title=""Giant-cell tumor of bone""> giant cell tumor of bone</a> that is unresectable or where surgical resection is likely to result in severe morbidity. <i>(Based on Amgen 20040215 and Amgen 20062004)</i>","2022-09-05"
"Denosumab","HC","2011-05-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-05-10: Initial notice of compliance","2023-07-31"
"Denosumab","PMDA","2012-01-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-01-18: Initial approval for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor.","2023-06-16"
"Denosumab","PMDA","2014-05-23","Giant-cell tumor of bone",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-05-23: New additional indication and a new dosage for the treatment of <a href=""/wiki/Giant-cell_tumor_of_bone"" title=""Giant-cell tumor of bone""> giant cell tumor of bone</a>.","2023-06-16"
"Desmopressin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dexamethasone","EMA","1952-01-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1952-01-01: EURD","2023-07-31"
"Dexamethasone","FDA","Uncertain date","Warm autoimmune hemolytic anemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved for certain hematologic disorders: <a href=""/wiki/Warm_autoimmune_hemolytic_anemia"" title=""Warm autoimmune hemolytic anemia"">acquired (autoimmune) hemolytic anemia</a>, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">idiopathic thrombocytopenic purpura in adults</a>, pure red cell aplasia, and selected cases of secondary thrombocytopenia.","2024-12-02"
"Dexamethasone","FDA","Uncertain date","Immune thrombocytopenia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved for certain hematologic disorders: <a href=""/wiki/Warm_autoimmune_hemolytic_anemia"" title=""Warm autoimmune hemolytic anemia"">acquired (autoimmune) hemolytic anemia</a>, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">idiopathic thrombocytopenic purpura in adults</a>, pure red cell aplasia, and selected cases of secondary thrombocytopenia.","2024-12-02"
"Dexamethasone","FDA","Uncertain date","Leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved for certain neoplastic diseases: For the palliative management of <a href=""/wiki/Category:Leukemias"" title=""Category:Leukemias"">leukemias</a> and <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">lymphomas</a>.","2024-12-02"
"Dexamethasone","FDA","Uncertain date","Lymphoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Approved for certain neoplastic diseases: For the palliative management of <a href=""/wiki/Category:Leukemias"" title=""Category:Leukemias"">leukemias</a> and <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">lymphomas</a>.","2024-12-02"
"Dexamethasone","PMDA","2010-06-18","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2010-06-18: New additional indication and a new dosage for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Dexamethasone","PMDA","2021-08-25","Light-chain (AL) amyloidosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-08-25: New indication and a new dosage for the treatment of <a href=""/wiki/Light-chain_(AL)_amyloidosis"" title=""Light-chain (AL) amyloidosis"">systemic AL amyloidosis</a>.","2023-06-16"
"Dexchlorpheniramine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dexrazoxane","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Diethylstilbestrol","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dinutuximab","EMA","2015-08-14","Neuroblastoma",FALSE,FALSE,FALSE,"","","","high-risk","","","",NA,"","","","","","","",NA,"","2015-08-14: Initial authorization for the treatment of high risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>.","2023-05-08"
"Dinutuximab","EMA","2017-03-20","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2017-03-20: Authorization withdrawn at the request of the manufacturer, for supply chain reasons","2023-05-08"
"Dinutuximab","FDA","2015-03-10","Neuroblastoma",FALSE,FALSE,TRUE,"","","","high-risk","pediatric","","Multiagent/multimodality therapy","FALSE","","at least PR","","","Sargramostim AND Aldesleukin AND Isotretinoin","","",TRUE,"COG ANBL0032","2015-03-10: Initial FDA approval in combination with <a href=""/wiki/Sargramostim_(Leukine)"" title=""Sargramostim (Leukine)"">granulocyte-macrophage colony-stimulating factor (GM-CSF)</a>, <a href=""/wiki/Aldesleukin_(Proleukin)"" title=""Aldesleukin (Proleukin)"">interleukin-2 (IL-2)</a>, and <a href=""/wiki/Isotretinoin_(Accutane)"" title=""Isotretinoin (Accutane)"">13-cis-retinoic acid (RA)</a>, for the treatment of pediatric patients with high-risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> who achieve at least a partial response to prior first-line multiagent, multimodality therapy. <i>(Based on COG ANBL0032)</i>","2022-09-05"
"Dinutuximab","HC","2018-11-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-11-29: Initial notice of compliance","2023-07-31"
"Dinutuximab","PMDA","2021-06-23","Neuroblastoma",FALSE,FALSE,FALSE,"","","","","","","High-dose chemotherapy","FALSE","","","","","","","",NA,"","2021-06-23: Initial approval for the treatment of <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> following high-dose chemotherapy.","2023-06-16"
"Dinutuximab beta","EMA","2017-05-08","Neuroblastoma",FALSE,FALSE,FALSE,"","","","high-risk","pediatric aged 1 year and older","","chemotherapy AND auto HSCT",NA,"Induction","at least PR","","","","","",NA,"","2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of high-risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation. In patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin 2 (IL 2).","2023-11-07"
"Dinutuximab beta","EMA","2017-05-08","Neuroblastoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","other suitable measures",NA,"","stabilised","","","Interleukin-2","","",NA,"","2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of patients with history of relapsed or refractory <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. Qarziba should be combined with interleukin 2 (IL 2).","2023-11-07"
"Diphenhydramine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dipyridamole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Docetaxel","EMA","1995-11-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-11-27: Initial marketing authorization as Taxotere","2023-05-08"
"Docetaxel","EMA","2006-04-27","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0",NA,"Metastatic","","","","Cisplatin AND Fluorouracil","","",NA,"","2006-04-27: Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric adenocarcinoma</a>, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.","2023-09-17"
"Docetaxel","EMA","2006-10-23","Head and neck cancer",FALSE,FALSE,FALSE,"","Induction","Inoperable locally advanced","","","","",NA,"","","","","Cisplatin AND Fluorouracil","","",NA,"","2006-10-23: Extension of indication for induction treatment in combination with cisplatin and 5-fluorouracil of patients with inoperable locally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a>.","2023-09-17"
"Docetaxel","EMA","2007-11-23","Head and neck cancer",FALSE,FALSE,FALSE,"","Induction","Locally advanced","","","","",NA,"","","","","Cisplatin AND Fluorouracil","","",NA,"","2007-11-23: Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck</a>.","2023-09-17"
"Docetaxel","EMA","2010-07-01","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Operable node-negative","","","eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer","",NA,"","","","","Cyclophosphamide AND Doxorubicin","","",TRUE,"GEICAM 9805","2010-07-01: Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. Adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. <i>(Based on GEICAM 9805)</i>","2023-09-17"
"Docetaxel","EMA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","Prednisone OR Prednisolone","","",NA,"","Uncertain date: Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-09-17"
"Docetaxel","FDA","1996-05-14","Breast cancer",TRUE,FALSE,FALSE,"","","Locally advanced","","","","Anthracycline-based regimen","FALSE","Adjuvant","relapsed during","","","","","",TRUE,"TAX 303","<b>1996-05-14: Initial accelerated approval</b> for treatment of patients with locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> who have relapsed during <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline-based</a> adjuvant therapy. <i>(Based on TAX 303 and TAX 304)</i>","2023-05-08"
"Docetaxel","FDA","1996-05-14","Breast cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Anthracycline-based regimen","FALSE","","progressed during","","","","","",TRUE,"TAX 303","<b>1996-05-14: Initial accelerated approval</b> for treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> who have progressed during <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline-based</a> therapy. <i>(Based on TAX 303 and TAX 304)</i>","2023-05-08"
"Docetaxel","FDA","1996-05-14","Breast cancer",TRUE,FALSE,FALSE,"","","Locally advanced","","","","Anthracycline-based regimen","FALSE","Adjuvant","relapsed during","","","","","",TRUE,"TAX 304","<b>1996-05-14: Initial accelerated approval</b> for treatment of patients with locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> who have relapsed during <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline-based</a> adjuvant therapy. <i>(Based on TAX 303 and TAX 304)</i>","2023-05-08"
"Docetaxel","FDA","1996-05-14","Breast cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Anthracycline-based regimen","FALSE","","progressed during","","","","","",TRUE,"TAX 304","<b>1996-05-14: Initial accelerated approval</b> for treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> who have progressed during <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline-based</a> therapy. <i>(Based on TAX 303 and TAX 304)</i>","2023-05-08"
"Docetaxel","FDA","1998-06-22","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Chemotherapy","FALSE","","","","","","","",TRUE,"TAX 313","1998-06-22: Converted to regular approval and indication revised for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> after failure of prior chemotherapy. <i>(No longer limited to prior anthracycline-based chemotherapy exposure; based on TAX 313)</i>","2022-09-05"
"Docetaxel","FDA","1999-12-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",TRUE,"TAX 317","1999-12-23: Label expanded to include treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer</a> after failure of prior <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes""> platinum-based chemotherapy</a>. <i>(New disease entity; based on TAX 317 and TAX 320)</i>","2022-09-05"
"Docetaxel","FDA","1999-12-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",TRUE,"TAX 320","1999-12-23: Label expanded to include treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer</a> after failure of prior <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes""> platinum-based chemotherapy</a>. <i>(New disease entity; based on TAX 317 and TAX 320)</i>","2022-09-05"
"Docetaxel","FDA","2002-11-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Metastatic","","","","0","FALSE","","","","","Cisplatin","","",TRUE,"TAX 326","2002-11-27: Label expanded: In combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> is indicated for the treatment of patients with unresectable, locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer</a> who have not previously received chemotherapy for this condition. <i>(No longer limited to prior chemotherapy exposure; based on TAX 326)</i>","2022-09-05"
"Docetaxel","FDA","2004-05-19","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","Prednisone","","",TRUE,"TAX 327","2004-05-19: Label expanded as follows: in combination with <a href=""/wiki/Prednisone_(Sterapred)"" title=""Prednisone (Sterapred)""> prednisone</a> is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a>. <i>(New disease entity; based on TAX 327)</i>","2022-09-05"
"Docetaxel","FDA","2004-08-18","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Operable node-positive","","","","Surgery","FALSE","","","","","Doxorubicin AND Cyclophosphamide","","",TRUE,"BCIRG 001","2004-08-18: Breast cancer indication expanded: in combination with <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a> and <a href=""/wiki/Cyclophosphamide_(Cytoxan)"" title=""Cyclophosphamide (Cytoxan)""> cyclophosphamide</a> is indicated for the adjuvant treatment of patients with operable node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a>. <i>(No longer limited to the relapsed or metastatic setting; based on BCIRG 001)</i>","2022-09-05"
"Docetaxel","FDA","2006-03-22","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","Chemotherapy","TRUE","Advanced disease","","","","Cisplatin AND Fluorouracil","","",TRUE,"TAX 325","2006-03-22: Label expanded as follows: in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> and <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> fluorouracil</a> is indicated for the treatment of patients with advanced <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric adenocarcinoma</a>, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. <i>(New disease entity; based on TAX 325)</i>","2022-09-05"
"Docetaxel","FDA","2006-10-17","Head and neck cancer",FALSE,FALSE,FALSE,"","","Inoperable locally advanced","","","","0","FALSE","","","","","Cisplatin AND Fluorouracil","","",TRUE,"TAX 323","2006-10-17: Label expanded as follows: in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> and <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> fluorouracil</a> is indicated for the induction treatment of patients with inoperable locally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer""> squamous cell carcinoma of the head and neck (SCCHN)</a>. <i>(New disease entity; based on TAX 323)</i>","2022-09-05"
"Docetaxel","FDA","2007-09-28","Head and neck cancer",FALSE,FALSE,FALSE,"","","Locally advanced","","","","0","FALSE","","","","","Cisplatin AND Fluorouracil","","",TRUE,"TAX 324","2007-09-28: Approved for use in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> and <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">fluorouracil (5-FU)</a> for the induction treatment of patients with locally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinoma of the head and neck (SCCHN)</a>. <i>(Requirement that disease be inoperable was removed; based on TAX 324)</i>","2022-09-05"
"Docetaxel","HC","1995-07-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-07-21: Initial notice of compliance","2023-05-08"
"Docetaxel","PMDA","2005-08-18","Endometrial cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2005-08-18: New indication for the treatment of <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">cancer of the uterus body</a>.","2023-06-16"
"Docetaxel","PMDA","2008-08-29","Prostate cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-08-29: New indication and a new dosage for the treatment of <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Docusate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dolasetron","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Domperidone","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Donafenib","NMPA","2023-06-21","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","SACT","TRUE","","","","","","","",NA,"","2021-06: Initial approval for the treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> who have not previously received systemic treatment.","2023-09-09"
"Dostarlimab","EMA","2021-04-21","Endometrial cancer",TRUE,FALSE,FALSE,"","","Recurrent OR Advanced","","adults","","platinum-containing regimen",NA,"","progression","","","0","MSI-H|dMMR","",NA,"","2021-04-21: Initial conditional authorization at Jemperli. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer (EC)</a> that has progressed on or following prior treatment with a platinum-containing regimen.","2023-11-07"
"Dostarlimab","EMA","2023-10-12","Endometrial cancer",FALSE,FALSE,FALSE,"","","Primary advanced OR Recurrent","","adults","candidates for systemic therapy","",NA,"","","","","Carboplatin AND Palictaxel","MSI-H|dMMR","",NA,"","2023-10-12: CHMP adopted new indication Jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer (EC)</a> and who are candidates for systemic therapy.","2023-11-07"
"Dostarlimab","FDA","2021-04-22","Endometrial cancer",TRUE,FALSE,FALSE,"","","Recurrent OR Advanced","","adults","","Platinum-based regimen","FALSE","","","","","","dMMR","FALSE",TRUE,"GARNET_endometrial","2021-04-22: Granted accelerated approval for adult patients with <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> recurrent or advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer</a>, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. <i>(Based on GARNET_endometrial)</i>","2022-09-05"
"Dostarlimab","FDA","2021-08-17","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Recurrent OR Advanced","","adults","","1+","FALSE","","","","","","dMMR","FALSE",TRUE,"GARNET_MSI-H","2021-08-17: Granted accelerated approval for adult patients with <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> recurrent or advanced <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a>, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. <i>(Based on GARNET_MSI-H)</i>","2022-09-05"
"Dostarlimab","FDA","2023-02-09","Endometrial cancer",FALSE,FALSE,FALSE,"","not candidates for curative surgery or radiation","Recurrent OR Advanced","","adults","","platinum-containing regimen","FALSE","Any","progression","","","","dMMR","FALSE",TRUE,"GARNET_endometrial","2023-02-09: Regular approval for adult patients with <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> recurrent or advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer</a>, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. <i>(Based on GARNET_endometrial)</i>","2023-03-15"
"Dostarlimab","FDA","2023-07-31","Endometrial cancer",FALSE,FALSE,FALSE,"","","Primary advanced OR Recurrent","","","","",NA,"","","","","Carboplatin AND Paclitaxel","dMMR|MSI-H","FALSE",TRUE,"RUBY","2023-07-31: Approved in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer (EC)</a> that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H). <i>(Based on RUBY)</i>","2023-09-09"
"Dostarlimab","FDA","2024-08-01","Endometrial cancer",FALSE,FALSE,FALSE,"","","Primary advanced OR Recurrent","","adults","","",NA,"","","","","Carboplatin AND Paclitaxel","","",TRUE,"RUBY","2024-08-01: Approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer (EC)</a>. <i>(Based on RUBY)</i>","2024-09-06"
"Dostarlimab","HC","2021-12-23","Endometrial cancer",TRUE,FALSE,FALSE,"","","Recurrent OR Advanced","","adults","","Platinum-based regimen","FALSE","","progression","","","0","MSI-H|dMMR","FALSE",NA,"","2021-12-23: Initial notice of compliance with conditions as a monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer (EC)</a> that has progressed on or following prior treatment with a platinum containing regimen.","2023-05-08"
"Doxifluridine","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Doxorubicin","EMA","1996-06-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-06-21: EURD","2023-07-31"
"Doxorubicin","FDA","1974-08-07","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1974-08-07: Initial FDA approval","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Bladder cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Thyroid cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Doxorubicin","FDA","2003-05-08","Wilms tumor",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2024-12-02"
"Doxorubicin","FDA","2003-05-08","Neuroblastoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",FALSE,"","2003-05-08: Earliest date with label information at Drugs @ FDA: ""Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as <a href=""/wiki/Acute_lymphocytic_leukemia"" class=""mw-redirect"" title=""Acute lymphocytic leukemia""> acute lymphoblastic leukemia</a>, <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloblastic leukemia</a>, <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue and bone sarcomas</a>, <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast carcinoma</a>, <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian carcinoma</a>, <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> transitional cell bladder carcinoma</a>, <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer""> thyroid carcinoma</a>, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric carcinoma</a>, <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma""> Hodgkin's disease</a>, <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and bronchogenic carcinoma in which the <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell histologic type</a> is the most responsive compared to other cell types. <i>(No supporting studies are cited)</i>","2024-12-02"
"Doxorubicin","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Axillary lymph node involvement","","","","Surgery","FALSE","","","","","","","",TRUE,"EBCTCG meta-analysis","Uncertain date: Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a>. <i>(Based on EBCTCG 1998 meta-analysis)</i>","2022-09-05"
"Doxorubicin","PMDA","2014-12-18","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-12-18: Revised indication and a new dosage for the relief of symptoms of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a>.","2023-06-16"
"Doxycycline","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Dronabinol","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Durvalumab","EMA","2018-09-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced unresectable","","adults","","Platinum-based chemoradiation",NA,"","no progression","","","0","PD-L1 TPS at least 1%","",TRUE,"PACIFIC","2018-09-21: Initial authorization as Imfinzi. Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. <i>(Based on PACIFIC)</i>","2023-09-17"
"Durvalumab","EMA","2020-08-27","Small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Extensive-stage","","adults","","",NA,"","","","","(Carboplatin OR Cisplatin) AND Etoposide","","",TRUE,"CASPIAN","2020-08-27: Extension of Indication to include the use of IMFINZI in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC). <i>(Based on CASPIAN)</i>","2023-09-17"
"Durvalumab","EMA","2022-12-16","Biliary tract cancer",FALSE,FALSE,FALSE,"","First-line","Unresectable OR Metastatic","","adults","","",NA,"","","","","Cisplatin AND Gemcitabine","","",TRUE,"TOPAZ-1","2022-12-16: Extension of indication to include IMFINZI in combination with gemcitabine and cisplatin for the first-line treatment of adults with unresectable or metastatic <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer (BTC)</a>. <i>(Based on TOPAZ-1)</i>","2023-09-17"
"Durvalumab","EMA","2023-01-30","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced OR Unresectable","","adults","","",NA,"","","","","Tremelimumab","","",TRUE,"HIMALAYA","2023-01-30: Extension of indication to include IMFINZI in combination with tremelimumab for the first line treatment of adults with advanced or unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (uHCC)</a>. <i>(Based on HIMALAYA)</i>","2023-09-17"
"Durvalumab","EMA","2023-01-30","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Platinum-based chemotherapy AND Tremelimumab","EGFR AND ALK","TRUE|TRUE",TRUE,"POSEIDON","2023-01-30: Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) positive mutations. <i>(Based on POSEIDON)</i>","2023-09-17"
"Durvalumab","EMA","2023-10-12","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced OR Unresectable","","adults","","",NA,"","","","","0","","",NA,"","2023-10-12: CHMP adopted new indication Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a>.","2023-11-07"
"Durvalumab","FDA","2017-05-01","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","","","","","","",TRUE,"Study 1108","2017-05-01: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm"">Granted accelerated approval</a> for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression within 12 months of neoadjuvant or adjuvant treatment with <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(Initial approval; based on Study 1108)</i>","2022-09-05"
"Durvalumab","FDA","2017-05-01","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","neoadjuvant or adjuvant","progression","within 12 months","","","","",TRUE,"Study 1108","2017-05-01: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm"">Granted accelerated approval</a> for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> <i>(Initial approval; based on Study 1108)</i>","2022-09-05"
"Durvalumab","FDA","2018-02-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable stage III","","","","Platinum-based chemoradiation","FALSE","","without progression","","","","","",TRUE,"PACIFIC","2018-02-16: Approved for patients with unresectable stage III <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose disease has not progressed following <a href=""/wiki/Regimen_classes#Platinum-based_chemoradiation"" title=""Regimen classes"">concurrent platinum-based chemotherapy and radiation therapy</a>. <i>(New disease entity; based on PACIFIC)</i>","2022-09-05"
"Durvalumab","FDA","2020-03-27","Small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Etoposide AND (Carboplatin OR Cisplatin)","","",TRUE,"CASPIAN","2020-03-27: Approved in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC). <i>(New disease entity; based on CASPIAN)</i>","2022-09-05"
"Durvalumab","FDA","2021-02-19","Urothelial carcinoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"DANUBE","2021-02-19: Indication for <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> withdrawn after the confirmatory trial did not meet its primary endpoints. <i>(Based on DANUBE)</i>","2022-09-05"
"Durvalumab","FDA","2022-09-02","Cholangiocarcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","",NA,"","","","","Cisplatin AND Gemcitabine","","",TRUE,"TOPAZ-1","2022-09-02: Approved in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">biliary tract cancer (BTC)</a>. <i>(Based on TOPAZ-1)</i>","2022-09-05"
"Durvalumab","FDA","2024-06-14","Endometrial cancer",FALSE,FALSE,FALSE,"","","Primary advanced OR Recurrent","","adults","","",NA,"","","","","Carboplatin AND Paclitaxel","dMMR","FALSE",TRUE,"DUO-E","2024-06-14: Approved with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer</a> that is mismatch repair deficient (dMMR). <i>(Based on DUO-E)</i>","2024-09-06"
"Durvalumab","FDA","2024-08-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Resectable","","adults","","",NA,"","","","","Platinum-based chemotherapy","ALK rearrangement AND EGFR","TRUE|TRUE",TRUE,"AEGEAN","2024-08-15: Approved with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors â‰¥ 4 cm and/or node positive) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. <i>(Based on AEGEAN)</i>","2024-09-06"
"Durvalumab","HC","2017-11-03","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","during or following","","","","",NA,"","2017-11-03: Initial notice of compliance with conditions for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following platinum containing chemotherapy.","2023-05-08"
"Durvalumab","HC","2017-11-03","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","neoadjuvant or adjuvant","progression","within 12 months","","","","",NA,"","2017-11-03: Initial notice of compliance with conditions for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.","2023-05-08"
"Durvalumab","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Durvalumab","PMDA","2018-07-02","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Maintenance","Locally advanced unresectable","","","","Chemoradiotherapy","FALSE","Definitive","","","","","","",NA,"","2018-07-02: Newly indicated for the maintenance treatment of locally-advanced, unresectable <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> following definitive chemoradiation therapy.","2023-06-16"
"Durvalumab","PMDA","2020-08-21","Small cell lung cancer",FALSE,FALSE,FALSE,"","","Extensive-stage","","","","",NA,"","","","","","","",NA,"","2020-08-21: New indication and a new dosage for the treatment of extensive-stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small-cell lung cancer</a>.","2023-06-16"
"Dutasteride","FDA","2001-11-20","Benign prostatic hyperplasia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2001-11-20: Initial FDA approval for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland.","2022-09-05"
"Dutasteride","FDA","2011-06-09","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-06-09: New FDA Limitation of Use: AVODART is not approved for the prevention of prostate cancer.","2022-09-05"
"Duvelisib","EMA","2021-05-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-05-19: Initial authorization","2023-05-08"
"Duvelisib","FDA","2018-09-24","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+","FALSE","","","","","","","",TRUE,"DUO","2018-09-24: Regular approval for adult patients with relapsed or refractory <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a> after at least two prior therapies. <i>(Based on DUO)</i>","2022-09-05"
"Duvelisib","FDA","2018-09-24","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"DYNAMO","2018-09-24: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> after at least two prior systemic therapies. <i>(Based on DYNAMO)</i>","2022-09-05"
"Eculizumab","EMA","2007-06-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-06-20: Initial authorization","2023-05-08"
"Eculizumab","FDA","2007-03-16","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"SHEPHERD","2007-03-16: Initial approval for the treatment of patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria""> paroxysmal nocturnal hemoglobinuria (PNH)</a> to reduce hemolysis. <i>(Based on SHEPHERD and TRIUMPH)</i>","2022-09-05"
"Eculizumab","FDA","2007-03-16","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"TRIUMPH","2007-03-16: Initial approval for the treatment of patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria""> paroxysmal nocturnal hemoglobinuria (PNH)</a> to reduce hemolysis. <i>(Based on SHEPHERD and TRIUMPH)</i>","2022-09-05"
"Eculizumab","FDA","2011-09-23","Atypical hemolytic uremic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"C08-002","2011-09-23: Additional indication for the treatment of patients with <a href=""/wiki/Atypical_hemolytic_uremic_syndrome"" title=""Atypical hemolytic uremic syndrome"">atypical hemolytic uremic syndrome (aHUS)</a> to inhibit complement-mediated thrombotic microangiopathy. <i>(Based on C08-002, C08-003, C10-004)</i>","2022-09-05"
"Eculizumab","FDA","2011-09-23","Atypical hemolytic uremic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"C08-003","2011-09-23: Additional indication for the treatment of patients with <a href=""/wiki/Atypical_hemolytic_uremic_syndrome"" title=""Atypical hemolytic uremic syndrome"">atypical hemolytic uremic syndrome (aHUS)</a> to inhibit complement-mediated thrombotic microangiopathy. <i>(Based on C08-002, C08-003, C10-004)</i>","2022-09-05"
"Eculizumab","FDA","2011-09-23","Atypical hemolytic uremic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"C10-004","2011-09-23: Additional indication for the treatment of patients with <a href=""/wiki/Atypical_hemolytic_uremic_syndrome"" title=""Atypical hemolytic uremic syndrome"">atypical hemolytic uremic syndrome (aHUS)</a> to inhibit complement-mediated thrombotic microangiopathy. <i>(Based on C08-002, C08-003, C10-004)</i>","2022-09-05"
"Eculizumab","PMDA","2013-09-13","Atypical hemolytic uremic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-09-13: New additional indication and a new dosage for the treatment of patients with <a href=""/wiki/Atypical_hemolytic_uremic_syndrome"" title=""Atypical hemolytic uremic syndrome"">atypical hemolytic uremic syndrome (aHUS)</a> to inhibit complement-mediated thrombotic microangiopathy.","2023-06-16"
"Eculizumab-aeeb","FDA","2024-05-28","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2024-05-28: Approved for the treatment of patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a> to reduce hemolysis.","2024-12-02"
"Eculizumab-aeeb","FDA","2024-05-28","Atypical hemolytic uremic syndrome",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2024-05-28: Approved for the treatment of patients with <a href=""/wiki/Atypical_hemolytic_uremic_syndrome"" title=""Atypical hemolytic uremic syndrome"">atypical hemolytic uremic syndrome (aHUS)</a> to inhibit complement-mediated thrombotic microangiopathy.","2024-12-02"
"Eculizumab-aeeb","EMA","2023-04-19","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","adults and pediatric","","",NA,"","","","","","","",NA,"","2023-04-19: Bekemv is indicated in adults and children for the treatment of <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal haemoglobinuria (PNH)</a>. Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.","2023-09-17"
"Eculizumab-epys","EMA","2023-05-26","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","adults and pediatric","","",NA,"","","","","","","",NA,"","2023-05-26: Epysqli is indicated in adults and children for the treatment of <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">Paroxysmal nocturnal haemoglobinuria (PNH)</a>. Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.","2023-09-17"
"Edoxaban","FDA","2015-01-08","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Hokusai VTE Cancer","2015-01-08: Approved for the treatment of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT) and pulmonary embolism (PE)</a> following 5-10 days of initial therapy with a parenteral anticoagulant. <i>(Based on Hokusai-VTE and Hokusai VTE Cancer)</i>","2022-09-05"
"Edoxaban","FDA","2015-01-08","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Hokusai-VTE","2015-01-08: Approved for the treatment of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT) and pulmonary embolism (PE)</a> following 5-10 days of initial therapy with a parenteral anticoagulant. <i>(Based on Hokusai-VTE and Hokusai VTE Cancer)</i>","2022-09-05"
"Edoxaban","FDA","2015-01-08","Atrial fibrillation",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-01-08: Approved to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). <i>(Non-hematologic indication)</i>","2022-09-05"
"Edoxaban","PMDA","2014-09-26","Venous thromboembolism",FALSE,FALSE,FALSE,"","Treatment AND Prevention","","","","","",NA,"","","","","","","",NA,"","2014-09-26: New additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation, or for the treatment and prevention of the recurrence of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">venous thromboembolism</a> (deep vein thrombosis and pulmonary thromboembolism).","2023-06-16"
"Edrecolomab","","","",FALSE,FALSE,TRUE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Efanesoctocog alfa","FDA","2023-02-22","Hemophilia A",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"XTEND-1","2023-02-22: Initial approval for use in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding. <i>(Based on XTEND-1)</i>","2024-09-06"
"Efanesoctocog alfa","FDA","2024-05-10","Hemophilia A",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"XTEND-Kids","2024-05-10: Approval updated to include additional evidence. <i>(Based on XTEND-Kids)</i>","2024-09-06"
"Eflornithine","FDA","2023-12-13","Neuroblastoma",FALSE,FALSE,TRUE,"","","","","adults and pediatric","","multiagent, multimodality therapy including anti-GD2 immunotherapy",NA,"","at least PR","","","","","",TRUE,"NMTRC003B","2023-12-13: Approved to reduce the risk of relapse in adult and pediatric patients with high-risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. <i>(Based on NMTRC003B)</i>","2024-02-01"
"Elacestrant","EMA","2023-09-20","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","postmenopausal women OR men","","1+ Endocrine therapy AND CDK4/6 inhibitor",NA,"","progression","","","0","ER+ AND HER2- AND activating ESR1 mutation","",NA,"","2023-09-20: Initial marketing authorization as Orserdu. Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)â€‘positive, HER2-negative, locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.","2023-11-07"
"Elacestrant","FDA","2023-01-27","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women OR adult men","","1+ Endocrine therapy","FALSE","","progression","","","","ER+|HER2-|ESR1-mutated","FALSE",TRUE,"EMERALD","2023-01-27: Approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with disease progression following at least one line of endocrine therapy. <i>(Based on EMERALD)</i>","2023-03-15"
"Elotuzumab","EMA","2016-05-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-05-11: Initial authorization","2023-05-08"
"Elotuzumab","FDA","2015-11-30","Multiple myeloma",FALSE,FALSE,TRUE,"","","","","","","1 to 3","FALSE","","","","","Lenalidomide AND Dexamethasone","","",TRUE,"ELOQUENT-2","2015-11-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474719.htm"">FDA approved</a> to be used in combination with <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)""> lenalidomide</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)""> dexamethasone</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma""> multiple myeloma</a> who have received one to three prior therapies. <i>(Based on ELOQUENT-2)</i>","2022-09-05"
"Elotuzumab","FDA","2018-11-06","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","2+, including Lenalidomide AND Proteasome inhibitor","FALSE","","","","","Pomalidomide AND Dexamethasone","","",TRUE,"ELOQUENT-3","2018-11-06: Approved in combination with pomalidomide and dexamethasone for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. <i>(Based on ELOQUENT-3)</i>","2022-09-05"
"Elotuzumab","HC","2016-06-21","",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-06-21: Initial notice of compliance","2023-06-15"
"Elotuzumab","PMDA","2016-09-28","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2016-09-28: New approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Elranatamab","EMA","2023-10-12","Multiple myeloma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","3+, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody",NA,"","progression","","","0","","",NA,"","2023-10-12: CHMP recommends conditional marketing authorisation as Elrexfio. Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.","2023-11-07"
"Elranatamab","FDA","2023-08-14","Multiple myeloma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","4+ SACT, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody","FALSE","","","","","","","",TRUE,"MagnetisMM-3","2023-08-14: Granted accelerated approval for adults with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. <i>(Based on MagnetisMM-3)</i>","2023-09-09"
"Eltrombopag","EMA","2010-03-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-03-11: Initial authorization as Revolade","2023-05-08"
"Eltrombopag","FDA","2008-11-20","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-11-20: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129214.htm"">Initial approval</a> for treatment of thrombocytopenia in patients with <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia""> chronic immune (idiopathic) thrombocytopenia (ITP)</a> who have had an insufficient response to <a href=""/wiki/Category:Steroids"" title=""Category:Steroids"">corticosteroids</a>, immunoglobulins, or splenectomy.","2022-09-05"
"Eltrombopag","FDA","2012-11-19","Chronic HCV",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-11-19: Approved for treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. <i>(Non-hematologic indication)</i>","2022-09-05"
"Eltrombopag","FDA","2014-08-26","Aplastic anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-08-26: Approved for patients with <a href=""/wiki/Aplastic_anemia"" title=""Aplastic anemia""> severe aplastic anemia</a> who have had an insufficient response to immunosuppressive therapy.","2022-09-05"
"Eltrombopag","FDA","2015-08-24","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-08-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm"">Approved</a> for the treatment of thrombocytopenia in pediatric patients 1 year and older with <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">chronic immune (idiopathic) thrombocytopenia (ITP)</a> who have had an insufficient response to <a href=""/wiki/Category:Steroids"" title=""Category:Steroids"">corticosteroids</a>, immunoglobulins, or splenectomy.","2022-09-05"
"Eltrombopag","PMDA","2017-08-25","Aplastic anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-08-25: New additional indication and a new dosage for the treatment of <a href=""/wiki/Aplastic_anemia"" title=""Aplastic anemia"">aplastic anemia</a>.","2023-06-16"
"Emapalumab","FDA","2018-11-20","Hemophagocytic lymphohistiocytosis",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"NI-0501-04","2018-11-20: Initial approval for adult and pediatric (newborn and older) patients with primary <a href=""/wiki/Hemophagocytic_lymphohistiocytosis"" title=""Hemophagocytic lymphohistiocytosis"">hemophagocytic lymphohistiocytosis (HLH)</a> with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. <i>(Based on NI-0501-04)</i>","2022-09-05"
"Emicizumab","EMA","2018-02-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-02-23: Initial authorisation","2023-07-31"
"Emicizumab","EMA","2023-03-06","Hemophilia A",FALSE,FALSE,FALSE,"","","","without FVIII inhibitor","severe disease OR moderate disease with severe bleeding phenotype","","",NA,"","","","","","","",NA,"","2023-03-06: Indicated revised to include patients with <a href=""/w/index.php?title=Hemophilia_Aandaction=editandredlink=1"" class=""new"" title=""Hemophilia A (page does not exist)"">haemophilia A (congenital factor VIII deficiency)</a> without factor VIII inhibitors who have severe disease (FVIII &lt; 1%) or moderate disease (FVIII at least 1% and up to 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups.","2023-07-31"
"Emicizumab","EMA","Uncertain date","Hemophilia A",FALSE,FALSE,FALSE,"","","with factor VIII inhibitor","","","","",NA,"","","","","","","",NA,"","Uncertain date: Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with <a href=""/w/index.php?title=Hemophilia_Aandaction=editandredlink=1"" class=""new"" title=""Hemophilia A (page does not exist)"">haemophilia A (congenital factor VIII deficiency)</a> with factor VIII inhibitors. Hemlibra can be used in all age groups.","2023-07-31"
"Emicizumab","FDA","2017-11-16","Hemophilia A",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2017-11-16: Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with <a href=""/w/index.php?title=Hemophilia_Aandaction=editandredlink=1"" class=""new"" title=""Hemophilia A (page does not exist)"">hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors</a>.","2023-07-31"
"Emicizumab","FDA","2018-10-04","Hemophilia A",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-10-04: Approval expanded for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with <a href=""/w/index.php?title=Hemophilia_Aandaction=editandredlink=1"" class=""new"" title=""Hemophilia A (page does not exist)"">hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors</a>. (<i>requirement for inhibitor to be present was removed</i>)","2023-07-31"
"Emicizumab","PMDA","2022-06-20","Acquired hemophilia A",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2022-06-20: Drugs with a new indication and a new dosage for the control of bleeding tendency in patients with <a href=""/wiki/Acquired_hemophilia_A"" title=""Acquired hemophilia A"">acquired hemophilia A</a>.","2023-06-16"
"Enasidenib","FDA","2017-08-01","Acute myeloid leukemia",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","IDH2 mutation","FALSE",TRUE,"AG-221-C-001 relapsed","2017-08-01: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm"">FDA regular approval</a> for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a> with an <a href=""/wiki/Biomarkers#IDH2"" title=""Biomarkers"">isocitrate dehydrogenase-2 (IDH2)</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a> as detected by an FDA-approved test. <i>(Based on AG-221-C-001 relapsed)</i>","2022-09-05"
"Enasidenib","HC","2019-02-06","Acute myeloid leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","IDH2 mutation","FALSE",NA,"","2019-02-06: Initial notice of compliance with conditions for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">Acute Myeloid Leukemia (AML)</a> with an isocitrate dehydrogenase-2 IDH2 mutation.","2023-05-08"
"Encorafenib","EMA","2018-09-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-19: Iniital authorization","2023-05-08"
"Encorafenib","FDA","2018-06-27","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Binimetinib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COLUMBUS","2018-06-27: Initial approval in combination with <a href=""/wiki/Binimetinib_(Mektovi)"" title=""Binimetinib (Mektovi)"">Binimetinib (Mektovi)</a> for patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutation</a>, as detected by an FDA-approved test. <i>(Based on COLUMBUS)</i>","2022-09-05"
"Encorafenib","FDA","2020-04-09","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","1+","FALSE","","","","","Cetuximab","BRAF p.V600E","FALSE",TRUE,"BEACON CRC","2020-04-09: Approved in combination with cetuximab for the treatment of adult patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a>, detected by an FDA-approved test, after prior therapy. <i>(Based on BEACON CRC)</i>","2022-09-05"
"Encorafenib","FDA","2023-10-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","Binimetinib","BRAF p.V600E","FALSE",TRUE,"PHAROS","2023-10-11: Approved with <a href=""/wiki/Binimetinib_(Mektovi)"" title=""Binimetinib (Mektovi)"">Binimetinib (Mektovi)</a> for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a BRAF V600E mutation, as detected by an FDA-approved test. <i>(Based on PHAROS)</i>","2023-11-07"
"Encorafenib","HC","2021-03-02","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Binimetinib","BRAF p.V600","",NA,"","2021-03-02: Initial notice of compliance for use in combination with binimetinib for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation, as detected by a validated test.","2023-05-20"
"Encorafenib","PMDA","2019-01-08","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2019-01-08: New approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with BRAF gene mutation.","2023-06-16"
"Encorafenib","PMDA","2020-11-27","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","BRAF mutation","FALSE",NA,"","2020-11-27: New indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Enfortumab vedotin","EMA","2022-04-13","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen AND (anti-PD-1 antibody OR anti-PD-L1 antibody)","FALSE","","","","","0","","",NA,"","2022-04-13: Initial authorization as monotherapy for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.","2023-05-08"
"Enfortumab vedotin","FDA","2019-12-18","Urothelial carcinoma",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","(anti-PD-1 antibody OR anti-PD-L1 antibody) AND Platinum-based regimen","FALSE","Any","","","","","","",TRUE,"EV-201","2019-12-18: Granted accelerated approval for adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> in the neoadjuvant/adjuvant, locally advanced or metastatic setting. <i>(Based on EV-201)</i>","2022-09-05"
"Enfortumab vedotin","FDA","2021-07-09","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","(anti-PD-1 antibody OR anti-PD-L1 antibody) AND Platinum-based regimen","FALSE","","","","","","","",TRUE,"EV-301","2021-07-09: Regular approval for adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy. <i>(Based on EV-301)</i>","2022-09-05"
"Enfortumab vedotin","FDA","2021-07-09","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","ineligible for cisplatin-containing chemotherapy","1+","FALSE","","","","","","","",TRUE,"EV-301","2021-07-09: Regular approval for adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. <i>(Based on EV-301)</i>","2022-09-05"
"Enfortumab vedotin","FDA","2023-04-03","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","Ineligible for cisplatin-containing chemotherapy","",NA,"","","","","Pembrolizumab","","",TRUE,"EV-103","2023-04-03: Granted accelerated approval with pembrolizumab for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are ineligible for cisplatin-containing chemotherapy. <i>(Based on EV-103)</i>","2023-04-21"
"Enfortumab vedotin","FDA","2023-12-15","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","",NA,"","","","","Pembrolizumab","","",TRUE,"EV-302","2023-12-15: Approved in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> (la/mUC). <i>(Based on EV-302)</i>","2024-01-06"
"Enfortumab vedotin","HC","2021-10-29","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","Platinum-based regimen AND (anti-PD-1 antibody OR anti-PD-L1 antibody)","FALSE","","","","","","","",NA,"","2021-10-29: Initial notice of compliance for the treatment of adult patients with unresectable locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> who have previously received a platinum-containing chemotherapy and programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy.","2023-05-20"
"Enfortumab vedotin","PMDA","2021-09-27","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2021-09-27: Newly indicated for the treatment of unresectable <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Enoxaparin","FDA","1993-03-29","Venous thromboembolism",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1993-03-29: Initial FDA approval: prevention of DVT following hip replacement","2022-09-05"
"Ensartinib","NMPA","2020-11-17","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Second-line","","","","","Crizotinib","FALSE","","Progression OR Intolerance","","","","ALK rearrangement","FALSE",TRUE,"X396-CLI-101","2020-11-17: Initial approval for the second-line treatment of ALK-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> after progression or intolerance of crizotinib. <i>(Based on X396-CLI-101)</i>","2023-05-08"
"Ensartinib","NMPA","2023-03-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"eXalt3","2022-03: Approved for the first-line treatment of ALK-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on eXalt3)</i>","2023-05-08"
"Entrectinib","EMA","2020-07-31","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","ROS1 inhibitor","TRUE","","","","","0","ROS1 rearrangement","",NA,"","2020-07-31: Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> not previously treated with ROS1 inhibitors.","2023-11-07"
"Entrectinib","EMA","2020-07-31","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic OR surgical resection is likely to result in severe morbidity","","adults AND pediatric patients 12 years and older","satisfactory treatment options","0 NTRK inhibitor",NA,"","","","","0","NTRK rearrangement","",NA,"","2020-07-31: Initial conditional authorization as Rozlytrek. Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumours</a> expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options.","2023-11-07"
"Entrectinib","FDA","2019-08-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","ROS1 rearrangement","FALSE",TRUE,"ALKA-372-001","2019-08-15: Approved for adults with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ROS1"" title=""Biomarkers"">ROS1</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2019-08-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","ROS1 rearrangement","FALSE",TRUE,"STARTRK-1","2019-08-15: Approved for adults with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ROS1"" title=""Biomarkers"">ROS1</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2019-08-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","ROS1 rearrangement","FALSE",TRUE,"STARTRK-2","2019-08-15: Approved for adults with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ROS1"" title=""Biomarkers"">ROS1</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2019-08-15","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","Metastatic OR surgical resection is likely to result in severe morbidity","","","adults AND pediatric patients 12 years and older","","1+ OR no satisfactory standard therapy","FALSE","","","","","","NTRK rearrangement without a known resistance mutation","FALSE",TRUE,"ALKA-372-001","2019-08-15: Granted accelerated approval for adults and pediatric patients 12 years of age and older with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2019-08-15","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","Metastatic OR surgical resection is likely to result in severe morbidity","","","adults AND pediatric patients 12 years and older","","1+ OR no satisfactory standard therapy","FALSE","","","","","","NTRK rearrangement without a known resistance mutation","FALSE",TRUE,"STARTRK-1","2019-08-15: Granted accelerated approval for adults and pediatric patients 12 years of age and older with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2019-08-15","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","Metastatic OR surgical resection is likely to result in severe morbidity","","","adults AND pediatric patients 12 years and older","","1+ OR no satisfactory standard therapy","FALSE","","","","","","NTRK rearrangement without a known resistance mutation","FALSE",TRUE,"STARTRK-2","2019-08-15: Granted accelerated approval for adults and pediatric patients 12 years of age and older with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. <i>(Based on ALKA-372-001, STARTRK-1, and STARTRK-2)</i>","2022-09-05"
"Entrectinib","FDA","2023-10-20","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","","Metastatic|Surgical resection likely to result in severe morbidity","","pediatric aged 1 month or older","","1+ OR no satisfactory standard therapy","FALSE","","Progression|NA","","","","NTRK rearrangement without a known acquired resistance mutation","FALSE",TRUE,"STARTRK-NG","2023-10-20: Granted accelerated approval for pediatric patients older than 1 month with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors</a> that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. <i>(Based on STARTRK-NG and TAPISTRY)</i>","2023-11-07"
"Entrectinib","FDA","2023-10-20","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","","Metastatic|Surgical resection likely to result in severe morbidity","","pediatric aged 1 month or older","","1+ OR no satisfactory standard therapy","FALSE","","Progression|NA","","","","NTRK rearrangement without a known acquired resistance mutation","FALSE",TRUE,"TAPISTRY","2023-10-20: Granted accelerated approval for pediatric patients older than 1 month with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors</a> that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. <i>(Based on STARTRK-NG and TAPISTRY)</i>","2023-11-07"
"Entrectinib","HC","2020-02-10","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable locally advanced OR Metastatic","","adults","","",NA,"","","","","","NTRK rearrangement without a known resistance mutation","FALSE",NA,"","2020-02-10: Initial notice of compliance with conditions for the treatment of adult patients with unresectable locally advanced or metastatic extracranial <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumours</a>, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.","2023-05-08"
"Entrectinib","PMDA","2019-06-18","Malignant solid neoplasm NTRK-mutated",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","",NA,"","","","","","NTRK rearrangement","FALSE",NA,"","2019-06-18: Newly indicated for the treatment of NTRK fusion gene positive advanced or recurrent <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumours</a>.","2023-06-16"
"Entrectinib","PMDA","2020-02-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","ROS1 rearrangement","FALSE",NA,"","2020-02-21: New indication and a new dosage for the treatment of ROS1 fusion gene-positive unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Envafolimab","NMPA","2021-11-26","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","no satisfactory alternative treatment options","Advanced","","adults","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",NA,"","2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.","2023-07-31"
"Envafolimab","NMPA","2021-11-26","Colorectal cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","","MSI-H|dMMR","FALSE",NA,"","2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.","2023-07-31"
"Enzalutamide","EMA","2013-06-21","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adult men","","Docetaxel",NA,"","progression","","","","","",TRUE,"AFFIRM","2013-06-21: Initial marketing authorization as Xtandi. Xtandi is indicated for the treatment of adult men with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> whose disease has progressed on or after docetaxel therapy. <i>(Based on AFFIRM)</i>","2023-09-17"
"Enzalutamide","EMA","2014-11-28","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","asymptomatic or mildly symptomatic","adult men","chemotherapy is not yet clinically indicated","ADT",NA,"","Failure","","","","","",NA,"","2014-11-28: Extension of indication for the treatment of adult men with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.","2023-09-17"
"Enzalutamide","EMA","2018-10-23","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-metastatic","high-risk","adult men","","",NA,"","","","","","","",NA,"","2018-10-23: Extension of Indication to include adult men with high-risk non-metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (CRPC).","2023-09-17"
"Enzalutamide","EMA","2021-04-30","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","adult men","","",NA,"","","","","ADT","","",TRUE,"ARCHES","2021-04-30: Extension of Indication to include the treatment of adult men with metastatic hormonesensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mHSPC) for Xtandi in combination with androgen deprivation therapy. <i>(Based on ARCHES)</i>","2023-09-17"
"Enzalutamide","FDA","2012-08-31","Prostate cancer",FALSE,FALSE,TRUE,"","Castrate-resistant","Metastatic","","","","Docetaxel","FALSE","","","","","","","",TRUE,"AFFIRM","2012-08-31: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm317997.htm"">Initial approval</a> for the treatment of patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> who have previously received <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a>. <i>(Based on AFFIRM)</i>","2022-09-05"
"Enzalutamide","FDA","2014-09-10","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","","","",TRUE,"PREVAIL","2014-09-10: Approved for the treatment of patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC). <i>(No longer needs to be after docetaxel; based on PREVAIL and TERRAIN)</i>","2022-09-05"
"Enzalutamide","FDA","2014-09-10","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","","","",TRUE,"TERRAIN","2014-09-10: Approved for the treatment of patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC). <i>(No longer needs to be after docetaxel; based on PREVAIL and TERRAIN)</i>","2022-09-05"
"Enzalutamide","FDA","2018-07-13","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","","","","","",NA,"","","","","","","",TRUE,"PROSPER_PrCA","2018-07-13: Approved for patients with <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">castration-resistant prostate cancer (CRPC)</a>. <i>(No longer needs to be metatstatic; based on PROSPER_PrCA)</i>","2022-09-05"
"Enzalutamide","FDA","2019-12-16","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Metastatic","","","","",NA,"","","","","","","",TRUE,"ARCHES","2019-12-16: Approved for patients with metastatic castration-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCSPC). <i>(No longer needs to be castration-resistant, if metastatic; based on ARCHES)</i>","2022-09-05"
"Enzalutamide","FDA","2023-11-16","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Non-metastatic with biochemical recurrence","High risk for metastasis","","","",NA,"","","","","","","",TRUE,"EMBARK","2023-11-16: Approved for non-metastatic castration-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). <i>(No longer needs to be castration-resistant; based on EMBARK)</i>","2024-01-06"
"Enzalutamide","HC","2013-05-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-05-29: Initial notice of compliance","2023-05-08"
"Enzalutamide","PMDA","2014-03-24","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","","","","","",NA,"","","","","","","",NA,"","2014-03-24: Initial approval for the treatment of castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Enzalutamide","PMDA","2020-05-29","Prostate cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",NA,"","2020-05-29: New indication for the treatment of metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Epcoritamab","EMA","2023-09-25","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","0","","",NA,"","2023-09-25: Granted conditional authorization at Tepkinly. Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> after two or more lines of systemic therapy.","2023-11-07"
"Epcoritamab","FDA","2023-05-19","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",TRUE,"EPCORE NHL-1","2023-05-19: Granted accelerated approval for relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> after two or more lines of systemic therapy. <i>(Based on EPCORE NHL-1)</i>","2023-05-20"
"Epcoritamab","FDA","2023-05-19","High-grade B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",TRUE,"EPCORE NHL-1","2023-05-19: Granted accelerated approval for relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> after two or more lines of systemic therapy. <i>(Based on EPCORE NHL-1)</i>","2023-05-20"
"Epcoritamab","FDA","2023-05-19","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",TRUE,"EPCORE NHL-1","2023-05-19: Granted accelerated approval for relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> after two or more lines of systemic therapy. <i>(Based on EPCORE NHL-1)</i>","2023-05-20"
"Epcoritamab","FDA","2024-06-26","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+",NA,"","","","","","","",TRUE,"EPCORE NHL-1_FL","2024-06-26: Granted accelerated approval for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> who received at least 2 prior lines of therapy. <i>(Based on EPCORE NHL-1_FL)</i>","2024-09-06"
"Epcoritamab","PMDA","2023-09-25","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2023-09-25: Newly indicated for the treatment of relapsed or refractory large B-cell lymphoma (<a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>) or relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-06-03"
"Epcoritamab","PMDA","2023-09-25","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-09-25: Newly indicated for the treatment of relapsed or refractory large B-cell lymphoma (<a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>) or relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-06-03"
"Epcoritamab","PMDA","2023-09-25","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-09-25: Newly indicated for the treatment of relapsed or refractory large B-cell lymphoma (<a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>) or relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-06-03"
"Epcoritamab","PMDA","2023-09-25","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2023-09-25: Newly indicated for the treatment of relapsed or refractory large B-cell lymphoma (<a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, and <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>) or relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-06-03"
"Epinephrine autoinjector","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Epirubicin","EMA","1982-06-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1982-06-28: EURD","2023-07-31"
"Epirubicin","FDA","1999-09-15","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Axillary lymph node involvement","","","","Surgery","FALSE","","","","","","","",TRUE,"FASG 05","1999-09-15: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on FASG 05 and NCIC-CTG MA.5)</i>","2022-09-05"
"Epirubicin","FDA","1999-09-15","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Axillary lymph node involvement","","","","Surgery","FALSE","","","","","","","",TRUE,"NCIC-CTG MA.5","1999-09-15: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on FASG 05 and NCIC-CTG MA.5)</i>","2022-09-05"
"Epoetin alfa","FDA","1989-06-01","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1989-06-01: Initial FDA approval","2022-09-05"
"Epoetin alfa-epbx","FDA","2018-05-15","Anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-05-15: FDA approved ""for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis, use of zidovudine in patients with HIV infection, and the effects of concomitant myelosuppressive chemotherapy. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.""","2022-09-05"
"Epoetin beta","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Eptifibatide","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Erdafitinib","FDA","2019-04-12","Urothelial carcinoma",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","1+, including Platinum-based regimen","FALSE","","","","","","FGFR2 mutation|FGFR3 mutation","FALSE",TRUE,"BLC2001","2019-04-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer"">Accelerated FDA approval</a> for adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> that has susceptible <a href=""/wiki/Biomarkers#FGFR3"" title=""Biomarkers"">FGFR3</a> or <a href=""/wiki/Biomarkers#FGFR2"" title=""Biomarkers"">FGFR2</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">genetic alterations</a> and progressed during or following at least one line of prior <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. <i>(Based on BLC2001)</i>","2022-09-05"
"Erdafitinib","FDA","2023-01-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT",NA,"","progression","","","","Susceptible FGFR3 mutations","",TRUE,"THOR cohort 1","2023-01-19: Approved for adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. <i>(Based on THOR cohort 1)</i>","2024-02-01"
"Erdafitinib","HC","2019-10-25","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ Chemotherapy","FALSE","","progression","","","","FGFR2 mutation|FGFR3 mutation","FALSE",NA,"","2019-10-25: Initial notice of compliance with conditions for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> whose tumors have susceptible fibroblast growth factor receptor (FGFR)2 or FGFR3 genetic alterations and who have disease progression during or following at least one line of prior chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy.","2023-05-08"
"Eribulin","EMA","2011-03-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-03-17: Initial marketing authorization as Halaven.","2023-05-08"
"Eribulin","EMA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.","2024-12-02"
"Eribulin","EMA","Uncertain date","Liposarcoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","Uncertain date: Indicated for the treatment of adult patients with unresectable <a href=""/wiki/Liposarcoma"" title=""Liposarcoma"">liposarcoma</a> who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.","2024-12-02"
"Eribulin","FDA","2010-11-15","Breast cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","2+ SACT, including Anthracycline-based regimen AND Taxane-based regimen","FALSE","Metastatic","","","","","","",TRUE,"EMBRACE","2010-11-15: Initial approval for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline</a> and a <a href=""/wiki/Regimen_classes#Taxane-based_regimen"" title=""Regimen classes"">taxane</a> in either the adjuvant or metastatic setting. <i>(Based on EMBRACE)</i>","2022-09-05"
"Eribulin","FDA","2016-01-28","Liposarcoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","Anthracycline-based regimen","FALSE","","","","","","","",TRUE,"E7389-G000-309","2016-01-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm"">Approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Liposarcoma"" title=""Liposarcoma"">liposarcoma</a> who have received a prior <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing regimen</a>. <i>(Based on E7389-G000-309)</i>","2022-09-05"
"Eribulin","HC","2011-12-14","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","2+ SACT, including Anthracycline-based regimen AND Taxane-based regimen","FALSE","Metastatic","","","","","","",NA,"","2011-12-14: Initial notice of compliance for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting.","2023-05-20"
"Eribulin","HC","2017-08-04","Liposarcoma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Metastatic","","adults","","Anthracycline-based regimen, unless not clinically appropriate","FALSE","","","","","","","",NA,"","2017-08-04: New indication for the treatment of adult patients with an unresectable advanced or metastatic <a href=""/wiki/Liposarcoma"" title=""Liposarcoma"">liposarcoma</a> subtype of soft tissue sarcoma. Prior therapy should have included an anthracycline-containing regimen, unless not clinically appropriate.","2023-05-20"
"Eribulin","PMDA","2011-04-22","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2011-04-22: Initial approval for the treatment of inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Eribulin","PMDA","2016-02-29","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-02-29: New additional indication for the treatment of <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">soft tissue sarcoma</a>.","2023-06-16"
"Erlotinib","EMA","2005-09-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","1+ Chemotherapy","FALSE","","Failure","","","","","",TRUE,"NCIC-CTG BR.21","2005-09-19: Initial marketing authorization as Tarceva. Tarceva is indicated for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> after failure of at least one prior chemotherapy regimen. <i>(Based on NCIC-CTG BR.21)</i>","2023-11-07"
"Erlotinib","EMA","2010-03-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line maintenance","Locally advanced OR Metastatic","","","","Platinum-based regimen x 4","FALSE","","stable disease","","","0","","",NA,"","2010-03-18: Extension of indication as monotherapy for maintenance treatment in patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.","2023-11-07"
"Erlotinib","EMA","2011-08-24","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","","EGFR activating mutations","FALSE",NA,"","2011-08-24: Extension of indication of Tarceva for the first-line treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> with EGFR activating mutations.","2023-11-07"
"Erlotinib","EMA","2016-01-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","Chemotherapy","FALSE","","stable disease","","","","EGFR activating mutations","FALSE",TRUE,"IUNO","2016-01-25: Modification of the indication to limit maintenance treatment to <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> patients with an EGFR-activating mutation and stable disease after first-line chemotherapy. <i>(Based on IUNO)</i>","2023-11-07"
"Erlotinib","FDA","2004-11-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","1+ Chemotherapy","FALSE","","","","","","","",TRUE,"NCIC-CTG BR.21","2004-11-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm"">Approved</a> for treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> NSCLC</a> after failure of at least one prior chemotherapy regimen. <i>(Based on NCIC-CTG BR.21)</i>","2022-09-05"
"Erlotinib","FDA","2005-11-02","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Unresectable OR Metastatic","","","","0","FALSE","","","","","Gemcitabine","","",TRUE,"NCIC-CTG PA.3","2005-11-02: Approved as first-line treatment of patients with locally advanced, unresectable or metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>, in combination with <a href=""/wiki/Gemcitabine_(Gemzar)"" title=""Gemcitabine (Gemzar)""> gemcitabine</a>. <i>(Based on NCIC-CTG PA.3)</i>","2022-09-05"
"Erlotinib","FDA","2010-04-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen x 4","FALSE","","without progression","","","","","",TRUE,"SATURN","2010-04-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm"">Approved</a> for maintenance treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> whose disease has not progressed after four cycles of <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes""> platinum-based</a> first-line chemotherapy. <i>(Based on SATURN)</i>","2022-09-05"
"Erlotinib","FDA","2013-05-14","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"EURTAC","2013-05-14: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352230.htm"">Approved</a> for first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 (L858R) substitution</a> mutations as detected by an FDA-approved test. <i>(Based on EURTAC)</i>","2022-09-05"
"Erlotinib","FDA","2016-10-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Maintenance or second-line or later treatment","","","","","",NA,"","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"IUNO","2016-10-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525739.htm"">Label revised</a> to limit use to those patients whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">EGFR</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 L858R substitution</a> mutations as detected by an FDA-approved test. This limitation pertains to patients with <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> receiving maintenance or second or greater line treatment. <i>(Based on IUNO)</i>","2022-09-05"
"Erlotinib","HC","2005-07-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2005-07-07: Initial notice of compliance (unclear details)","2023-05-20"
"Erlotinib","HC","2011-03-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Maintenance","Locally advanced OR Metastatic","","","","Platinum-based regimen x 4","FALSE","","stable disease","","","0","","",NA,"","2011-03-11: New Indication as monotherapy for maintenance treatment in patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.","2023-05-20"
"Erlotinib","HC","2012-07-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Unresectable stage IIIb OR Metastatic","","","","0","FALSE","","","","","0","Activating EGFR mutations","FALSE",NA,"","2012-07-20: New indication as monotherapy for the first-line treatment of patients with locally advanced (stage III b) not amenable to curative therapy) or metastatic (stage IV) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with EFGR activating mutations.","2023-05-20"
"Erlotinib","HC","2017-03-29","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Maintenance","Locally advanced OR Metastatic","","","","",NA,"","","","","","Activating EGFR mutations","FALSE",TRUE,"IUNO","2017-03-29: Revision to the maintenance indication for locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> based on the IUNO study and SATURN study results to limit use to patients with locally advanced or metastatic non-small cell lung cancer whose tumors have activating mutations in the epidermal growth factor receptor (EGFR) gene.","2023-05-20"
"Erlotinib","HC","2017-03-29","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Maintenance","Locally advanced OR Metastatic","","","","",NA,"","","","","","Activating EGFR mutations","FALSE",TRUE,"SATURN","2017-03-29: Revision to the maintenance indication for locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> based on the IUNO study and SATURN study results to limit use to patients with locally advanced or metastatic non-small cell lung cancer whose tumors have activating mutations in the epidermal growth factor receptor (EGFR) gene.","2023-05-20"
"Erlotinib","PMDA","2007-10-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","Exacerbated","","","","","",NA,"","2007-10-19: Initial approval for the treatment of unresectable, relapsed/advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> exacerbated after cancer chemotherapy.","2023-06-16"
"Erlotinib","PMDA","2011-07-01","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2011-07-01: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Erlotinib","PMDA","2013-06-14","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","TRUE","","","","","","EGFR mutation","FALSE",NA,"","2013-06-14: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with EGFR gene mutation in patients who have not been treated with chemotherapy.","2023-06-16"
"Estradiol","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Estramustine","EMA","1971-09-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1971-09-02: EURD","2023-07-31"
"Estramustine","FDA","1981-12-24","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1981-12-24: Initial FDA approval","2022-09-05"
"Ethinylestradiol","FDA","1943-06-25","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1943-06-25: Initial approval","2023-07-31"
"Ethinylestradiol","FDA","2004-06-04","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-06-04: Withdrawn at the request of the manufacturer","2023-07-31"
"Etoposide","EMA","1980-07-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1980-07-09: EURD","2023-07-31"
"Etoposide","FDA","1983-11-10","Testicular cancer",FALSE,FALSE,FALSE,"","Refractory","","","","","",NA,"","","","","","","",FALSE,"","1983-11-10: Initial FDA approval for refractory <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer""> testicular tumors</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Etoposide","FDA","Uncertain date","Small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Cisplatin","","",TRUE,"Hainsworth et al. 1995","Uncertain date: Approed for <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a>, in combination with cisplatin, as first-line treatment. <i>(Based on Hainsworth et al. 1995)</i>","2022-09-05"
"Etoposide","PMDA","2012-02-22","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","Progression","","","","","",NA,"","2012-02-22: New additional indication and a new dosage for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Etoposide","PMDA","2019-03-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.","2023-06-16"
"Etranacogene dezaparvovec","EMA","2023-02-20","Hemophilia B",TRUE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-02-20: Granted conditional authorisation for the treatment of severe and moderately severe <a href=""/wiki/Inherited_coagulopathy"" title=""Inherited coagulopathy"">Haemophilia B (congenital Factor IX deficiency)</a> in adult patients without a history of Factor IX inhibitors.","2023-05-08"
"Etranacogene dezaparvovec","FDA","2022-11-22","Hemophilia B",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2022-11-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b"">Approved</a> for the treatment of adults with <a href=""/wiki/Inherited_coagulopathy"" title=""Inherited coagulopathy"">Hemophilia B (congenital Factor IX deficiency)</a> who currently use <a href=""/wiki/Category:Coagulation_factors"" title=""Category:Coagulation factors"">Factor IX</a> prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.","2023-04-08"
"Everolimus","EMA","2009-08-02","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","VEGF-targeted therapy",NA,"","progression","","","","","",NA,"","2009-08-02: Initial marketing authorization as Afinitor. Afinitor is intended for the treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>, whose disease has progressed on or after treatment with VEGF-targeted therapy.","2023-09-17"
"Everolimus","EMA","2011-08-24","Pancreatic NET",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","Well- or moderately-differentiated","adults","","",NA,"","progression","","","","","",NA,"","2011-08-24: Extension of indication to include Afinitor is indicated for the treatment of unresectable or metastatic, well- or moderately-differentiated <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">neuroendocrine tumours of pancreatic origin</a> in adults with progressive disease.","2023-09-17"
"Everolimus","EMA","2012-06-21","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women without symptomatic visceral disease","","non-steroidal aromatase inhibitor",NA,"","recurrence|progression","","","Exemestane","HR+ and HER2-","",NA,"","2012-06-21: Extension of indication to include Afinitor for the treatment of hormone receptor-positive, HER2/neu negative advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","2023-09-17"
"Everolimus","EMA","2016-05-26","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","Well-differentiated non-functional GI or lung origin","adults","","",NA,"","progression","","","","","",NA,"","2016-05-26: Extension of indication to include a new indication for the treatment of unresectable or metastatic, well-differentiated non-functional <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumours of gastrointestinal or lung origin</a> in adults with progressive disease.","2023-09-17"
"Everolimus","FDA","2009-03-30","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","Sunitinib monotherapy OR Sorafenib monotherapy","FALSE","","","","","","","",TRUE,"RECORD-1","2009-03-30: <b>Initial approval</b> for the treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a> after failure of treatment with <a href=""/wiki/Renal_cell_carcinoma#Sunitinib_monotherapy"" title=""Renal cell carcinoma""> sunitinib</a> or <a href=""/wiki/Renal_cell_carcinoma#Sorafenib_monotherapy"" title=""Renal cell carcinoma""> sorafenib</a>. <i>(Based on RECORD-1)</i>","2022-09-05"
"Everolimus","FDA","2010-10-29","Subependymal giant cell astrocytoma",TRUE,FALSE,FALSE,"","","","","","Not candidate for curative surgical resection","",NA,"","","","","","","",TRUE,"CCHMC 06-07-50","2010-10-29: Accelerated approval for <a href=""/wiki/Subependymal_giant_cell_astrocytoma"" title=""Subependymal giant cell astrocytoma""> subependymal giant cell astrocytoma (SEGA)</a> associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection. <i>(Based on CCHMC 06-07-50)</i>","2022-09-05"
"Everolimus","FDA","2011-05-05","Pancreatic NET",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Metastatic","","","","",NA,"","","","","","","",TRUE,"RADIANT-3","2011-05-05: Approval expanded to include progressive <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET""> neuroendocrine tumors of pancreatic origin (PNET)</a> that is unresectable, locally advanced or metastatic. <i>(Based on RADIANT-3)</i>","2022-09-05"
"Everolimus","FDA","2012-04-26","Renal angiomyolipoma",TRUE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"EXIST-2","2012-04-26: Accelerated approval for adults with <a href=""/w/index.php?title=Renal_angiomyolipomaandaction=editandredlink=1"" class=""new"" title=""Renal angiomyolipoma (page does not exist)"">renal angiomyolipoma</a> and tuberous sclerosis complex (TSC), not requiring immediate surgery. <i>(Based on EXIST-2)</i>","2022-09-05"
"Everolimus","FDA","2012-07-20","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","Letrozole monotherapy OR Anastrozole monotherapy","FALSE","","","","","Exemestane","HR+ and HER2-","FALSE AND TRUE",TRUE,"BOLERO-2","2012-07-20: Approval expanded to include postmenopausal women with advanced <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (advanced HR+ BC) <a href=""/wiki/Breast_cancer#Exemestane_&_Everolimus"" title=""Breast cancer"">in combination with exemestane</a> after failure of treatment with <a href=""/wiki/Breast_cancer#Letrozole_monotherapy_2"" title=""Breast cancer""> letrozole</a> or <a href=""/wiki/Breast_cancer#Anastrozole_monotherapy_2"" title=""Breast cancer""> anastrozole</a>. <i>(Based on BOLERO-2)</i>","2022-09-05"
"Everolimus","FDA","2016-01-29","Subependymal giant cell astrocytoma",FALSE,FALSE,FALSE,"","","","","","Not candidate for curative surgical resection","",NA,"","","","","","","",TRUE,"EXIST-1","2016-01-29: Converted to regular approval for <a href=""/wiki/Subependymal_giant_cell_astrocytoma"" title=""Subependymal giant cell astrocytoma""> subependymal giant cell astrocytoma (SEGA)</a> associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection. <i>(Based on EXIST-1)</i>","2022-09-05"
"Everolimus","FDA","2016-02-18","Renal angiomyolipoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-02-18: Converted to regular approval","2022-09-05"
"Everolimus","FDA","2016-02-26","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Metastatic","","adults","","",NA,"","","","","","","",TRUE,"RADIANT-4","2016-02-26: Approval expanded for the treatment of adult patients with progressive, well-differentiated non-functional, <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin</a> with unresectable, locally advanced or metastatic disease. <i>(Based on RADIANT-4)</i>","2022-09-05"
"Everolimus","HC","2011-06-30","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-06-30: Initial notice of compliance with conditions","2023-05-08"
"Everolimus","HC","2016-09-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-09-23: Conditions were met","2023-05-08"
"Everolimus","PMDA","2007-01-26","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-01-26: Initial approval for the prophylaxis of organ rejection in cardiac transplant.","2023-07-31"
"Everolimus","PMDA","2010-01-20","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2010-01-20: New additional indication and a new dosage for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Everolimus","PMDA","2011-12-22","Pancreatic NET",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-12-22: New additional indication and a new dosage for the treatment of <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumor</a>.","2023-06-16"
"Everolimus","PMDA","2012-11-21","Subependymal giant cell astrocytoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-11-21: New additional indications and a new dosage for the treatment of renal angiomyolipoma associated with tuberous sclerosis complex and <a href=""/wiki/Subependymal_giant_cell_astrocytoma"" title=""Subependymal giant cell astrocytoma"">subependymal giant cell astrocytoma</a> associated with tuberous sclerosis complex.","2023-06-16"
"Everolimus","PMDA","2014-03-17","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2014-03-17: New additional indication and a new dosage for the treatment of unresectable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Everolimus","PMDA","2016-08-26","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-08-26: revised indication from ""pancreatic neuroendocrine tumor"" to ""<a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumor</a>.""","2023-06-16"
"Exagamglogene autotemcel","FDA","2023-12-08","Sickle cell anemia",FALSE,FALSE,TRUE,"","recurrent vaso-occlusive crises","","","","","",NA,"","","","","","","",TRUE,"CLIMB SCD-121","2023-12-08: Approved for the treatment of <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell disease (SCD)</a> with recurrent vaso-occlusive crises (VOCs). <i>(Based on CLIMB SCD-121)</i>","2024-06-03"
"Exagamglogene autotemcel","FDA","2024-01-16","Beta thalassemia",FALSE,FALSE,FALSE,"","transfusion-dependent","","","12 years and older","","",NA,"","","","","","","",TRUE,"CLIMB THAL-111","2024-01-16: Approved for the treatment of transfusion-dependent <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassemia</a> (TDT) in patients 12 years and older. <i>(Based on CLIMB THAL-111)</i>","2024-06-03"
"Exemestane","EMA","1998-12-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-12-16: EURD","2023-07-31"
"Exemestane","FDA","1999-10-21","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","Tamoxifen monotherapy","FALSE","","progression","","","","","",TRUE,"Kaufmann et al. 2000","1999-10-21: Initial FDA approval for the treatment of advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> in postmenopausal women whose disease has progressed following <a href=""/wiki/Tamoxifen_(Nolvadex)"" title=""Tamoxifen (Nolvadex)""> tamoxifen</a> therapy. <i>(Based on Kaufmann et al. 2000)</i>","2022-09-05"
"Exemestane","FDA","2005-10-05","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery AND 2 to 3 years of Tamoxifen monotherapy","FALSE","","","","","","ER+","FALSE",TRUE,"IES","2005-10-05: Approved for adjuvant treatment of postmenopausal women with <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. <i>(Based on IES)</i>","2022-09-05"
"Exemestane","HC","2006-05-12","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-05-12: Initial notice of compliance with conditions","2023-05-08"
"Exemestane","HC","2008-06-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-06-08: Conditions were met","2023-05-08"
"Factor IX human","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor IX recombinant","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor IX recombinant Fc fusion protein","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor VIIa recombinant","FDA","1999-03-25","Hemophilia",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1999-03-25: Initial approval for use in the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.","2022-09-05"
"Factor VIIa recombinant","FDA","2008-05-09","Hemophilia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-05-09: Approval of NovoSeven RT formulation for treatment of bleeding and the prevention of surgical bleeding in patients with hemophilia A or B, who have antibodies that neutralize the action of clotting Factors VIII or IX; the treatment of bleeding and the prevention of surgical bleeding in patients with congenital Factor VII deficiency; and the prevention of surgical bleeding in patients with acquired hemophilia.","2022-09-05"
"Factor VIII human","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor VIII recombinant","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor X human","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Factor XIII concentrate human","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Famciclovir","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Famotidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Fedratinib","EMA","2021-02-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-02-08: Initial authorization as Inrebic","2023-05-08"
"Fedratinib","FDA","2019-08-16","Myelofibrosis",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"JAKARTA","2019-08-16: Initial approval for adults with <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)</a>. <i>(Based on JAKARTA)</i>","2022-09-05"
"Ferric carboxymaltose","FDA","2013-07-25","Iron deficiency anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.","2023-05-20"
"Ferric carboxymaltose","FDA","2013-07-25","Iron deficiency anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non-dialysis-dependent chronic kidney disease.","2023-05-20"
"Ferric gluconate","FDA","1999-02-18","Iron deficiency anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1999-02-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1999/20955ltr.pdf"">Approved</a> for treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoetin therapy.","2022-09-05"
"Ferrous sulfate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ferumoxytol","FDA","2009-06-30","Iron deficiency anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2009-06-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf"">Initial approval</a> for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).","2022-09-05"
"Filgrastim","FDA","1991-02-20","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1991-02-20: Initial approval.","2022-09-05"
"Filgrastim","FDA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.","2023-05-20"
"Filgrastim","FDA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.","2023-05-20"
"Filgrastim","FDA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).","2023-05-20"
"Filgrastim","FDA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to reduce the incidence and duration of sequelae of severe neutropenia (e.g.,fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.","2023-05-20"
"Filgrastim","FDA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).","2023-05-20"
"Filgrastim","PMDA","2021-06-23","Neuroblastoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Dinutuximab","","",NA,"","2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>.","2023-06-16"
"Filgrastim","PMDA","2022-06-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","Antineoplastic agents","","",NA,"","2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Filgrastim-aafi","EMA","2010-06-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-06-07: Initial authorization as Nivestim","2023-05-08"
"Filgrastim-aafi","FDA","2018-07-20","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-07-20: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436953.htm"">Approved as a biosimilar</a> to US-licensed <a href=""/wiki/Filgrastim_(Neupogen)"" title=""Filgrastim (Neupogen)"">Neupogen</a> for the five indications for which US-licensed <a href=""/wiki/Filgrastim_(Neupogen)"" title=""Filgrastim (Neupogen)"">Neupogen</a> is approved:","2022-09-05"
"Filgrastim-ayow","FDA","2022-05-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-05-22: Approved as a biosimilar to US-licensed <a href=""/wiki/Filgrastim_(Neupogen)"" title=""Filgrastim (Neupogen)"">Neupogen</a>.","2023-07-31"
"Filgrastim-sndz","EMA","2009-02-06","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-02-06: Initial authorization as Zarzio","2023-05-08"
"Filgrastim-sndz","FDA","2015-03-06","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-03-06: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436953.htm"">FDA Approved as a biosimilar</a> to US-licensed <a href=""/wiki/Filgrastim_(Neupogen)"" title=""Filgrastim (Neupogen)"">Neupogen</a> for the five indications for which US-licensed <a href=""/wiki/Filgrastim_(Neupogen)"" title=""Filgrastim (Neupogen)"">Neupogen</a> is approved:","2022-09-05"
"Finasteride","FDA","1992-06-19","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1992-06-19: Initial approval","2023-11-07"
"Floxuridine","FDA","1970-12-18","Gastrointestinal cancer",FALSE,FALSE,FALSE,"","","Metastatic to liver AND Incurable by surgery or other means","","","","",NA,"","","","","","","",FALSE,"","1970-12-18: Initial FDA approval for the palliative management of <a href=""/wiki/Category:Gastrointestinal_cancers"" title=""Category:Gastrointestinal cancers"">gastrointestinal adenocarcinoma</a> metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents. <i>(No supporting studies are cited)</i>","2022-09-05"
"Fluconazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Fludarabine","EMA","1994-08-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1994-08-11: EURD","2023-07-31"
"Fludarabine","FDA","1991-04-18","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","1+ Alkylator-based regimen","FALSE","","","","","","","",TRUE,"Grever et al. 1990","1991-04-18: Initial FDA approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia (CLL)</a> who have not responded to or whose disease has progressed during treatment with at least one standard <a href=""/wiki/Category:Alkylating_agents"" title=""Category:Alkylating agents"">alkylating-agent</a> containing regimen. <i>(Based on Grever et al. 1990 and Keating et al. 1989)</i>","2022-09-05"
"Fludarabine","FDA","1991-04-18","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","1+ Alkylator-based regimen","FALSE","","","","","","","",TRUE,"Keating et al. 1989","1991-04-18: Initial FDA approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> B-cell chronic lymphocytic leukemia (CLL)</a> who have not responded to or whose disease has progressed during treatment with at least one standard <a href=""/wiki/Category:Alkylating_agents"" title=""Category:Alkylating agents"">alkylating-agent</a> containing regimen. <i>(Based on Grever et al. 1990 and Keating et al. 1989)</i>","2022-09-05"
"Fludarabine","FDA","2024-11-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2024-11-19: Project Renewal revision for the treatment of adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">B-cell CLL</a> who have not responded to or whose disease has progressed during treatment with at least one alkylating-agent containing regimen.","2024-12-02"
"Fludarabine","FDA","2024-11-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"GCLLSG CLL8","2024-11-19: Project Renewal revision as a component of a combination regimen for the treatment of adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">B-cell chronic lymphocytic leukemia (CLL)</a>. <i>(Based on GCLLSG CLL8, REACH)</i>","2024-12-02"
"Fludarabine","FDA","2024-11-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"REACH","2024-11-19: Project Renewal revision as a component of a combination regimen for the treatment of adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">B-cell chronic lymphocytic leukemia (CLL)</a>. <i>(Based on GCLLSG CLL8, REACH)</i>","2024-12-02"
"Fludarabine","PMDA","2007-01-26","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-01-26: New route of administation and additional indications for treatment of <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Fludarabine","PMDA","2007-01-26","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-01-26: New route of administation and additional indications for treatment of <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Fludarabine","PMDA","2008-05-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-05-20: New indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma.","2023-06-16"
"Fludarabine","PMDA","2008-05-20","Allogeneic HSCT",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2008-05-20: New indication and a new dosage for use as a <a href=""/wiki/Allogeneic_HSCT"" title=""Allogeneic HSCT"">conditioning prior to allogeneic hematopoietic stem cell transplantation</a> in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma.","2024-12-02"
"Fludarabine","PMDA","2009-11-06","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","Anemia|Thrombocytopenia","","",NA,"","","","","","","",NA,"","2009-11-06: New additional indication for the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a> with anemia or thrombocytopenia.","2023-06-16"
"Fludarabine","PMDA","2009-11-06","Indolent lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2009-11-06: New additional indications and a new dosage for the treatment of recurrent or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Fludarabine","PMDA","2009-11-06","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2009-11-06: New additional indications and a new dosage for the treatment of recurrent or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Fludarabine","PMDA","2019-03-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.","2023-06-16"
"Fludarabine","PMDA","2022-06-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2022-06-20: New indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Fludrocortisone","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Fluorouracil","EMA","1977-12-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1977-12-16: EURD","2023-07-31"
"Fluorouracil","FDA","1962-04-25","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1962-04-25: Initial FDA approval","2022-09-05"
"Fluorouracil","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for the treatment of patients with <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">adenocarcinoma of the colon and rectum</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">adenocarcinoma of the breast</a>; <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric adenocarcinoma</a>; and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Fluorouracil","FDA","Uncertain date","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for the treatment of patients with <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">adenocarcinoma of the colon and rectum</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">adenocarcinoma of the breast</a>; <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric adenocarcinoma</a>; and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Fluorouracil","FDA","Uncertain date","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for the treatment of patients with <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">adenocarcinoma of the colon and rectum</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">adenocarcinoma of the breast</a>; <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric adenocarcinoma</a>; and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Fluorouracil","FDA","Uncertain date","Pancreatic cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for the treatment of patients with <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">adenocarcinoma of the colon and rectum</a>; <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">adenocarcinoma of the breast</a>; <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric adenocarcinoma</a>; and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Fluorouracil","PMDA","2013-12-20","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2013-12-20: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Fluorouracil","PMDA","2018-09-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-21: New indication and a new dosage for the treatment of <a href=""/wiki/Small_bowel_adenocarcinoma"" title=""Small bowel adenocarcinoma"">small intestine cancer</a>.","2023-06-16"
"Fluorouracil","PMDA","2021-11-25","Esophageal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-11-25: New indication and a new dosage for the treatment of <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a>.","2023-06-16"
"Fluoxymesterone","FDA","1956-10-15","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1956-10-15: Initial FDA approval","2022-09-05"
"Flutamide","EMA","1982-03-24","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1982-03-24: EURD","2023-07-31"
"Flutamide","FDA","1989-01-27","Prostate cancer",FALSE,FALSE,FALSE,"","","Bulky locally advanced Stage B2 and Stage C","","","","",NA,"","","","","LHRH agonist AND external beam radiotherapy","","",TRUE,"Pilepich et al. 1995","1989-01-27: Also approved in combination with LHRH agonists are also indicated prior to and during definitive external beam radiotherapy for patients with bulky locally advanced Stage B2 and Stage C <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic carcinoma</a>. <i>(Based on Pilepich et al. 1995)</i>","2022-09-05"
"Flutamide","FDA","1989-01-27","Prostate cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","LHRH agonist","","",TRUE,"SWOG-8494","1989-01-27: Initial FDA approval for use in combination with LHRH agonistic analogs (such as leuprolide acetate) for the treatment of metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic carcinoma</a> (stage D2). To achieve the benefit of the adjunctive therapy with EUFLEX, treatment must be started simultaneously using both drugs. EUFLEX Tablets are also indicated as an adjunctive therapy to orchiectomy, in order to achieve complete androgen blockade. <i>(Based on SWOG-8494)</i>","2022-09-05"
"Folic acid","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Fondaparinux","EMA","2002-03-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2002-03-20: Initial authorization","2023-05-08"
"Fondaparinux","FDA","2001-12-07","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2001-12-07: Initial approval: prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery; patients undergoing hip replacement surgery; or patients undergoing knee replacement surgery.","2022-09-05"
"Formestane","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Forodesine","PMDA","2017-03-30","Peripheral T-cell lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-03-30: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>.","2023-06-16"
"Fosaprepitant","EMA","2008-01-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-01-11: Initial authorization as Ivemend","2023-05-08"
"Fosaprepitant","FDA","2008-01-25","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-01-25: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022023lbl.pdf"">Approved</a> for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose <a href=""/wiki/Cisplatin"" class=""mw-redirect"" title=""Cisplatin"">cisplatin</a> and prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.","2022-09-05"
"Fosnetupitant","PMDA","2022-03-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-03-28: Newly indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.).","2023-07-31"
"Fostamatinib","EMA","2020-01-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-01-09: Initial authorization as Tavlesse","2023-05-08"
"Fostamatinib","FDA","2018-04-17","Immune thrombocytopenia",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2018-04-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604956.htm"">Granted FDA regular approval</a> ""for the treatment of thrombocytopenia in adult patients with chronic <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">immune thrombocytopenia (ITP)</a> who have had an insufficient response to a previous treatment.""","2022-09-05"
"Fostamatinib","HC","2020-11-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-11-19: Initial notice of compliance","2023-07-31"
"Fostamatinib","PMDA","2022-12-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-12-23: Initial approval","2023-11-07"
"Fotemustine","EMA","1989-04-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1989-04-14: EURD","2023-07-31"
"Fruquintinib","FDA","2023-11-08","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND an anti-VEGF therapy AND if RAS wild-type and medically appropriate, an anti-EGFR therapy",NA,"","","","","","","",TRUE,"FRESCO","2023-11-08: Approved for adult patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. <i>(Based on FRESCO and FRESCO-2)</i>","2024-01-06"
"Fruquintinib","FDA","2023-11-08","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND an anti-VEGF therapy AND if RAS wild-type and medically appropriate, an anti-EGFR therapy",NA,"","","","","","","",TRUE,"FRESCO-2","2023-11-08: Approved for adult patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. <i>(Based on FRESCO and FRESCO-2)</i>","2024-01-06"
"Fruquintinib","NMPA","2018-09-01","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine AND Oxaliplain AND Irinotecan","FALSE","","","","","","","",TRUE,"FRESCO","2018-09: Approved for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). <i>(Based on FRESCO)</i>","2023-11-07"
"Fulvestrant","EMA","2004-03-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-03-09: Initial authorization","2023-05-08"
"Fulvestrant","FDA","2002-04-25","Breast cancer",FALSE,FALSE,TRUE,"","","Metastatic","","postmenopausal women","","Antiestrogen therapy","FALSE","","","","","","HR+","FALSE",TRUE,"Trial 0020","2002-04-25: Initial FDA approval for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers""> hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with disease progression following <a href=""/wiki/Regimen_classes#Antiestrogen_therapy"" title=""Regimen classes"">antiestrogen therapy</a>. <i>(Based on Trial 0021 and Trial 0020)</i>","2022-09-05"
"Fulvestrant","FDA","2002-04-25","Breast cancer",FALSE,FALSE,TRUE,"","","Metastatic","","postmenopausal women","","Antiestrogen therapy","FALSE","","","","","","HR+","FALSE",TRUE,"Trial 0021","2002-04-25: Initial FDA approval for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers""> hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with disease progression following <a href=""/wiki/Regimen_classes#Antiestrogen_therapy"" title=""Regimen classes"">antiestrogen therapy</a>. <i>(Based on Trial 0021 and Trial 0020)</i>","2022-09-05"
"Fulvestrant","FDA","2010-09-10","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HR+","",TRUE,"CONFIRM","2010-09-10: Approved at a dose of 500 mg for <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers""> hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (full details missing). <i>(Based on CONFIRM)</i>","2024-06-03"
"Fulvestrant","FDA","2016-03-02","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Endocrine-based regimen","FALSE","","","","","Palbociclib","HR+ and HER2-","FALSE AND TRUE",TRUE,"PALOMA-3","2016-03-02: Approved for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with palbociclib in women with disease progression after <a href=""/wiki/Regimen_classes#Endocrine-based_regimen"" title=""Regimen classes"">endocrine therapy</a>. <i>(Based on PALOMA-3)</i>","2022-09-05"
"Fulvestrant","FDA","2017-08-25","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","Endocrine therapy","TRUE","","","","","0","HR+ and HER2-","FALSE AND TRUE",TRUE,"FALCON","2017-08-25: Approved for a new indication as monotherapy for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women not previously treated with endocrine therapy. <i>(Based on FALCON)</i>","2022-09-05"
"Fulvestrant","FDA","2017-11-14","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","women","","Endocrine-based regimen","FALSE","","","","","Abemaciclib","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONALEESA-3","2017-11-14: Approved for treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with abemaciclib in women with disease progression after <a href=""/wiki/Regimen_classes#Endocrine-based_regimen"" title=""Regimen classes"">endocrine therapy</a>. <i>(Based on MONALEESA-3)</i>","2022-09-05"
"Fulvestrant","FDA","2019-03-11","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","0","FALSE","","","","","Ribociclib","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONARCH 2","2019-03-11: Approved for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women, in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. <i>(Based on MONARCH 2)</i>","2022-09-05"
"Fulvestrant","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HR+","FALSE",TRUE,"CONFIRM","Uncertain date: Approved at a dose of 500 mg for <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers""> hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (full details missing). <i>(Based on CONFIRM)</i>","2022-09-05"
"Fulvestrant","HC","2004-02-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-02-17: Initial notice of compliance","2023-07-31"
"Fulvestrant","HC","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","postmenopausal women","","endocrine","TRUE","","","","","","ER+ AND HER2-","FALSE AND TRUE",NA,"","Uncertain date: Indicated for treatment of estrogen receptor-positive, human epidermal growth receptor 2 (HER2)negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women not previously treated with endocrine therapy.","2023-07-31"
"Fulvestrant","HC","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","postmenopausal women","","Antiestrogen therapy","FALSE","","progression","","","","","",NA,"","Uncertain date: Indicated as hormonal treatment of locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women, regardless of age, who have disease progression following prior anti-estrogen therapy.","2023-07-31"
"Fulvestrant","PMDA","2011-09-26","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women","","",NA,"","","","","","","",NA,"","2011-09-26: Initial approval for the treatment of postmenopausal <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Fulvestrant","PMDA","2017-09-27","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-09-27: Revised indication and a new dosage for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Furmonertinib","NMPA","2021-03-03","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Second-line","","","","","",NA,"","","","","","EGFR sensitive mutation AND EGFR p.T790M","FALSE",NA,"","2021-03-03: Initial approval for the treatment (second-line) of the <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with EGFR sensitive mutation and EGFR T790M drug-resistant mutation.","2023-07-31"
"Furosemide","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Futibatinib","EMA","2023-07-04","Cholangiocarcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT",NA,"","progression","","","","FGFR2 rearrangement","",NA,"","2023-07-04: Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.","2023-09-17"
"Futibatinib","FDA","2022-09-30","Cholangiocarcinoma",TRUE,FALSE,FALSE,"","","Unresectable OR Locally advanced OR Metastatic","","adults","","1+","FALSE","","","","","","FGFR2 rearrangement","FALSE",TRUE,"FOENIX-CCA2","2022-09-30: Granted accelerated approval for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> harboring <a href=""/wiki/Biomarkers#FGFR2"" title=""Biomarkers"">fibroblast growth factor receptor 2 (FGFR2) gene</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusions</a> or other <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">rearrangements</a>. <i>(Based on FOENIX-CCA2)</i>","2022-11-03"
"Futibatinib","PMDA","2023-06-26","Biliary tract cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy",NA,"","progression","","","","FGFR2 fusion","FALSE",NA,"","2023-06-26: A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene positive <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer</a> that has progressed after cancer chemotherapy.","2024-06-03"
"Gefitinib","EMA","2009-06-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-06-24: Initial marketing authorization as Iressa.","2023-05-08"
"Gefitinib","FDA","2003-05-05","Non-small cell lung cancer",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen AND Docetaxel monotherapy","FALSE","","","","","0","","",TRUE,"IDEAL2","2003-05-05: Granted accelerated approval as monotherapy for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> after failure of both <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based</a> and <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> chemotherapies. <i>(Based on IDEAL2)</i>","2022-09-05"
"Gefitinib","FDA","2005-06-17","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"ISEL","2005-06-17: Due to the negative confirmatory trial, access of this drug was restricted to patients currently receiving and benefiting from Iressa; patients who have previously received and benefited from Iressa; and previously enrolled patients or new patients in non-Investigational New Drug (IND) clinical trials approved by an IRB prior to June 17, 2005. <i>(Based on ISEL)</i>","2022-09-05"
"Gefitinib","FDA","2012-04-25","Non-small cell lung cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2012-04-25: Accelerated approval withdrawn.","2022-09-05"
"Gefitinib","FDA","2015-07-13","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"IFUM","2015-07-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm454692.htm"">FDA approved</a> for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 (L858R) substitution</a> mutations. <i>(Based on IFUM and IPASS)</i>","2022-09-05"
"Gefitinib","FDA","2015-07-13","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"IPASS","2015-07-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm454692.htm"">FDA approved</a> for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 (L858R) substitution</a> mutations. <i>(Based on IFUM and IPASS)</i>","2022-09-05"
"Gefitinib","HC","2003-12-17","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2003-12-17: Initial notice of compliance with conditions","2023-05-08"
"Gefitinib","HC","2009-12-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-12-18: Conditions were met","2023-05-08"
"Gefitinib","PMDA","2011-11-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","EGFR mutation","FALSE",NA,"","2011-11-25: Revised indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> in patients with EGFR gene mutation.","2023-06-16"
"Gemcitabine","EMA","1995-12-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-12-01: EURD","2023-07-31"
"Gemcitabine","FDA","1996-05-15","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","0","FALSE","","","","","","","",TRUE,"Burris et al. 1997","1996-05-15: Initial FDA approval for first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer""> adenocarcinoma of the pancreas</a>. <i>(Based on Burris et al. 1997)</i>","2023-03-10"
"Gemcitabine","FDA","1996-05-15","Pancreatic cancer",FALSE,FALSE,FALSE,"","","","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"Rothenberg et al. 1996a","1996-05-15: Initial FDA approval for patients with <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer""> adenocarcinoma of the pancreas</a> previously treated with <a href=""/wiki/Regimen_classes#5-FU-based_regimen"" title=""Regimen classes""> 5-FU</a>. <i>(Based on Rothenberg et al. 1996a)</i>","2023-03-10"
"Gemcitabine","FDA","1998-08-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Inoperable locally advanced OR Metastatic","","","","0","FALSE","","","","","Cisplatin","","",TRUE,"Cardenal et al. 1999","1998-08-25: Indicated in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer</a>. <i>(Based on Cardenal et al. 1999 and Sandler et al. 2000)</i>","2022-09-05"
"Gemcitabine","FDA","1998-08-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Inoperable locally advanced OR Metastatic","","","","0","FALSE","","","","","Cisplatin","","",TRUE,"Sandler et al. 2000","1998-08-25: Indicated in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer</a>. <i>(Based on Cardenal et al. 1999 and Sandler et al. 2000)</i>","2022-09-05"
"Gemcitabine","FDA","2004-05-19","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0 in the metastatic setting AND Anthracycline-based chemotherapy in the adjuvant setting, unless contraindicated","FALSE","","","","","Paclitaxel","","",TRUE,"Albain et al. 2008","2004-05-19: New FDA indication in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> is indicated for the first-line treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> after failure of prior <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing</a> adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. <i>(Based on Albain et al. 2008)</i>","2022-09-05"
"Gemcitabine","FDA","2006-07-14","Ovarian cancer",FALSE,FALSE,FALSE,"","Relapsed","Advanced","","","","Platinum-based regimen, completed at least 6 months prior","FALSE","","","","","Carboplatin","","",TRUE,"AGO-OVAR 2.5","2006-07-14: FDA approved in combination with carboplatin for the treatment of patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> that has relapsed at least 6 months after completion of <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum based therapy</a>. <i>(Based on AGO-OVAR 2.5)</i>","2022-09-05"
"Gemcitabine","FDA","2010-03-19","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Carboplatin","","",FALSE,"","2010-03-19: New FDA indication for <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)""> carboplatin</a>. <i>(Prior exposure requirement removed; no supporting studies are cited)</i>","2022-09-05"
"Gemcitabine","FDA","2013-05-07","Ovarian cancer",FALSE,FALSE,FALSE,"","Relapsed","Advanced","","","","Platinum-based regimen, completed at least 6 months prior","FALSE","","","","","Carboplatin","","",FALSE,"","2013-05-07: FDA indication revised: in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)""> carboplatin</a>, for the treatment of advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> ovarian cancer</a> that has relapsed at least 6 months after completion of <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based therapy</a>. <i>(Prior exposure requirement restored; no supporting studies are cited)</i>","2022-09-05"
"Gemcitabine","PMDA","2006-06-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-06-15: New additional indication for <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer</a>.","2023-06-16"
"Gemcitabine","PMDA","2008-11-25","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-11-25: New additional indication for the treatment of <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a>.","2023-06-16"
"Gemcitabine","PMDA","2010-02-05","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2010-02-05: New additional indication and a new dosage for the treatment of inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Gemcitabine","PMDA","2011-02-23","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2011-02-23: New additional indication and a new dosage for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Gemcitabine","PMDA","2013-02-21","Lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2013-02-21: New additional indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a>.","2023-06-16"
"Gemtuzumab ozogamicin","EMA","2018-04-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-04-19: Marketing authorisation (unclear if this is initial or re-authorisation)","2023-07-31"
"Gemtuzumab ozogamicin","EMA","Uncertain date","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","15 years and older","","0",NA,"","","","","Cytarabine AND Daunorubicin","CD33+","",TRUE,"ALFA-0701","Uncertain date: Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a>, except acute promyelocytic leukaemia (APL). <i>(Based on ALFA-0701)</i>","2023-09-17"
"Gemtuzumab ozogamicin","FDA","2000-05-17","Acute myeloid leukemia",TRUE,FALSE,TRUE,"","","","","60 years of age or older","not candidates for cytotoxic chemotherapy","1","FALSE","","","","","","CD33+","FALSE",TRUE,"GO study 1","2000-05-17: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloid leukemia</a> in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. <i>(Based on GO study 1, GO study 2, and GO study 3)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2000-05-17","Acute myeloid leukemia",TRUE,FALSE,TRUE,"","","","","60 years of age or older","not candidates for cytotoxic chemotherapy","1","FALSE","","","","","","CD33+","FALSE",TRUE,"GO study 2","2000-05-17: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloid leukemia</a> in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. <i>(Based on GO study 1, GO study 2, and GO study 3)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2000-05-17","Acute myeloid leukemia",TRUE,FALSE,TRUE,"","","","","60 years of age or older","not candidates for cytotoxic chemotherapy","1","FALSE","","","","","","CD33+","FALSE",TRUE,"GO study 3","2000-05-17: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia""> acute myeloid leukemia</a> in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. <i>(Based on GO study 1, GO study 2, and GO study 3)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2011-11-28","Acute myeloid leukemia",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"SWOG S0106","2011-11-28: Accelerated approval for <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a> withdrawn. <i>(Based on SWOG S0106)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2017-09-01","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","0","FALSE","","","","","Cytarabine AND Daunorubicin","CD33+","FALSE",TRUE,"ALFA-0701","2017-09-01: New approval for the treatment of newly-diagnosed <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. Gemtuzumab ozogamicin may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML. <i>(Based on ALFA-0701 and EORTC/GIMEMA AML-19)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2017-09-01","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","0","FALSE","","","","","Cytarabine AND Daunorubicin","CD33+","FALSE",TRUE,"EORTC/GIMEMA AML-19","2017-09-01: New approval for the treatment of newly-diagnosed <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. Gemtuzumab ozogamicin may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML. <i>(Based on ALFA-0701 and EORTC/GIMEMA AML-19)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2017-09-01","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults AND pediatric patients 2 years and older","","",NA,"","","","","","CD33+","FALSE",TRUE,"MyloFrance-1","2017-09-01: New approval for treatment of relapsed or refractory <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">AML</a> in adults and in pediatric patients 2 years and older. <i>(Based on MyloFrance-1)</i>","2022-09-05"
"Gemtuzumab ozogamicin","FDA","2020-06-16","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults AND pediatric patients 1 month and older","","0","FALSE","","","","","","CD33+","FALSE",TRUE,"COG AAML0531","2020-06-16: Approved for newly-diagnosed <a href=""/wiki/Biomarkers#CD33"" title=""Biomarkers"">CD33</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> to include pediatric patients 1 month and older. <i>(Approval expanded to pediatric patients 1 month and older; based on COG AAML0531)</i>","2022-09-05"
"Gemtuzumab ozogamicin","HC","2019-11-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-11-28: Initial notice of compliance","2023-06-15"
"Gemtuzumab ozogamicin","PMDA","2005-07-25","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD33+","FALSE",NA,"","2005-07-25: Initial approval for the treatment of relapsing or intractable CD33 positive <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Gilteritinib","EMA","2019-10-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-10-24: Initial authorization","2023-05-08"
"Gilteritinib","FDA","2018-11-28","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","FLT3 mutation","FALSE",TRUE,"ADMIRAL","2018-11-28: Initial FDA approval for treatment of adult patients who have relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> with a <a href=""/wiki/Biomarkers#FLT3"" title=""Biomarkers"">FLT3</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a> as detected by an FDA-approved test. <i>(Based on ADMIRAL)</i>","2022-09-05"
"Gilteritinib","HC","2019-12-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-12-23: Initial notice of compliance","2023-06-15"
"Gilteritinib","PMDA","2018-09-21","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","FLT3 mutation","",NA,"","2018-09-21: New approval for the treatment of relapsed or refractory FLT3 mutation-positive <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Glasdegib","EMA","2020-06-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-06-26: Initial authorization","2023-05-08"
"Glasdegib","EMA","Uncertain date","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","First-line","","","","not candidate for standard induction chemotherapy","",NA,"","","","","Cytarabine","","",NA,"","Uncertain date: Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> in adult patients who are not candidates for standard induction chemotherapy.","2023-05-08"
"Glasdegib","FDA","2018-11-21","Acute myeloid leukemia",FALSE,FALSE,TRUE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","LoDAC","","",TRUE,"BRIGHT AML 1003","2018-11-21: Initial FDA approval for use in combination with low-dose <a href=""/wiki/Cytarabine_(Ara-C)"" title=""Cytarabine (Ara-C)"">cytarabine</a> (LDAC), for newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy. <i>(Based on BRIGHT AML 1003)</i>","2022-09-05"
"Glofitamab","FDA","2023-06-15","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",TRUE,"NP30179","2023-06-15: Initial accelerated approval for relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)</a> or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">large B-cell lymphoma (LBCL) arising from follicular lymphoma</a>, after two or more lines of systemic therapy. <i>(Based on NP30179)</i>","2023-07-31"
"Glofitamab","FDA","2023-06-15","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",TRUE,"NP30179","2023-06-15: Initial accelerated approval for relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)</a> or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">large B-cell lymphoma (LBCL) arising from follicular lymphoma</a>, after two or more lines of systemic therapy. <i>(Based on NP30179)</i>","2023-07-31"
"Glucarpidase","FDA","2012-01-17","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2012-01-17: Initial FDA approval for the treatment of toxic plasma <a href=""/wiki/Methotrexate_(MTX)"" title=""Methotrexate (MTX)"">methotrexate</a> concentrations (greater than 1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.","2022-09-05"
"Glucarpidase","PMDA","2021-09-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-09-27: Newly indicated to reduce toxic plasma methotrexate concentration in patients with delayed clearance of methotrexate due to methotrexate/leucovorin salvage therapy.","2023-06-16"
"Goserelin","EMA","1987-05-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1987-05-12: EURD","2023-07-31"
"Goserelin","FDA","1989-12-29","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Pilepich et al. 1995","1989-12-29: Initial FDA approval for palliative treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">carcinoma of the prostate</a>. <i>(Based on Pilepich et al. 1995)</i>","2022-09-05"
"Goserelin","PMDA","2014-03-17","Breast cancer",FALSE,FALSE,FALSE,"","","","","Premenopausal women","","",NA,"","","","","","","",NA,"","2014-03-17: New additional indication for the treatment of premenopausal <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Granisetron","FDA","2001-06-27","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2001-06-27: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21238lbl.pdf"">Initial FDA approval</a> ""for the prevention of: 1) nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. 2) nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.""","2022-09-05"
"Granisetron","FDA","2008-09-12","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-09-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022198lbl.pdf"">FDA approved as Sancuso</a> ""for the prevention of nausea and vomiting in patients receiving <a href=""/wiki/Antiemesis"" title=""Antiemesis"">moderately and/or highly emetogenic chemotherapy</a> for up to 5 consecutive days.""","2022-09-05"
"Granisetron","FDA","2016-08-09","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-08-09: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s001lbl.pdf"">FDA approved as Sustol</a> ""in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of <a href=""/wiki/Antiemesis#Antiemetics_for_moderately_emetogenic_IV_chemotherapy"" title=""Antiemesis"">moderately emetogenic chemotherapy (MEC)</a> or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.""","2022-09-05"
"Haloperidol","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Hematopoetic progenitor cells cord blood","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Heptaplatin","KFDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Histrelin","FDA","2004-10-12","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Schlegel 2006","2004-10-12: Initial approval in the palliative treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on Schlegel 2006)</i>","2022-09-05"
"Histrelin","HC","2006-03-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-03-10: Initial notice of compliance (unclear details)","2023-05-20"
"Hydrocortisone","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Hydroxyurea","EMA","1967-12-07","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1967-12-07: EURD","2023-07-31"
"Hydroxyurea","FDA","1967-12-07","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1967-12-07: Initial FDA approval","2022-09-05"
"Hydroxyurea","FDA","2017-12-21","Sickle cell anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-12-21: Granted regular FDA approval (as Siklos) to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients from 2 years of age and older with <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell anemia</a> with recurrent moderate to severe painful crises.","2022-09-05"
"Hydroxyurea","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Resistant","","","","",NA,"","","","","","","",FALSE,"Koller and Miller 1986","Uncertain date: Approved for the treatment of resistant <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a>. <i>(Based on Koller and Miller 1986)</i>","2022-09-05"
"Hydroxyurea","FDA","Uncertain date","Head and neck cancer",FALSE,FALSE,FALSE,"","","Locally advanced","","","","",NA,"","","","","Chemoradiotherapy-based regimen","","",FALSE,"","Uncertain date: Approved for the treatment of locally advanced <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell carcinomas of the head and neck</a> (excluding the lip) in combination with chemoradiation. <i>(No supporting studies are cited)</i>","2022-09-05"
"Hydroxyurea","PMDA","2013-03-25","Essential thrombocythemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indications for the treatment of <a href=""/wiki/Essential_thrombocythemia"" title=""Essential thrombocythemia"">essential thrombocythemia</a> and <a href=""/wiki/Polycythemia_vera"" title=""Polycythemia vera"">polycythemia vera</a>.","2023-06-16"
"Hydroxyurea","PMDA","2013-03-25","Polycythemia vera",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indications for the treatment of <a href=""/wiki/Essential_thrombocythemia"" title=""Essential thrombocythemia"">essential thrombocythemia</a> and <a href=""/wiki/Polycythemia_vera"" title=""Polycythemia vera"">polycythemia vera</a>.","2023-06-16"
"Hydroxyzine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ibandronate","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ibritumomab tiuxetan","EMA","2004-01-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-01-16: Initial authorization","2023-05-08"
"Ibritumomab tiuxetan","EMA","Uncertain date","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","Rituximab","FALSE","","","","","","CD20+","FALSE",NA,"","Uncertain date: [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular B-cell non-Hodgkin's lymphoma (NHL)</a>.","2023-05-08"
"Ibritumomab tiuxetan","EMA","Uncertain date","Follicular lymphoma",FALSE,FALSE,FALSE,"","First-line consolidation","","","adults","","1","FALSE","","remission","","","","","",NA,"","Uncertain date: [90Y]-radiolabelled Zevalin is indicated in adults as consolidation therapy after remission induction in previously untreated patients with <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.","2023-05-08"
"Ibritumomab tiuxetan","FDA","2002-02-19","Follicular lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Wiseman et al. 2002","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2002-02-19","Indolent lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Wiseman et al. 2002","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2023-07-31"
"Ibritumomab tiuxetan","FDA","2002-02-19","Transformed lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Wiseman et al. 2002","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2002-02-19","Follicular lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002a","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2002-02-19","Indolent lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002a","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2023-07-31"
"Ibritumomab tiuxetan","FDA","2002-02-19","Transformed lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002a","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2002-02-19","Follicular lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002b","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2002-02-19","Indolent lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002b","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2023-07-31"
"Ibritumomab tiuxetan","FDA","2002-02-19","Transformed lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"Witzig et al. 2002b","2002-02-19: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma. <i>(Based on Wiseman et al. 2002, Witzig et al. 2002a, Witzig et al. 2002b)</i>","2022-09-05"
"Ibritumomab tiuxetan","FDA","2009-09-03","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","PR or CR","","","","","",TRUE,"FIT","2009-09-03: Granted FDA full approval; label expanded for the treatment of previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma""> follicular NHL</a> in patients who achieve a partial or complete response to first-line chemotherapy. <i>(Based on FIT)</i>","2022-09-05"
"Ibritumomab tiuxetan","PMDA","2008-01-25","Indolent lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2008-01-25: Initial approval for the treatment of relapsed or refractory, CD20-positive lymphomas of the following: <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Ibritumomab tiuxetan","PMDA","2008-01-25","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2008-01-25: Initial approval for the treatment of relapsed or refractory, CD20-positive lymphomas of the following: <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade B-cell non-Hodgkin's lymphoma</a> and <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Ibrutinib","EMA","2014-10-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-10-21: Initial authorization","2023-05-08"
"Ibrutinib","FDA","2013-11-13","Mantle cell lymphoma",TRUE,FALSE,TRUE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"PCYC-1104-CA","2013-11-13: Accelerated approval for the treatment of patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma""> mantle cell lymphoma (MCL)</a> who have received at least one prior therapy. <i>(Based on PCYC-1104-CA)</i>","2022-09-05"
"Ibrutinib","FDA","2014-02-12","Chronic lymphocytic leukemia",TRUE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"HELIOS","2014-02-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm385878.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a> who have received at least one prior therapy. <i>(Based on PCYC-1102 relapsed, RESONATE, HELIOS)</i>","2022-09-05"
"Ibrutinib","FDA","2014-02-12","Chronic lymphocytic leukemia",TRUE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"PCYC-1102 relapsed","2014-02-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm385878.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a> who have received at least one prior therapy. <i>(Based on PCYC-1102 relapsed, RESONATE, HELIOS)</i>","2022-09-05"
"Ibrutinib","FDA","2014-02-12","Chronic lymphocytic leukemia",TRUE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","","",TRUE,"RESONATE","2014-02-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm385878.htm"">Granted accelerated approval</a> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a> who have received at least one prior therapy. <i>(Based on PCYC-1102 relapsed, RESONATE, HELIOS)</i>","2022-09-05"
"Ibrutinib","FDA","2014-07-28","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","del17p","FALSE",TRUE,"iLLUMINATE","2014-07-28: Converted to regular approval and approval expanded to include patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a> who carry a deletion in chromosome 17 (<a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>). <i>(Based on RESONATE and iLLUMINATE)</i>","2022-09-05"
"Ibrutinib","FDA","2014-07-28","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","del17p","FALSE",TRUE,"RESONATE","2014-07-28: Converted to regular approval and approval expanded to include patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a> who carry a deletion in chromosome 17 (<a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>). <i>(Based on RESONATE and iLLUMINATE)</i>","2022-09-05"
"Ibrutinib","FDA","2015-01-29","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"DFCI 12-015","2015-01-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432240.htm"">FDA approval expanded</a> for the treatment of patients with <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinemia (WM)</a>. <i>(Based on DFCI 12-015 and iNNOVATE)</i>","2022-11-22"
"Ibrutinib","FDA","2015-01-29","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"iNNOVATE","2015-01-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432240.htm"">FDA approval expanded</a> for the treatment of patients with <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinemia (WM)</a>. <i>(Based on DFCI 12-015 and iNNOVATE)</i>","2022-11-22"
"Ibrutinib","FDA","2016-03-04","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"HELIOS","2016-03-04: Approval expanded for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(Based on RESONATE-2 and HELIOS)</i>","2022-09-05"
"Ibrutinib","FDA","2016-03-04","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"RESONATE-2","2016-03-04: Approval expanded for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(Based on RESONATE-2 and HELIOS)</i>","2022-09-05"
"Ibrutinib","FDA","2017-01-18","Marginal zone lymphoma",TRUE,FALSE,FALSE,"","","","","","","1+ anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"PCYC-1121-CA","2017-01-18: Accelerated approval for treatment of patients with <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who require systemic therapy and have received at least one prior <a href=""/wiki/Regimen_classes#Anti-CD20-based_regimen"" title=""Regimen classes"">anti-CD20-based therapy</a>. <i>(Based on PCYC-1121-CA)</i>","2022-09-05"
"Ibrutinib","FDA","2017-08-02","Graft versus host disease",FALSE,FALSE,FALSE,"","","","","adults","","1+ systemic","FALSE","","failure","","","","","",TRUE,"PCYC-1129-CA","2017-08-02: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569711.htm"">FDA indication expanded</a> for the treatment of adult patients with <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">chronic graft versus host disease (cGVHD)</a> after failure of one or more lines of systemic therapy. <i>(Based on PCYC-1129-CA)</i>","2022-09-05"
"Ibrutinib","FDA","2020-04-21","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Rituximab","","",TRUE,"ECOG E1912","2020-04-21: Approval expanded to include its combination with rituximab for the initial treatment of adult patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>. <i>(Based on ECOG E1912)</i>","2022-09-05"
"Ibrutinib","FDA","2022-08-24","Graft versus host disease",FALSE,FALSE,FALSE,"","","","","pediatric patients 1 year and older","","1+ systemic","FALSE","","failure","","","","","",TRUE,"iMAGINE","2022-08-24: Approved for pediatric patients at least 1 year of age with <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">chronic graft versus host disease (cGVHD)</a> after failure of 1 or more lines of systemic therapy. <i>(Based on iMAGINE)</i>","2023-01-03"
"Ibrutinib","FDA","2023-05-18","Mantle cell lymphoma",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-05-18: Accelerated approval for the treatment of patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma""> mantle cell lymphoma (MCL)</a> who have received at least one prior therapy withdrawn.","2024-06-03"
"Ibrutinib","FDA","2023-05-18","Marginal zone lymphoma",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-05-18: Accelerated approval for treatment of patients with <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who require systemic therapy and have received at least one prior <a href=""/wiki/Regimen_classes#Anti-CD20-based_regimen"" title=""Regimen classes"">anti-CD20-based therapy</a> withdrawn.","2024-06-03"
"Ibrutinib","HC","2015-07-28","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-07-28: Initial notice of compliance with conditions","2023-05-08"
"Ibrutinib","HC","2017-09-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-09-12: Conditions were met","2023-05-08"
"Ibrutinib","PMDA","2016-03-26","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2016-03-26: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia/small lymphocytic lymphoma</a>.","2023-06-16"
"Ibrutinib","PMDA","2016-12-02","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2016-12-02: New additional indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma</a>.","2023-06-16"
"Ibrutinib","PMDA","2018-07-02","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-07-02: New additional indication for the treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (including small lymphocytic lymphoma)</a>.","2023-06-16"
"Ibrutinib","PMDA","2021-09-27","Graft versus host disease",FALSE,FALSE,FALSE,"","","Chronic","","","","Steroids","FALSE","","Not sufficiently effective","","","","","",NA,"","2021-09-27: new indication and a new dosage for the treatment of chronic <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">graft-versus-host disease after hematopoietic stem cell transplantation</a> (for use when steroid drugs are not sufficiently effective).","2023-06-16"
"Icotinib","NMPA","2011-06-07","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"ICOGEN","2011-06-07: Initial approval for <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>. <i>(Based on ICOGEN)</i>","2023-07-31"
"Icotinib","NMPA","2023-06-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early stage","","","","Surgery","FALSE","","","","","","","",TRUE,"EVIDENCE","2021-06: Approved for the postoperative adjuvant treatment of early-stage <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">lung cancer</a> with EGFR mutation. <i>(Based on EVIDENCE)</i>","2023-07-31"
"Idarubicin","EMA","1989-11-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1989-11-29: EURD","2023-07-31"
"Idarubicin","FDA","1990-09-27","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Other approved antileukemic drugs","","",TRUE,"L-19 Protocol","1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. <i>(Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)</i>","2022-09-05"
"Idarubicin","FDA","1990-09-27","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Other approved antileukemic drugs","","",TRUE,"Mandelli et al. 1991","1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. <i>(Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)</i>","2022-09-05"
"Idarubicin","FDA","1990-09-27","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Other approved antileukemic drugs","","",TRUE,"Vogler et al. 1992","1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. <i>(Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)</i>","2022-09-05"
"Idarubicin","FDA","1990-09-27","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Other approved antileukemic drugs","","",TRUE,"Wiernik et al. 1992","1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. <i>(Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)</i>","2022-09-05"
"Idarubicin","FDA","2014-12-04","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Other approved antileukemic drugs","","",NA,"","2014-12-04 (most recent label available on Drugs @ FDA): ""in combination with other approved antileukemic drugs is indicated for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults. This includes French-American- British (FAB) classifications M1 through M7.""","2023-05-20"
"Idarucizumab","FDA","2015-10-16","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-10-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm"">Approved</a> in patients treated with <a href=""/wiki/Dabigatran_(Pradaxa)"" title=""Dabigatran (Pradaxa)""> Pradaxa</a> when reversal of the anticoagulant effects of <a href=""/wiki/Dabigatran_(Pradaxa)"" title=""Dabigatran (Pradaxa)""> dabigatran</a> is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.","2022-09-05"
"Idarucizumab","PMDA","2016-09-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-09-28: New approval for the reversal of anticoagulant effect of dabigatran under the following situations: life-threatening or uncontrolled bleeding; and when performing emergency surgery or procedures in which serious bleeding is expected.","2023-06-16"
"Idecabtagene vicleucel","EMA","2021-08-25","Multiple myeloma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","3+, including a proteasome inhibitor and an IMiD and anti-CD38 antibody","FALSE","","progression on the last therapy","","","","","",TRUE,"KarMMa","2021-08-25: Initial conditional authorization for the treatment of adult patients with relapsed and refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy. <i>(Based on KarMMa)</i>","2023-05-08"
"Idecabtagene vicleucel","FDA","2021-03-26","Multiple myeloma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","4+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","","","","","","",TRUE,"KarMMa","2021-03-26: Approved for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. <i>(Based on KarMMa)</i>","2022-09-05"
"Idecabtagene vicleucel","HC","2021-05-26","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","adults","","3+, including a proteasome inhibitor and an IMiD and anti-CD38 antibody","FALSE","","refractory to last therapy","","","","","",NA,"","2021-05-26: Initial notice of compliance with conditions for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment.","2023-05-08"
"Idecabtagene vicleucel","PMDA","2022-01-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-01-20: Initial approval","2023-06-15"
"Idelalisib","EMA","2014-09-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-09-18: Initial authorization","2023-05-08"
"Idelalisib","FDA","2014-07-23","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","Relapsed","","","","patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities","",NA,"","","","","Rituximab","","",TRUE,"GS-US-312-0116","2014-07-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm"">FDA approved</a> for the treatment of patients with relapsed <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a>, in combination with <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)""> rituximab</a>, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. <i>(Based on GS-US-312-0116)</i>","2022-09-05"
"Idelalisib","FDA","2014-07-23","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","Relapsed","","","","","2+ SACT","FALSE","","","","","","","",TRUE,"DELTA","2014-07-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm"">Accelerated approval</a> for the treatment of patients with relapsed <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> small lymphocytic lymphoma (SLL)</a> in patients who have received at least two prior systemic therapies. <i>(Based on DELTA)</i>","2022-09-05"
"Idelalisib","FDA","2014-07-23","Follicular lymphoma",TRUE,FALSE,FALSE,"","Relapsed","","","","","2+ SACT","FALSE","","","","","","","",TRUE,"DELTA","2014-07-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm"">Accelerated approval</a> for the treatment of patients with relapsed <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma""> follicular B-cell non-Hodgkin lymphoma (FL)</a> in patients who have received at least two prior systemic therapies. <i>(Based on DELTA)</i>","2022-09-05"
"Idelalisib","FDA","2022-01-14","Chronic lymphocytic leukemia",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",FALSE,"","2022-01-14: Accelerated approval for the treatment of patients with relapsed <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> small lymphocytic lymphoma (SLL)</a> in patients who have received at least two prior systemic therapies voluntarily withdrawn by the manufacturer. <i>(No supporting studies are cited)</i>","2022-09-21"
"Idelalisib","FDA","2022-01-14","Follicular lymphoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",FALSE,"","2022-01-14: Accelerated approval for the treatment of patients with relapsed <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma""> follicular B-cell non-Hodgkin lymphoma (FL)</a> in patients who have received at least two prior systemic therapies voluntarily withdrawn by the manufacturer. <i>(No supporting studies are cited)</i>","2022-09-21"
"Idelalisib","HC","2015-03-27","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-03-27: Initial notice of compliance with conditions","2023-05-08"
"Idelalisib","HC","2020-04-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-04-21: Conditions were met","2023-05-08"
"Ifosfamide","EMA","1976-07-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1976-07-13: EURD","2023-07-31"
"Ifosfamide","FDA","1988-12-30","Testicular cancer",FALSE,FALSE,FALSE,"","","","","","","2","FALSE","","","","","certain other approved antineoplastic agents","","",TRUE,"Loehrer et al. 1986","1988-12-30: Initial approval in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">testicular cancer</a>. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna. <i>(Based on Loehrer et al. 1986)</i>","2022-09-05"
"Ifosfamide","PMDA","2012-03-21","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-03-21: New additional indication and a new dosage for the treatment of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a>.","2023-06-16"
"Imatinib","EMA","2001-11-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-11-07: Initial marketing authorization as Glivec.","2023-05-08"
"Imatinib","FDA","2001-05-10","Chronic myeloid leukemia",TRUE,FALSE,TRUE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","","","Interferon alpha","FALSE","","failure","","","","","",TRUE,"Sawyers et al. 2002","<b>2001-05-10: Initial accelerated approval</b> for the treatment of patients with <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. <i>(Based on Sawyers et al. 2002, STI571 0109, STIA 0110)</i>","2022-09-05"
"Imatinib","FDA","2001-05-10","Chronic myeloid leukemia",TRUE,FALSE,TRUE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","","","Interferon alpha","FALSE","","failure","","","","","",TRUE,"STI571 0109","<b>2001-05-10: Initial accelerated approval</b> for the treatment of patients with <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. <i>(Based on Sawyers et al. 2002, STI571 0109, STIA 0110)</i>","2022-09-05"
"Imatinib","FDA","2001-05-10","Chronic myeloid leukemia",TRUE,FALSE,TRUE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","","","Interferon alpha","FALSE","","failure","","","","","",TRUE,"STIA 0110","<b>2001-05-10: Initial accelerated approval</b> for the treatment of patients with <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. <i>(Based on Sawyers et al. 2002, STI571 0109, STIA 0110)</i>","2022-09-05"
"Imatinib","FDA","2002-02-01","Gastrointestinal stromal tumor",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","CD117+","FALSE",TRUE,"EORTC 62005","2002-02-01: Accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD117"" title=""Biomarkers"">Kit (CD117)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> unresectable and/or metastatic malignant <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumors (GIST)</a>. <i>(New disease entity; based on EORTC 62005 and SWOG S0033)</i>","2022-09-05"
"Imatinib","FDA","2002-02-01","Gastrointestinal stromal tumor",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","CD117+","FALSE",TRUE,"SWOG S0033","2002-02-01: Accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD117"" title=""Biomarkers"">Kit (CD117)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> unresectable and/or metastatic malignant <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumors (GIST)</a>. <i>(New disease entity; based on EORTC 62005 and SWOG S0033)</i>","2022-09-05"
"Imatinib","FDA","2002-12-20","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","","","adults","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"IRIS","2002-12-20: Additional accelerated approval for the treatment of newly diagnosed adult patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a>. <i>(Indication expanded to first-line; based on IRIS)</i>","2022-09-05"
"Imatinib","FDA","2003-05-20","Chronic myeloid leukemia pediatric",FALSE,FALSE,FALSE,"","","Chronic phase","","pediatric","","Allogeneic HSCT, with recurrence OR Interferon alfa","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"COG P9973","2003-05-20: Additional indication for the treatment of pediatric patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> chronic phase <a href=""/wiki/Chronic_myeloid_leukemia,_pediatric"" title=""Chronic myeloid leukemia, pediatric"">CML</a> whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy. <i>(Indication expanded to the relapsed/refractory pediatric population; based on COG P9973)</i>","2022-09-21"
"Imatinib","FDA","2003-12-08","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2003-12-08: Converted to regular approval.","2022-09-05"
"Imatinib","FDA","2006-09-27","Chronic myeloid leukemia pediatric",TRUE,FALSE,FALSE,"","","","","pediatric","","0","FALSE","","","","","0","BCR-ABL1","FALSE",TRUE,"COG AAML0123","2006-09-27: Additional accelerated approval as a single agent for the treatment of pediatric patients with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia,_pediatric"" title=""Chronic myeloid leukemia, pediatric"">chronic myelogenous leukemia</a> (Ph+ CML). <i>(Pediatric indication expanded to first-line; based on COG AAML0123)</i>","2022-09-21"
"Imatinib","FDA","2006-10-19","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent OR Metastatic","","adults","","",NA,"","","","","","","",TRUE,"EORTC 62027","2006-10-19: Additional indication for adult patients with unresectable, recurrent and/or metastatic <a href=""/wiki/Dermatofibrosarcoma_protuberans"" title=""Dermatofibrosarcoma protuberans"">dermatofibrosarcoma protuberans (DFSP)</a>. <i>(New disease entity; based on EORTC 62027)</i>","2022-09-05"
"Imatinib","FDA","2006-10-19","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"Ottmann et al. 2002","2006-10-19: Additional indication for adult patients with relapsed or refractory <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a> (Ph+ ALL). <i>(New disease entity; based on Ottmann et al. 2002)</i>","2022-09-05"
"Imatinib","FDA","2006-10-19","Hypereosinophilic syndrome",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","FIP1L1-PDGFRA","FALSE",NA,"","2006-10-19: Additional indications for adult patients with <a href=""/wiki/Hypereosinophilic_syndrome"" title=""Hypereosinophilic syndrome"">hypereosinophilic syndrome (HES)</a> and/or chronic eosinophilic leukemia (CEL) who have the <a href=""/wiki/Biomarkers#FIP1L1-PDGFRA"" title=""Biomarkers"">FIP1L1-PDGFRÎ± fusion kinase</a> (mutational analysis or FISH demonstration of CHIC2 allele deletion)","2023-01-03"
"Imatinib","FDA","2006-10-19","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","PDGFR rearrangement","",NA,"","2006-10-19: Additional indication for adult patients with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic/ myeloproliferative diseases (MDS/MPD)</a> associated with <a href=""/wiki/Biomarkers#PDGFR"" title=""Biomarkers"">PDGFR (platelet-derived growth factor receptor) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">rearrangements</a>. <i>(New disease entity)</i>","2022-09-05"
"Imatinib","FDA","2006-10-19","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","KIT p.D816V","TRUE",NA,"","2006-10-19: Additional indication for adult patients with <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">aggressive systemic mastocytosis (ASM)</a> <b>without</b> the <a href=""/wiki/Biomarkers#D816V"" title=""Biomarkers"">D816V</a> <a href=""/wiki/Biomarkers#KIT"" title=""Biomarkers"">c-Kit</a> mutation or with c-Kit mutational status unknown. <i>(New disease entity)</i>","2022-09-05"
"Imatinib","FDA","2006-10-19","Hypereosinophilic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","FIP1L1-PDGFRA|FIP1L1-PDGFRA unknown","TRUE|UNKNOWN",NA,"","2006-10-19: Additional indications for patients with <a href=""/wiki/Hypereosinophilic_syndrome"" title=""Hypereosinophilic syndrome"">HES</a> and/or CEL who are <a href=""/wiki/Biomarkers#FIP1L1-PDGFRA"" title=""Biomarkers"">FIP1L1-PDGFRÎ± fusion kinase</a> <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">negative</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a>. <i>(New disease entity)</i>","2023-01-03"
"Imatinib","FDA","2008-09-26","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-09-26: Converted to regular approval.","2022-09-05"
"Imatinib","FDA","2008-12-19","Gastrointestinal stromal tumor",TRUE,FALSE,FALSE,"","Adjuvant","","","adults","","Surgery","FALSE","","complete gross resection","","","","CD117+","FALSE",TRUE,"ACOSOG Z9001","2008-12-19: Granted accelerated approval for the adjuvant treatment of adult patients following complete gross resection of <a href=""/wiki/Biomarkers#CD117"" title=""Biomarkers"">Kit (CD117)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor (GIST)</a>. <i>(Indication extended to the adjuvant setting; based on ACOSOG Z9001 and SSG XVIII/AIO)</i>","2022-09-05"
"Imatinib","FDA","2008-12-19","Gastrointestinal stromal tumor",TRUE,FALSE,FALSE,"","Adjuvant","","","adults","","Surgery","FALSE","","complete gross resection","","","","CD117+","FALSE",TRUE,"SSG XVIII/AIO","2008-12-19: Granted accelerated approval for the adjuvant treatment of adult patients following complete gross resection of <a href=""/wiki/Biomarkers#CD117"" title=""Biomarkers"">Kit (CD117)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor (GIST)</a>. <i>(Indication extended to the adjuvant setting; based on ACOSOG Z9001 and SSG XVIII/AIO)</i>","2022-09-05"
"Imatinib","FDA","2009-05-27","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2009-05-27: Converted to regular approval.","2022-09-05"
"Imatinib","FDA","2011-04-01","Chronic myeloid leukemia pediatric",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-04-01: Converted to regular approval.","2022-09-05"
"Imatinib","FDA","2012-01-31","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-01-31: Converted to regular approval.","2022-09-05"
"Imatinib","FDA","2013-01-25","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","pediatric","","0","FALSE","","","","","Chemotherapy","BCR-ABL1","FALSE",TRUE,"COG AALL0031","2013-01-25: Additional indication for pediatric patients with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a> (Ph+ ALL) in combination with chemotherapy. <i>(Indication expanded to the first-line pediatric population; based on COG AALL0031)</i>","2022-09-05"
"Imatinib","HC","2001-09-20","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-09-20: Initial notice of compliance with conditions","2023-05-08"
"Imatinib","HC","2004-12-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-12-29: Conditions were met","2023-05-08"
"Imatinib","PMDA","2007-01-31","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","Ph+","FALSE",NA,"","2007-01-31: New indication and dosage for treatment of Philadelphia chromosome-positive <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>.","2023-06-16"
"Imatinib","PMDA","2012-02-22","Chronic eosinophilic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","FIP1L1-PDGFRA","FALSE",NA,"","2012-02-22: New additional indications and a new dosage for the treatment of FIP1L1-PDGFRÎ±-positive <a href=""/wiki/Hypereosinophilic_syndrome"" title=""Hypereosinophilic syndrome"">hypereosinophilic syndrome</a> or <a href=""/w/index.php?title=Chronic_eosinophilic_leukemiaandaction=editandredlink=1"" class=""new"" title=""Chronic eosinophilic leukemia (page does not exist)"">chronic eosinophilic leukemia</a>.","2023-11-07"
"Imatinib","PMDA","2012-02-22","Hypereosinophilic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","FIP1L1-PDGFRA","FALSE",NA,"","2012-02-22: New additional indications and a new dosage for the treatment of FIP1L1-PDGFRÎ±-positive <a href=""/wiki/Hypereosinophilic_syndrome"" title=""Hypereosinophilic syndrome"">hypereosinophilic syndrome</a> or <a href=""/w/index.php?title=Chronic_eosinophilic_leukemiaandaction=editandredlink=1"" class=""new"" title=""Chronic eosinophilic leukemia (page does not exist)"">chronic eosinophilic leukemia</a>.","2023-06-16"
"Imetelstat","FDA","2024-06-06","Myelodysplastic syndrome",FALSE,FALSE,TRUE,"","transfusion-dependent anemia","","low- to intermediate-risk","adults","","",NA,"erythropoeisis-stimulating agents","","","","","","",TRUE,"IMerge","2024-06-06: Approved for adults with low- to intermediate-1 risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). <i>(Based on IMerge)</i>","2024-09-06"
"Inavolisib","FDA","2024-10-10","Breast cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"INAVO120","2024-10-10: Approved with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. <i>(Based on INAVO120)</i>","2024-12-02"
"Indomethacin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Infigratinib","FDA","2021-05-28","Cholangiocarcinoma",TRUE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","1+","FALSE","","","","","","FGFR2 rearrangement","FALSE",TRUE,"CBGJ398X2204","2021-05-28: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with a <a href=""/wiki/Biomarkers#FGFR2"" title=""Biomarkers"">fibroblast growth factor receptor 2 (FGFR2)</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion</a> or other <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">rearrangement</a> as detected by an FDA-approved test. <i>(Based on CBGJ398X2204)</i>","2022-09-05"
"Infigratinib","HC","2021-09-27","Cholangiocarcinoma",TRUE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","1+","FALSE","","","","","","FGFR2 rearrangement","FALSE",NA,"","2021-09-27: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with a fibroblast growth factor receptor 2 fusion or other rearrangement.","2023-05-08"
"Inotuzumab ozogamicin","EMA","2017-06-28","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-06-28: Initial authorization","2023-05-08"
"Inotuzumab ozogamicin","FDA","2017-08-17","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",TRUE,"INO-VATE ALL","2017-08-17: Approved for the treatment of adults with relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a>. <i>(Based on INO-VATE ALL)</i>","2022-09-05"
"Inotuzumab ozogamicin","FDA","2024-03-06","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","pediatric patients 1 year and older","","",NA,"","","","","","CD22+","",NA,"","2024-03-06: Approved for pediatric patients 1 year and older with relapsed or refractory CD22-positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a>.","2024-06-03"
"Inotuzumab ozogamicin","HC","2018-03-15","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","0","CD22+","FALSE",NA,"","2018-03-15: Initial notice of compliance as monotherapy for the treatment of adults with relapsed or refractory CD22-positive <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a>.","2023-06-15"
"Inotuzumab ozogamicin","PMDA","2018-01-19","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD22+","FALSE",NA,"","2018-01-19: New approval for the treatment of relapsed or refractory CD22-positive <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>.","2023-06-16"
"Interferon alfa-2a","FDA","1986-06-04","Hairy cell leukemia",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"N2752","1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a> <i>(Based on N2752)</i>","2022-09-05"
"Interferon alfa-2a","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","minimally pretreated (within 1 year of diagnosis)","","",NA,"","","","","","","",TRUE,"DM 84-38","Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> patients who are minimally pretreated (within 1 year of diagnosis). <i>(Based on DM 84-38 and MI400)</i>","2022-09-05"
"Interferon alfa-2a","FDA","Uncertain date","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","minimally pretreated (within 1 year of diagnosis)","","",NA,"","","","","","","",TRUE,"MI400","Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> patients who are minimally pretreated (within 1 year of diagnosis). <i>(Based on DM 84-38 and MI400)</i>","2022-09-05"
"Interferon alfa-2b","FDA","1986-06-04","Hairy cell leukemia",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"Golomb et al. 1988","1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a>. <i>(Based on Golomb et al. 1988)</i>","2022-09-05"
"Interferon alfa-2b","FDA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","","High risk for systemic recurrence","adults","","Surgery","FALSE","","","56 days","","","","",TRUE,"ECOG E1684","Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with <a href=""/wiki/Melanoma"" title=""Melanoma"">malignant melanoma</a> who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. <i>(Based on ECOG E1684 and ECOG E1690)</i>","2022-09-05"
"Interferon alfa-2b","FDA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","","High risk for systemic recurrence","adults","","Surgery","FALSE","","","56 days","","","","",TRUE,"ECOG E1690","Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with <a href=""/wiki/Melanoma"" title=""Melanoma"">malignant melanoma</a> who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. <i>(Based on ECOG E1684 and ECOG E1690)</i>","2022-09-05"
"Interferon alfa-2b","FDA","Uncertain date","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Clinically aggressive","","adults","","0","FALSE","","","","","Anthracycline-based regimen","","",TRUE,"GELA GELF-86","Uncertain date: Indicated for the initial treatment of clinically aggressive <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular Non-Hodgkin's Lymphoma</a> in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin's Lymphoma has not been demonstrated. <i>(Based on GELA GELF-86)</i>","2022-09-05"
"Interferon alfa-2b","FDA","Uncertain date","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"Lane et al. 1988","Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-Related Kaposi's Sarcoma</a>. <i>(Based on Lane et al. 1988 and Volberding et al. 1987)</i>","2022-09-05"
"Interferon alfa-2b","FDA","Uncertain date","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"Volberding et al. 1987","Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-Related Kaposi's Sarcoma</a>. <i>(Based on Lane et al. 1988 and Volberding et al. 1987)</i>","2022-09-05"
"Interferon alfa-2c","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Interferon alfa-n1","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Interferon gamma-1a","PMDA","2014-05-23","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-05-23: New additional indications and a new dosage for the treatment of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides and Sezary syndrome</a>.","2023-07-31"
"Interferon gamma-1b","FDA","1999-02-25","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1999-02-25: Initial FDA approval","2022-09-05"
"Intravenous immunoglobulin","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Iobenguane I 131","FDA","2018-07-30","Pheochromocytoma",FALSE,FALSE,FALSE,"","","","","adults and pediatric","","",NA,"","","","","","","",TRUE,"MIP-IB12B","2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a> or <a href=""/w/index.php?title=Paragangliomaandaction=editandredlink=1"" class=""new"" title=""Paraganglioma (page does not exist)"">paraganglioma</a> who require systemic anticancer therapy. <i>(Based on MIP-IB12B)</i>","2023-04-21"
"Iobenguane I 131","FDA","2018-07-30","Paraganglioma",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","iobenguane scan positive","FALSE",TRUE,"MIP-IB12B","2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a> or <a href=""/w/index.php?title=Paragangliomaandaction=editandredlink=1"" class=""new"" title=""Paraganglioma (page does not exist)"">paraganglioma</a> who require systemic anticancer therapy. <i>(Based on MIP-IB12B)</i>","2023-11-07"
"Iobenguane I 131","PMDA","2021-09-27","Paraganglioma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","MIBG+","FALSE",NA,"","2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a>/<a href=""/w/index.php?title=Paragangliomaandaction=editandredlink=1"" class=""new"" title=""Paraganglioma (page does not exist)"">paraganglioma</a>.","2023-11-07"
"Iobenguane I 131","PMDA","2021-09-27","Pheochromocytoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","MIBG+","FALSE",NA,"","2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a>/<a href=""/w/index.php?title=Paragangliomaandaction=editandredlink=1"" class=""new"" title=""Paraganglioma (page does not exist)"">paraganglioma</a>.","2023-06-16"
"Iodine-131","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ipilimumab","EMA","2011-07-13","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","1+",NA,"","","","","","","",TRUE,"MDX010-20","2011-07-13: Initial marketing authorization as Yervoy. Yervoy is indicated for the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults who have received prior therapy. <i>(Based on MDX010-20)</i>","2023-09-17"
"Ipilimumab","EMA","2013-10-31","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","0",NA,"","","","","","","",NA,"","2013-10-31: Extension of indication of Yervoy for the treatment of previously untreated adult patients with advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-09-17"
"Ipilimumab","EMA","2018-01-18","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","","",NA,"","2018-01-18: Extension of indication to include the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults and adolescents 12 years of age and older.","2023-09-17"
"Ipilimumab","EMA","2018-05-31","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","",NA,"","","","","Nivolumab","","",NA,"","2018-05-31: Extension of indication to include the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults in combination with nivolumab for Yervoy.","2023-09-17"
"Ipilimumab","EMA","2019-01-11","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","Intermediate-risk OR Poor-risk","adults","","",NA,"","","","","Nivolumab","","",NA,"","2019-01-11: Extension of indication to include the combination treatment with nivolumab and ipilimumab of adult patients with intermediate/poor-risk advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-09-17"
"Ipilimumab","EMA","2020-11-05","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","Nivolumab AND Chemotherapy","No EGFR mutations AND No ALK mutations","TRUE",NA,"","2020-11-05: Extension of indication to include first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> in adults whose tumours have no sensitising EGFR mutation or ALK translocation for combination of OPDIVO/Yervoy and chemotherapy.","2023-09-17"
"Ipilimumab","EMA","2021-06-01","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","First-line","Unresectable","","adults","","",NA,"","","","","Nivolumab","","",NA,"","2021-06-01: Extension of indication to include first-line treatment of adult patients with unresectable <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma (MPM)</a> for combination treatment of Opdivo and Yervoy.","2023-09-17"
"Ipilimumab","EMA","2021-06-24","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based combination chemotherapy","FALSE","","","","","Nivolumab","dMMR|MSI-H","FALSE",NA,"","2021-06-24: Extension of indication to include the combination of nivolumab with ipilimumab in the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> after prior fluoropyrimidine based combination chemotherapy.","2023-09-17"
"Ipilimumab","EMA","2022-04-01","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Unresectable advanced OR Recurrent OR Metastatic","","adults","","",NA,"","","","","Nivolumab","PD-L1 at least 1%","",NA,"","2022-04-01: Extension of indication to include first-line treatment of adult patients with unresectable advanced, recurrent or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">oesophageal squamous cell carcinoma (OSCC)</a> with tumour cell PD-L1 expression at least 1% for Opdivo in combination with Yervoy.","2023-09-17"
"Ipilimumab","EMA","2023-05-23","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","pediatric patients 12 years and older","","",NA,"","","","","Nivolumab","","",TRUE,"ADVL1412","2023-05-23: Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on ADVL1412)</i>","2023-09-17"
"Ipilimumab","FDA","2011-03-25","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",TRUE,"MDX010-20","2011-03-25: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm"">FDA approved</a> for the treatment of unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma""> melanoma</a>. <i>(Initial approval; based on MDX010-20)</i>","2022-09-05"
"Ipilimumab","FDA","2015-10-28","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Pathologic involvement of regional lymph nodes of more than 1 mm","","","","Surgery","FALSE","","complete resection","","","","","",TRUE,"EORTC 18071","2015-10-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm"">FDA approved</a> for adjuvant treatment of patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">cutaneous melanoma</a> with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. <i>(Approval extended to adjuvant setting; based on EORTC 18071)</i>","2022-09-05"
"Ipilimumab","FDA","2018-04-16","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","Intermediate-risk OR Poor-risk","","","0","FALSE","","","","","Nivolumab","","",TRUE,"CheckMate 214","2018-04-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm"">FDA approved</a> to be used in combination with <a href=""/wiki/Nivolumab_(Opdivo)"" title=""Nivolumab (Opdivo)"">Nivolumab (Opdivo)</a> for the treatment of intermediate or poor risk, previously untreated <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">advanced renal cell carcinoma</a>. <i>(New disease entity; based on CheckMate 214)</i>","2022-09-05"
"Ipilimumab","FDA","2018-07-10","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults AND pediatric patients 12 years and older","","Fluoropyrimidine AND Oxaliplain AND Irinotecan AND Nivolumab","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"CheckMate 142","2018-07-10: Accelerated approval for treatment of adult and pediatric patients 12 years of age and older with <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab. <i>(New disease entity; based on CheckMate 142)</i>","2022-09-05"
"Ipilimumab","FDA","2020-03-10","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","Nivolumab","","",TRUE,"CheckMate 040_combo","2020-03-10: Accelerated approval in combination with nivolumab for patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with sorafenib. <i>(Based on CheckMate 040_combo)</i>","2022-09-05"
"Ipilimumab","FDA","2020-05-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Nivolumab","PD-L1 at least 1% AND No EGFR mutations AND No ALK mutations","FALSE",TRUE,"CheckMate 227","2020-05-15: Approved in combination with <a href=""/wiki/Nivolumab_(Opdivo)"" title=""Nivolumab (Opdivo)"">nivolumab</a> as first-line treatment for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (at least 1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <i>(New disease entity; based on CheckMate 227)</i>","2023-01-03"
"Ipilimumab","FDA","2020-05-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic or Recurrent","","","","0","FALSE","","","","","Nivolumab AND Platinum doublet","No EGFR mutations AND No ALK mutations","TRUE",TRUE,"CheckMate 9LA","2020-05-26: Approved in combination with <a href=""/wiki/Nivolumab_(Opdivo)"" title=""Nivolumab (Opdivo)"">nivolumab</a> and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <i>(PD-L1 expression requirement removed when given with chemotherapy; based on CheckMate 9LA)</i>","2022-09-05"
"Ipilimumab","FDA","2020-10-02","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable","","adults","","0","FALSE","","","","","Nivolumab","","",TRUE,"CheckMate 743","2020-10-02: Approved in combination with <a href=""/wiki/Nivolumab_(Opdivo)"" title=""Nivolumab (Opdivo)"">nivolumab</a> as first-line treatment for adult patients with unresectable <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a>. <i>(New disease entity; based on CheckMate 743)</i>","2022-09-05"
"Ipilimumab","HC","2012-02-01","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","SACT","FALSE","advanced disease","failure or intolerance","","","","","",NA,"","2012-02-01: Initial notice of compliance for the treatment of unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in patients who have failed or do not tolerate other systemic therapy for advanced disease.","2023-05-20"
"Ipilimumab","HC","2014-09-10","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2014-09-10: Revised indication for the treatment of unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-05-20"
"Ipilimumab","HC","2017-04-13","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","0","FALSE","","","","","Nivolumab","","",NA,"","2017-04-13: New indication in combination with Opdivo (nivolumab) for the treatment of unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in previously untreated adults.","2023-05-20"
"Ipilimumab","HC","2018-12-04","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","Intermediate-risk OR Poor-risk","adults","","",NA,"","","","","Nivolumab","","",NA,"","2018-12-04: New indication in combination with Opdivo (nivolumab) for the treatment of adult patients with intermediate/poor-risk advanced or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-05-20"
"Ipilimumab","HC","2022-03-03","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Nivolumab","MSI-H|dMMR","FALSE",NA,"","2022-03-03: New indication in combination with nivolumab for Microsatellite Instability-High (MSI-H)/ Mismatch Repair Deficient (dMMR) Metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-05-20"
"Ipilimumab","HC","2022-03-03","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Nivolumab","","",NA,"","2022-03-03: New indication in combination with nivolumab for unresectable <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">Malignant Pleural Mesothelioma (MPM)</a>.","2023-05-20"
"Ipilimumab","HC","2022-03-03","Melanoma",FALSE,TRUE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2022-03-03: New reduction of indication for Unresectable or Metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">Melanoma</a> (unclear details).","2023-05-20"
"Ipilimumab","HC","2022-03-03","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Nivolumab","","",NA,"","2022-03-03: New indication in combination with nivolumab for metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">Non-Small Cell Lung Cancer (NSCLC)</a>.","2023-05-20"
"Ipilimumab","PMDA","2015-07-03","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2015-07-03: Initial approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Ipilimumab","PMDA","2018-08-21","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2018-08-21: New indication and a new dosage for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Ipilimumab","PMDA","2020-09-25","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","MSI-H","FALSE",NA,"","2020-09-25: New indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Ipilimumab","PMDA","2020-11-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2020-11-27: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Ipilimumab","PMDA","2021-05-27","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2021-05-27: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a>.","2023-06-16"
"Ipilimumab","PMDA","2022-05-26","Esophageal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2022-05-26: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a>.","2023-06-16"
"Iptacopan","FDA","2023-12-05","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"APPLY-PNH","2023-12-05: Approved for the treatment of adults with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on APPLY-PNH and APPOINT-PNH)</i>","2024-06-03"
"Iptacopan","FDA","2023-12-05","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"APPOINT-PNH","2023-12-05: Approved for the treatment of adults with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on APPLY-PNH and APPOINT-PNH)</i>","2024-06-03"
"Irinotecan","EMA","1995-05-05","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-05-05: EURD","2023-07-31"
"Irinotecan","FDA","1996-06-14","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"Pitot et al. 1997","1996-06-14: Initial accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)</i>","2022-09-05"
"Irinotecan","FDA","1996-06-14","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"Rothenberg et al. 1996","1996-06-14: Initial accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)</i>","2022-09-05"
"Irinotecan","FDA","1996-06-14","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"Rothenberg et al. 1999","1996-06-14: Initial accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)</i>","2022-09-05"
"Irinotecan","FDA","1996-06-14","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"Rougier et al. 1997","1996-06-14: Initial accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)</i>","2022-09-05"
"Irinotecan","FDA","1998-10-22","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"V301","1998-10-22: Converted to regular approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on V301 and V302)</i>","2022-09-05"
"Irinotecan","FDA","1998-10-22","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","5-FU-based regimen","FALSE","","","","","","","",TRUE,"V302","1998-10-22: Converted to regular approval for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed following <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU-based</a> therapy. <i>(Based on V301 and V302)</i>","2022-09-05"
"Irinotecan","FDA","2000-04-20","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Fluorouracil AND Leucovorin","","",TRUE,"Douillard et al. 2000","2000-04-20: Indicated as a component of first-line therapy in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-fluorouracil</a> and <a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> leucovorin</a> for patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a>. <i>(Based on Douillard et al. 2000 and Saltz et al. 2000)</i>","2022-09-05"
"Irinotecan","FDA","2000-04-20","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Fluorouracil AND Leucovorin","","",TRUE,"Saltz et al. 2000","2000-04-20: Indicated as a component of first-line therapy in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-fluorouracil</a> and <a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> leucovorin</a> for patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a>. <i>(Based on Douillard et al. 2000 and Saltz et al. 2000)</i>","2022-09-05"
"Irinotecan","PMDA","2013-03-25","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","","","pediatric","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indication and a new dosage for the treatment of pediatric <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">malignant solid tumor</a>.","2023-06-16"
"Irinotecan","PMDA","2013-12-20","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2013-12-20: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Irinotecan liposome","EMA","2016-10-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-10-14: Initial authorization","2023-05-08"
"Irinotecan liposome","FDA","2015-10-22","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Gemcitabine-based regimen","FALSE","","progression","","","Fluorouracil AND Leucovorin","","",TRUE,"NAPOLI-1","2015-10-22: Approved in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">fluorouracil (5FU)</a> and <a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)"">leucovorin (LV)</a>, for the treatment of patients with metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">adenocarcinoma of the pancreas</a> whose disease has progressed following <a href=""/wiki/Gemcitabine_(Gemzar)"" title=""Gemcitabine (Gemzar)"">gemcitabine</a>-based therapy. <i>(Based on NAPOLI-1)</i>","2022-09-05"
"Irinotecan liposome","FDA","2024-02-13","Pancreatic cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","Fluorouracil AND Leucovorin AND Oxaliplatin","","",TRUE,"NAPOLI 3","2024-02-13: Approved with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>. <i>(Based on NAPOLI 3)</i>","2024-06-03"
"Irinotecan liposome","HC","2017-08-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-08-09: Initial notice of compliance (unclear details)","2023-05-20"
"Irinotecan liposome","PMDA","2020-03-25","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2020-03-25: Newly indicated for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Iron dextran","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Iron sucrose","FDA","2000-11-06","Iron deficiency anemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2000-11-06: Approved for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD).","2022-09-05"
"Isatuximab","EMA","2020-05-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-05-30: Initial authorization","2023-05-08"
"Isatuximab","FDA","2020-03-02","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","2+, including Lenalidomide AND Proteasome inhibitor","FALSE","","","","","Pomalidomide AND Dexamethasone","","",TRUE,"ICARIA-MM","2020-03-02: Approved in combination with pomalidomide and dexamethasone for adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. <i>(Based on ICARIA-MM)</i>","2022-09-05"
"Isatuximab","FDA","2021-03-31","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1 to 3","FALSE","","","","","Carfilzomib AND Dexamethasone","","",TRUE,"IKEMA","2021-03-31: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received one to three prior lines of therapy. <i>(Based on IKEMA)</i>","2022-09-05"
"Isatuximab","FDA","2024-09-20","Multiple myeloma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"IMROZ","2024-09-20: Approved with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who are not eligible for autologous stem cell transplant (ASCT). <i>(Based on IMROZ)</i>","2024-12-02"
"Isatuximab","HC","2020-04-29","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-04-29: Initial notice of compliance","2023-06-15"
"Isatuximab","PMDA","2020-06-29","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2020-06-29: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Isotretinoin","EMA","1982-05-07","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1982-05-07: EURD","2023-07-31"
"Itraconazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ivosidenib","EMA","2023-05-04","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","not eligible to receive standard induction chemotherapy","0",NA,"","","","","Azacitidine","IDH1 p.R132","",NA,"","2023-05-04: Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.","2023-09-17"
"Ivosidenib","EMA","2023-05-04","Cholangiocarcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT",NA,"","","","","0","IDH1 p.R132","",NA,"","2023-05-04: Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.","2023-09-17"
"Ivosidenib","FDA","2018-07-20","Acute myeloid leukemia",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","IDH1 mutation","FALSE",TRUE,"AG120-C-001 r/r","2018-07-20: Granted approval for adult patients with relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> with a susceptible <a href=""/wiki/Biomarkers#IDH1"" title=""Biomarkers"">IDH1</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a> as detected by an FDA-approved test. <i>(Based on AG120-C-001 r/r)</i>","2022-09-05"
"Ivosidenib","FDA","2019-05-02","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","","IDH1 mutation","FALSE",TRUE,"AG120-C-001 untreated","2019-05-02: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation"">FDA approval expanded</a> for newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> with a susceptible <a href=""/wiki/Biomarkers#IDH1"" title=""Biomarkers"">IDH1</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. <i>(approval expanded to first-line setting with limitations; based on AG120-C-001 untreated)</i>","2022-09-05"
"Ivosidenib","FDA","2021-08-25","Cholangiocarcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+","FALSE","","","","","","IDH1 mutation","FALSE",TRUE,"ClarIDHy","2021-08-25: Approved for adult patients with previously treated, locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with an <a href=""/wiki/Biomarkers#IDH1"" title=""Biomarkers"">isocitrate dehydrogenase-1 (IDH1)</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>. <i>(Based on ClarIDHy)</i>","2022-09-05"
"Ivosidenib","FDA","2022-05-25","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","Azacitidine","IDH1 mutation","FALSE",TRUE,"AGILE","2022-05-25: Approved in combination with azacitidine for newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> with a susceptible <a href=""/wiki/Biomarkers#IDH1"" title=""Biomarkers"">IDH1</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. <i>(Based on AGILE)</i>","2022-09-05"
"Ivosidenib","FDA","2023-10-24","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","IDH1 mutation","FALSE",TRUE,"AG120-C-001 r/r","2023-10-24: Approved for adult patients with relapsed or refractory <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS)</a> with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. <i>(Based on AG120-C-001 r/r)</i>","2023-11-07"
"Ixabepilone","FDA","2007-10-16","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Anthracycline AND Taxane","FALSE","","","","","Capecitabine","","",TRUE,"CA163-046","2007-10-16: Initial approval in combination with <a href=""/wiki/Capecitabine_(Xeloda)"" title=""Capecitabine (Xeloda)""> capecitabine</a> for the treatment of metastatic or locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> in patients after failure of an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a> and a <a href=""/wiki/Category:Taxanes"" title=""Category:Taxanes"">taxane</a>. <i>(Based on CA163-046 and CA163-048)</i>","2022-09-05"
"Ixabepilone","FDA","2007-10-16","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Anthracycline AND Taxane","FALSE","","","","","Capecitabine","","",TRUE,"CA163-048","2007-10-16: Initial approval in combination with <a href=""/wiki/Capecitabine_(Xeloda)"" title=""Capecitabine (Xeloda)""> capecitabine</a> for the treatment of metastatic or locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> in patients after failure of an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a> and a <a href=""/wiki/Category:Taxanes"" title=""Category:Taxanes"">taxane</a>. <i>(Based on CA163-046 and CA163-048)</i>","2022-09-05"
"Ixabepilone","FDA","2007-10-16","Breast cancer",FALSE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","","","Anthracycline AND Taxane AND Capecitabine","FALSE","","","","","0","","",TRUE,"CA163-081","2007-10-16: Initial approval as monotherapy for the treatment of metastatic or locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> in patients after failure of an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a>, a <a href=""/wiki/Category:Taxanes"" title=""Category:Taxanes"">taxane</a>, and <a href=""/wiki/Capecitabine_(Xeloda)"" title=""Capecitabine (Xeloda)""> capecitabine</a>. <i>(Based on CA163-081)</i>","2022-09-05"
"Ixazomib","EMA","2016-11-21","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-11-21: Initial conditional approval","2023-05-08"
"Ixazomib","FDA","2015-11-20","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Lenalidomide AND Dexamethasone","","",TRUE,"TOURMALINE-MM1","2015-11-20: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm"">FDA approved</a> in combination with <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)"">lenalidomide</a> and <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)"">dexamethasone</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy. <i>(Based on TOURMALINE-MM1)</i>","2022-09-05"
"Ixazomib","HC","2016-08-04","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-08-04: Initial notice of compliance","2023-06-15"
"Ixazomib","PMDA","2017-03-30","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-03-30: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Ixazomib","PMDA","2020-03-25","Multiple myeloma",FALSE,FALSE,FALSE,"","Maintenance","","","","","Autologous HSCT","FALSE","","","","","","","",NA,"","2020-03-25: New indication and a new dosage for the maintenance treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in patients after autologous hematopoietic stem-cell transplantation.","2023-06-16"
"Ixazomib","PMDA","2021-05-27","Multiple myeloma",FALSE,FALSE,FALSE,"","Maintenance","","","","","",NA,"","","","","","","",NA,"","2021-05-27: New indication for the maintenance therapy of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Ketoconazole","EMA","1980-06-01","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1980-06-01: EURD","2023-07-31"
"L-glutamine","FDA","2017-07-07","Sickle cell anemia",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2017-07-07: Approved for patients age five years and older with <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell disease</a> to reduce severe complications associated with the blood disorder.","2022-09-05"
"Lactulose","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lamivudine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lanreotide","FDA","2007-08-30","Acromegaly",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-30: FDA approved for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a>","2022-09-05"
"Lanreotide","FDA","2014-12-16","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","unresectable OR locally advanced OR metastatic","Well or moderately differentiated","","","",NA,"","","","","","","",TRUE,"CLARINET","2014-12-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427065.htm"">FDA approved</a> for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">gastroenteropancreatic neuroendocrine tumors (GEP-NETs)</a> to improve progression-free survival. <i>(Based on CLARINET)</i>","2022-09-05"
"Lanreotide","PMDA","2017-07-03","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-07-03: New additional indication and a new dosage indicated for the treatment of <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumors</a> of the pancreas and gastrointestinal tract.","2023-06-16"
"Lanreotide LAR","FDA","2007-08-30","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-30: Initial FDA approval","2022-09-21"
"Lanreotide LAR","HC","2006-07-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-07-17: Initial notice of compliance for long-term treatment of patients with acromegaly due to pituitary tumours who have had inadequate response to or cannot be treated with surgery and/or radiotherapy.","2023-05-20"
"Lanreotide LAR","HC","2006-07-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-07-17: Initial notice of compliance for relief of symptoms associated with acromegaly.","2023-05-20"
"Lanreotide LAR","HC","2015-09-28","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","unresectable OR locally advanced OR metastatic","","","","",NA,"","","","","","","",NA,"","2015-09-28: New indication for the treatment of enteropancreatic <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumors</a> in patients with unsectable, locally advanced or metastatic disease.","2023-05-20"
"Lanreotide LAR","HC","2018-02-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-02-02: New indication for the treatment of adult patients with carcinoid syndrome.","2023-05-20"
"Lansoprazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lapatinib","EMA","2008-06-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-06-10: Initial marketing authorization as Tyverb.","2023-05-08"
"Lapatinib","FDA","2007-03-13","Breast cancer",FALSE,FALSE,TRUE,"","","Advanced OR Metastatic","","","","Anthracycline AND Taxane AND Trastuzumab","FALSE","","","","","Capecitabine","HER2+","FALSE",TRUE,"EGF100151","2007-03-13: Initial approval in combination with <a href=""/wiki/Capecitabine_(Xeloda)"" title=""Capecitabine (Xeloda)""> capecitabine</a>, for the treatment of patients with advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> whose tumors <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpress</a> <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> and who have received prior therapy including an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines""> anthracycline</a>, a <a href=""/wiki/Category:Taxanes"" title=""Category:Taxanes""> taxane</a>, and <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)""> trastuzumab</a>. <i>(Based on EGF100151)</i>","2022-09-05"
"Lapatinib","FDA","2010-01-29","Breast cancer",TRUE,FALSE,FALSE,"","","","","postmenopausal women","","",NA,"","","","","Letrozole","EGF30008","FALSE",TRUE,"EGF30008","2010-01-29: Accelerated approval in combination with <a href=""/wiki/Letrozole_(Femara)"" title=""Letrozole (Femara)""> letrozole</a> for the treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> that <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpresses</a> the <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2 receptor</a> for whom hormonal therapy is indicated. <i>(Based on EGF30008)</i>","2022-09-05"
"Lapatinib","FDA","2018-12-06","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-12-06: Converted to regular approval.","2022-09-05"
"Lapatinib","HC","2009-05-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-05-15: Initial notice of compliance (unclear details)","2023-05-20"
"Lapatinib","HC","2010-09-30","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women","suitable for endocrine therapy","",NA,"","","","","Letrozole","","",NA,"","2010-09-30: New indication in combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy.","2023-05-20"
"Lapatinib","PMDA","2009-04-22","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2009-04-22: Initial approval for the treatment of inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with HER2 overexpression.","2023-06-16"
"Larotrectinib","EMA","2019-09-19","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","","No satisfactory treatment options","","adults and pediatric","","",NA,"","","","","0","","",NA,"","2019-09-19: Initial conditional authorisation as Vitrakvi. Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumours</a> that display a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">Neurotrophic Tyrosine Receptor Kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a>, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","2023-05-08"
"Larotrectinib","FDA","2018-11-26","Malignant solid neoplasm",TRUE,FALSE,TRUE,"","","Metastatic OR surgical resection is likely to result in severe morbidity","","adults and pediatric","","No satisfactory alternative treatment or 1+","FALSE","","","","","","NTRK rearrangement without a known acquired resistance mutation","FALSE",TRUE,"LOXO-TRK-14001","2018-11-26: Granted accelerated approval for adult and pediatric patients with <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. <i>(Based on LOXO-TRK-14001, SCOUT, and NAVIGATE)</i>","2022-09-05"
"Larotrectinib","FDA","2018-11-26","Malignant solid neoplasm",TRUE,FALSE,TRUE,"","","Metastatic OR surgical resection is likely to result in severe morbidity","","adults and pediatric","","No satisfactory alternative treatment or 1+","FALSE","","","","","","NTRK rearrangement without a known acquired resistance mutation","FALSE",TRUE,"NAVIGATE","2018-11-26: Granted accelerated approval for adult and pediatric patients with <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. <i>(Based on LOXO-TRK-14001, SCOUT, and NAVIGATE)</i>","2022-09-05"
"Larotrectinib","FDA","2018-11-26","Malignant solid neoplasm",TRUE,FALSE,TRUE,"","","Metastatic OR surgical resection is likely to result in severe morbidity","","adults and pediatric","","No satisfactory alternative treatment or 1+","FALSE","","","","","","NTRK rearrangement without a known acquired resistance mutation","FALSE",TRUE,"SCOUT","2018-11-26: Granted accelerated approval for adult and pediatric patients with <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have a <a href=""/wiki/Biomarkers#NTRK"" title=""Biomarkers"">neurotrophic tyrosine receptor kinase (NTRK) gene</a> <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">fusion</a> without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. <i>(Based on LOXO-TRK-14001, SCOUT, and NAVIGATE)</i>","2022-09-05"
"Larotrectinib","HC","2019-07-10","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","","No satisfactory treatment options","","adults and pediatric","","",NA,"","","","","","","",NA,"","2019-07-10: Initial notice of compliance with conditions for the treatment of adult and pediatric patients with <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumours</a> that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity, and have no satisfactory treatment options.","2023-05-08"
"Larotrectinib","PMDA","2021-03-23","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","",NA,"","","","","","NTRK rearrangement","FALSE",NA,"","2021-03-23: Newly indicated for the treatment of NTRK fusion gene-positive advanced or recurrent <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumours</a>.","2023-06-16"
"Lazertinib","FDA","2024-08-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","Amivantamab","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"MARIPOSA","2024-08-19: Approved in combination with amivantamab for the first-line treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. <i>(Based on MARIPOSA)</i>","2024-09-06"
"Lenalidomide","EMA","2007-06-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-06-14: Initial authorization","2023-05-08"
"Lenalidomide","FDA","2005-12-28","Myelodysplastic syndrome",FALSE,FALSE,TRUE,"","","","low- or intermediate-1-risk","transfusion-dependent anemia","","",NA,"","","","","","del(5q)","FALSE",TRUE,"CC-5013-MDS-003","2005-12-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108546.htm"">Approved</a> for patients with transfusion-dependent anemia due to low- or intermediate-1-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome""> myelodysplastic syndromes (MDS)</a> associated with a <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a> <a href=""/wiki/Biomarkers#5q"" title=""Biomarkers"">5q</a> abnormality with or without additional cytogenetic abnormalities.<sup id=""cite_ref-insert_1-4"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(Initial approval; based on CC-5013-MDS-003)</i>","2022-09-05"
"Lenalidomide","FDA","2006-06-29","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Dexamethasone","","",TRUE,"MM-009","2006-06-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm"">Approved</a> for treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma (MM)</a>, in combination with <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)""> dexamethasone</a>, in patients who have received at least one prior therapy.] <i>(New disease entity; based on MM-009 and MM-010)</i>","2022-09-05"
"Lenalidomide","FDA","2006-06-29","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Dexamethasone","","",TRUE,"MM-010","2006-06-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm"">Approved</a> for treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma (MM)</a>, in combination with <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)""> dexamethasone</a>, in patients who have received at least one prior therapy.] <i>(New disease entity; based on MM-009 and MM-010)</i>","2022-09-05"
"Lenalidomide","FDA","2013-06-05","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+, including Bortezomib","FALSE","","","","","","","",TRUE,"EMERGE","2013-06-05: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm"">Approved</a> for patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> whose disease has relapsed or progressed after two prior therapies, one of which included <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)""> bortezomib</a>.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(New disease entity; based on EMERGE)</i>","2022-09-05"
"Lenalidomide","FDA","2015-02-17","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Dexamethasone","","",TRUE,"FIRST_MM","2015-02-17: Approved for <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma (MM)</a>, in combination with dexamethasone. <i>(Prior treatment requirement removed; based on FIRST_MM)</i>","2022-09-05"
"Lenalidomide","FDA","2017-02-22","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","Autologous HSCT","FALSE","","","","","","","",TRUE,"CALGB 100104","2017-02-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm"">Approval expanded</a> as maintenance therapy for patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> following autologous stem cell transplant. <i>(Approval expanded to maintenance therapy after upfront treatment; based on CALGB 100104 and IFM 2005-02)</i>","2022-09-05"
"Lenalidomide","FDA","2017-02-22","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","Autologous HSCT","FALSE","","","","","","","",TRUE,"IFM 2005-02","2017-02-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm"">Approval expanded</a> as maintenance therapy for patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> following autologous stem cell transplant. <i>(Approval expanded to maintenance therapy after upfront treatment; based on CALGB 100104 and IFM 2005-02)</i>","2022-09-05"
"Lenalidomide","FDA","2019-05-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Rituximab","","",TRUE,"AUGMENT","2019-05-28: Approved in combination with a rituximab product for previously treated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> and previously treated <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a>. <i>(New disease entity; based on AUGMENT and MAGNIFY)</i>","2022-09-05"
"Lenalidomide","FDA","2019-05-28","Marginal zone lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Rituximab","","",TRUE,"AUGMENT","2019-05-28: Approved in combination with a rituximab product for previously treated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> and previously treated <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a>. <i>(New disease entity; based on AUGMENT and MAGNIFY)</i>","2022-09-05"
"Lenalidomide","FDA","2019-05-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Rituximab","","",TRUE,"MAGNIFY","2019-05-28: Approved in combination with a rituximab product for previously treated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> and previously treated <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a>. <i>(New disease entity; based on AUGMENT and MAGNIFY)</i>","2022-09-05"
"Lenalidomide","FDA","2019-05-28","Marginal zone lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","Rituximab","","",TRUE,"MAGNIFY","2019-05-28: Approved in combination with a rituximab product for previously treated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> and previously treated <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a>. <i>(New disease entity; based on AUGMENT and MAGNIFY)</i>","2022-09-05"
"Lenalidomide","HC","2008-01-17","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-01-17: Initial notice of compliance with conditions","2023-05-08"
"Lenalidomide","HC","2013-06-06","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-06-06: Conditions were met","2023-05-08"
"Lenalidomide","PMDA","2010-06-25","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2010-06-25: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Lenalidomide","PMDA","2010-08-20","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","5q-","FALSE",NA,"","2010-08-20: New additional indication and a new dosage for the treatment of <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a> associated with a deletion 5q cytogenetic abnormality.","2023-06-16"
"Lenalidomide","PMDA","2015-12-21","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-12-21: revised indication for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Lenalidomide","PMDA","2017-03-02","Adult T-cell leukemia-lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-03-02: New additional indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Adult_T-cell_leukemia-lymphoma"" title=""Adult T-cell leukemia-lymphoma"">adult T-cell leukemia/lymphoma</a>.","2023-06-16"
"Lenalidomide","PMDA","2020-02-21","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2020-02-21: New indications and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> and <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma</a>.","2023-06-16"
"Lenalidomide","PMDA","2020-02-21","Marginal zone lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2020-02-21: New indications and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> and <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma</a>.","2023-06-16"
"Lenograstim","EMA","1991-10-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1991-10-11: EURD","2023-07-31"
"Lenograstim","PMDA","2022-06-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","Antineoplastic agents","","",NA,"","2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Lenvatinib","EMA","2015-05-28","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","Refractory","Locally advanced OR Metastatic","","adults","","Radioactive iodine",NA,"","progression","","","0","","",NA,"","2015-05-28: Initial authorization as Lenvima. Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma (DTC)</a>, refractory to radioactive iodine (RAI).","2023-09-17"
"Lenvatinib","EMA","2016-08-25","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","1 VEGF inhibitor",NA,"","","","","Everolimus","","",TRUE,"E7080-G000-205","2016-08-25: Initial authorization as Kisplyx. Kisplyx is indicated in combination with everolimus for the treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> following one prior vascular endothelial growth factor (VEGF)-targeted therapy. <i>(Based on E7080-G000-205)</i>","2023-09-17"
"Lenvatinib","EMA","2018-08-20","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Unresectable","","adults","","0 SACT",NA,"","","","","0","","",NA,"","2018-08-20: Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have received no prior systemic therapy.","2023-09-17"
"Lenvatinib","EMA","2021-11-26","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","","adults","","",NA,"","","","","Pembrolizumab","","",NA,"","2021-11-26: Extension of indication to include Kisplyx in combination with pembrolizumab first line treatment of adults with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>.","2023-09-17"
"Lenvatinib","EMA","2021-11-26","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","not candidates for curative surgery or radiation","1+ SACT",NA,"any","progression","","","Pembrolizumab","","",NA,"","2021-11-26: Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma (EC)</a> who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.","2023-09-17"
"Lenvatinib","FDA","2015-02-13","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","Refractory","Locally recurrent OR Metastatic","","","","Iodine-131","FALSE","","","","","","","",TRUE,"SELECT","2015-02-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm"">Approved</a> for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated thyroid cancer</a>. <i>(Initial approval; based on SELECT)</i>","2022-09-05"
"Lenvatinib","FDA","2016-05-13","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","1 VEGF inhibitor","FALSE","","","","","Everolimus","","",TRUE,"E7080-G000-205","2016-05-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm"">Approved</a> in combination with <a href=""/wiki/Everolimus_(Afinitor)"" title=""Everolimus (Afinitor)"">everolimus</a>, for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> following one prior <a href=""/wiki/Category:VEGFR_inhibitors"" title=""Category:VEGFR inhibitors"">anti-angiogenic therapy</a>. <i>(Based on E7080-G000-205)</i>","2022-09-05"
"Lenvatinib","FDA","2018-08-16","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","0","FALSE","","","","","","","",TRUE,"REFLECT","2018-08-16: Approved for first-line treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a>. <i>(Based on REFLECT)</i>","2022-09-05"
"Lenvatinib","FDA","2019-09-17","Endometrial cancer",TRUE,FALSE,FALSE,"","","Advanced","","","not candidate for curative surgical resection or radiation","",NA,"","","","","Pembrolizumab","not MSI-H AND not dMMR","TRUE",TRUE,"KEYNOTE-146","2019-09-17: Accelerated approval in combination with <a href=""/wiki/Pembrolizumab_(Keytruda)"" title=""Pembrolizumab (Keytruda)"">Pembrolizumab (Keytruda)</a> for the treatment of patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. <i>(Based on KEYNOTE-146)</i>","2022-09-05"
"Lenvatinib","FDA","2021-07-21","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced","","","not candidate for curative surgical resection or radiation","",NA,"","","","","Pembrolizumab","not MSI-H AND not dMMR","TRUE",TRUE,"KEYNOTE-775","2021-07-21: Converted to regular approval in combination with <a href=""/wiki/Pembrolizumab_(Keytruda)"" title=""Pembrolizumab (Keytruda)"">Pembrolizumab (Keytruda)</a> for the treatment of patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. <i>(Based on KEYNOTE-775)</i>","2022-09-05"
"Lenvatinib","FDA","2021-08-10","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","0","FALSE","","","","","Pembrolizumab","","",TRUE,"CLEAR","2021-08-10: Approved in combination with <a href=""/wiki/Pembrolizumab_(Keytruda)"" title=""Pembrolizumab (Keytruda)"">Pembrolizumab (Keytruda)</a> for first-line treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on CLEAR)</i>","2022-09-05"
"Lenvatinib","HC","2019-09-20","Endometrial cancer",TRUE,FALSE,FALSE,"","","Advanced","","adults","not candidate for curative surgical resection or radiation","Platinum-based regimen","FALSE","","progression","","","Pembrolizumab","not MSI-H AND not dMMR","TRUE",NA,"","2019-09-20: Notice of compliance with conditions in combination with pembrolizumab, for the treatment of adult patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.","2023-05-08"
"Lenvatinib","PMDA","2015-03-26","Thyroid cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2015-03-26: Initial approval for the treatment of unresectable <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a>.","2023-06-16"
"Lenvatinib","PMDA","2018-03-23","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2018-03-23: New additional indication and a new dosage indicated for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatic cell carcinoma</a>.","2023-06-16"
"Lenvatinib","PMDA","2021-03-21","Thymoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2021-03-21: New indication for the treatment of unresectable <a href=""/wiki/Thymoma"" title=""Thymoma"">thymic carcinoma</a>.","2023-06-16"
"Lenvatinib","PMDA","2021-12-24","Endometrial cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2021-12-24: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Lenvatinib","PMDA","2022-02-25","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2022-02-25: New indication and a new dosage for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Lepirudin","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Letrozole","EMA","1996-07-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-07-24: EURD","2023-07-31"
"Letrozole","FDA","1997-07-25","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","",NA,"","","","","","","",NA,"","1997-07-25: Initial approval for the treatment of advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women","2022-09-05"
"Letrozole","FDA","2004-10-29","Breast cancer",TRUE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery AND 5 years of Tamoxifen","FALSE","","","","","","","",TRUE,"NCIC-CTG MA.17","2004-10-29: Accelerated approval for the extended adjuvant treatment of early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. <i>(Indication expanded to adjuvant setting after prior therapy; based on NCIC-CTG MA.17)</i>","2022-09-05"
"Letrozole","FDA","2005-12-28","Breast cancer",TRUE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery","FALSE","","","","","","HR+","FALSE",TRUE,"BIG 1-98","2005-12-28: Accelerated approval for the adjuvant treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Indication expanded to adjuvant setting; based on BIG 1-98)</i>","2022-09-05"
"Letrozole","FDA","2010-03-02","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","0 or 1","FALSE","","","","","","HR+|HR unknown","FALSE",TRUE,"AR/BC2","2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on ILBCG, AR/BC2, AR/BC3)</i>","2022-09-05"
"Letrozole","FDA","2010-03-02","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","0 or 1","FALSE","","","","","","HR+|HR unknown","FALSE",TRUE,"AR/BC3","2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on ILBCG, AR/BC2, AR/BC3)</i>","2022-09-05"
"Letrozole","FDA","2010-03-02","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced","","postmenopausal women","","0 or 1","FALSE","","","","","","HR+|HR unknown","FALSE",TRUE,"ILBCG","2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on ILBCG, AR/BC2, AR/BC3)</i>","2022-09-05"
"Letrozole","FDA","2010-03-02","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery","FALSE","","","","","","HR+","FALSE",NA,"","2010-03-02: Label simplified to adjuvant treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(No change)</i>","2022-09-05"
"Letrozole","FDA","2010-03-02","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","postmenopausal women","","Surgery AND standard Tamoxifen","FALSE","","","","","","","",NA,"","2010-03-02: Label simplified to extended adjuvant treatment of postmenopausal women with early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received prior standard adjuvant tamoxifen therapy. <i>(Years requirement removed)</i>","2022-09-05"
"Letrozole","FDA","2010-04-30","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2010-04-30: Converted to regular approval.","2022-09-05"
"Letrozole","HC","2005-04-01","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2005-04-01: Initial notice of compliance with conditions","2023-05-08"
"Letrozole","HC","2010-12-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-12-17: Conditions were met","2023-05-08"
"Letrozole","PMDA","2006-01-23","Breast cancer",FALSE,FALSE,FALSE,"","","","","postmenopausal women","","",NA,"","","","","","","",NA,"","2006-01-23: Initial approval for the treatment of post-menopausal <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Leucovorin","FDA","1952-06-20","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1952-06-20: Initial FDA approval","2022-09-05"
"Leucovorin","FDA","Uncertain date","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fluorouracil","","",TRUE,"O'Connell 1989","Uncertain date: Indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>. <i>(Based on O'Connell 1989 and Poon et al. 1989)</i>","2022-09-05"
"Leucovorin","FDA","Uncertain date","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fluorouracil","","",TRUE,"Poon et al. 1989","Uncertain date: Indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>. <i>(Based on O'Connell 1989 and Poon et al. 1989)</i>","2022-09-05"
"Leuprolide","EMA","1984-07-31","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1984-07-31: EURD","2023-07-31"
"Leuprolide","FDA","1985-04-09","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",NA,"","1985-04-09: Initial FDA approval for palliative treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2022-09-05"
"Leuprolide","FDA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"L-PC07-169","Uncertain date: Lupron depot 45 mg for 6-month administration approved for treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic cancer</a>. <i>(Based on L-PC07-169)</i>","2022-09-05"
"Leuprolide","FDA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Sharifi and Soloway 1990","Uncertain date: Lupron depot 7.5 mg for 1-month administration approved for treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic cancer</a>. <i>(Based on Sharifi and Soloway 1990)</i>","2022-09-05"
"Leuprolide","FDA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Sharifi et al. 1996","Uncertain date: Lupron depot 22.5 mg for 3-month administration approved for treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic cancer</a>. <i>(Based on Sharifi et al. 1996)</i>","2022-09-05"
"Leuprolide","FDA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Sharifi et al. 1998","Uncertain date: Lupron depot 30 mg for 4-month administration approved for treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostatic cancer</a>. <i>(Based on Sharifi et al. 1998)</i>","2022-09-05"
"Leuprolide","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Leuprolide","PMDA","2005-08-18","Breast cancer",FALSE,FALSE,FALSE,"","","","","premenopausal women","","",NA,"","","","","","","",NA,"","2005-08-18: New indication for the treatment of premenopausal <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Leuprolide","PMDA","2015-09-28","Breast cancer",FALSE,FALSE,FALSE,"","","","","premenopausal women","","",NA,"","","","","","","",NA,"","2015-09-28: New dosage form indicated for the treatment of premenopausal <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Leuprolide","PMDA","2015-09-28","Prostate cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-09-28: New dosage form indicated for the treatment of <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Levamisole","EMA","1966-06-14","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1966-06-14: EURD","2023-07-31"
"Levamisole","FDA","1990-06-18","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Dukes' stage C","","","","Surgery","FALSE","","","","","Fluorouracil","","",TRUE,"Laurie et al. 1989","1990-06-18: indicated as adjuvant treatment in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">5-fluorouracil</a> after surgical resection in patients with Dukes' stage C <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>. <i>(Based on Laurie et al. 1989 and SWOG S8591)</i>","2022-09-05"
"Levamisole","FDA","1990-06-18","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Dukes' stage C","","","","Surgery","FALSE","","","","","Fluorouracil","","",TRUE,"SWOG S8591","1990-06-18: indicated as adjuvant treatment in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)"">5-fluorouracil</a> after surgical resection in patients with Dukes' stage C <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>. <i>(Based on Laurie et al. 1989 and SWOG S8591)</i>","2022-09-05"
"Levofloxacin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Levoleucovorin","FDA","2008-03-07","Bone sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-03-07: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020140lbl.pdf"">FDA approved</a> ""to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists."" ""Levoleucovorin rescue is indicated after high-dose methotrexate therapy in <a href=""/wiki/Bone_sarcoma"" title=""Bone sarcoma""> osteosarcoma</a>.""","2022-09-05"
"Levoleucovorin","PMDA","2013-12-20","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2013-12-20: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Levoleucovorin","PMDA","2018-09-21","Small bowel adenocarcinoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-09-21: New indication and a new dosage for the treatment of <a href=""/wiki/Small_bowel_adenocarcinoma"" title=""Small bowel adenocarcinoma"">small intestine cancer</a>.","2023-06-16"
"Lifileuecel","FDA","2024-02-16","Melanoma",TRUE,FALSE,TRUE,"","","Unresectable OR Metastatic","","adults","","Anti-PD-1 antibody",NA,"","","","BRAF V600: BRAFi +/- MEKi","","","",NA,"","2024-02-16: Granted accelerated approval for adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.","2024-06-03"
"Lipefilgrastim","EMA","2013-07-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-07-25: Initial authorization","2023-05-08"
"Lisocabtagene maraleucel","EMA","2022-04-04","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",NA,"","2022-04-04: Breyanzi is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> and follicular lymphoma grade 3B (FL3B), after two or more lines of systemic therapy.","2023-05-08"
"Lisocabtagene maraleucel","EMA","2022-04-04","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",NA,"","2022-04-04: Breyanzi is indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> and follicular lymphoma grade 3B (FL3B), after two or more lines of systemic therapy.","2023-05-08"
"Lisocabtagene maraleucel","EMA","2023-05-25","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","Chemoimmunotherapy",NA,"First-line","relapsed","within 12 months of completion OR refractory","","","","",NA,"","2023-05-25: Revised indication for the treatment of adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high grade B-cell lymphoma (HGBCL)</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.","2023-09-17"
"Lisocabtagene maraleucel","EMA","2023-05-25","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","Chemoimmunotherapy",NA,"First-line","relapsed","within 12 months of completion OR refractory","","","","",NA,"","2023-05-25: Revised indication for the treatment of adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high grade B-cell lymphoma (HGBCL)</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.","2023-09-17"
"Lisocabtagene maraleucel","EMA","2023-05-25","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","Chemoimmunotherapy",NA,"First-line","relapsed","within 12 months of completion OR refractory","","","","",NA,"","2023-05-25: Revised indication for the treatment of adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high grade B-cell lymphoma (HGBCL)</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.","2023-09-17"
"Lisocabtagene maraleucel","FDA","2021-02-05","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"TRANSCEND NHL-001","2021-02-05: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a> (including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>), <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, and follicular lymphoma grade 3B. <i>(Based on TRANSCEND NHL-001)</i>","2022-09-05"
"Lisocabtagene maraleucel","FDA","2021-02-05","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"TRANSCEND NHL-001","2021-02-05: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a> (including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>), <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, and follicular lymphoma grade 3B. <i>(Based on TRANSCEND NHL-001)</i>","2023-03-15"
"Lisocabtagene maraleucel","FDA","2021-02-05","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"TRANSCEND NHL-001","2021-02-05: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a> (including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>), <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, and follicular lymphoma grade 3B. <i>(Based on TRANSCEND NHL-001)</i>","2022-09-05"
"Lisocabtagene maraleucel","FDA","2021-02-05","Transformed lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"TRANSCEND NHL-001","2021-02-05: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a> (including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from indolent lymphoma</a>), <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>, <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>, and follicular lymphoma grade 3B. <i>(Based on TRANSCEND NHL-001)</i>","2022-09-05"
"Lisocabtagene maraleucel","FDA","2022-06-24","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","First-line chemoimmunotherapy","FALSE","","","","","","","",TRUE,"TRANSFORM","2022-06-24: Approved for adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">large B-cell lymphoma (LBCL)</a> who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy. <i>(Based on TRANSFORM)</i>","2022-09-05"
"Lisocabtagene maraleucel","FDA","2022-06-24","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","First-line chemoimmunotherapy, not eligible for autologous HSCT","FALSE","","","","","","","",TRUE,"TRANSFORM","2022-06-24: Approved for adult patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">large B-cell lymphoma (LBCL)</a> who have refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. <i>(Based on TRANSFORM)</i>","2022-09-05"
"Lisocabtagene maraleucel","FDA","2024-05-15","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","","","",TRUE,"TRANSCEND-FL","2024-05-15: Granted accelerated approval for adults with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> who have received two or more prior lines of systemic therapy. <i>(Based on TRANSCEND-FL)</i>","2024-06-03"
"Lisocabtagene maraleucel","FDA","2024-05-30","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT, including BTKi",NA,"","","","","","","",TRUE,"TRANSCEND-MCL","2024-05-30: Approved for adult patients with relapsed or refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi). <i>(Based on TRANSCEND-MCL)</i>","2024-06-03"
"Lisocabtagene maraleucel","HC","2022-05-06","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-05-06: Initial notice of compliance","2023-06-15"
"Lisocabtagene maraleucel","PMDA","2021-03-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-03-22: Initial approval","2023-06-15"
"Lobaplatin","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lomustine","EMA","1976-01-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1976-01-26: EURD","2023-07-31"
"Lomustine","FDA","1976-08-04","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1976-08-04: Initial approval","2022-09-05"
"Lomustine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2009-04-30: (oldest available label) has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's Disease</a>-secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. <i>(No supporting studies are cited)</i>","2023-01-03"
"Lomustine","FDA","Uncertain date","CNS cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2009-04-30: (oldest available label) has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">brain tumors</a> - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures. <i>(No supporting studies are cited)</i>","2023-01-03"
"Loncastuximab tesirine","EMA","2022-12-20","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","0","","",NA,"","2022-12-20: Granted conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a>, after two or more lines of systemic therapy.","2023-05-08"
"Loncastuximab tesirine","EMA","2022-12-20","High-grade B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","0","","",NA,"","2022-12-20: Granted conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a>, after two or more lines of systemic therapy.","2023-05-08"
"Loncastuximab tesirine","FDA","2021-04-23","Diffuse large B-cell lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"LOTIS-2","2021-04-23: Granted accelerated approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>. <i>(Based on LOTIS-2)</i>","2022-09-05"
"Loncastuximab tesirine","FDA","2021-04-23","High-grade B-cell lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"LOTIS-2","2021-04-23: Granted accelerated approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>. <i>(Based on LOTIS-2)</i>","2023-03-15"
"Loncastuximab tesirine","FDA","2021-04-23","Transformed lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"LOTIS-2","2021-04-23: Granted accelerated approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, and <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a>. <i>(Based on LOTIS-2)</i>","2022-09-05"
"Loperamide","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lorazepam","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Lorlatinib","EMA","2019-05-06","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-05-06: Initial conditional approval as Lorviqua","2023-05-08"
"Lorlatinib","FDA","2018-11-02","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","(Crizotinib AND One other ALK inhibitor) OR (Alectinib OR Ceritinib)","FALSE","","","","","","ALK rearrangement","FALSE",TRUE,"B7461001","2018-11-02: Granted accelerated approval for patients with <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. <i>(Based on B7461001)</i>","2022-09-05"
"Lorlatinib","FDA","2021-03-03","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ALK rearrangement","FALSE",TRUE,"CROWN","2021-03-03: Granted regular approval for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors are <a href=""/wiki/Biomarkers#ALK"" title=""Biomarkers"">anaplastic lymphoma kinase (ALK)</a>-<a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">positive</a>. <i>(Converted to regular approval; prior therapy requirement removed; based on CROWN)</i>","2022-09-05"
"Lorlatinib","HC","2019-02-22","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-02-22: Initial notice of compliance with conditions","2023-05-08"
"Lorlatinib","HC","2022-05-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-05-20: Conditions were met","2023-05-08"
"Lorlatinib","PMDA","2018-09-21","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","1+ ALK TKI","FALSE","","Resistance OR intolerance","","","","ALK rearrangement","FALSE",NA,"","2018-09-21: Conditional new approval for the treatment of unresectable or recurrent anaplastic lymphoma kinase (ALK)-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with resistance or intolerance to ALK tyrosine kinase inhibitors.","2023-06-16"
"Lorlatinib","PMDA","2021-11-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Advanced OR Recurrent","","","","",NA,"","","","","","ALK rearrangement","FALSE",NA,"","2021-11-25: New indication for the treatment of unresectable or advanced/recurrent anaplastic lymphoma kinase (ALK) fusion gene-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Lurbinectedin","FDA","2020-06-15","Small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"PM1183-B-005-14","2020-06-15: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer"">Accelerated FDA approval</a> for adult patients with metastatic <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer (SCLC)</a> with disease progression on or after <a href=""/wiki/Category:Platinum_agents"" title=""Category:Platinum agents"">platinum-based chemotherapy</a>. <i>(Based on PM1183-B-005-14)</i>","2022-09-05"
"Lurbinectedin","HC","2021-09-29","Small cell lung cancer",TRUE,FALSE,FALSE,"","","Stage III or Metastatic","","adults","","Platinum-based regimen","FALSE","","progression","","","","","",NA,"","2021-09-29: Initial notice of compliance with conditions for the treatment of adults with Stage III or metastatic <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer (SCLC)</a> who have progressed on or after platinum-containing therapy.","2023-05-08"
"Luspatercept","EMA","2020-06-25","Beta thalassemia",FALSE,FALSE,FALSE,"","","transfusion-dependent anemia","","adults","","",NA,"","","","","","","",NA,"","2020-06-25: Initial authorization as Reblozyl. Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia associated with <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassaemia</a>.","2023-09-17"
"Luspatercept","EMA","2020-06-25","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","transfusion-dependent anemia","Very low risk|Low-risk|Intermediate-risk","adults","","","","","unsatisfactory","","","","","",NA,"","2020-06-25: Initial authorization as Reblozyl. Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS) with ring sideroblasts</a>, who had an unsatisfactory response to erythropoietin-based therapy.","2024-12-02"
"Luspatercept","EMA","2020-06-25","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","transfusion-dependent anemia","Very low risk|Low-risk|Intermediate-risk","adults","","erythropoietin-based therapy","","","","","","","","",NA,"","2020-06-25: Initial authorization as Reblozyl. Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS) with ring sideroblasts</a>, who are ineligible for erythropoietin-based therapy.","2024-12-02"
"Luspatercept","EMA","2023-02-27","Beta thalassemia",FALSE,FALSE,FALSE,"","","non-transfusion dependent","","adults","","",NA,"","","","","","","",NA,"","2023-02-27: Extension of indication in <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassaemia</a> to include adult patients with non-transfusion dependent beta-thalassaemia (NTDT).","2023-09-17"
"Luspatercept","EMA","2023-03-20","Beta thalassemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2023-03-20: Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassaemia</a>.","2023-05-08"
"Luspatercept","EMA","Uncertain date","Beta thalassemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","Uncertain date: Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia associated with <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassaemia</a>.","2023-05-08"
"Luspatercept","EMA","Uncertain date","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","Very low risk|Low-risk|Intermediate-risk","adults","","",NA,"","","","","","","",NA,"","Uncertain date: Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes (MDS) with ring sideroblasts</a>, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.","2023-05-08"
"Luspatercept","FDA","2019-11-08","Beta thalassemia",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"BELIEVE","2019-11-08: Initial FDA approval for adult patients with <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">beta thalassemia</a> who require regular red blood cell (RBC) transfusions. <i>(Based on BELIEVE)</i>","2022-09-05"
"Luspatercept","FDA","2020-04-03","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"MEDALIST","2020-04-03: Approved for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndromes with ring sideroblasts (MDS-RS)</a> or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>(Based on MEDALIST)</i>","2022-09-05"
"Luspatercept","PMDA","2024-01-18","Myelodysplastic syndrome",FALSE,FALSE,FALSE,"","","anemia","","","","",NA,"","","","","","","",NA,"","2024-01-18: Newly indicated for the treatment of anemia associated with <a href=""/wiki/Myelodysplastic_syndrome"" title=""Myelodysplastic syndrome"">myelodysplastic syndrome</a>.","2024-06-03"
"Lusutrombopag","FDA","2018-07-31","Thrombocytopenia in liver disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-07-31: Approved for <a href=""/wiki/Thrombocytopenia_in_liver_disease"" title=""Thrombocytopenia in liver disease"">thrombocytopenia in adults with chronic liver disease</a> who are scheduled to undergo a medical or dental procedure.","2022-09-05"
"Lusutrombopag","PMDA","2015-09-28","Thrombocytopenia in liver disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-09-28: New approval for the improvement of <a href=""/wiki/Thrombocytopenia_in_liver_disease"" title=""Thrombocytopenia in liver disease"">thrombocytopenia in patients with chronic liver disease</a> for whom an elective invasive procedure is planned.","2023-06-16"
"Lutetium Lu 177 dotatate","EMA","2017-09-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-09-26: Initial authorization","2023-05-08"
"Lutetium Lu 177 dotatate","FDA","2018-01-26","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","Somatostatin receptor+","FALSE",TRUE,"ERASMUS","2018-01-26: Approved for the treatment of <a href=""/wiki/Biomarkers#Somatostatin_receptor"" title=""Biomarkers"">somatostatin receptor</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">gastroenteropancreatic neuroendocrine tumors (GEP-NETs)</a>, including foregut, midgut, and hindgut neuroendocrine tumors in adults. <i>(Based on NETTER-1 and ERASMUS)</i>","2022-09-05"
"Lutetium Lu 177 dotatate","FDA","2018-01-26","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","Somatostatin receptor+","FALSE",TRUE,"NETTER-1","2018-01-26: Approved for the treatment of <a href=""/wiki/Biomarkers#Somatostatin_receptor"" title=""Biomarkers"">somatostatin receptor</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">gastroenteropancreatic neuroendocrine tumors (GEP-NETs)</a>, including foregut, midgut, and hindgut neuroendocrine tumors in adults. <i>(Based on NETTER-1 and ERASMUS)</i>","2022-09-05"
"Lutetium Lu 177 dotatate","FDA","2024-04-23","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","pediatric patients 12 years and older","","",NA,"","","","","","Somatostatin receptor+","",TRUE,"NETTER-P","2024-04-23: Approved for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">gastroenteropancreatic neuroendocrine tumors (GEP-NETs)</a>, including foregut, midgut, and hindgut neuroendocrine tumors. <i>(Based on NETTER-P)</i>","2024-06-03"
"Lutetium Lu 177 dotatate","HC","2019-01-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-01-09: Initial notice of compliance (unclear details)","2023-05-20"
"Lutetium Lu 177 dotatate","PMDA","2021-06-23","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","Somatostatin receptor+","FALSE",NA,"","2021-06-23: Newly indicated for the treatment of somatostatin receptor-positive <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumor</a>.","2023-06-16"
"Lutetium Lu 177 vipivotide tetraxetan","EMA","2022-12-09","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","Antiandrogen AND Taxane-based regimen",NA,"","progression","","","ADT OR (ADT AND Androgen receptor inhibitor)","PSMA-positive","",NA,"","2022-12-09: Initial authorization in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.","2023-05-08"
"Lutetium Lu 177 vipivotide tetraxetan","FDA","2022-03-23","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","Antiandrogen AND Taxane-based regimen","FALSE","","","","","","PSMA-positive","FALSE",TRUE,"VISION_PrCA","2022-03-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer"">FDA approved</a> for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. <i>(Based on VISION_PrCA)</i>","2022-09-05"
"Mannitol","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Margetuximab","FDA","2020-12-16","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","2+ Anti-HER2-based regimen, 1+ of which was for metastatic disease","FALSE","","","","","Chemotherapy","HER2+","FALSE",TRUE,"SOPHIA","2020-12-16: Approved in combination with chemotherapy, for the treatment of adult patients with metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. <i>(Based on SOPHIA)</i>","2022-09-05"
"Mavorixafor","FDA","2024-04-30","WHIM syndrome",FALSE,FALSE,FALSE,"","","","","adults AND children 12 years of age or older","","",NA,"","","","","","","",TRUE,"4WHIM","2024-04-30: Initial approval in patients 12 years of age and older with <a href=""/wiki/WHIM_syndrome"" title=""WHIM syndrome"">WHIM syndrome</a> (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. <i>(Based on 4WHIM)</i>","2024-09-06"
"Mechlorethamine","FDA","1949-03-15","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1949-03-15: Initial FDA approval (<b>This is the first chemotherapy agent ever approved</b>)","2022-09-05"
"Mechlorethamine","FDA","2004-02-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-02-09 (only label available at Drugs @ FDA):","2023-05-08"
"Medroxyprogesterone acetate","EMA","1959-08-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1959-08-20: EURD","2023-07-31"
"Medroxyprogesterone acetate","FDA","1959-06-18","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1959-06-18: Initial approval","2023-07-31"
"Megestrol","EMA","1971-08-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1971-08-18: EURD","2023-07-31"
"Melphalan","EMA","1963-09-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1963-09-26: EURD","2023-07-31"
"Melphalan","FDA","1964-01-17","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1964-01-17: Initial FDA approval<sup id=""cite_ref-5"" class=""reference""><a href=""#cite_note-5"">&#91;5&#93;</a>","2022-09-05"
"Melphalan","FDA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"SWG01","Uncertain date: Indicated for the palliative treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>. <i>(Based on SWG01)</i>","2022-09-05"
"Melphalan","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Indicated for the palliation of non-resectable <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial carcinoma of the ovary</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Melphalan flufenamide","EMA","2022-08-17","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","3+, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody",NA,"","progression","For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation","","Dexamethasone","","",NA,"","2022-08-17: Initial authorization as Pepaxti. Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one antiCD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.","2023-09-17"
"Melphalan flufenamide","FDA","2021-02-26","Multiple myeloma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","4+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","","","","Dexamethasone","","",TRUE,"HORIZON_RRMM","2021-02-26: Granted accelerated approval to in combination with dexamethasone for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. <i>(Based on HORIZON_RRMM)</i>","2022-09-05"
"Melphalan flufenamide","FDA","2021-10-22","NONE",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"OCEAN","2024-02-23: Accelerated approval withdrawn. <i>(Based on OCEAN)</i>","2022-09-05"
"Melphalan for Injection-Hepatic Delivery System","FDA","2023-08-14","Uveal melanoma",FALSE,FALSE,FALSE,"","","unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation","","adults","","",NA,"","","","","","","",TRUE,"FOCUS_HCC","2023-08-14: Initial approval as a liver-directed treatment for adult patients with <a href=""/wiki/Uveal_melanoma"" title=""Uveal melanoma"">uveal melanoma</a> with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. <i>(Based on FOCUS_HCC)</i>","2023-11-07"
"Meperidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Mepolizumab","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-05-08"
"Mercaptopurine","EMA","1953-09-11","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1953-09-11: EURD","2023-07-31"
"Mercaptopurine","FDA","1953-09-11","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1953-09-11: Initial FDA approval","2022-09-05"
"Mercaptopurine","FDA","2003-01-10","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","Induction and Maintenance","","","","","",NA,"","","","","","","",FALSE,"","2003-01-10 (oldest label on Drugs @ FDA): Indicated for remission induction and maintenance therapy of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphatic leukemia</a>. <i>(No supporting studies are cited)</i>","2023-05-20"
"Mercaptopurine","FDA","2014-04-28","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Combination maintenance therapy","","",FALSE,"","2014-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist"">Purixan (mercaptopurine oral suspension formulation) FDA approved</a> for the treatment of patients with <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia (ALL)</a> as a component of a combination maintenance therapy regimen. <i>(No supporting studies are cited)</i>","2022-09-05"
"Mesna","FDA","1988-12-30","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1988-12-30: Initial FDA approval","2022-09-05"
"Methotrexate","EMA","1962-01-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1962-01-01: EURD","2023-07-31"
"Methotrexate","FDA","1953-12-07","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1953-12-07: Initial FDA approval","2022-09-05"
"Methotrexate","FDA","Uncertain date","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: In <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a>, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is used alone or in combination with other anticancer agents in the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">epidermoid cancers of the head and neck</a>, advanced <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (cutaneous T cell lymphoma)</a>, and lung cancer, particularly <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous cell</a> and <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","CNS leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is also indicated in the treatment of <a href=""/wiki/CNS_leukemia"" title=""CNS leukemia"">meningeal leukemia</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is used alone or in combination with other anticancer agents in the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">epidermoid cancers of the head and neck</a>, advanced <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (cutaneous T cell lymphoma)</a>, and lung cancer, particularly <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous cell</a> and <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Gestational trophoblastic neoplasia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is indicated in the treatment of <a href=""/wiki/Gestational_trophoblastic_neoplasia"" title=""Gestational trophoblastic neoplasia"">gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Head and neck cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is used alone or in combination with other anticancer agents in the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">epidermoid cancers of the head and neck</a>, advanced <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (cutaneous T cell lymphoma)</a>, and lung cancer, particularly <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous cell</a> and <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","Uncertain date: Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's lymphomas</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is used alone or in combination with other anticancer agents in the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">epidermoid cancers of the head and neck</a>, advanced <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (cutaneous T cell lymphoma)</a>, and lung cancer, particularly <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous cell</a> and <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Methotrexate is used alone or in combination with other anticancer agents in the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">epidermoid cancers of the head and neck</a>, advanced <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (cutaneous T cell lymphoma)</a>, and lung cancer, particularly <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous cell</a> and <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell</a> types. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methotrexate","FDA","Uncertain date","Osteosarcoma",FALSE,FALSE,FALSE,"","","Non-metastatic","","","","Surgical resection OR Amputation","FALSE","","","","","Chemotherapy","","",FALSE,"","Uncertain date: Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non- metastatic <a href=""/wiki/Osteosarcoma"" title=""Osteosarcoma"">osteosarcoma</a> who have undergone surgical resection or amputation for the primary tumor. <i>(No supporting studies are cited)</i>","2022-09-05"
"Methoxsalen","EMA","1958-03-31","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1958-03-31: EURD","2023-07-31"
"Methoxsalen","FDA","1999-02-25","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","unresponsive","","","","","",TRUE,"Edelson et al. 1987","1999-02-25: Initial FDA approval for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma (CTCL)</a> that is unresponsive to other forms of treatment. <i>(Based on Edelson et al. 1987)</i>","2022-09-05"
"Methoxsalen","FDA","2013-10-31","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","unresponsive","","","","","",FALSE,"","2013-10-31: Indication revised for extracorporeal administration with the UVAR^TM XTS^TM or THERAKOS^TM CELLEX^TM Photopheresis System in the palliative treatment of the skin manifestations of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma (CTCL)</a> that is unresponsive to other forms of treatment. <i>(No supporting studies are cited)</i>","2023-01-03"
"Methylprednisolone","EMA","1957-12-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1957-12-18: EURD","2023-07-31"
"Metoclopramide","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Metronidazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Midostaurin","EMA","2017-09-18","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","Cytarabine AND Daunorubicin","FLT3 mutation","",NA,"","2017-09-18: Initial authorization in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukaemia (AML)</a> who are FLT3 mutation positive.","2023-09-17"
"Midostaurin","EMA","2017-09-18","Systemic mastocytosis",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","0","","",NA,"","2017-09-18: Initial authorization as monotherapy for the treatment of adult patients with <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">aggressive systemic mastocytosis (ASM)</a>, systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).","2023-09-17"
"Midostaurin","FDA","2017-04-28","Systemic mastocytosis",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"CEREMAST","2017-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm"">FDA approved</a> for the treatment of adults with <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">aggressive systemic mastocytosis (SM)</a>, SM with associated hematological neoplasm, or mast cell leukemia. <i>(Based on CPKC412D2201 and CEREMAST)</i>","2022-09-05"
"Midostaurin","FDA","2017-04-28","Systemic mastocytosis",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"CPKC412D2201","2017-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm"">FDA approved</a> for the treatment of adults with <a href=""/wiki/Systemic_mastocytosis"" title=""Systemic mastocytosis"">aggressive systemic mastocytosis (SM)</a>, SM with associated hematological neoplasm, or mast cell leukemia. <i>(Based on CPKC412D2201 and CEREMAST)</i>","2022-09-05"
"Midostaurin","FDA","2017-04-28","Acute myeloid leukemia",FALSE,FALSE,TRUE,"","","","","adults","","0","FALSE","","","","","Cytarabine AND Daunorubicin","FLT3 mutation","FALSE",TRUE,"RATIFY","2017-04-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm"">FDA approved</a> for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> who are <a href=""/wiki/Biomarkers#FLT3"" title=""Biomarkers"">FLT3</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation-positive</a> (FLT3+), as detected by an FDA-approved test, in combination with standard <a href=""/wiki/Cytarabine_(Ara-C)"" title=""Cytarabine (Ara-C)"">cytarabine</a> and <a href=""/wiki/Daunorubicin_(Cerubidine)"" title=""Daunorubicin (Cerubidine)"">daunorubicin</a> induction and cytarabine consolidation. <i>(Based on RATIFY)</i>","2022-09-05"
"Mifamurtide","EMA","2023-03-09","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-03: Initial marketing authorisation","2023-07-31"
"Miriplatin","PMDA","2009-10-16","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2009-10-16: Initial approval for lipiodolization in <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a>.","2023-07-31"
"Mirvetuximab soravtansine","FDA","2022-11-14","Ovarian cancer",TRUE,FALSE,TRUE,"","","","","adults","","1 to 3 SACT","FALSE","","Platinum-resistant","","","","Folate receptor alpha positive","FALSE",TRUE,"SORAYA","2022-11-14: Granted accelerated approval for adult patients with folate receptor alpha positive, platinum-resistant <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who have received one to three prior systemic treatment regimens. <i>(Based on SORAYA)</i>","2023-01-03"
"Mirvetuximab soravtansine","FDA","2024-03-22","Ovarian cancer",FALSE,FALSE,FALSE,"","Platinum resistant","","","adults","","1 to 3 SACT",NA,"","","","","","Folate receptor alpha positive","",TRUE,"MIRASOL","2024-03-22: Regular approval for adult patients with folate receptor alpha positive, platinum-resistant <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. <i>(Based on MIRASOL)</i>","2024-06-03"
"Mitapivat","FDA","2022-02-17","Pyruvate kinase deficiency",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ACTIVATE","2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with <a href=""/wiki/Pyruvate_kinase_deficiency"" title=""Pyruvate kinase deficiency"">pyruvate kinase (PK) deficiency</a>. <i>(Based on ACTIVATE and ACTIVATE-T)</i>","2023-07-31"
"Mitapivat","FDA","2022-02-17","Pyruvate kinase deficiency",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ACTIVATE-T","2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with <a href=""/wiki/Pyruvate_kinase_deficiency"" title=""Pyruvate kinase deficiency"">pyruvate kinase (PK) deficiency</a>. <i>(Based on ACTIVATE and ACTIVATE-T)</i>","2023-07-31"
"Mitomycin","EMA","1962-10-05","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1962-10-05: EURD","2023-07-31"
"Mitomycin","FDA","1981-08-24","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1981-08-24: Initial FDA approval","2022-09-05"
"Mitomycin","FDA","Uncertain date","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">adenocarcinoma of the stomach</a> or <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreas</a> in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. <i>(No supporting studies are cited)</i>","2022-09-05"
"Mitomycin","FDA","Uncertain date","Pancreatic cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">adenocarcinoma of the stomach</a> or <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreas</a> in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. <i>(No supporting studies are cited)</i>","2022-09-05"
"Mitomycin pyelocalyceal","FDA","2020-04-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",TRUE,"OLYMPUS","2020-04-15: Approved for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). <i>(Based on OLYMPUS)</i>","2023-11-07"
"Mitotane","EMA","2004-04-28","Adrenocortical carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",FALSE,"","2004-04-28: Indicated for symptomatic treatment of advanced (unresectable, metastatic or relapsed) <a href=""/wiki/Adrenocortical_carcinoma"" title=""Adrenocortical carcinoma"">adrenal cortical carcinoma</a>. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. <i>(No supporting studies are cited)</i>","2023-05-08"
"Mitotane","FDA","1970-07-08","Adrenocortical carcinoma",FALSE,FALSE,TRUE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","1970-07-08: Approved for the treatment of inoperable, functional or nonfunctional, <a href=""/wiki/Adrenocortical_carcinoma"" title=""Adrenocortical carcinoma"">adrenal cortical carcinoma</a>.","2022-09-05"
"Mitoxantrone","EMA","1981-06-15","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1981-06-15: EURD","2023-07-31"
"Mitoxantrone","FDA","1987-12-23","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","","","",TRUE,"Arlin et al. 1990","1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">myelogenous</a>, <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">promyelocytic</a>, monocytic, and erythroid acute leukemias. <i>(Based on Arlin et al. 1990)</i>","2022-09-05"
"Mitoxantrone","FDA","1987-12-23","Acute promyelocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","","","",TRUE,"Arlin et al. 1990","1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">myelogenous</a>, <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">promyelocytic</a>, monocytic, and erythroid acute leukemias. <i>(Based on Arlin et al. 1990)</i>","2022-09-05"
"Mitoxantrone","FDA","1996-11-13","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Advanced","","","","0","FALSE","","","","","Steroids","","",TRUE,"CALGB 9182","1996-11-13: Approved in combination with <a href=""/wiki/Category:Steroids"" title=""Category:Steroids"">corticosteroids</a> as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a>. <i>(Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)</i>","2022-09-05"
"Mitoxantrone","FDA","1996-11-13","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Advanced","","","","0","FALSE","","","","","Steroids","","",TRUE,"CCI-NOV22","1996-11-13: Approved in combination with <a href=""/wiki/Category:Steroids"" title=""Category:Steroids"">corticosteroids</a> as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a>. <i>(Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)</i>","2022-09-05"
"Mitoxantrone","FDA","1996-11-13","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Advanced","","","","0","FALSE","","","","","Steroids","","",TRUE,"Moore et al. 1994","1996-11-13: Approved in combination with <a href=""/wiki/Category:Steroids"" title=""Category:Steroids"">corticosteroids</a> as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a>. <i>(Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)</i>","2022-09-05"
"Mobocertinib","FDA","2021-09-15","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen","FALSE","","progression","","","","EGFR exon 20 insertion","FALSE",TRUE,"AP32788-15-101","2021-09-15: Granted accelerated approval for adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_20"" title=""Biomarkers"">exon 20</a> <a href=""/wiki/Biomarkers#Insertion"" title=""Biomarkers"">insertion</a> mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. <i>(Based on AP32788-15-101)</i>","2022-09-05"
"Mobocertinib","FDA","2024-07-09","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","","","","","","","","","",NA,"","2024-07-09: Drug withdrawn due to failure of confirmatory trial.","2024-12-02"
"Mogamulizumab","EMA","2018-11-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-11-22: Initial authorization","2023-05-08"
"Mogamulizumab","FDA","2018-08-08","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1+ SACT","FALSE","","","","","","","",TRUE,"MAVORIC","2018-08-08: Initial approval for adult patients with relapsed or refractory <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (MF) or Sezary syndrome (SS)</a> after at least one prior systemic therapy. <i>(Based on MAVORIC)</i>","2022-09-05"
"Mogamulizumab","HC","2022-06-02","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1+ SACT","FALSE","","","","","","","",NA,"","2022-06-02: Initial notice of compliance for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides (MF) or Sezary syndrome (SS)</a> after at least one prior systemic therapy.","2023-06-15"
"Mogamulizumab","PMDA","2012-03-30","Adult T-cell leukemia-lymphoma",FALSE,FALSE,TRUE,"","","Recurrent","","","","",NA,"","","","","","CCR4+","FALSE",NA,"","2012-03-30: Initial approval for the treatment of recurrent or relapsed CCR4-positive <a href=""/wiki/Adult_T-cell_leukemia-lymphoma"" title=""Adult T-cell leukemia-lymphoma"">adult T-cell leukemia/lymphoma</a>.","2023-06-16"
"Mogamulizumab","PMDA","2014-03-17","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CCR4+","FALSE",NA,"","2014-03-17: New additional indications for the treatment of relapsed or refractory CCR4-positive <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a> and relapsed or refractory CCR4-positive <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Mogamulizumab","PMDA","2014-03-17","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CCR4+","FALSE",NA,"","2014-03-17: New additional indications for the treatment of relapsed or refractory CCR4-positive <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a> and relapsed or refractory CCR4-positive <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Mogamulizumab","PMDA","2014-12-18","Adult T-cell leukemia-lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","CCR4+","FALSE",NA,"","2014-12-18: Revised indication and a new dosage for the treatment of CCR4-positive <a href=""/wiki/Adult_T-cell_leukemia-lymphoma"" title=""Adult T-cell leukemia-lymphoma"">adult T-cell leukemia/lymphoma</a>.","2023-06-16"
"Mogamulizumab","PMDA","2018-08-21","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2018-08-21: New indications and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Momelotinib","EMA","2023-11-09","Myelofibrosis",FALSE,FALSE,FALSE,"","","disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia ","","adults","","JAK inhibitor|ruxolitinib","FALSE|TRUE","","","","","","","",NA,"","2023-11-09: CHMP recommendation for marketing authorisation - Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis</a>, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naive or have been treated with ruxolitinib.","2024-01-06"
"Momelotinib","EMA","2024-01-24","Myelofibrosis",FALSE,FALSE,FALSE,"","","moderate to severe anemia","","adults","","JAK inhibitor|ruxolitinib","FALSE|TRUE","","","","","","","",TRUE,"MOMENTUM","2024-01-24: Initial authorization as Omjjara. Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis</a>, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naive or have been treated with ruxolitinib. <i>(Based on MOMENTUM and SIMPLIFY-1)</i>","2024-06-03"
"Momelotinib","EMA","2024-01-24","Myelofibrosis",FALSE,FALSE,FALSE,"","","moderate to severe anemia","","adults","disease-related splenomegaly or symptoms","JAK inhibitor|ruxolitinib","FALSE|TRUE","","","","","","","",TRUE,"SIMPLIFY-1","2024-01-24: Initial authorization as Omjjara. Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis</a>, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naive or have been treated with ruxolitinib. <i>(Based on MOMENTUM and SIMPLIFY-1)</i>","2024-06-03"
"Momelotinib","FDA","2023-09-15","Myelofibrosis",FALSE,FALSE,FALSE,"","","anemia","Intermediate-risk OR High-risk","adults","","",NA,"","","","","","","",TRUE,"MOMENTUM","2023-09-15: Approved for the treatment of intermediate or high-risk <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis (MF)</a>, including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. <i>(Based on MOMENTUM and SIMPLIFY-1)</i>","2024-06-03"
"Momelotinib","FDA","2023-09-15","Myelofibrosis",FALSE,FALSE,FALSE,"","","anemia","Intermediate-risk OR High-risk","adults","","",NA,"","","","","","","",TRUE,"SIMPLIFY-1","2023-09-15: Approved for the treatment of intermediate or high-risk <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis (MF)</a>, including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. <i>(Based on MOMENTUM and SIMPLIFY-1)</i>","2024-06-03"
"Montelukast","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Mosunetuzumab","EMA","2022-06-03","Follicular lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","0","","",TRUE,"GO29781","2022-06-03: Initial conditional authorization as monotherapy for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> who have received at least two prior systemic therapies. <i>(Based on GO29781)</i>","2023-05-08"
"Mosunetuzumab","FDA","2022-12-22","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"GO29781","2022-12-22: Initial approval for adults with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> after two or more lines of systemic therapy. <i>(Based on GO29781)</i>","2023-03-10"
"Motixafortide","FDA","2023-09-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",TRUE,"GENESIS","2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. <i>(Based on GENESIS)</i>","2023-11-07"
"Moxetumomab pasudotox","EMA","2021-02-08","Hairy cell leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","","","",NA,"","2021-02-08: Initial authorization for treatment of adult patients with relapsed or refractory <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukaemia (HCL)</a> after receiving at least two prior systemic therapies.","2023-05-08"
"Moxetumomab pasudotox","EMA","2021-07-23","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2021-07-23: Authorization withdrawn at manufacturer request, for commercial reasons","2023-05-08"
"Moxetumomab pasudotox","FDA","2018-09-13","Hairy cell leukemia",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+ SACT, including Purine analog","FALSE","","","","","","","",TRUE,"Study 1053","2018-09-13: Initial approval for adult patients with relapsed or refractory <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia (HCL)</a> who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). <i>(Based on Study 1053)</i>","2022-09-05"
"Mycophenolate mofetil","EMA","1996-02-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-02-14: Initial authorization","2023-05-08"
"Mycophenolate mofetil","FDA","1995-05-03","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1995-05-03: Initial FDA approval","2022-09-05"
"Mycophenolate mofetil","PMDA","2021-06-25","Graft versus host disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-06-25: New indication and a new dosage for the suppression of <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">graft-versus-host disease in hematopoietic stem cell transplantation</a>.","2023-06-16"
"Nabilone","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Nadofaragene firadenovec","FDA","2022-12-16","Bladder cancer",FALSE,FALSE,TRUE,"","","Non-muscle invasive","High-risk","adults","","BCG","FALSE","","unresponsive","","","","","",TRUE,"rAd-IFN-CS-003","2022-12-16: Initial approval for adult patients with high-risk BCG vaccine unresponsive non-muscle invasive <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">bladder cancer</a> (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. <i>(Based on rAd-IFN-CS-003)</i>","2023-03-10"
"Nadroparin","HC","1997-11-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1997-11-27: Initial notice of compliance.","2023-07-31"
"Naxitamab","FDA","2020-11-24","Neuroblastoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","High-risk","","","1+","FALSE","","partial response, minor response, or stable disease","","","Granulocyte macrophage colony-stimulating factor","","",TRUE,"Study 12-230","2020-11-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow"">FDA accelerated approval</a> to be used in combination with <a href=""/wiki/Category:Granulocyte_macrophage_colony-stimulating_factors"" title=""Category:Granulocyte macrophage colony-stimulating factors"">granulocyte-macrophage colony-stimulating factor (GM-CSF)</a> for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. <i>(Based on Study 12-230 and Study 201)</i>","2022-09-05"
"Naxitamab","FDA","2020-11-24","Neuroblastoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","High-risk","","","1+","FALSE","","partial response, minor response, or stable disease","","","Granulocyte macrophage colony-stimulating factor","","",TRUE,"Study 201","2020-11-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow"">FDA accelerated approval</a> to be used in combination with <a href=""/wiki/Category:Granulocyte_macrophage_colony-stimulating_factors"" title=""Category:Granulocyte macrophage colony-stimulating factors"">granulocyte-macrophage colony-stimulating factor (GM-CSF)</a> for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a> in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. <i>(Based on Study 12-230 and Study 201)</i>","2022-09-05"
"Necitumumab","EMA","2016-02-15","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2016-02-15: Initial authorization for the treatment of <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer</a>.","2023-05-08"
"Necitumumab","EMA","2021-02-18","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2021-02-18: Authorization withdrawn at the request of the manufacturer, for commercial reasons","2023-05-08"
"Necitumumab","FDA","2015-11-24","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Cisplatin AND Gemcitabine","","",TRUE,"SQUIRE","2015-11-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm"">FDA approved</a> to be used in combination with <a href=""/wiki/Gemcitabine_(Gemzar)"" title=""Gemcitabine (Gemzar)"">gemcitabine</a> and <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin</a>, for first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer</a>. <i>(Based on SQUIRE)</i>","2022-09-05"
"Necitumumab","HC","2017-03-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-03-16: Initial notice of compliance","2023-05-20"
"Necitumumab","PMDA","2019-06-18","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2019-06-18: Newly indicated for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer</a>.","2023-06-16"
"Nedaplatin","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Nedaplatin","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Nelarabine","EMA","2007-08-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-08-22: Initial authorization as Atriance","2023-05-08"
"Nelarabine","FDA","2005-10-28","T-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ Chemotherapy-based regimen","FALSE","","","","","","","",TRUE,"Berg et al. 2005","2005-10-28: Accelerated approval for the treatment of patients with <a href=""/wiki/T-cell_acute_lymphoblastic_leukemia"" title=""T-cell acute lymphoblastic leukemia""> T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma</a> whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. <i>(Based on Berg et al. 2005 and CALGB 19801)</i>","2022-09-05"
"Nelarabine","FDA","2005-10-28","T-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ Chemotherapy-based regimen","FALSE","","","","","","","",TRUE,"CALGB 19801","2005-10-28: Accelerated approval for the treatment of patients with <a href=""/wiki/T-cell_acute_lymphoblastic_leukemia"" title=""T-cell acute lymphoblastic leukemia""> T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma</a> whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. <i>(Based on Berg et al. 2005 and CALGB 19801)</i>","2022-09-05"
"Nelarabine","FDA","2019-07-31","T-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults AND pediatric patients 1 year and older","","2+ Chemotherapy-based regimen","FALSE","","","","","","","",TRUE,"COG AALL0434","2019-07-31: Converted to regular approval for the treatment of patients with <a href=""/wiki/T-cell_acute_lymphoblastic_leukemia"" title=""T-cell acute lymphoblastic leukemia"">T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma</a> in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. <i>(Based on COG AALL0434)</i>","2022-09-05"
"Nelarabine","HC","2007-09-22","T-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ Chemotherapy-based regimen","FALSE","","","","","","","",NA,"","2007-09-22: Initial notice of compliance with conditions for use in the treatment of patients with <a href=""/wiki/T-cell_acute_lymphoblastic_leukemia"" title=""T-cell acute lymphoblastic leukemia"">T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma</a> whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.","2023-05-08"
"Nelarabine","HC","2020-01-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-01-22: Conditions were met","2023-05-08"
"Nelarabine","PMDA","2007-10-19","T-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2007-10-19: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/T-cell_acute_lymphoblastic_leukemia"" title=""T-cell acute lymphoblastic leukemia"">T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma</a>.","2023-06-16"
"Neratinib","EMA","2018-08-31","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early stage","","adults","","Trastuzumab-based regimen",NA,"Adjuvant","","Less than one year","","","HER2+","",TRUE,"ExteNET","2018-08-31: Initial authorization as Nerlynx. Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. <i>(Based on ExteNET)</i>","2023-11-07"
"Neratinib","FDA","2017-07-17","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early stage","","adults","","Surgery AND Trastuzumab-based regimen","FALSE","","","","","","HER2+","FALSE",TRUE,"ExteNET","2017-07-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm"">FDA approved</a> for the extended adjuvant treatment of adult patients with early stage <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressed/amplified</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, to follow adjuvant <a href=""/wiki/Regimen_classes#Trastuzumab-based_regimen"" title=""Regimen classes"">trastuzumab-based therapy</a>. <i>(Based on ExteNET)</i>","2022-09-05"
"Neratinib","FDA","2020-02-25","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","2+ Anti-HER2-based regimen","FALSE","Metastatic","","","","Capecitabine","HER2+","FALSE",TRUE,"NALA","2020-02-25: Approved in combination with capecitabine for adult patients with advanced or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received two or more prior <a href=""/wiki/Regimen_classes#Anti-HER2-based_regimen"" title=""Regimen classes"">anti-HER2 based regimens</a> in the metastatic setting. <i>(Based on NALA)</i>","2022-09-05"
"Neratinib","HC","2019-07-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early stage","","women","","Trastuzumab-based regimen","FALSE","Adjuvant","","within 12 months","","","HER2+","FALSE",NA,"","2019-07-16: Initial notice of compliance for the extended adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> within one year after completion of trastuzumab-based adjuvant therapy.","2023-05-20"
"Neratinib","HC","2021-06-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-06-23: New indication (unclear details)","2023-05-20"
"Netupitant and palonosetron","EMA","2015-05-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-05-27: Initial authorization","2023-05-08"
"Netupitant and palonosetron","FDA","2014-10-10","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-10-10: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418375.htm"">FDA approved</a> for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.","2022-09-05"
"Nilotinib","EMA","2007-11-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-11-19: Initial authorization","2023-05-08"
"Nilotinib","FDA","2007-10-29","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","1+, including Imatinib","FALSE","","Resistance OR intolerance","","","","BCR-ABL1","FALSE",TRUE,"A2101","2007-10-29: Granted accelerated approval for the treatment of chronic phase and accelerated phase <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> in adult patients resistant to or intolerant to prior therapy that included <a href=""/wiki/Imatinib_(Gleevec)"" title=""Imatinib (Gleevec)"">Imatinib (Gleevec)</a>. <i>(Based on A2101)</i>","2022-09-21"
"Nilotinib","FDA","2010-06-17","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase","","adults","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"ENESTnd","2010-06-17: Granted accelerated approval for the treatment of newly diagnosed adult patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> (Ph+ CML) in chronic phase. <i>(Approval extended to first-line setting; based on ENESTnd)</i>","2022-09-21"
"Nilotinib","FDA","2011-01-14","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","1+, including Imatinib","FALSE","","Resistance OR intolerance","","","","BCR-ABL1","FALSE",NA,"","2011-01-14: Converted to regular approval for the treatment of chronic phase and accelerated phase <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia (CML)</a> in adult patients resistant to or intolerant to prior therapy that included <a href=""/wiki/Imatinib_(Gleevec)"" title=""Imatinib (Gleevec)"">Imatinib (Gleevec)</a>.","2023-05-08"
"Nilotinib","FDA","2015-01-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-01-27: Converted to regular approval.","2023-05-08"
"Nilotinib","FDA","2017-12-22","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"ENESTfreedom","2017-12-22: FDA label updated: Patients with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a> in the chronic phase (CP) and resistant or intolerant Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5) may be considered for discontinuation after at least three years of nilotinib. To be considered for discontinuation, patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detection limit below at least MR4.5 must be used to determine discontinuation eligibility. Patients must be frequently monitored by this test to detect possible loss of remission. <i>(Based on ENESTfreedom and ENESTop)</i>","2022-09-21"
"Nilotinib","FDA","2017-12-22","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"ENESTop","2017-12-22: FDA label updated: Patients with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a> in the chronic phase (CP) and resistant or intolerant Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5) may be considered for discontinuation after at least three years of nilotinib. To be considered for discontinuation, patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detection limit below at least MR4.5 must be used to determine discontinuation eligibility. Patients must be frequently monitored by this test to detect possible loss of remission. <i>(Based on ENESTfreedom and ENESTop)</i>","2022-09-21"
"Nilotinib","FDA","2018-03-22","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","pediatric patients 1 year and older","","Tyrosine kinase inhibitor therapy","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"CAMN107A2120","2018-03-22: FDA approved for pediatric patients 1 year of age or older with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Ph+</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a>-CP resistant or intolerant to prior <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine-kinase inhibitor (TKI) therapy</a>. <i>(Approval extended to pediatric setting; based on CAMN107A2120)</i>","2022-09-21"
"Nilotinib","FDA","2018-03-22","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase","","pediatric patients 1 year and older","","0","FALSE","","","","","","BCR-ABL1","FALSE",TRUE,"DIALOG","2018-03-22: FDA approved for pediatric patients 1 year of age or older with newly diagnosed <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> in chronic phase (Ph+ CML-CP). <i>(Approval extended to pediatric setting; based on DIALOG)</i>","2022-09-21"
"Nilotinib","HC","2008-09-09","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-09-09: Initial notice of compliance with conditions","2023-05-08"
"Nilotinib","HC","2011-11-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-11-30: Conditions were met","2023-05-08"
"Nilotinib","PMDA","2009-01-21","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","","","Imatinib","FALSE","","resistance","","","","","",NA,"","2009-01-21: Initial approval for the treatment of imatinib-resistant, chronic phase and accelerated phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia</a>.","2023-06-16"
"Nilotinib","PMDA","2010-12-21","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","","","",NA,"","","","","","","",NA,"","2010-12-21: New additional indications and a new dosage for the treatment of chronic- or accelerated-phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelocytic leukaemia</a>.","2023-06-16"
"Nilutamide","EMA","1986-07-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1986-07-02: EURD","2023-07-31"
"Nilutamide","FDA","1996-09-19","Prostate cancer",FALSE,FALSE,FALSE,"","","Stage D2","","","","",NA,"","","","","Surgical castration","","",TRUE,"International Anandron Study","1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">carcinoma of the prostate</a>. <i>(Based on International Anandron Study)</i>","2022-09-05"
"Nimotuzumab","NMPA","2008-01-07","Nasopharyngeal carcinoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2008-01-07: Initial approval in combination with RT for a treatment of <a href=""/wiki/Nasopharyngeal_carcinoma"" title=""Nasopharyngeal carcinoma"">nasopharyngeal carcinoma</a>.","2024-12-02"
"Nimustine","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Nintedanib","EMA","2014-11-21","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic OR Locally recurrent","","adults","","chemotherapy",NA,"First-line","","","","Docetaxel","","",TRUE,"LUME-Lung 1","2014-11-21: Initial marketing authorization as Vargatef. Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology</a> after first line chemotherapy. <i>(Based on LUME-Lung 1)</i>","2023-09-17"
"Niraparib","EMA","2017-11-16","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Platinum-sensitive","","adults","","Platinum-based regimen",NA,"Relapsed","At least PR","","","0","","",TRUE,"NOVA","2017-11-16: Initial marketing authorization as Zejula. Zejula is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete or partial) to platinum-based chemotherapy. <i>(Based on NOVA)</i>","2023-09-17"
"Niraparib","EMA","2020-10-27","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","FIGO stage III/IV","","adults","","Platinum-based regimen",NA,"First-line","At least PR","","","0","","",NA,"","2020-10-27: Extension of indication to include the use of Zejula as monotherapy for the maintenance treatment of adult patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","2023-09-17"
"Niraparib","FDA","2017-03-27","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","adults","","Platinum-based regimen","FALSE","","PR or CR","","","","","",TRUE,"NOVA","2017-03-27: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm"">Initial approval</a> for the maintenance treatment of adult patients with recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in complete or partial response to <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Based on NOVA)</i>","2022-09-05"
"Niraparib","FDA","2019-10-23","Ovarian cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","3+ Chemotherapy-based regimen, with progression at least 6 months after a platinum-based regimen","FALSE","","progression","at least 6 months","","","BRCAm|genomic instability","FALSE",TRUE,"QUADRA","2019-10-23: Approved for patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian, fallopian tube, or primary peritoneal cancer</a> treated with three or more prior chemotherapy regimens and whose cancer is associated with <a href=""/wiki/Biomarkers#HRD"" title=""Biomarkers"">homologous recombination deficiency (HRD)-positive</a> status. HRD is defined by either a deleterious or suspected deleterious <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>, or <a href=""/wiki/Biomarkers#Genomic_instability"" title=""Biomarkers"">genomic instability</a> in patients with disease progression greater than six months after response to the last <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Based on QUADRA)</i>","2022-09-05"
"Niraparib","FDA","2020-04-29","Ovarian cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","Platinum-based regimen","FALSE","","PR or CR","","","","","",TRUE,"PRIMA_OV","2020-04-29: Approved for the maintenance treatment of adult patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in a complete or partial response to first-line platinum-based chemotherapy. <i>(Based on PRIMA_OV)</i>","2022-09-05"
"Niraparib","FDA","2022-09-14","Ovarian cancer",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2022-09-14: Indication voluntarily withdrawn by the manufacturer; awaiting FDA withdrawal notice.","2022-11-03"
"Niraparib","HC","2019-06-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-06-27: Initial notice of compliance","2023-06-15"
"Niraparib","PMDA","2020-09-29","Ovarian cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","Platinum-based regimen","FALSE","","CR or PR","","","","HRD+","FALSE",NA,"","2020-09-29: Newly indicated for the treatment of homologous recombination deficiency (HRD)-positive recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who are in a complete or partial response to platinum-based chemotherapy.","2023-06-16"
"Niraparib","PMDA","2020-09-29","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","chemotherapy","FALSE","","","","","","","",NA,"","2020-09-29: Newly indicated for the maintenance treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who have received first chemotherapy.","2023-06-16"
"Niraparib","PMDA","2020-09-29","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Recurrent","","","","Platinum-based regimen","FALSE","","CR or PR","","","","","",NA,"","2020-09-29: Newly indicated for the maintenance treatment of recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who are in a complete or partial response to platinum-based chemotherapy.","2023-06-16"
"Niraparib and abiraterone","EMA","2023-04-19","Prostate cancer",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2023-04-19: Initial authorisation for treatment of adult patients with <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-09-17"
"Niraparib and abiraterone","FDA","2023-08-11","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","",NA,"","","","","Prednisone","BRCAm","FALSE",TRUE,"MAGNITUDE","2023-08-11: Initial approval with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC), as determined by an FDA-approved test. <i>(Based on MAGNITUDE)</i>","2023-09-09"
"Nirogacestat","FDA","2023-11-27","Desmoid tumor",FALSE,FALSE,TRUE,"","","Progressing","","adults","require systemic treatment","",NA,"","","","","","","",TRUE,"DeFi","2023-11-27: Approved for adult patients with progressing <a href=""/wiki/Desmoid_tumor"" title=""Desmoid tumor"">desmoid tumors</a> who require systemic treatment. <i>(Based on DeFi)</i>","2024-01-06"
"Nivolumab","EMA","2015-06-19","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","",NA,"","","","","0","","",NA,"","2015-06-19: Initial marketing authorization as Opdivo. Opdivo as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults.","2023-09-17"
"Nivolumab","EMA","2015-10-28","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","chemotherapy",NA,"","","","","","","",NA,"","2015-10-28: Extension of indication to include treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer (NSCLC)</a> after prior chemotherapy in adults.","2023-09-17"
"Nivolumab","EMA","2016-04-04","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","Therapy",NA,"","","","","0","","",TRUE,"CheckMate 025","2016-04-04: Extension of Indication to add treatment as monotherapy of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> after prior therapy in adults. <i>(Based on CheckMate 025)</i>","2023-09-17"
"Nivolumab","EMA","2016-04-04","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Chemotherapy",NA,"","","","","0","","",TRUE,"CheckMate 057","2016-04-04: Extension of Indication to include treatment as monotherapy of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous NSCLC</a> after prior chemotherapy in adults. <i>(Based on CheckMate 057)</i>","2023-09-17"
"Nivolumab","EMA","2016-05-11","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","",NA,"","","","","Ipilimumab","","",TRUE,"CheckMate 067","2016-05-11: Extension of Indication to include treatment in combination with ipilimumab of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults. <i>(Based on CheckMate 067 and CheckMate 069)</i>","2023-09-17"
"Nivolumab","EMA","2016-05-11","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","",NA,"","","","","Ipilimumab","","",TRUE,"CheckMate 069","2016-05-11: Extension of Indication to include treatment in combination with ipilimumab of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults. <i>(Based on CheckMate 067 and CheckMate 069)</i>","2023-09-17"
"Nivolumab","EMA","2017-04-28","Head and neck cancer",FALSE,FALSE,FALSE,"","","","","adults","","Platinum-based regimen",NA,"","progression","","","0","","",NA,"","2017-04-28: Extension of Indication to include treatment of <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">squamous cell cancer of the head and neck (SCCHN)</a> in adults progressing on or after platinum-based therapy for OPDIVO as monotherapy.","2023-09-17"
"Nivolumab","EMA","2017-06-02","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","Platinum-based regimen",NA,"","failure","","","","","",NA,"","2017-06-02: Extension of Indication to include the treatment of locally advanced unresectable or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> in adults after failure of prior platinum-containing therapy for OPDIVO.","2023-09-17"
"Nivolumab","EMA","2018-07-30","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","N+ or M+","","adults","","Surgery",NA,"","complete resection","","","","","",TRUE,"CheckMate 238","2018-07-30: Extension of Indication to include adjuvant treatment of adults with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with involvement of lymph nodes or metastatic disease who have undergone complete resection. <i>(Based on CheckMate 238)</i>","2023-09-17"
"Nivolumab","EMA","2019-01-11","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","","Intermediate-risk OR Poor-risk","adults","","",NA,"","","","","Ipilimumab","","",NA,"","2019-01-11: Extension of indication to include the combination treatment with nivolumab and ipilimumab of adult patients with intermediate/poor-risk advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-09-17"
"Nivolumab","EMA","2020-11-05","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","Ipilimumab AND Chemotherapy","No EGFR mutations AND No ALK mutations","TRUE",NA,"","2020-11-05: Extension of indication to include first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> in adults whose tumours have no sensitising EGFR mutation or ALK translocation for combination of OPDIVO/Yervoy and chemotherapy.","2023-09-17"
"Nivolumab","EMA","2020-11-20","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent OR Metastatic","","adults","","Fluoropyrimidine- and platinum-based regimen",NA,"","","","","","","",NA,"","2020-11-20: Extension of indication to include treatment of adult patients with unresectable advanced, recurrent or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">oesophageal squamous cell carcinoma (OSCC)</a> after prior fluoropyrimidine- and platinumbased chemotherapy.","2023-09-17"
"Nivolumab","EMA","2021-04-13","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Cabozantinib","","",NA,"","2021-04-13: Extension of indication to include in combination with cabozantinib for the first line treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> for Opdivo.","2023-09-17"
"Nivolumab","EMA","2021-06-01","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","First-line","Unresectable","","adults","","",NA,"","","","","Ipilimumab","","",NA,"","2021-06-01: Extension of indication to include first-line treatment of adult patients with unresectable <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma (MPM)</a> for combination treatment of Opdivo and Yervoy.","2023-09-17"
"Nivolumab","EMA","2021-06-24","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based combination chemotherapy","FALSE","","","","","Ipilimumab","dMMR|MSI-H","FALSE",NA,"","2021-06-24: Extension of indication to include the combination of nivolumab with ipilimumab in the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> after prior fluoropyrimidine based combination chemotherapy.","2023-09-17"
"Nivolumab","EMA","2021-07-28","Esophageal cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","adults","","Chemoradiotherapy",NA,"neoadjuvant","residual pathologic disease","","","","","",TRUE,"CheckMate 577","2021-07-28: Extension of indication to include adjuvant treatment of adult patients with <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">oesophageal</a>, or gastrooesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy for OPDIVO. <i>(Based on CheckMate 577)</i>","2023-09-17"
"Nivolumab","EMA","2021-10-19","Esophageal adenocarcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced OR Metastatic","","adults","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","HER2- AND PD-L1 CPS at least 5","TRUE",TRUE,"CheckMate 649","2021-10-19: Extension of indication to use OPDIVO (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with HER2-negative advanced or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a>, gastro-oesophageal junction (GEJ) or <a href=""/wiki/Esophageal_adenocarcinoma"" title=""Esophageal adenocarcinoma"">oesophageal adenocarcinoma</a> whose tumours express PD-L1 with a combined positive score (CPS) at least 5. <i>(Based on CheckMate 649)</i>","2023-09-17"
"Nivolumab","EMA","2021-10-19","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","HER2- AND PD-L1 CPS at least 5","",TRUE,"CheckMate 649","2021-10-19: Extension of indication to use OPDIVO (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with HER2-negative advanced or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a>, gastro-oesophageal junction (GEJ) or <a href=""/wiki/Esophageal_adenocarcinoma"" title=""Esophageal adenocarcinoma"">oesophageal adenocarcinoma</a> whose tumours express PD-L1 with a combined positive score (CPS) at least 5. <i>(Based on CheckMate 649)</i>","2023-09-17"
"Nivolumab","EMA","2022-04-01","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Unresectable advanced OR Recurrent OR Metastatic","","adults","","",NA,"","","","","Ipilimumab","PD-L1 TPS at least 1%","",NA,"","2022-04-01: Extension of indication to include treatment of firstline treatment of adult patients with unresectable advanced, recurrent or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">oesophageal squamous cell carcinoma (OSCC)</a> with tumour cell PD-L1 expression at least 1% for Opdivo in combination with Yervoy.","2023-09-17"
"Nivolumab","EMA","2022-04-01","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Muscle-invasive","High-risk for recurrence","adults","","Radical resection",NA,"","","","","0","PD-L1 at least 1%","",NA,"","2022-04-01: Extension of indication for Opdivo to include as monotherapy for the adjuvant treatment of adults with muscle invasive <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> (MIUC) with tumour cell PD-L1 expression at least 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.","2023-09-17"
"Nivolumab","EMA","2023-06-16","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","N+ or M+","","adults AND children 12 years of age or older","","Resection",NA,"","complete resection","","","0","","",NA,"","2023-06-16: Opdivo as monotherapy is indicated for the adjuvant treatment of adults and <b>adolescents 12 years of age and older</b> with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with involvement of lymph nodes or metastatic disease who have undergone complete resection.","2023-09-17"
"Nivolumab","EMA","2023-06-16","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults AND children 12 years of age or older","","",NA,"","","","","0","","",NA,"","2023-06-16: Opdivo as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults <b>and adolescents 12 years of age and older</b>.","2024-06-03"
"Nivolumab","EMA","2023-06-16","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults AND children 12 years of age or older","","",NA,"","","","","Ipilimumab","","",NA,"","2023-06-16: Opdivo in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults <b>and adolescents 12 years of age and older</b>.","2024-06-03"
"Nivolumab","EMA","2023-06-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Resectable","","adults","","",NA,"","","","","Platinum-based chemotherapy","","",TRUE,"CheckMate 816","2023-06-26: Extension of indication to include OPDIVO in combination with platinum-based chemotherapy for neoadjuvant treatment of adult patients with resectable Stage IB-IIIA <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on CheckMate 816)</i>","2023-09-17"
"Nivolumab","EMA","2023-08-21","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage IIB/C","","adults AND children 12 years of age or older","","Surgery",NA,"","complete resection","","","","","",TRUE,"CheckMate 76K","2023-08-21: Extension of indication to include OPDIVO for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> who have undergone complete resection. <i>(Based on CheckMate 76K)</i>","2023-09-17"
"Nivolumab","FDA","2014-12-22","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","Ipilimumab","FALSE","","progression","","","","","",TRUE,"CheckMate 037","2014-12-22: Accelerated approval for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> and disease progression following <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a>, and if <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600 mutation positive</a>, a <a href=""/wiki/Regimen_classes#BRAF_TKI_therapy"" title=""Regimen classes"">BRAF inhibitor</a>.<i>(Based on CheckMate 037)</i>","2022-09-05"
"Nivolumab","FDA","2015-03-04","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"CheckMate 017","2015-03-04: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm"">Approved</a> for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous""> squamous non-small cell lung cancer (NSCLC)</a> with progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(New disease entity; based on CheckMate 017)</i>","2022-09-05"
"Nivolumab","FDA","2015-09-30","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Ipilimumab","BRAF","TRUE",TRUE,"CheckMate 066","2015-09-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm"">Granted accelerated approval</a> in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a> for the treatment of patients with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600</a> <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a>, unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on CheckMate 066 and CheckMate 067)</i>","2022-09-05"
"Nivolumab","FDA","2015-09-30","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Ipilimumab","BRAF","TRUE",TRUE,"CheckMate 067","2015-09-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm"">Granted accelerated approval</a> in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a> for the treatment of patients with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600</a> <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a>, unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on CheckMate 066 and CheckMate 067)</i>","2022-09-05"
"Nivolumab","FDA","2015-10-09","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"CheckMate 057","2015-10-09: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm466576.htm"">Approval expanded</a> for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> with progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Histology indication expanded to include nonsquamous; based on CheckMate 057)</i>","2022-09-05"
"Nivolumab","FDA","2015-11-23","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","VEGFR inhibitor therapy","FALSE","","","","","","","",TRUE,"CheckMate 025","2015-11-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474092.htm"">FDA approval expanded</a> for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> in patients who have received prior <a href=""/wiki/Regimen_classes#VEGFR_inhibitor_therapy"" title=""Regimen classes"">anti-angiogenic therapy</a>. <i>(New disease entity; based on CheckMate 025)</i>","2022-09-05"
"Nivolumab","FDA","2016-05-17","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Autologous HSCT, then Brentuximab vedotin","FALSE","","relapse OR progression","","","","","",TRUE,"CheckMate 039","2016-05-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm"">Accelerated approval</a> for the treatment of patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> that has relapsed or progressed after <a href=""/wiki/Classical_Hodgkin_lymphoma#Autologous_stem_cell_transplant"" title=""Classical Hodgkin lymphoma"">autologous hematopoietic stem cell transplantation (HSCT)</a> and post-transplantation <a href=""/wiki/Brentuximab_vedotin_(Adcetris)"" title=""Brentuximab vedotin (Adcetris)"">brentuximab vedotin (Adcetris)</a>. <i>(New disease entity; based on CheckMate 039 and CheckMate 205)</i>","2022-09-05"
"Nivolumab","FDA","2016-05-17","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Autologous HSCT, then Brentuximab vedotin","FALSE","","relapse OR progression","","","","","",TRUE,"CheckMate 205","2016-05-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm"">Accelerated approval</a> for the treatment of patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> that has relapsed or progressed after <a href=""/wiki/Classical_Hodgkin_lymphoma#Autologous_stem_cell_transplant"" title=""Classical Hodgkin lymphoma"">autologous hematopoietic stem cell transplantation (HSCT)</a> and post-transplantation <a href=""/wiki/Brentuximab_vedotin_(Adcetris)"" title=""Brentuximab vedotin (Adcetris)"">brentuximab vedotin (Adcetris)</a>. <i>(New disease entity; based on CheckMate 039 and CheckMate 205)</i>","2022-09-05"
"Nivolumab","FDA","2016-11-10","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"CheckMate 141","2016-11-10: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm"">FDA approved</a> for the treatment of patients with recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer""> squamous cell carcinoma of the head and neck (SCCHN)</a> with disease progression on or after a <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based therapy</a>. <i>(New disease entity; based on CheckMate 141)</i>","2022-09-05"
"Nivolumab","FDA","2017-02-02","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","","","","","Adjuvant or neoadjuvant platinum-containing chemotherapy","FALSE","","progression","within 12 months","","","","",TRUE,"CheckMate 275","2017-02-02: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm"">Granted accelerated approval</a> for treatment of patients with <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression within 12 months of neoadjuvant or adjuvant treatment with a <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(New disease entity; based on CheckMate 275)</i>","2023-03-10"
"Nivolumab","FDA","2017-02-02","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"CheckMate 275","2017-02-02: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm"">Granted accelerated approval</a> for treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following  <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(New disease entity; based on CheckMate 275)</i>","2023-03-10"
"Nivolumab","FDA","2017-08-01","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","12 years and older","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","","","","","dMMR|MSI-H","FALSE",TRUE,"CheckMate 142","2017-08-01: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm"">Granted FDA accelerated approval</a> for the treatment of patients 12 years and older with <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> and <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability high (MSI-H)</a> metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following treatment with a <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan</a>. <i>(Based on CheckMate 142)</i>","2022-09-05"
"Nivolumab","FDA","2017-09-22","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","","","",TRUE,"CheckMate 040","2017-09-22: Granted FDA accelerated approval for the treatment of <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> in patients who have been previously treated with <a href=""/wiki/Sorafenib_(Nexavar)"" title=""Sorafenib (Nexavar)"">sorafenib</a>. <i>(New disease entity; based on CheckMate 040)</i>","2022-09-05"
"Nivolumab","FDA","2017-12-20","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","N+ or M+","","","","Surgery","FALSE","","complete resection","","","","","",TRUE,"CheckMate 238","2017-12-20: Granted regular approval for the adjuvant treatment of patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. <i>(Based on CheckMate 238)</i>","2022-09-05"
"Nivolumab","FDA","2018-04-16","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","Intermediate-risk OR Poor-risk","","","0","FALSE","","","","","Ipilimumab","","",TRUE,"CheckMate 214","2018-04-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm"">FDA approved</a> to be used in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">Ipilimumab (Yervoy)</a> for the treatment of intermediate or poor risk, previously untreated advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>. <i>(Based on CheckMate 214)</i>","2022-09-05"
"Nivolumab","FDA","2018-07-10","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","12 years and older","","Fluoropyrimidine AND Oxaliplain AND Irinotecan","FALSE","","","","","Ipilimumab","MSI-H|dMMR","FALSE",TRUE,"CheckMate 142","2018-07-10: Accelerated approval for treatment of adult and pediatric patients 12 years of age and older with <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with ipilimumab. <i>(Based on CheckMate 142)</i>","2022-09-05"
"Nivolumab","FDA","2018-08-16","Small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","2+, including Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"CheckMate 032_SCLC","2018-08-16: Granted FDA accelerated approval for patients with metastatic <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer (SCLC)</a> with progression after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a> and at least one other line of therapy. <i>(Based on CheckMate 032_SCLC)</i>","2022-09-05"
"Nivolumab","FDA","2019-03-07","Melanoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"CheckMate 037","2019-03-07: Converted to regular approval. <i>(Based on CheckMate 037 and CheckMate 067)</i>","2022-09-05"
"Nivolumab","FDA","2019-03-07","Melanoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"CheckMate 067","2019-03-07: Converted to regular approval. <i>(Based on CheckMate 037 and CheckMate 067)</i>","2022-09-05"
"Nivolumab","FDA","2020-03-10","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","Ipilimumab","","",TRUE,"CheckMate 040_combo","2020-03-10: Accelerated approval in combination with ipilimumab for patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with sorafenib. <i>(Approval extended to combination therapy; based on CheckMate 040_combo)</i>","2022-09-05"
"Nivolumab","FDA","2020-05-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Ipilimumab","PD-L1 at least 1%","FALSE",TRUE,"CheckMate 227","2020-05-15: Approved in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a> as first-line treatment for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (at least 1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <i>(Expanded to first-line setting, with PD-L1 expression requirement; based on CheckMate 227)</i>","2023-01-03"
"Nivolumab","FDA","2020-05-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic or Recurrent","","","","0","FALSE","","","","","Ipilimumab AND Platinum doublet","No EGFR mutations AND No ALK mutations","TRUE",TRUE,"CheckMate 9LA","2020-05-26: Approved in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a> and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <i>(PD-L1 expression requirement removed when given with chemotherapy; based on CheckMate 9LA)</i>","2022-09-05"
"Nivolumab","FDA","2020-06-10","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent OR Metastatic","","","","Fluoropyrimidine- and platinum-based regimen","FALSE","","","","","","","",TRUE,"ATTRACTION-3","2020-06-10: for patients with unresectable advanced, recurrent or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">esophageal squamous cell carcinoma (ESCC)</a> after prior fluoropyrimidine- and platinum-based chemotherapy. <i>(New disease entity; based on ATTRACTION-3)</i>","2022-09-05"
"Nivolumab","FDA","2020-10-02","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable","","adults","","0","FALSE","","","","","Ipilimumab","","",TRUE,"CheckMate 743","2020-10-02: Approved in combination with <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a> as first-line treatment for adult patients with unresectable <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a>. <i>(New disease entity; based on CheckMate 743)</i>","2022-09-05"
"Nivolumab","FDA","2020-12-29","Small cell lung cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"CheckMate 331","2020-12-29: Accelerated approval withdrawn. <i>(Based on CheckMate 331 and CheckMate 451)</i>","2022-09-05"
"Nivolumab","FDA","2020-12-29","Small cell lung cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"CheckMate 451","2020-12-29: Accelerated approval withdrawn. <i>(Based on CheckMate 331 and CheckMate 451)</i>","2022-09-05"
"Nivolumab","FDA","2021-01-22","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","Cabozantinib","","",TRUE,"CheckMate 9ER","2021-01-22: Approved to be used in combination with <a href=""/wiki/Cabozantinib_(Cabometyx)"" class=""mw-redirect"" title=""Cabozantinib (Cabometyx)"">Cabozantinib (Cabometyx)</a> as first-line treatment for patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on CheckMate 9ER)</i>","2022-09-05"
"Nivolumab","FDA","2021-04-16","Esophageal adenocarcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","","",TRUE,"CheckMate 649","2021-04-16: Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and <a href=""/wiki/Esophageal_adenocarcinoma"" title=""Esophageal adenocarcinoma"">esophageal adenocarcinoma</a>. <i>(Based on CheckMate 649)</i>","2022-09-05"
"Nivolumab","FDA","2021-04-16","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","","",TRUE,"CheckMate 649","2021-04-16: Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, gastroesophageal junction cancer, and esophageal adenocarcinoma. <i>(Based on CheckMate 649)</i>","2022-09-05"
"Nivolumab","FDA","2021-05-20","Esophageal cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Chemoradiotherapy-based regimen, then Surgery","FALSE","","residual pathologic disease","","","","","",TRUE,"CheckMate 577","2021-05-20: Approved for patients with completely resected <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal</a> or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. <i>(Based on CheckMate 577)</i>","2022-09-05"
"Nivolumab","FDA","2021-07-23","Hepatocellular carcinoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"CheckMate 459","2021-07-23: Accelerated approval withdrawn. <i>(Based on CheckMate 459)</i>","2022-09-05"
"Nivolumab","FDA","2021-08-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","High-risk for recurrence","","","Radical cystectomy","FALSE","","","","","","","",TRUE,"CheckMate 274","2021-08-19: Full approval for the adjuvant treatment of patients with <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> who are at high risk of recurrence after undergoing radical resection. <i>(Extended to adjuvant setting; converted to regular approval; based on CheckMate 274)</i>","2022-09-05"
"Nivolumab","FDA","2022-03-04","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Resectable","","adults","","0","FALSE","","","","","Platinum-doublet","","",TRUE,"CheckMate 816","2022-03-04: Approved with platinum-doublet chemotherapy for adult patients with resectable <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> in the neoadjuvant setting. <i>(Based on CheckMate 816)</i>","2022-09-05"
"Nivolumab","FDA","2022-05-27","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","0","FALSE","","","","","Fluoropyrimidine- and platinum-based regimen","","",TRUE,"CheckMate 648","2022-05-27: Approved for the first-line treatment of patients with advanced or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">esophageal squamous cell carcinoma (ESCC)</a> in combination with fluoropyrimidine- and platinum-based chemotherapy. <i>(Based on CheckMate 648)</i>","2022-09-05"
"Nivolumab","FDA","2022-05-27","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","0","FALSE","","","","","Ipilimumab","","",TRUE,"CheckMate 648","2022-05-27: Approved for the first-line treatment of patients with advanced or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">esophageal squamous cell carcinoma (ESCC)</a> in combination with ipilimumab. <i>(Based on CheckMate 648)</i>","2022-09-05"
"Nivolumab","FDA","2023-10-13","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage IIB/C","","12 years and older","","Surgery","FALSE","","complete resection","","","","","",TRUE,"CheckMate 76K","2023-10-13: Approved for the adjuvant treatment of completely resected Stage IIB/C <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in patients 12 years and older. <i>(Based on CheckMate 76K)</i>","2023-11-07"
"Nivolumab","FDA","2024-03-06","Urothelial carcinoma",FALSE,FALSE,FALSE,"","First-line","Unresectable OR Metastatic","","adults","","",NA,"","","","","Cisplatin AND Gemcitabine","","",TRUE,"CheckMate 901 part 1","2024-03-06: Approved in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a>. <i>(Based on CheckMate 901 part 1)</i>","2024-06-03"
"Nivolumab","FDA","2024-10-03","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"CheckMate 77T","2024-10-03: Approved with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors â‰¥ 4 cm and/or node positive) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. <i>(Based on CheckMate 77T)</i>","2024-12-02"
"Nivolumab","HC","2016-10-26","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","0","FALSE","","","","","","BRAF p.V600","FALSE",NA,"","2016-10-26: Notice of compliance with conditions for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in previously untreated adults.","2023-05-08"
"Nivolumab","HC","2016-10-26","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","0","FALSE","","","","","Ipilimumab","","",NA,"","2016-10-26: Notice of compliance with conditions for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in previously untreated adults when used in combination with ipilimumab.","2023-05-08"
"Nivolumab","HC","2018-03-23","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","Sorafenib","FALSE","","progression OR intolerance","","","0","","",NA,"","2018-03-23: Notice of compliance with conditions as a monotherapy for the treatment of adult patients with advanced (not amenable to curative therapy or local therapeutic measures) or metastatic <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who are intolerant to or have progressed on sorafenib therapy.","2023-05-08"
"Nivolumab","HC","2021-02-11","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","Fluoropyrimidine AND (Oxaliplain OR Irinotecan)","FALSE","","","","","Ipilimumab","MSI-H|dMMR","FALSE",NA,"","2021-02-11: Notice of compliance with conditions in combination with ipilimumab. Indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.","2023-05-08"
"Nivolumab","HC","2022-06-27","Urothelial carcinoma",TRUE,FALSE,FALSE,"","Adjuvant","","High-risk for recurrence","adults","","Radical resection","FALSE","","","","","","","",NA,"","2022-06-27: Notice of compliance with conditions as a monotherapy for the adjuvant treatment of adult patients with <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> who are at high risk of recurrence after undergoing radical resection of UC.","2023-05-08"
"Nivolumab","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Nivolumab","PMDA","2014-07-04","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2014-07-04: Initial approval for the treatment of unresectable malignant <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Nivolumab","PMDA","2015-12-17","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2015-12-17: New additional indication and a new dosage for the treatment of unresectable advanced/relapsed <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Nivolumab","PMDA","2016-08-26","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2016-08-26: New additional indication for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Nivolumab","PMDA","2016-12-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-12-02: New additional indication for the treatment of relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin's lymphoma</a>.","2023-06-16"
"Nivolumab","PMDA","2017-03-24","Head and neck cancer",FALSE,FALSE,FALSE,"","","Local relapse OR Distant metastasis","","","","",NA,"","","","","","","",NA,"","2017-03-24: New additional indication for the treatment of relapse or distant metastasis of <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>.","2023-06-16"
"Nivolumab","PMDA","2017-09-22","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","chemotherapy","FALSE","","progression","","","","","",NA,"","2017-09-22: New additional indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Nivolumab","PMDA","2018-08-21","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","chemotherapy","FALSE","","progression","","","","","",NA,"","2018-08-21: New indication and a new dosage for the treatment of unresectable or recurrent <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a> and melanoma that has progressed after chemotherapy.","2023-06-16"
"Nivolumab","PMDA","2018-08-21","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","chemotherapy","FALSE","","progression","","","","","",NA,"","2018-08-21: New indication and a new dosage for the treatment of unresectable or recurrent <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> that has progressed after chemotherapy.","2023-06-16"
"Nivolumab","PMDA","2020-02-21","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","chemotherapy","FALSE","","progression","","","","MSI-H","FALSE",NA,"","2020-02-21: New indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Nivolumab","PMDA","2020-02-21","Esophageal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","chemotherapy","FALSE","","progression","","","","","",NA,"","2020-02-21: New indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Nivolumab","PMDA","2021-05-27","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2021-05-27: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a>.","2023-06-16"
"Nivolumab","PMDA","2021-11-25","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2021-11-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Nivolumab","PMDA","2021-11-25","Esophageal cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2021-11-25: New indication and a new dosage for postoperative adjuvant therapy for <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a>.","2023-06-16"
"Nivolumab","PMDA","2021-12-24","Carcinoma of unknown primary",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Tanizaki et al. 2021","2021-12-24: New indication and a new dosage for the treatment of <a href=""/wiki/Carcinoma_of_unknown_primary"" title=""Carcinoma of unknown primary"">carcinoma of unknown primary</a>. <i>(Based on Tanizaki et al. 2021)</i>","2023-06-16"
"Nivolumab","PMDA","2022-03-28","Urothelial carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2022-03-28: New indication and a new dosage for the postoperative adjuvant therapy for <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a>.","2023-06-16"
"Nivolumab","PMDA","2022-05-26","Esophageal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2022-05-26: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a>.","2023-06-16"
"Nivolumab","PMDA","2023-11-24","Mesothelioma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-11-24: New indication and a new dosage for the treatment of <a href=""/wiki/Category:Mesotheliomas"" title=""Category:Mesotheliomas"">malignant mesothelioma</a> (excluding malignant pleural mesothelioma).","2024-06-03"
"Nivolumab and relatlimab","EMA","2022-09-15","Melanoma",FALSE,FALSE,FALSE,"","First-line","Unresectable OR Metastatic","","12 years and older","","",NA,"","","","","","PD-L1 TPS at least 1%","FALSE",NA,"","2022-09-15: initial authorization for the first line treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults and adolescents 12 years of age and older with tumour cell PD L1 expression &lt; 1%.","2023-05-08"
"Nivolumab and relatlimab","FDA","2022-03-18","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","12 years and older","","",NA,"","","","","","","",TRUE,"RELATIVITY-047","2022-03-18: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on RELATIVITY-047)</i>","2022-09-05"
"Nogapendekin alfa inbakicept","FDA","2024-04-22","Bladder cancer",FALSE,FALSE,TRUE,"","","","","adults","","BCG vaccine",NA,"","Unresponsive","","","BCG vacine","","",TRUE,"QUILT-3.032","2024-04-22: Approved with Bacillus Calmette-Guerin (BCG) for adult patients with BCG-unresponsive non-muscle invasive <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">bladder cancer</a> (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. <i>(Based on QUILT-3.032)</i>","2024-06-03"
"Nolatrexed","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Non-pegylated liposomal doxorubicin","EMA","2000-07-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2000-07-13: Initial marketing authorization as Myocet.","2023-05-08"
"Non-pegylated liposomal doxorubicin","EMA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","women","","",NA,"","","","","Cyclophosphamide","","",NA,"","Uncertain date: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in adult women.","2023-05-20"
"Non-pegylated liposomal doxorubicin","HC","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Norethandrolone","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"NovoTTF-100A system (Optune)","FDA","2011-04-08","Glioblastoma",FALSE,FALSE,TRUE,"","","","","adults","","chemotherapy AND radiation",NA,"","recurrence OR progression","","","","","",NA,"","2011-04-08: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm"">FDA approved</a> ""to treat adults with <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma multiforme (GBM)</a> that recurs or progresses after receiving chemotherapy and radiation therapy.""<sup id=""cite_ref-10"" class=""reference""><a href=""#cite_note-10"">&#91;10&#93;</a>","2024-09-06"
"NovoTTF-100A system (Optune)","FDA","2015-10-05","Glioblastoma",FALSE,FALSE,FALSE,"","","","","adults 22 years and older","","debulking surgery AND radiation",NA,"","","","","Chemotherapy","","",NA,"","2015-10-05: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm465744.htm"">FDA approved expanded indication</a> ""as a treatment for adult patients (22 years of age or older) with histologically-confirmed <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma multiforme (GBM)</a>...for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.""","2024-09-06"
"Nystatin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Obecabtagene autoleucel","FDA","2024-11-08","B-cell acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"FELIX","2024-11-08: Approved for adults with relapsed or refractory <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a>. <i>(Based on FELIX)</i>","2024-12-02"
"Obinutuzumab","EMA","2014-07-22","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","comorbidities making them unsuitable for full-dose fludarabine-based therapy","0","FALSE","","","","","Chlorambucil","","",TRUE,"GCLLSG CLL11","2014-07-22: Initial authorization as Gazyvaro for the treatment in combination with chlorambucil of adult patients with previously untreated <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a> and with comorbidities making them unsuitable for full-dose fludarabine based therapy. <i>(Based on GCLLSG CLL11)</i>","2023-09-17"
"Obinutuzumab","EMA","2016-06-13","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"GADOLIN","2016-06-13: Extension of indication to add the treatment of patients with <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>. <i>(Based on GADOLIN)</i>","2023-09-17"
"Obinutuzumab","EMA","2017-09-18","Follicular lymphoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2017-09-18: Extension of Indication to include a new indication for Gazyvaro in combination with chemotherapy for the treatment of patients with previously untreated advanced <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-12-02"
"Obinutuzumab","EMA","2017-09-18","Follicular lymphoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",NA,"","2017-09-18: Extension of Indication to include a new indication for Gazyvaro maintenance therapy in patients achieving a response to Gazyvaro in combination with chemotherapy, for the treatment of patients with previously untreated advanced <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2024-12-02"
"Obinutuzumab","FDA","2013-11-01","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Chlorambucil","","",TRUE,"GCLLSG CLL11","2013-11-01: Granted FDA approval for use <a href=""/wiki/Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)#Chlorambucil_and_Obinutuzumab_(GClb)_(GClb)"" class=""mw-redirect"" title=""Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)"">in combination with chlorambucil</a> for the treatment of patients with previously untreated <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia""> chronic lymphocytic leukemia (CLL)</a>. <i>(Based on GCLLSG CLL11)</i>","2022-09-05"
"Obinutuzumab","FDA","2016-02-26","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab-containing regimen","FALSE","","","","","Bendamustine","","",TRUE,"GADOLIN","2016-02-26: FDA approval expanded for use <a href=""/wiki/Follicular_lymphoma#Bendamustine_&_Obinutuzumab"" title=""Follicular lymphoma"">in combination with bendamustine</a> followed by <a href=""/wiki/Follicular_lymphoma#Obinutuzumab_monotherapy_3"" title=""Follicular lymphoma"">obinutuzumab monotherapy</a> for the treatment of patients with <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> who relapsed after, or are refractory to, a <a href=""/wiki/Regimen_classes#Rituximab-containing_regimen"" title=""Regimen classes"">rituximab-containing regimen</a>. <i>(Based on GADOLIN)</i>","2022-09-05"
"Obinutuzumab","FDA","2017-11-16","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Stage II bulky, Stage III, or Stage IV","","adults","","0","FALSE","","","","","Chemotherapy","","",TRUE,"GALLIUM","2017-11-16: Granted regular FDA approval in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a>. <i>(Based on GALLIUM)</i>","2022-09-05"
"Obinutuzumab","HC","2014-11-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-11-25: Initial notice of compliance","2023-07-31"
"Obinutuzumab","PMDA","2018-07-02","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2018-07-02: Initial approval for the treatment of CD20-positive <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a>.","2023-06-16"
"Octreotide","EMA","1995-06-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-06-23: EURD","2023-07-31"
"Octreotide","FDA","1988-10-21","Neuroendocrine tumor",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",FALSE,"","1988-10-21: Initial approval for treatment of chronic and severe diarrhea and flushing episodes associated with <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">carcinoid tumors</a> and vasoactive intestinal peptide-secreting tumors (VIPomas). <i>(No supporting studies are cited)</i>","2022-09-05"
"Octreotide LAR","PMDA","2011-11-25","Neuroendocrine tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-11-25: New additional indication and a new dosage for the treatment of gastrointestinal <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">neuroendocrine tumor</a>.","2023-06-16"
"Ofatumumab","EMA","2010-04-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","Fludarabine AND Alemtuzumab","FALSE","","Refractory","","","","","",TRUE,"Hx-CD20-406","2010-04-19: Initial authorization as Arzerra for treatment of <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a> in patients refractory to fludarabine and alemtuzumab. <i>(Based on Hx-CD20-406)</i>","2023-09-17"
"Ofatumumab","EMA","2014-06-30","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","Untreated","","","","ineligible for fludarabine-based therapy","0","","","","","","Chlorambucil OR Bendamustine","","",NA,"","2014-06-30: Extension of Indication to include in previously untreated <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL) patients</a>, the treatment in combination with chlorambucil or bendamustine of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.","2023-09-17"
"Ofatumumab","EMA","2016-12-08","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed","","adults","","",NA,"","","","","Fludarabine AND Cyclophosphamide","","",NA,"","2016-12-08: Extension of indication to include the combination of Arzerra with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">Chronic Lymphocytic Leukaemia</a>.","2023-09-17"
"Ofatumumab","EMA","2019-02-28","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2019-02-28: Approval withdrawn at the request of the manufacturer, for commercial reasons","2023-05-08"
"Ofatumumab","FDA","2009-10-26","Chronic lymphocytic leukemia",TRUE,FALSE,FALSE,"","Refractory","","","","","Fludarabine AND Alemtuzumab","FALSE","","","","","","","",TRUE,"Hx-CD20-406","2009-10-26: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a> refractory to <a href=""/wiki/Fludarabine_(Fludara)"" title=""Fludarabine (Fludara)"">Fludarabine (Fludara)</a> and <a href=""/wiki/Alemtuzumab_(Campath)"" title=""Alemtuzumab (Campath)"">Alemtuzumab (Campath)</a>. <i>(Based on Hx-CD20-406)</i>","2022-09-05"
"Ofatumumab","FDA","2014-04-17","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","Fludarabine-based therapy considered inappropriate","0","FALSE","","","","","Chlorambucil","","",TRUE,"COMPLEMENT 1","2014-04-17: Converted to full approval in combination with <a href=""/wiki/Chlorambucil_(Leukeran)"" title=""Chlorambucil (Leukeran)"">Chlorambucil (Leukeran)</a>, for the treatment of previously untreated patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>, for whom <a href=""/wiki/Fludarabine_(Fludara)"" title=""Fludarabine (Fludara)"">fludarabine</a>-based therapy is considered inappropriate. <i>(Based on COMPLEMENT 1)</i>","2022-09-05"
"Ofatumumab","FDA","2016-01-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","Maintenance","","","","","2+","FALSE","","CR or PR","","","","","",TRUE,"PROLONG","2016-01-19: Approval expanded for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(Based on PROLONG)</i>","2022-09-05"
"Ofatumumab","FDA","2016-08-30","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","Relapsed","","","","","",NA,"","","","","Fludarabine AND Cyclophosphamide","","",TRUE,"COMPLEMENT 2","2016-08-30: Approved in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">CLL</a>. <i>(Based on COMPLEMENT 2)</i>","2022-09-05"
"Ofatumumab","FDA","2020-08-20","Multiple sclerosis",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2020-08-20: Approved as <b>Kesimpta</b> for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. <i>(Non-cancer indication)</i>","2022-09-05"
"Ofatumumab","HC","2012-03-09","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-03-09: Initial notice of compliance with conditions","2023-05-08"
"Ofatumumab","HC","2017-01-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-01-17: Conditions were met","2023-05-08"
"Ofatumumab","PMDA","2013-03-25","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2013-03-25: Initial approval for the treatment of relapsed or refractory CD20-positive <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a>.","2023-06-16"
"Olanzapine","PMDA","2017-12-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-12-25: New additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.).","2023-06-16"
"Olaparib","EMA","2014-12-16","Ovarian cancer",FALSE,FALSE,TRUE,"","Maintenance","Platinum-sensitive","","adults","","Platinum-based regimen",NA,"Relapsed","At least PR","","","0","","",TRUE,"Study 19","2014-12-16: Initial marketing authorization as Lynparza. Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete or partial) to platinum-based chemotherapy. <i>(Based on Study 19)</i>","2023-09-17"
"Olaparib","EMA","2019-04-08","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Anthracycline AND Taxane unless not suitable",NA,"","","","HR-positive: endocrine therapy or be considered inappropriate for endocrine therapy","0","gBRCAm and HER2-","",NA,"","2019-04-08: Indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy","2023-09-17"
"Olaparib","EMA","2019-06-12","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Advanced (FIGO stages III and IV)","","adults","","Platinum-based regimen",NA,"First-line","PR or CR","","","0","BRCAm","",NA,"","2019-06-12: Indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","2023-09-17"
"Olaparib","EMA","2020-03-11","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Advanced (FIGO stages III and IV)","","adults","","Platinum-based regimen AND Bevacizumab",NA,"First-line","PR or CR","","","Bevacizumab","HRD+","",NA,"","2020-03-11: Indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","2023-09-17"
"Olaparib","EMA","2020-03-11","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","New hormonal agent",NA,"","progression","","","0","BRCAm","",NA,"","2020-03-11: Indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.","2023-09-17"
"Olaparib","EMA","2020-07-03","Pancreatic cancer",FALSE,FALSE,FALSE,"","Maintenance","Metastatic","","adults","","Platinum-based regimen",NA,"First-line","Not progressed","At least 16 weeks","","0","gBRCAm","",TRUE,"POLO","2020-07-03: Indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">adenocarcinoma of the pancreas</a> and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. <i>(Based on POLO)</i>","2023-09-17"
"Olaparib","EMA","2022-08-02","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk","adults","","Chemotherapy",NA,"neoadjuvant|adjuvant","","","","0","gBRCAm and HER2-","",NA,"","2022-08-02: Indicated as monotherapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> previously treated with neoadjuvant or adjuvant chemotherapy.","2023-09-17"
"Olaparib","EMA","2022-08-02","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk","adults","","Chemotherapy",NA,"neoadjuvant|adjuvant","","","","endocrine therapy","gBRCAm and HER2-","",NA,"","2022-08-02: Indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> previously treated with neoadjuvant or adjuvant chemotherapy.","2023-09-17"
"Olaparib","EMA","2022-12-16","Prostate cancer",FALSE,FALSE,FALSE,"","Chemotherapy is not clinically indicated","metastatic","","adults","","",NA,"","","","","Abiraterone AND (Prednisone|Prednisolone)","","",TRUE,"PROpel","2022-12-16: Indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">mCRPC</a> in whom chemotherapy is not clinically indicated. <i>(Based on PROpel)</i>","2023-05-08"
"Olaparib","EMA","2022-12-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","high-risk","adults","","Chemotherapy","FALSE","neoadjuvant|adjuvant","","","","0","gBRCAm and HER2-","FALSE",NA,"","2022-12-16: Indicated as monotherapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> previously treated with neoadjuvant or adjuvant chemotherapy.","2023-07-31"
"Olaparib","EMA","2022-12-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","high-risk","adults","","Chemotherapy","FALSE","neoadjuvant|adjuvant","","","","endocrine therapy","gBRCAm and HER2-","FALSE",NA,"","2022-12-16: Indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> previously treated with neoadjuvant or adjuvant chemotherapy.","2023-07-31"
"Olaparib","EMA","2022-12-16","Ovarian cancer",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2022-12-16: Indication withdrawn as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete response or partial response) to platinum based chemotherapy.","2023-05-08"
"Olaparib","EMA","Uncertain date","Pancreatic cancer",FALSE,FALSE,FALSE,"","Maintenance","Metastatic","","adults","","Platinum-based regimen","FALSE","First-line","Not progressed","At least 16 weeks","","0","gBRCAm","FALSE",NA,"","Uncertain date: Indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">adenocarcinoma of the pancreas</a> and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.","2023-05-08"
"Olaparib","EMA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Anthracycline AND Taxane unless not suitable","FALSE","","","","","0","gBRCAm and HER2-","FALSE",NA,"","Uncertain date: Indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy","2023-05-08"
"Olaparib","EMA","Uncertain date","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","New hormonal agent","FALSE","","progression","","","0","gBRCAm|sBRCAm","FALSE",NA,"","Uncertain date: Indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.","2023-05-08"
"Olaparib","EMA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","FIGO stage III/IV","","adults","","Platinum-based regimen","FALSE","First-line","CR or PR","","","0","gBRCAm|sBRCAm","FALSE",NA,"","Uncertain date: Indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","2023-05-08"
"Olaparib","EMA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","FIGO stage III/IV","","adults","","Platinum- and Bevacizumab-based regimen","FALSE","First-line","CR or PR","","","Bevacizumab","HRD","FALSE",NA,"","Uncertain date: Indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","2023-05-08"
"Olaparib","EMA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","","Platinum-sensitive","adults","","Platinum-based regimen","FALSE","Relapsed","CR or PR","","","","","",NA,"","Uncertain date: Indicated as maintenance treatment of adult patients with platinum sensitive relapsed <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete or partial) to platinum based chemotherapy.","2023-05-08"
"Olaparib","FDA","2014-12-19","Ovarian cancer",TRUE,FALSE,FALSE,"","","Advanced","","","","3+ Chemotherapy-based regimen","FALSE","","","","","0","gBRCAm","FALSE",TRUE,"Study 42","2014-12-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://wayback.archive-it.org/7993/20170111160837/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm"">Granted initial accelerated approval</a> as monotherapy in patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (as detected by an FDA-approved test) advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> who have been treated with three or more prior lines of chemotherapy. <i>(Based on Study 42)</i>","2022-09-05"
"Olaparib","FDA","2017-08-17","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","","","",TRUE,"SOLO2","2017-08-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm"">Granted regular approval</a> for the maintenance treatment of adult patients with recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who are in a complete or partial response to <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Approval expanded to maintenance after second-line therapy; based on SOLO2 and Study 19)</i>","2022-09-05"
"Olaparib","FDA","2017-08-17","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","","","",TRUE,"Study 19","2017-08-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm"">Granted regular approval</a> for the maintenance treatment of adult patients with recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who are in a complete or partial response to <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Approval expanded to maintenance after second-line therapy; based on SOLO2 and Study 19)</i>","2022-09-05"
"Olaparib","FDA","2018-01-12","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Chemotherapy","FALSE","Any","","","HR-positive: endocrine therapy or be considered inappropriate for endocrine therapy","","gBRCAm and HER2-","FALSE",TRUE,"OlympiAD","2018-01-12: Granted regular approval for the treatment of patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (gBRCAm), <a href=""/wiki/Biomarkers#ERBB2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#negative"" title=""Biomarkers"">negative</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#positive"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. <i>(New disease entity; based on OlympiAD)</i>","2022-09-05"
"Olaparib","FDA","2018-12-19","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line maintenance","Advanced","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","","gBRCAm|sBRCAm","FALSE",TRUE,"SOLO1","2018-12-19: Approved for the maintenance treatment of adult patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> or <a href=""/wiki/Biomarkers#Somatic"" title=""Biomarkers"">somatic</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (gBRCAm or sBRCAm) advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube or primary peritoneal cancer</a> who are in complete or partial response to first-line <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Approval expanded to maintenance after first-line therapy; based on SOLO1)</i>","2022-09-05"
"Olaparib","FDA","2019-12-27","Pancreatic cancer",FALSE,FALSE,FALSE,"","First-line maintenance","Metastatic","","adults","","Platinum-based regimen","FALSE","","","No progression within 16 weeks of starting platinum-based regimen","","","gBRCAm","FALSE",TRUE,"POLO","2019-12-27: Approved for the maintenance treatment of adult patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (gBRCAm) metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic adenocarcinoma</a>, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy regimen</a>. <i>(New disease entity; based on POLO)</i>","2022-09-05"
"Olaparib","FDA","2020-05-08","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line maintenance","Advanced","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","Bevacizumab","BRCAm|genomic instability","FALSE",TRUE,"PAOLA-1","2020-05-08: Approval expanded to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with <a href=""/wiki/Biomarkers#HRD"" title=""Biomarkers"">homologous recombination deficiency positive status</a> defined by either a deleterious or suspected deleterious <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>, and/or <a href=""/wiki/Biomarkers#Genomic_instability"" title=""Biomarkers"">genomic instability</a>. <i>(Approval expanded to combination maintenance after first-line therapy; based on PAOLA-1)</i>","2022-09-05"
"Olaparib","FDA","2020-05-19","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","Enzalutamide OR Abiraterone","FALSE","","progression","","","","HRD","FALSE",TRUE,"PROfound","2020-05-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer"">Approved</a> for adult patients with deleterious or suspected deleterious germline or somatic <a href=""/wiki/Biomarkers#HRD"" title=""Biomarkers"">homologous recombination repair (HRR) gene-mutated</a> metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. <i>(New disease entity; based on PROfound)</i>","2022-09-05"
"Olaparib","FDA","2022-03-11","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk","adults","","Surgery AND Chemotherapy","FALSE","","","","","","gBRCAm and HER2-","FALSE",TRUE,"OlympiA","2022-03-11: Approved for the adjuvant treatment of adult patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (gBRCAm) <a href=""/wiki/Biomarkers#ERBB2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#negative"" title=""Biomarkers"">negative</a> high-risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have been treated with neoadjuvant or adjuvant chemotherapy. <i>(Based on OlympiA)</i>","2022-09-05"
"Olaparib","FDA","2022-08-26","Ovarian cancer",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2022-08-26: Accelerated approval voluntarily withdrawn by the manufacturer; awaiting FDA withdrawal notice.","2022-11-03"
"Olaparib","FDA","2023-05-31","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","","",NA,"","","","","Abiraterone AND (Prednisone|Prednisolone)","BRCAm","FALSE",TRUE,"PROpel","2023-05-31: Approved with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC), as determined by an FDA-approved companion diagnostic test. <i>(Based on PROpel)</i>","2023-07-31"
"Olaparib","HC","2016-04-29","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-04-29: Initial notice of compliance with conditions","2023-05-08"
"Olaparib","HC","2018-05-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-05-02: Conditions were met","2023-05-08"
"Olaparib","HC","2018-05-04","Ovarian cancer",TRUE,FALSE,FALSE,"","Maintenance","Platinum-sensitive","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","0","BRAF","TRUE",NA,"","2018-05-04: Notice of compliance with conditions as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA wild type <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete response or partial response) to platinum-based chemotherapy.","2023-05-08"
"Olaparib","HC","2022-07-27","Breast cancer",TRUE,FALSE,FALSE,"","Adjuvant","Early","High-risk","adults","","Surgery AND Chemotherapy","FALSE","","","","","","gBRCAm and HER2-","FALSE",NA,"","2022-07-27: Notice of compliance with conditions for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have been treated with neoadjuvant or adjuvant chemotherapy.","2023-05-08"
"Olaparib","PMDA","2018-01-19","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Recurrent","","","","Platinum-based regimen","FALSE","","CR or PR","","","","","",NA,"","2018-01-19: New approval for the maintenance treatment of recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who are in a complete or partial response to platinum-based chemotherapy.","2023-06-16"
"Olaparib","PMDA","2018-07-02","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","chemotherapy","FALSE","","","","","","BRCAm|HER2-","FALSE",NA,"","2018-07-02: New additional indication for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in patients who have previously been treated with chemotherapy.","2023-06-16"
"Olaparib","PMDA","2019-06-18","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","chemotherapy","FALSE","","","","","","BRCAm","FALSE",NA,"","2019-06-18: New indication for maintenance treatment of BRCA mutation-positive <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who have received first chemotherapy.","2023-06-16"
"Olaparib","PMDA","2020-12-25","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","","BRCAm","FALSE",NA,"","2020-12-25: New indication and new dosage for the treatment of metastatic, BRCA mutation-positive, castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2023-06-16"
"Olaparib","PMDA","2020-12-25","Pancreatic cancer",FALSE,FALSE,FALSE,"","Maintenance","Unresectable","","","","Platinum-based regimen","FALSE","","","","","","BRCAm","FALSE",NA,"","2020-12-25: new indication and a new dosage for maintenance therapy of unresectable BRCA mutation-positive <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a> after chemotherapy including treatment with platinum-based antineoplastic drugs.","2023-06-16"
"Olaparib","PMDA","2020-12-25","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","chemotherapy AND bevacizumab","FALSE","","","","","","HRD+","FALSE",NA,"","2020-12-25: New indication and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients who have received first chemotherapy including treatment with bevacizumab.","2023-06-16"
"Olaparib","PMDA","2022-08-24","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","High-risk for recurrence","","","Surgery","FALSE","","","","","","BRCAm|HER2-","FALSE",NA,"","2022-08-24: New indication and a new dosage for the postoperative adjuvant treatment of BRCA mutation-positive and HER2-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with a high risk of recurrence.","2023-06-16"
"Olaratumab","EMA","2016-11-09","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","not amenable to curative treatment with surgery or radiotherapy","Doxorubicin","TRUE","","","","","Doxorubicin","","",NA,"","2016-11-09: Initial authorization as Lartruvo. Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">soft tissue sarcoma</a> who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.","2023-09-17"
"Olaratumab","EMA","2019-04-26","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"ANNOUNCE","2019-04-26: Approval withdrawn. <i>(Based on ANNOUNCE)</i>","2023-05-08"
"Olaratumab","FDA","2016-10-19","Soft tissue sarcoma",TRUE,FALSE,TRUE,"","","","","","not amenable to curative treatment with radiotherapy or surgery and an anthracycline-containing regimen is appropriate","",NA,"","","","","","","",TRUE,"CP15-0806","2016-10-19: Accelerated approval for the treatment of patients with <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">soft tissue sarcoma (STS)</a> not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate. <i>(Based on CP15-0806)</i>","2022-09-05"
"Olaratumab","FDA","2020-02-25","Soft tissue sarcoma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"ANNOUNCE","2020-02-25: Accelerated approval withdrawn. <i>(Based on ANNOUNCE)</i>","2022-09-05"
"Olaratumab","HC","2017-11-23","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-11-23: Initial notice of compliance with conditions","2023-05-08"
"Olaratumab","HC","2020-10-08","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2020-10-08: Approval withdrawn.","2023-05-08"
"Olutasidenib","FDA","2022-12-01","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","IDH1 mutation","FALSE",TRUE,"2102-HEM-101","2022-12-01: Granted approval for adult patients with relapsed or refractory <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> with a susceptible <a href=""/wiki/Biomarkers#IDH1"" title=""Biomarkers"">IDH1</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a>. <i>(Based on 2102-HEM-101)</i>","2023-03-10"
"Olverembatinib","NMPA","2021-11-01","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","TKI-resistant","Chronic phase OR Accelerated phase","","adults","","TKI","FALSE","","","","","","Bcr-Abl p.T315I","FALSE",TRUE,"HQP1351CC202","2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML-CP or CML-AP</a> harboring the T315I mutation as confirmed by a validated diagnostic test. <i>(Based on HQP1351CC202 and HQP1351CC203)</i>","2024-12-02"
"Olverembatinib","NMPA","2023-11-17","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"HQP1351CC203","2023-11-17: Approved for the treatment of adult patients with chronic-phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia</a> (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs). <i>(Based on HQP1351CC203)</i>","2024-12-02"
"Olverembatinib","NMPA","2023-11-21","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","TKI-resistant","Chronic phase OR Accelerated phase","","adults","","TKI","FALSE","","","","","","Bcr-Abl p.T315I","FALSE",TRUE,"HQP1351CC203","2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML-CP or CML-AP</a> harboring the T315I mutation as confirmed by a validated diagnostic test. <i>(Based on HQP1351CC202 and HQP1351CC203)</i>","2023-09-09"
"Omacetaxine","FDA","2012-10-26","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","2+ Tyrosine kinase inhibitor therapy","FALSE","","Resistance OR intolerance","","","","","",TRUE,"CGX-635-CML-202","2012-10-26: Accelerated approval for treatment of adult patients with chronic or accelerated phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> with resistance and/or intolerance to two or more <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitors (TKI)</a>. <i>(Based on CGX-635-CML-202 and CGX-635-CML-203)</i>","2022-09-21"
"Omacetaxine","FDA","2012-10-26","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","2+ Tyrosine kinase inhibitor therapy","FALSE","","Resistance OR intolerance","","","","","",TRUE,"CGX-635-CML-203","2012-10-26: Accelerated approval for treatment of adult patients with chronic or accelerated phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> with resistance and/or intolerance to two or more <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitors (TKI)</a>. <i>(Based on CGX-635-CML-202 and CGX-635-CML-203)</i>","2022-09-21"
"Omacetaxine","FDA","2014-02-10","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","2+ Tyrosine kinase inhibitor therapy","FALSE","","","","","","","",TRUE,"CGX-635-CML-202","2014-02-10: Converted to regular approval for treatment of adult patients with chronic or accelerated phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> with resistance and/or intolerance to two or more <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitors (TKI)</a>. <i>(Based on CGX-635-CML-202 and CGX-635-CML-203)</i>","2022-09-21"
"Omacetaxine","FDA","2014-02-10","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase","","adults","","2+ Tyrosine kinase inhibitor therapy","FALSE","","","","","","","",TRUE,"CGX-635-CML-203","2014-02-10: Converted to regular approval for treatment of adult patients with chronic or accelerated phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> with resistance and/or intolerance to two or more <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitors (TKI)</a>. <i>(Based on CGX-635-CML-202 and CGX-635-CML-203)</i>","2022-09-21"
"Omeprazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ondansetron","FDA","1991-01-04","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1991-01-04: Initial FDA approval","2022-09-05"
"Oprelvekin","FDA","1997-11-25","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1997-11-25: Initial FDA approval (no label available on Drugs @ FDA)","2023-07-31"
"Oprelvekin","FDA","2002-09-18","Thrombocytopenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2002-09-18: Label indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.","2023-07-31"
"Osimertinib","EMA","2016-02-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-02-01: Initial marketing authorization as Tagrisso.","2023-05-08"
"Osimertinib","FDA","2015-11-13","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","EGFR TKI therapy","FALSE","","progression","","","","EGFR p.T790M","FALSE",TRUE,"AURA","2015-11-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm"">FDA granted accelerated approval</a> for the treatment of patients with metastatic <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#T790M"" title=""Biomarkers"">T790M mutation-positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as detected by an FDA-approved test, who have progressed on or after <a href=""/wiki/Regimen_classes#EGFR_TKI_therapy"" title=""Regimen classes"">EGFR tyrosine kinase inhibitor (TKI) therapy</a>.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(Based on AURA and AURA2)</i>","2022-09-05"
"Osimertinib","FDA","2015-11-13","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","EGFR TKI therapy","FALSE","","progression","","","","EGFR p.T790M","FALSE",TRUE,"AURA2","2015-11-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm"">FDA granted accelerated approval</a> for the treatment of patients with metastatic <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#T790M"" title=""Biomarkers"">T790M mutation-positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as detected by an FDA-approved test, who have progressed on or after <a href=""/wiki/Regimen_classes#EGFR_TKI_therapy"" title=""Regimen classes"">EGFR tyrosine kinase inhibitor (TKI) therapy</a>.<sup id=""cite_ref-insert_1-3"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(Based on AURA and AURA2)</i>","2022-09-05"
"Osimertinib","FDA","2017-03-30","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","EGFR TKI therapy","FALSE","","progression","","","","EGFR p.T790M","FALSE",TRUE,"AURA3","2017-03-30: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549683.htm"">FDA granted regular approval</a> for the treatment of patients with metastatic <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#T790M"" title=""Biomarkers"">T790M mutation-positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as detected by an FDA-approved test, who have progressed on or after <a href=""/wiki/Regimen_classes#EGFR_TKI_therapy"" title=""Regimen classes"">EGFR tyrosine kinase inhibitor (TKI) therapy</a>.<sup id=""cite_ref-insert_1-4"" class=""reference""><a href=""#cite_note-insert-1"">&#91;1&#93;</a> <i>(Based on AURA3)</i>","2022-09-05"
"Osimertinib","FDA","2018-04-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"FLAURA","2018-04-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm"">FDA approved</a> for the first-line treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 L858R mutations</a>. <i>(Based on FLAURA)</i>","2022-09-05"
"Osimertinib","FDA","2020-12-18","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Tumor resection","FALSE","","","","","","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"ADAURA","2020-12-18: Approved for adjuvant therapy after tumor resection in patients with <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 L858R mutations</a>. <i>(Based on ADAURA)</i>","2022-09-05"
"Osimertinib","FDA","2024-02-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","",NA,"","","","","Platinum-based chemotherapy","EGFR exon 19 deletion|EGFR p.L858R","",TRUE,"FLAURA2","2024-02-16: Approved with platinum-based chemotherapy for patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. <i>(Based on FLAURA2)</i>","2024-06-03"
"Osimertinib","FDA","2024-09-25","Non-small cell lung cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"LAURA","2024-09-25: Approved for adult patients with locally advanced, unresectable (stage III) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. <i>(Based on LAURA)</i>","2024-12-02"
"Osimertinib","HC","2016-07-05","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-07-05: Initial notice of compliance with conditions","2023-05-08"
"Osimertinib","HC","2018-01-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-01-19: Conditions were met","2023-05-08"
"Osimertinib","PMDA","2016-03-28","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","EGFR TKI therapy","FALSE","","resistance","","","","EGFR p.T790M","FALSE",NA,"","2016-03-28: Initial approval for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> with resistance to EGFR tyrosine kinase inhibitors.","2023-06-16"
"Osimertinib","PMDA","2018-08-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","EGFR mutation","FALSE",NA,"","2018-08-21: New indication for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Osimertinib","PMDA","2022-08-24","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","EGFR mutation","FALSE",NA,"","2022-08-24: New indication, a new dosage, and other characteristics for postoperative adjuvant treatment for epidermal growth factor receptor (EGFR) mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Oxaliplatin","EMA","1996-04-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-04-12: EURD","2023-07-31"
"Oxaliplatin","FDA","2002-08-09","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","FOLFIRI","FALSE","","recurrence OR progression","within 6 months of completion","","Fluorouracil AND Leucovorin","","",TRUE,"BRCC-00036","2002-08-09: Initial accelerated approval in combination with infusional <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU</a>/<a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> LV</a>, is indicated for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a> whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU</a>/<a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> LV</a> and <a href=""/wiki/Irinotecan_(Camptosar)"" title=""Irinotecan (Camptosar)""> irinotecan</a>. <i>(Based on BRCC-00036)</i>","2022-09-05"
"Oxaliplatin","FDA","2004-01-09","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fluorouracil AND Leucovorin","","",TRUE,"NCCTG N9741","2004-01-09: Converted to regular approval in combination with infusional <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU</a>/<a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> LV</a>, is indicated for the treatment of advanced <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">carcinoma of the colon or rectum</a>. <i>(Based on NCCTG N9741)</i>","2022-09-05"
"Oxaliplatin","FDA","2004-11-04","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage III","","","","Surgery","FALSE","","complete resection","","","","","",TRUE,"MOSAIC","2004-11-04: New indication: used in combination with infusional <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-FU</a>/<a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> LV</a>, is indicated for adjuvant treatment of stage III <a href=""/wiki/Colon_cancer"" title=""Colon cancer""> colon cancer</a> patients who have undergone complete resection of the primary tumor. <i>(Based on MOSAIC)</i>","2022-09-05"
"Oxaliplatin","PMDA","2005-03-18","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2005-03-18: Initial approval for <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colonic and rectal cancers</a>.","2023-06-16"
"Oxaliplatin","PMDA","2009-08-20","Colon cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2009-08-20: New additional indication for post-operative adjuvant chemotherapy for <a href=""/wiki/Colon_cancer"" title=""Colon cancer"">colon cancer</a>.","2023-06-16"
"Oxaliplatin","PMDA","2009-09-18","Colorectal cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","not suited for curative resection","",NA,"","","","","Oxaliplatin AND Bevacizumab","","",NA,"","2009-09-18: New additional indication for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> not suited for curative resection.","2023-06-16"
"Oxaliplatin","PMDA","2013-12-20","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2013-12-20: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Oxaliplatin","PMDA","2015-03-20","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2015-03-20: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Oxaliplatin","PMDA","2015-11-20","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-11-20: Revised indication for the treatment of <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Oxaliplatin","PMDA","2018-09-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-21: New indication and a new dosage for the treatment of <a href=""/wiki/Small_bowel_adenocarcinoma"" title=""Small bowel adenocarcinoma"">small intestine cancer</a>.","2023-06-16"
"Paclitaxel","EMA","1992-12-29","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1992-12-29: EURD","2023-07-31"
"Paclitaxel","FDA","1992-12-29","Ovarian cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","1+ chemotherapy","FALSE","","","","","","","",TRUE,"Eisenhauer et al. 1994","1992-12-29: Initial FDA approval for treatment of patients with metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">carcinoma of the ovary</a> after failure of first-line or subsequent chemotherapy. <i>(Based on Eisenhauer et al. 1994)</i>","2022-09-05"
"Paclitaxel","FDA","1998-06-30","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","Not candidate for potentially curative surgery and/or radiation therapy","0","FALSE","","","","","Cisplatin","","",TRUE,"ECOG E5592","1998-06-30: New indication added: in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a>, is indicated for the first-line treatment of <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> in patients who are not candidates for potentially curative surgery and/or radiation therapy. <i>(Based on ECOG E5592)</i>","2022-09-05"
"Paclitaxel","FDA","1999-10-25","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","Doxorubicin-based regimen","FALSE","","","","","","","",TRUE,"INT 0148/CALGB 9344","1999-10-25: New indication for the adjuvant treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> administered sequentially to standard <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a>-containing combination chemotherapy. <i>(Based on INT 0148/CALGB 9344)</i>","2022-09-05"
"Paclitaxel","FDA","Uncertain date","Kaposi sarcoma",FALSE,FALSE,FALSE,"","Second-line","","","","","",NA,"","","","","","","",TRUE,"CA139-174","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma""> AIDS-related Kaposi's sarcoma</a>. <i>(Based on CA139-174 and CA139-281)</i>","2023-05-08"
"Paclitaxel","FDA","Uncertain date","Kaposi sarcoma",FALSE,FALSE,FALSE,"","Second-line","","","","","",NA,"","","","","","","",TRUE,"CA139-281","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma""> AIDS-related Kaposi's sarcoma</a>. <i>(Based on CA139-174 and CA139-281)</i>","2023-05-08"
"Paclitaxel","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Cisplatin","","",TRUE,"GOG 111","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> for the treatment of advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a>. <i>(Based on GOG 111 and OV10)</i>","2023-07-31"
"Paclitaxel","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Subsequent line","Advanced","","","","",NA,"","","","","","","",TRUE,"GOG 111","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a>. <i>(Based on GOG 111 and OV10)</i>","2023-07-31"
"Paclitaxel","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy including anthracyclines unless clinically contraindicated","FALSE","adjuvant","relapsed","within 6 months","","","","",TRUE,"Nabholtz et al. 1996","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a> unless clinically contraindicated. <i>(Based on Nabholtz et al. 1996)</i>","2023-07-31"
"Paclitaxel","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Combination therapy including anthracyclines unless clinically contraindicated","FALSE","","failure","","","","","",TRUE,"Nabholtz et al. 1996","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer""> breast cancer</a> after failure of combination therapy for metastatic disease. Prior therapy should have included an <a href=""/wiki/Category:Anthracyclines"" title=""Category:Anthracyclines"">anthracycline</a> unless clinically contraindicated. <i>(Based on Nabholtz et al. 1996)</i>","2023-07-31"
"Paclitaxel","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Cisplatin","","",TRUE,"OV10","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> for the treatment of advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a>. <i>(Based on GOG 111 and OV10)</i>","2023-07-31"
"Paclitaxel","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Subsequent line","Advanced","","","","",NA,"","","","","","","",TRUE,"OV10","1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a>. <i>(Based on GOG 111 and OV10)</i>","2023-07-31"
"Paclitaxel","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Paclitaxel","PMDA","2005-05-31","Endometrial cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2005-05-31: New indication for the treatment of <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">cancer of the uterus body</a>.","2023-06-16"
"Paclitaxel","PMDA","2012-03-21","Angiosarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-03-21: New additional indications and new dosages for the treatment of <a href=""/wiki/Angiosarcoma"" title=""Angiosarcoma"">angiosarcoma</a>.","2023-06-16"
"Paclitaxel","PMDA","2012-03-21","Cervical cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2012-03-21: New additional indications and new dosages for the treatment of advanced or relapsed <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>.","2023-06-16"
"Paclitaxel","PMDA","2012-03-21","Esophageal cancer",FALSE,FALSE,FALSE,"","","Relapsed or Metastatic","","","","",NA,"","","","","","","",NA,"","2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophagus cancer</a>.","2023-06-16"
"Paclitaxel","PMDA","2012-03-21","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","",NA,"","","","","","","",NA,"","2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>.","2023-06-16"
"Paclitaxel","PMDA","2013-02-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-02-21: New additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors).","2023-06-16"
"Paclitaxel nanoparticle albumin-bound","EMA","2008-01-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-01-11: Initial marketing authorization as Abraxane","2023-05-08"
"Paclitaxel nanoparticle albumin-bound","FDA","2005-01-07","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Combination chemotherapy for metastatic disease OR relapse within 6 months of adjuvant chemotherapy, including an anthracycline-based regimen unless clinically contraindicated","FALSE","","","","","","","",TRUE,"CA012-0","2005-01-07: FDA approved for metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline</a> unless clinically contraindicated. <i>(Based on CA012-0 and Ibrahim et al. 2005)</i>","2022-09-05"
"Paclitaxel nanoparticle albumin-bound","FDA","2005-01-07","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Combination chemotherapy for metastatic disease OR relapse within 6 months of adjuvant chemotherapy, including an anthracycline-based regimen unless clinically contraindicated","FALSE","","","","","","","",TRUE,"Ibrahim et al. 2005","2005-01-07: FDA approved for metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline</a> unless clinically contraindicated. <i>(Based on CA012-0 and Ibrahim et al. 2005)</i>","2022-09-05"
"Paclitaxel nanoparticle albumin-bound","FDA","2012-10-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","Not candidate for potentially curative surgery and/or radiation therapy","0","FALSE","","","","","Carboplatin","","",TRUE,"CA031","2012-10-11: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm"">FDA approved</a> for locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> Non-Small Cell Lung Cancer (NSCLC)</a>, as first-line treatment in combination with <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)""> carboplatin</a>, in patients who are not candidates for curative surgery or radiation therapy. <i>(Based on CA031)</i>","2022-09-05"
"Paclitaxel nanoparticle albumin-bound","FDA","2013-09-06","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Gemcitabine","","",TRUE,"MPACT","2013-09-06: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm"">FDA approved</a> for treatment of metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer""> adenocarcinoma of the pancreas</a> as first-line treatment, in combination with <a href=""/wiki/Gemcitabine_(Gemzar)"" title=""Gemcitabine (Gemzar)""> gemcitabine</a>. <i>(Based on MPACT)</i>","2022-09-05"
"Paclitaxel nanoparticle albumin-bound","HC","2006-06-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-06-07: Initial notice of compliance (unclear details)","2023-05-20"
"Paclitaxel nanoparticle albumin-bound","HC","2014-07-16","Pancreatic cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","0","FALSE","","","","","Gemcitabine","","",NA,"","2014-07-16: New indication for the first-line treatment of locally advanced unresectable or metastatic <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">adenocarcinoma of the pancreas</a>, in combination with gemcitabine.","2023-05-20"
"Paclitaxel nanoparticle albumin-bound","PMDA","2010-07-23","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2010-07-23: Initial approval in a new dosage form and with a new dosage indicated for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Paclitaxel nanoparticle albumin-bound","PMDA","2013-02-21","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-02-21: New additional indications and a new dosage for the treatment of <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> and <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Paclitaxel nanoparticle albumin-bound","PMDA","2013-02-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-02-21: New additional indications and a new dosage for the treatment of <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> and <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Paclitaxel nanoparticle albumin-bound","PMDA","2014-12-18","Pancreatic cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2014-12-18: New additional indication and a new dosage for the treatment of unresectable <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Pacritinib","FDA","2022-03-01","Myelofibrosis",TRUE,FALSE,FALSE,"","platelet count less than 50k","","Intermediate-risk OR High-risk","adults","","",NA,"","","","","","","",TRUE,"PERSIST-2","2022-03-01: Granted accelerated approval for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis</a> with a platelet count below 50 x 10^9/L. <i>(Based on PERSIST-2)</i>","2023-01-03"
"Palbociclib","EMA","2016-11-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-11-09: Initial authorization","2023-05-08"
"Palbociclib","FDA","2015-02-03","Breast cancer",TRUE,FALSE,TRUE,"","First-line metastatic","Advanced","","postmenopausal women","","0","FALSE","","","","","Letrozole","ER+|HER2-","FALSE",TRUE,"PALOMA-2","2015-02-03: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm"">Accelerated FDA approval</a> to be used in combination with <a href=""/wiki/Letrozole_(Femara)"" title=""Letrozole (Femara)""> letrozole</a> for the treatment of postmenopausal women with <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen receptor (ER)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as initial endocrine-based therapy for their metastatic disease. <i>(Based on PALOMA-2)</i>","2022-09-05"
"Palbociclib","FDA","2016-02-19","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","women","","Endocrine therapy","FALSE","","progression","","","Fulvestrant","HR+ and HER2-","FALSE AND TRUE",TRUE,"PALOMA-3","2016-02-19: FDA approval expanded in combination with <a href=""/wiki/Fulvestrant_(Faslodex)"" title=""Fulvestrant (Faslodex)"">fulvestrant</a> for the treatment of women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with disease progression following endocrine therapy. <i>(Based on PALOMA-3)</i>","2022-09-05"
"Palbociclib","FDA","2017-03-31","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","0","FALSE","","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"PALOMA-2","2017-03-31: Granted regular approval for the treatment of <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a> <a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women. <i>(Based on PALOMA-2)</i>","2022-09-05"
"Palbociclib","HC","2016-03-16","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-03-16: Initial notice of compliance with conditions","2023-05-08"
"Palbociclib","HC","2016-11-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-11-17: Conditions were met","2023-05-08"
"Palbociclib","PMDA","2017-09-27","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2017-09-27: New approval for the treatment of unresectable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Palbociclib","PMDA","2020-01-23","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","HR+ and HER2-","FALSE AND TRUE",NA,"","2020-01-23: New indication in a new dosage form for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Palifermin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Palonosetron","EMA","2005-03-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2005-03-22: Initial authorization","2023-05-08"
"Palonosetron","FDA","2003-07-25","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2003-07-25: Approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.","2022-09-05"
"Pamidronate","FDA","1991-10-31","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1991-10-31: Initial FDA approval","2022-09-05"
"Panitumumab","EMA","2007-12-03","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-12-03: Initial authorization","2023-05-08"
"Panitumumab","FDA","2006-09-27","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","","EGFR+","FALSE",TRUE,"20020408","2006-09-27: Accelerated FDA approval for the treatment of <a href=""/wiki/Biomarkers#EGFR_protein"" title=""Biomarkers"">EGFR</a>-<a href=""/wiki/Biomarkers#expression"" title=""Biomarkers"">expressing</a>, metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal carcinoma</a> with disease progression on or following <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin-</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-</a> containing chemotherapy regimens. <i>(Based on 20020408)</i>","2022-09-05"
"Panitumumab","FDA","2009-07-17","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"20100007","2009-07-17: Restriction placed: <b>not indicated</b> for the treatment of patients with KRAS mutation-positive mCRC or for whom KRAS mCRC status is unknown. <i>(Based on 20100007 and PRIME)</i>","2022-09-05"
"Panitumumab","FDA","2009-07-17","Colorectal cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",TRUE,"PRIME","2009-07-17: Restriction placed: <b>not indicated</b> for the treatment of patients with KRAS mutation-positive mCRC or for whom KRAS mCRC status is unknown. <i>(Based on 20100007 and PRIME)</i>","2022-09-05"
"Panitumumab","FDA","2014-05-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","0","KRAS","TRUE",TRUE,"20100007","2014-05-23: Full approval for the treatment of <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a> <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">KRAS</a> (<a href=""/wiki/Biomarkers#Exon_2"" title=""Biomarkers"">exon 2</a>) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) as monotherapy following disease progression after prior treatment with <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin-</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-</a> containing chemotherapy. <i>(Based on 20100007 and ASPECCT)</i>","2022-09-05"
"Panitumumab","FDA","2014-05-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","0","KRAS","TRUE",TRUE,"ASPECCT","2014-05-23: Full approval for the treatment of <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a> <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">KRAS</a> (<a href=""/wiki/Biomarkers#Exon_2"" title=""Biomarkers"">exon 2</a>) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) as monotherapy following disease progression after prior treatment with <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin-</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-</a> containing chemotherapy. <i>(Based on 20100007 and ASPECCT)</i>","2022-09-05"
"Panitumumab","FDA","2014-05-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","FOLFOX","KRAS","TRUE",TRUE,"PRIME","2014-05-23: Full approval for the treatment of <a href=""/wiki/Biomarkers#Wild-type"" title=""Biomarkers"">wild-type</a> <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">KRAS</a> (<a href=""/wiki/Biomarkers#Exon_2"" title=""Biomarkers"">exon 2</a>) metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) in combination with <a href=""/wiki/Colorectal_cancer,_RAS_wild-type#FOLFOX4_&_Panitumumab"" title=""Colorectal cancer"">FOLFOX</a> for first-line treatment. <i>(Based on PRIME)</i>","2022-09-05"
"Panitumumab","HC","2008-04-03","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-04-03: Initial notice of compliance with conditions","2023-05-08"
"Panitumumab","HC","2015-02-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-02-19: Conditions were met","2023-05-08"
"Panitumumab","PMDA","2010-04-16","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","KRAS","TRUE",NA,"","2010-04-16: Initial approval for the treatment of unresectable, advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> with wild-type KRAS.","2023-06-16"
"Panobinostat","EMA","2015-08-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-08-28: Initial marketing authorization as Farydak.","2023-05-08"
"Panobinostat","EMA","Uncertain date","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+, including Bortezomib AND Immunomodulator","FALSE","","","","","Bortezomib AND Dexamethasone","","",NA,"","Uncertain date: Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least two prior regimens including bortezomib and an immunomodulatory agent.","2023-05-20"
"Panobinostat","FDA","2015-02-23","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","","","2+, including Bortezomib AND Immunomodulator","FALSE","","","","","","","",TRUE,"PANORAMA 1","2015-02-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm"">FDA accelerated approval</a> for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 2 prior regimens, including <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> and an <a href=""/wiki/Category:Immunomodulatory_drugs_(IMiDs)"" title=""Category:Immunomodulatory drugs (IMiDs)"">immunomodulatory agent</a>. <i>(Based on PANORAMA 1)</i>","2022-09-05"
"Panobinostat","FDA","2022-03-24","Multiple myeloma",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",FALSE,"","2022-03-24: Accelerated approval for the treatment of patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 2 prior regimens, including <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> and an <a href=""/wiki/Category:Immunomodulatory_drugs_(IMiDs)"" title=""Category:Immunomodulatory drugs (IMiDs)"">immunomodulatory agent</a> withdrawn at the request of the manufacturer. <i>(No supporting studies are cited)</i>","2022-09-21"
"Panobinostat","PMDA","2015-07-03","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2015-07-03: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Pantoprazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pazopanib","EMA","2010-06-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"To be dissected","First-line","Advanced","","","","","","","","","","","","",TRUE,"VEG105192","2010-06-14: Initial marketing authorization as Votrient. Votrient is indicated for the first line treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">Renal Cell Carcinoma (RCC)</a>. <i>(Based on VEG105192)</i>","2024-12-02"
"Pazopanib","EMA","2010-06-14","Renal cell carcinoma",FALSE,FALSE,FALSE,"To be dissected","","Advanced","","","","Cytokines","","Advanced disease","","","","","","",TRUE,"VEG105192","2010-06-14: Initial marketing authorization as Votrient. Votrient is indicated for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">Renal Cell Carcinoma (RCC)</a> for patients who have received prior cytokine therapy for advanced disease. <i>(Based on VEG105192)</i>","2024-12-02"
"Pazopanib","EMA","2012-08-03","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",NA,"","2012-08-03: Extension of indication for the treatment of patients with advanced <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">Soft Tissue Sarcoma (STS)</a>.","2023-09-17"
"Pazopanib","FDA","2009-10-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"VEG105192","2009-10-19: Initial FDA approval for the treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a>. <i>(Based on VEG105192)</i>","2022-09-05"
"Pazopanib","FDA","2012-04-26","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","Advanced","","","","Chemotherapy","FALSE","","","","","","","",TRUE,"PALETTE","2012-04-26: New indication for patients with advanced <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma""> soft tissue sarcoma</a> who have received prior chemotherapy. The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. <i>(Based on PALETTE)</i>","2022-09-05"
"Pazopanib","HC","2010-05-27","Clear cell renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","SACT","TRUE","","","","","","","",NA,"","2010-05-27: Initial notice of compliance for the treatment of patients with metastatic <a href=""/wiki/Clear_cell_renal_cell_carcinoma"" title=""Clear cell renal cell carcinoma"">renal cell (clear cell) carcinoma</a> (mRCC) who have received no prior systemic therapies.","2023-06-16"
"Pazopanib","HC","2010-05-27","Clear cell renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","Cytokines","FALSE","Metastatic","","","","","","",NA,"","2010-05-27: Initial notice of compliance for the treatment of patients with metastatic <a href=""/wiki/Clear_cell_renal_cell_carcinoma"" title=""Clear cell renal cell carcinoma"">renal cell (clear cell) carcinoma</a> (mRCC) who have received prior treatment with cytokines for metastatic disease.","2023-06-16"
"Pazopanib","HC","2012-07-12","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","adults","","Chemotherapy","FALSE","Metastatic","","","","","","",NA,"","2012-07-12: New indication for the treatment of adult patients with selective subtypes of advanced <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">Soft Tissue Sarcoma (STS)</a> who have received prior chemotherapy for metastatic disease. Patients were required to have disease progression on or after, or be intolerant to, an anthracyline-based regimen in the pivotal phase III study in STS.","2023-06-16"
"Pazopanib","HC","2012-07-12","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","adults","","SACT","FALSE","(neo)adjuvant","progression","within 12 months","","","","",NA,"","2012-07-12: New indication for the treatment of adult patients with selective subtypes of advanced <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">Soft Tissue Sarcoma (STS)</a> who have progressed within 12 months after (neo)adjuvant therapy. Patients were required to have disease progression on or after, or be intolerant to, an anthracyline-based regimen in the pivotal phase III study in STS.","2023-06-16"
"Pazopanib","HC","2013-07-19","Clear cell renal cell carcinoma",FALSE,FALSE,FALSE,"","","Metastatic","","","","Cytokines","FALSE","Metastatic","","","","","","",NA,"","2013-07-19: Revisions to the indication for renal cell carcinoma to: Indicated for the treatment of metastatic <a href=""/wiki/Clear_cell_renal_cell_carcinoma"" title=""Clear cell renal cell carcinoma"">renal cell (clear cell) carcinoma</a> (mRCC) for patients who have received prior treatment with cytokines for metastatic disease.","2023-06-16"
"Pazopanib","HC","2013-07-19","Clear cell renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","","","",NA,"","2013-07-19: Revisions to the indication for renal cell carcinoma to: Indicated for the first line treatment of patients with metastatic <a href=""/wiki/Clear_cell_renal_cell_carcinoma"" title=""Clear cell renal cell carcinoma"">renal cell (clear cell) carcinoma</a> (mRCC).","2023-06-16"
"Pazopanib","PMDA","2012-09-28","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-09-28: Initial approval for the treatment of <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">soft tissue sarcoma</a>.","2023-06-16"
"Pazopanib","PMDA","2014-03-17","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2014-03-17: New additional indication for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Pegaspargase","EMA","2016-01-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-01-14: Initial authorization","2023-05-08"
"Pegaspargase","FDA","1994-02-01","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","hypersensitivity to the native forms of L-asparaginase","",NA,"","","","","","","",TRUE,"CCG 1962","1994-02-01: Initial FDA approval for treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia (ALL)</a> in patients who require L-asparaginase in their treatment regimen but have developed hypersensitivity to the native forms of L-asparaginase. <i>(Based on CCG 1962)</i>","2022-09-05"
"Pegaspargase","FDA","2006-07-24","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","","","",TRUE,"CCG 1962","2006-07-24: FDA approved for the first-line treatment of patients with <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>. <i>(Based on CCG 1962)</i>","2022-09-05"
"Pegaspargase","PMDA","2023-06-26","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-06-26: A drug with a new active ingredient indicated for the treatment of <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphocytic leukemia</a>.","2024-06-03"
"Pegaspargase","PMDA","2023-06-26","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-06-26: A drug with a new active ingredient indicated for the treatment of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a>.","2024-06-03"
"Pegfilgrastim","EMA","2022-08-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-08-22: Initial authorization","2023-05-08"
"Pegfilgrastim-apgf","FDA","2020-06-11","Neutropenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2020-06-11: Approved to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.","2022-09-05"
"Pegfilgrastim-bmez","FDA","2019-11-05","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2019-11-05: Approved","2022-09-05"
"Pegfilgrastim-cbqv","FDA","2018-11-02","Neutropenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-11-02: Approved to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.","2022-09-05"
"Pegfilgrastim-fpgk","FDA","2022-09-06","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-09-06: Approved as a biosimilar to US-licensed <a href=""/wiki/Pegfilgrastim_(Neulasta)"" title=""Pegfilgrastim (Neulasta)"">Neulasta</a>.","2023-07-31"
"Pegfilgrastim-jmdb","FDA","2018-06-04","Neutropenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-06-04: Approved to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.","2022-09-05"
"Pegfilgrastim-pbbk","FDA","2022-06-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-06-01: Approved as a biosimilar to US-licensed <a href=""/wiki/Pegfilgrastim_(Neulasta)"" title=""Pegfilgrastim (Neulasta)"">Neulasta</a>.","2023-07-31"
"Peginterferon alfa-2a","EMA","2001-07-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-07-05: EURD","2023-07-31"
"Peginterferon alfa-2a","FDA","2002-10-16","Chronic HCV",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2002-10-16: Initial approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.","2022-09-05"
"Peginterferon alfa-2b","FDA","2001-01-19","Chronic HCV",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2001-01-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/pegsche011901L.htm"">FDA approved</a> (as PegIntron) for treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease.<sup id=""cite_ref-pegintron_4-1"" class=""reference""><a href=""#cite_note-pegintron-4"">&#91;4&#93;</a>","2022-09-05"
"Peginterferon alfa-2b","FDA","2011-03-29","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Definitive surgical resection including complete lymphadenectomy","FALSE","","Microscopic or gross nodal involvement","Within 84 days","","","","",TRUE,"EORTC 18991","2011-03-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm249263.htm"">FDA approved</a> for the adjuvant treatment of <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. <i>(Based on EORTC 18991)</i>","2022-09-05"
"Peginterferon alfa-2b","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Peginterferon alfa-2b","PMDA","2015-05-26","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","","","","","",NA,"","","","","","","",NA,"","2015-05-26: New additional indication and a new dosage for the adjuvant treatment of <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Pegylated liposomal doxorubicin","EMA","1996-06-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-06-20: Initial marketing authorization as Caelyx.","2023-05-08"
"Pegylated liposomal doxorubicin","FDA","1995-11-17","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","","","","","Multi-agent cytotoxic chemotherapy","FALSE","","progression OR intolerance","","","","","",TRUE,"Harrison et al. 1995","1995-11-17: Initial approval for treatment of <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-related Kaposi's sarcoma</a> in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. <i>(Based on Harrison et al. 1995)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","1999-06-28","Ovarian cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen AND Paclitaxel-containing regimen","FALSE","","refractory","during or within 6 months of completion","","","","",TRUE,"Gordon et al. 2000","1999-06-28: Accelerated approval for treatment of metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">carcinoma of the ovary</a> in patients with disease that is refractory to both paclitaxel- and <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based</a> chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. <i>(Based on Muggia et al. 1997 and Gordon et al. 2000)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","1999-06-28","Ovarian cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen AND Paclitaxel-containing regimen","FALSE","","refractory","during or within 6 months of completion","","","","",TRUE,"Muggia et al. 1997","1999-06-28: Accelerated approval for treatment of metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">carcinoma of the ovary</a> in patients with disease that is refractory to both paclitaxel- and <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based</a> chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. <i>(Based on Muggia et al. 1997 and Gordon et al. 2000)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","2005-01-28","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen AND Paclitaxel-containing regimen","FALSE","","refractory","","","","","",TRUE,"Doxil Study 30-49","2005-01-28: Converted to regular approval for metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian carcinoma</a> refractory to paclitaxel and platinum-based chemotherapy. <i>(Based on Doxil Study 30-49)</i>","2023-05-08"
"Pegylated liposomal doxorubicin","FDA","2007-05-17","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","1+, not including bortezomib","FALSE","","","","","Bortezomib","","",TRUE,"MMY-3001","2007-05-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129249.htm"">Approved</a> for use in combination with <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">bortezomib</a> in patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have not previously received bortezomib and have received at least one prior therapy. <i>(Based on MMY-3001)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","2008-06-10","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen AND Paclitaxel-containing regimen","FALSE","","refractory","","","","","",NA,"","2008-06-10: Converted to regular approval.","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","2013-02-04","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","failure OR intolerance","","","","","",NA,"","2013-02-04: Approved for <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">AIDS-related Kaposi's sarcoma</a> after failure of prior systemic chemotherapy or intolerance to such therapy. <i>(Requirement for prior combination chemotherapy removed)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","FDA","2013-02-04","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","Platinum-based regimen","FALSE","","progression OR recurrence","","","","","",NA,"","2013-02-04: Approved for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> in patients whose disease has progressed or recurred after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Approval extended to platinum-sensitive disease)</i>","2022-09-05"
"Pegylated liposomal doxorubicin","HC","1998-07-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-07-20: Initial notice of compliance","2023-07-31"
"Pegylated liposomal doxorubicin","PMDA","2009-04-22","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2009-04-22: New indication and a new dosage for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Pembrolizumab","EMA","2015-07-17","Melanoma",FALSE,FALSE,FALSE,"","","Advanced unresectable OR metastatic","","adults","","",NA,"","","","","0","","",TRUE,"KEYNOTE-001_melanoma","2015-07-17: Initial marketing authorization as Keytruda. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> in adults. <i>(Based on KEYNOTE-001_melanoma)</i>","2023-09-17"
"Pembrolizumab","EMA","2016-07-29","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Second-line","","","","","",NA,"","","","","","","",NA,"","2016-07-29: Extension of Indication to include a new indication for Keytruda in second line <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">Non-Small Cell Lung Cancer (NSCLC)</a>.","2023-09-17"
"Pembrolizumab","EMA","2017-01-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","","PD-L1 TPS at least 50% AND No EGFR mutations AND No ALK mutations","",NA,"","2017-01-27: Extension of Indication to include first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung carcinoma (NSCLC)</a> in adults whose tumours express PD-L1 with at least 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.","2023-09-17"
"Pembrolizumab","EMA","2017-05-02","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","Autologous HSCT AND Brentuximab vedotin",NA,"","failure","","","0","","",TRUE,"KEYNOTE-087","2017-05-02: Extension of indication to include monotherapy treatment of adult patients with relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV). <i>(Based on KEYNOTE-087)</i>","2024-06-03"
"Pembrolizumab","EMA","2017-05-02","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","transplant ineligible","Brentuximab vedotin",NA,"","failure","","","0","","",TRUE,"KEYNOTE-087","2017-05-02: Extension of indication to include monotherapy treatment of adult patients with relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> who are transplant-ineligible and have failed BV. <i>(Based on KEYNOTE-087)</i>","2024-06-03"
"Pembrolizumab","EMA","2017-08-24","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Platinum-based regimen",NA,"","","","","0","","",TRUE,"KEYNOTE-045","2017-08-24: Extension of indication for KEYTRUDA as monotherapy of locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> in adults who have received prior platinum-containing chemotherapy. <i>(Based on KEYNOTE-045)</i>","2023-09-17"
"Pembrolizumab","EMA","2017-08-24","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","cisplatin-ineligible","",NA,"","","","","0","","",TRUE,"KEYNOTE-052","2017-08-24: Extension of Indication to add treatment as monotherapy of locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> in adults who are not eligible for cisplatin-containing chemotherapy. <i>(Based on KEYNOTE-052)</i>","2023-09-17"
"Pembrolizumab","EMA","2018-07-06","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","","","","cisplatin-ineligible","",NA,"","","","","","PD-L1 CPS at least 10%","",TRUE,"KEYNOTE-361","2018-07-06: Restriction of indication in cisplatin-ineligible <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> patients to exclude patients whose tumours express PD-L1 with a combined positive score (CPS) less than 10. <i>(Based on KEYNOTE-361)</i>","2023-09-17"
"Pembrolizumab","EMA","2018-09-04","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","adults","","Platinum-based regimen",NA,"","progression","","","0","PD-L1 TPS at least 50%","",TRUE,"KEYNOTE-040","2018-09-04: Extension of Indication to include treatment as monotherapy of recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck squamous cell carcinoma (HNSCC)</a> in adults whose tumours express PD-L1 with at least 50% TPS and progressing on or after platinum-containing chemotherapy. <i>(Based on KEYNOTE-040)</i>","2023-09-17"
"Pembrolizumab","EMA","2018-09-04","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Pemetrexed AND Platinum agent","No EGFR mutations AND No ALK mutations","",TRUE,"KEYNOTE-189","2018-09-04: Extension of Indication to include 1st line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSCLC)</a> in adults whose tumours have no EGFR or ALK positive mutations, in combination with pemetrexed and platinum chemotherapy. <i>(Based on KEYNOTE-189)</i>","2023-09-17"
"Pembrolizumab","EMA","2018-12-12","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage III and N+","","adults","","Surgery",NA,"","complete resection","","","0","","",TRUE,"KEYNOTE-054","2018-12-12: Extension of Indication to include (as monotherapy) adjuvant treatment of adults with Stage III <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> and lymph node involvement who have undergone complete resection. <i>(Based on KEYNOTE-054)</i>","2023-09-17"
"Pembrolizumab","EMA","2019-03-11","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","Carboplatin AND (Paclitaxel OR nab-Paclitaxel)","","",NA,"","2019-03-11: Extension of indication to include, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous NSCLC</a> in adults.","2023-09-17"
"Pembrolizumab","EMA","2019-08-26","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced OR Metastatic","","","","",NA,"","","","","Axitinib","","",TRUE,"KEYNOTE-426","2019-08-26: Extension of Indication to include first line treatment of advanced or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> as combination therapy of pembrolizumab together with axitinib. <i>(Based on KEYNOTE-426)</i>","2023-09-17"
"Pembrolizumab","EMA","2019-11-14","Head and neck cancer",FALSE,FALSE,FALSE,"","First-line","Recurrent OR Metastatic","","adults","","",NA,"","","","","0 OR Platinum- and 5-FU","PD-L1 CPS at least 1%","",TRUE,"KEYNOTE-048","2019-11-14: Extension of indication to include, as monotherapy or in combination with platinum and 5-fluorouracil (5FU) chemotherapy, the first-line treatment of recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck squamous cell carcinoma (HNSCC)</a> in adults whose disease expresses PD-L1 with CPS score at least 1. <i>(Based on KEYNOTE-048)</i>","2023-09-17"
"Pembrolizumab","EMA","2021-01-21","Colorectal cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","adults","","",NA,"","","","","","MSI-H|dMMR","",TRUE,"KEYNOTE-177","2021-01-21: Extension of indication to include first-line treatment of metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> in adults. <i>(Based on KEYNOTE-177)</i>","2023-09-17"
"Pembrolizumab","EMA","2021-03-09","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric patients 3 years and older","","Autologous HSCT OR 2+ when AHSCT is not a treatment option",NA,"","","","","0","","",NA,"","2021-03-09: Extension of indication as follows: KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma</a> who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.","2023-09-17"
"Pembrolizumab","EMA","2021-06-24","Esophageal cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"KEYNOTE-590","2021-06-24: Extension of indication to include in combination with platinum and fluoropyrimidine-based chemotherapy, first-line treatment of locally advanced unresectable or metastatic <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">carcinoma of the oesophagus</a> in adults whose tumours express PD L1 with a CPS of at least 10. <i>(Based on KEYNOTE-590)</i>","2024-12-02"
"Pembrolizumab","EMA","2021-06-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","","","","","","","","","",TRUE,"KEYNOTE-590","2021-06-24: Extension of indication to include in combination with platinum and fluoropyrimidine-based chemotherapy, first-line treatment of locally advanced unresectable or metastatic HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD L1 with a CPS of at least 10. <i>(Based on KEYNOTE-590)</i>","2024-12-02"
"Pembrolizumab","EMA","2021-10-19","Breast cancer",FALSE,FALSE,FALSE,"","","Locally recurrent unresectable OR Metastatic","","","","0","FALSE","Metastatic","","","","Chemotherapy","TNBC AND PD-L1 with a CPS of at least 10","FALSE",NA,"","2021-10-19: Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in adults whose tumours express PD L1 with a CPS of at least 10 and who have not received prior chemotherapy for metastatic disease.","2023-09-17"
"Pembrolizumab","EMA","2021-11-15","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","","adults","","",NA,"","","","","Lenvatinib","","",NA,"","2021-11-15: Extension of indication to include Keytruda in combination with lenvatinib first line treatment of adults with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>.","2023-09-17"
"Pembrolizumab","EMA","2021-11-15","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","adults","not candidates for curative surgery or radiation","Platinum-based regimen",NA,"Any","progression","","","Lenvatinib","","",NA,"","2021-11-15: Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation.","2023-09-17"
"Pembrolizumab","EMA","2022-01-24","Renal cell carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","increased risk of recurrence","adults","","Nephrectomy|Nephrectomy and resection of metastatic lesions",NA,"","","","","0","","",NA,"","2022-01-24: Extension of indication to include the adjuvant treatment in monotherapy of adults with <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Biliary tract cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","1+",NA,"","progression","","","0","MSI-H|dMMR","FALSE|FALSE",TRUE,"KEYNOTE-158","2022-04-25: Extension of indication for KEYTRUDA as monotherapy in adults with unresectable or metastatic MSI-H or dMMR <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a>, who have disease progression on or following at least one prior therapy. <i>(Based on KEYNOTE-158)</i>","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","1+",NA,"","progression","","","0","","",TRUE,"KEYNOTE-158","2022-04-25: Extension of indication for KEYTRUDA as monotherapy in adults with unresectable or metastatic MSI-H or dMMR <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, who have disease progression on or following at least one prior therapy. <i>(Based on KEYNOTE-158)</i>","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Small bowel adenocarcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","1+",NA,"","progression","","","0","","",TRUE,"KEYNOTE-158","2022-04-25: Extension of indication for KEYTRUDA as monotherapy in adults with unresectable or metastatic MSI-H or dMMR <a href=""/wiki/Small_bowel_adenocarcinoma"" title=""Small bowel adenocarcinoma"">small intestine cancer</a>, who have disease progression on or following at least one prior therapy. <i>(Based on KEYNOTE-158)</i>","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Fluoropyrimidine-based combination therapy",NA,"","","","","0","MSI-H|dMMR","",TRUE,"KEYNOTE-164","2022-04-25: Extension of indication for KEYTRUDA as monotherapy in adults with unresectable or metastatic MSI-H or dMMR <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> after previous fluoropyrimidine-based combination therapy. <i>(Based on KEYNOTE-164)</i>","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","adults","","",NA,"","","","","Chemotherapy AND Optional Bevacizumab","","",NA,"","2022-04-25: Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> in adults.","2023-09-17"
"Pembrolizumab","EMA","2022-04-25","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","adults","not candidates for curative surgery or radiation","Platinum-based regimen",NA,"Any","progression","","","0","MSI-H|dMMR","",TRUE,"KEYNOTE-158_endometrial","2022-04-25: Extension of indication for KEYTRUDA as monotherapy in adults with advanced or recurrent MSI-H or dMMR <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a>, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. <i>(Based on KEYNOTE-158_endometrial)</i>","2023-09-17"
"Pembrolizumab","EMA","2022-05-19","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant, then Adjuvant","Locally advanced","","adults","","",NA,"","","","","Chemotherapy, then 0","","",NA,"","2022-05-19: Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with locally advanced <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2024-01-06"
"Pembrolizumab","EMA","2022-05-19","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant, then Adjuvant","Early stage","High-risk for recurrence","adults","","",NA,"","","","","Chemotherapy, then 0","","",NA,"","2022-05-19: Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with early-stage triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high-risk of recurrence.","2024-01-06"
"Pembrolizumab","EMA","2023-06-22","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage IIB or Stage IIC or Stage III","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","","",NA,"","2023-06-22: Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or stage III <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-09-17"
"Pembrolizumab","EMA","2023-06-22","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Advanced","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","","",NA,"","2023-06-22: Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with advanced <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-09-17"
"Pembrolizumab","EMA","2023-08-23","Gastric cancer",FALSE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","","","",NA,"","","","","Trastuzumab AND Platinum agent AND Fluoropyrimidine","HER2+","",TRUE,"KEYNOTE-811","2023-08-23: Extension of indication to include in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for treatment of locally advanced unresectable or metastatic HER2-positive <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastro-oesophageal junction adenocarcinoma for Keytruda. <i>(Based on KEYNOTE-811)</i>","2023-09-17"
"Pembrolizumab","EMA","2023-10-12","Esophageal cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","PD-L1 CPS at least 10%","",NA,"","2023-10-12: CHMP approved revised indication to include in combination with platinum and fluoropyrimidine-based chemotherapy, first-line treatment of locally advanced unresectable or metastatic <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">carcinoma of the oesophagus</a> in adults whose tumours express PD L1 with a CPS of at least 10.","2023-11-07"
"Pembrolizumab","EMA","2023-10-12","Gastric cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","Fluoropyrimidine- and platinum-based regimen","HER2- AND PD-L1 CPS at least 1","",NA,"","2023-10-12: CHMP adopted new indication Keytruda, in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS at least 1","2023-11-07"
"Pembrolizumab","EMA","2023-11-09","Biliary tract cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","Cisplatin AND Gemcitabine","","",NA,"","2023-11-09: CHMP recommendation - KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract carcinoma</a> in adults.","2024-01-06"
"Pembrolizumab","FDA","2014-09-04","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","Ipilimumab","FALSE","","progression","","","","","",TRUE,"KEYNOTE-002","<b>2014-09-04: Initial accelerated approval</b> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> and disease progression following <a href=""/wiki/Ipilimumab_(Yervoy)"" title=""Ipilimumab (Yervoy)"">ipilimumab</a>, and if <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600 mutation positive</a>, a <a href=""/wiki/Regimen_classes#BRAF_TKI_therapy"" title=""Regimen classes"">BRAF inhibitor</a>. <i>(Based on KEYNOTE-002)</i>","2023-05-08"
"Pembrolizumab","FDA","2015-10-02","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","PD-L1+","FALSE",TRUE,"KEYNOTE-010","2015-10-02: Accelerated approval for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">programmed death ligand 1 (PD-L1)</a> as determined by an FDA-approved test, with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab. <i>(New disease indication; based on KEYNOTE-010)</i>","2022-09-05"
"Pembrolizumab","FDA","2015-12-18","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",TRUE,"KEYNOTE-006","2015-12-18: Converted to regular approval for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Converted to regular approval; requirement for progression removed; based on KEYNOTE-006)</i>","2022-09-05"
"Pembrolizumab","FDA","2016-08-05","Head and neck cancer",TRUE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"KEYNOTE-012","2016-08-05: Accelerated approval for the treatment of patients with recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck squamous cell carcinoma (HNSCC)</a> with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(New disease indication; based on KEYNOTE-012)</i>","2022-09-05"
"Pembrolizumab","FDA","2016-10-24","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","","PD-L1 TPS at least 50% AND No EGFR mutations AND No ALK mutations","FALSE",TRUE,"KEYNOTE-024","2016-10-24: Full approval for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> whose tumors have <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">high</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> expression (Tumor Proportion Score [TPS] greater than or equal to 50%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC. <i>(First-line indication with biomarker requirement; based on KEYNOTE-024)</i>","2022-09-05"
"Pembrolizumab","FDA","2016-10-24","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","PD-L1 TPS at least 1%","FALSE",TRUE,"KEYNOTE-042","2016-10-24: Full approval for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (TPS greater than or equal to 1%) as determined by an FDA-approved test, with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these <a href=""/wiki/Biomarkers#alteration"" title=""Biomarkers"">aberrations</a> prior to receiving pembrolizumab. <i>(Indication with biomarker requirement; based on KEYNOTE-042)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-03-14","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","Relapsed","","","adults and pediatric","","3+","FALSE","","relapsed","","","","","",TRUE,"KEYNOTE-087","2017-03-14: Accelerated approval for the treatment of adult and pediatric patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> that has relapsed after three or more prior lines of therapy. <i>(New disease indication; based on KEYNOTE-087)</i>","2023-03-10"
"Pembrolizumab","FDA","2017-03-14","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","Refractory","","","adults and pediatric","","",NA,"","","","","","","",TRUE,"KEYNOTE-087","2017-03-14: Accelerated approval for the treatment of adult and pediatric patients with refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a>. <i>(New disease indication; based on KEYNOTE-087)</i>","2023-03-10"
"Pembrolizumab","FDA","2017-05-10","Non-small cell lung cancer nonsquamous",TRUE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Carboplatin and Pemetrexed","","",TRUE,"KEYNOTE-189","2017-05-10: Accelerated approval in combination with <a href=""/wiki/Pemetrexed_(Alimta)"" title=""Pemetrexed (Alimta)"">pemetrexed</a> and <a href=""/wiki/Carboplatin_(Paraplatin)"" title=""Carboplatin (Paraplatin)"">carboplatin</a> for the treatment of patients with previously untreated metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSCLC)</a>. <i>(First-line indication with histology requirement; based on KEYNOTE-189)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-18","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","not eligible for cisplatin-based chemotherapy","",NA,"","","","","","","",TRUE,"KEYNOTE-052","2017-05-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm"">Accelerated approval</a> for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)"">cisplatin-containing</a> chemotherapy. <i>(New disease indication; based on KEYNOTE-052)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-18","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"KEYNOTE-045","2017-05-18: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm"">Regular approval</a> for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who have disease progression during or following <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> or within 12 months of neoadjuvant or adjuvant treatment with <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a>. <i>(New disease indication; based on KEYNOTE-045)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-012","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-016","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-028","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-158","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-164","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-05-23","Colorectal cancer",TRUE,FALSE,FALSE,"","","","","adults and pediatric","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-164","2017-05-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm"">Granted FDA accelerated approval</a> for adult and pediatric patients with <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">MSI-H</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">dMMR</a> <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following treatment with a <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan</a>. <i>(New disease indication; based on KEYNOTE-164)</i>","2022-09-05"
"Pembrolizumab","FDA","2017-09-22","Gastric cancer",TRUE,FALSE,FALSE,"","","Recurrent locally advanced OR Metastatic","","","","2+ SACT, including Fluoropyrimidine-based regimen AND Platinum-based regimen","FALSE","","progression","","","","PD-L1+","FALSE",TRUE,"KEYNOTE-059","2017-09-22: Accelerated approval for patients with recurrent locally advanced or metastatic, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction adenocarcinoma whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> as determined by an FDA-approved test. Patients must have had disease progression on or after two or more prior systemic therapies, including <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a> and <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> and, if appropriate, HER2/neu-targeted therapy. <i>(New disease indication; based on KEYNOTE-059)</i>","2022-09-05"
"Pembrolizumab","FDA","2018-06-12","Cervical cancer",TRUE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","Chemotherapy","FALSE","","progression","","","","PD-L1 CPS at least 1%","FALSE",TRUE,"KEYNOTE-158_cervical","2018-06-12: Accelerated approval for patients with recurrent or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> with disease progression on or after chemotherapy whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (CPS at least 1) as determined by an FDA-approved test. <i>(New disease indication; based on KEYNOTE-158_cervical)</i>","2023-01-03"
"Pembrolizumab","FDA","2018-06-13","Primary mediastinal B-cell lymphoma",TRUE,FALSE,FALSE,"","","","","adults and pediatric","","2+","FALSE","","relapsed","","","","","",TRUE,"KEYNOTE-170","2018-06-13: Accelerated approval for the treatment of adult and pediatric patients with <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a> who have relapsed after two or more prior lines of therapy. <i>(New disease indication; based on KEYNOTE-170)</i>","2023-05-08"
"Pembrolizumab","FDA","2018-06-13","Primary mediastinal B-cell lymphoma",TRUE,FALSE,FALSE,"","Refractory","","","adults and pediatric","","",NA,"","","","","","","",TRUE,"KEYNOTE-170","2018-06-13: Accelerated approval for the treatment of adult and pediatric patients with refractory <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma (PMBCL)</a>. <i>(New disease indication; based on KEYNOTE-170)</i>","2023-05-08"
"Pembrolizumab","FDA","2018-06-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","not eligible for cisplatin-based regimen","",NA,"","","","","","PD-L1 CPS at least 10%","FALSE",TRUE,"KEYNOTE-361","2018-06-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients"">Label revised</a> for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for <a href=""/wiki/Regimen_classes#Cisplatin-based_regimen"" title=""Regimen classes"">cisplatin-containing therapy</a> and whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Combined Positive Score at least 10). <i>(Biomarker restriction; based on KEYNOTE-361)</i>","2023-01-03"
"Pembrolizumab","FDA","2018-06-19","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","not eligible for platinum-based regimen","",NA,"","","","","","","",TRUE,"KEYNOTE-361","2018-06-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients"">Label revised</a> for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a> who are not eligible for any <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> regardless of PD-L1 status. <i>(Based on KEYNOTE-361)</i>","2022-09-05"
"Pembrolizumab","FDA","2018-08-20","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Pemetrexed AND Platinum agent","No EGFR mutations AND No ALK mutations","TRUE",TRUE,"KEYNOTE-189","2018-08-20: Granted regular approval in combination with <a href=""/wiki/Pemetrexed_(Alimta)"" title=""Pemetrexed (Alimta)"">pemetrexed</a> and <a href=""/wiki/Category:Platinum_agents"" title=""Category:Platinum agents"">platinum</a> as first-line treatment of patients with metastatic, <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous non-small cell lung cancer (NSqNSCLC)</a>, with no EGFR or ALK genomic tumor aberrations. <i>(Conversion to regular approval; based on KEYNOTE-189)</i>","2022-09-05"
"Pembrolizumab","FDA","2018-10-30","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Carpoplatin AND (Paclitaxel OR nab-Paclitaxel)","","",TRUE,"KEYNOTE-407","2018-10-30: Approval expanded in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer (NSCLC)</a>. <i>(First-line indication with histology requirement; based on KEYNOTE-407)</i>","2022-09-05"
"Pembrolizumab","FDA","2018-11-09","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","","","",TRUE,"KEYNOTE-224","2018-11-09: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma"">Accelerated approval</a> for patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with <a href=""/wiki/Sorafenib_(Nexavar)"" title=""Sorafenib (Nexavar)"">sorafenib</a>. <i>(New disease indication; based on KEYNOTE-224)</i>","2022-09-05"
"Pembrolizumab","FDA","2018-12-19","Merkel cell carcinoma",TRUE,FALSE,FALSE,"","","Recurrent locally advanced OR Metastatic","","adults and pediatric","","",NA,"","","","","","","",TRUE,"KEYNOTE-017","2018-19-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/fda-approves-pembrolizumab-merkel-cell-carcinoma"">Accelerated approval</a> for adult and pediatric patients with recurrent locally advanced or metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma (MCC)</a>. <i>(New disease indication; based on KEYNOTE-017)</i>","2022-09-05"
"Pembrolizumab","FDA","2019-02-15","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","Surgical resection","FALSE","","complete resection","","","","","",TRUE,"KEYNOTE-054","2019-02-15: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adjuvant-treatment-melanoma"">Approved</a> for the adjuvant treatment of patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with involvement of lymph node(s) following complete resection. <i>(Indication expanded to adjuvant setting; based on KEYNOTE-054)</i>","2022-09-05"
"Pembrolizumab","FDA","2019-04-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Stage III who are not candidates for surgical resection or definitive chemoradiation OR metastatic","","","","0","FALSE","","","","","","PD-L1 TPS at least 1% AND No EGFR mutations AND No ALK mutations","FALSE",TRUE,"KEYNOTE-042","2019-04-11: Approval expanded for the first-line treatment of patients with stage III <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients' tumors must have no EGFR or ALK genomic aberrations and <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Tumor Proportion Score [TPS] greater than or equal to 1%) <i>(Approval expanded to the non-metastatic setting; based on KEYNOTE-042)</i>","2022-09-05"
"Pembrolizumab","FDA","2019-04-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","0","FALSE","","","","","Axitinib","","",TRUE,"KEYNOTE-426","2019-04-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma"">Approved</a> to be used together with <a href=""/wiki/Axitinib_(Inlyta)"" title=""Axitinib (Inlyta)"">Axitinib (Inlyta)</a> for the first-line treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(New disease indication; based on KEYNOTE-426)</i>","2022-09-05"
"Pembrolizumab","FDA","2019-06-10","Head and neck cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","0","FALSE","Metastatic","recurrence","","","0","PD-L1 CPS at least 1%","FALSE",TRUE,"KEYNOTE-048","2019-06-10: Converted to regular approval and approved for the first-line treatment of patients with metastatic or unresectable recurrent <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck squamous cell carcinoma (HNSCC)</a> as a single agent for patients whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Combined Positive Score [CPS] at least 1) <i>(Approval extended to first-line setting; based on KEYNOTE-048)</i>","2023-03-10"
"Pembrolizumab","FDA","2019-06-10","Head and neck cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","0","FALSE","Metastatic","recurrence","","","Platinum AND Fluorouracil","","",TRUE,"KEYNOTE-048","2019-06-10: Converted to regular approval and approved for the first-line treatment of patients with metastatic or unresectable recurrent <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck squamous cell carcinoma (HNSCC)</a> in combination with platinum and fluorouracil (FU) for all patients. <i>(Approval extended to first-line setting; based on KEYNOTE-048)</i>","2023-03-10"
"Pembrolizumab","FDA","2019-06-17","Small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","","","2+, including Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"KEYNOTE-028_SCLC","2019-06-17: Accelerated approval for patients with metastatic <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer (SCLC)</a> with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a> and at least one other prior line of therapy. <i>(New disease indication; based on KEYNOTE-028_SCLC)</i>","2022-09-05"
"Pembrolizumab","FDA","2019-07-30","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Recurrent locally advanced OR Metastatic","","","","1+ SACT","FALSE","","progression","","","","PD-L1 CPS at least 10%","FALSE",TRUE,"KEYNOTE-180","2019-07-30: Approved for patients with recurrent, locally advanced or metastatic, <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">squamous cell carcinoma of the esophagus (ESCC)</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Combined Positive Score [CPS] at least 10), as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy. <i>(New disease indication; based on KEYNOTE-180 and KEYNOTE-181)</i>","2023-01-03"
"Pembrolizumab","FDA","2019-07-30","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Recurrent locally advanced OR Metastatic","","","","1+ SACT","FALSE","","progression","","","","PD-L1 CPS at least 10%","FALSE",TRUE,"KEYNOTE-181","2019-07-30: Approved for patients with recurrent, locally advanced or metastatic, <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">squamous cell carcinoma of the esophagus (ESCC)</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Combined Positive Score [CPS] at least 10), as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy. <i>(New disease indication; based on KEYNOTE-180 and KEYNOTE-181)</i>","2023-01-03"
"Pembrolizumab","FDA","2019-09-17","Endometrial cancer",TRUE,FALSE,FALSE,"","","Advanced","","","Not candidate for potentially curative surgery and/or radiation therapy","1+ SACT","FALSE","","progression","","","Lenvatinib","Not MSI-H or dMMR","TRUE",TRUE,"KEYNOTE-146","2019-09-17: Accelerated approval in combination with <a href=""/wiki/Lenvatinib_(Lenvima)"" title=""Lenvatinib (Lenvima)"">Lenvatinib (Lenvima)</a> for the treatment of patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. <i>(New disease indication; based on KEYNOTE-146)</i>","2022-09-05"
"Pembrolizumab","FDA","2020-01-08","Bladder cancer",FALSE,FALSE,FALSE,"","","Non-muscle invasive","high-risk","","ineligible or have elected not to undergo cystectomy","BCG","FALSE","","unresponsive","","","","","",TRUE,"KEYNOTE-057","2020-01-08: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer"">Approved</a> for the treatment of patients with <a href=""/wiki/BCG_vaccine"" title=""BCG vaccine"">Bacillus Calmette-Guerin (BCG)</a>-unresponsive, high-risk, non-muscle invasive <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">bladder cancer</a> (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. <i>(Based on KEYNOTE-057)</i>","2022-11-22"
"Pembrolizumab","FDA","2020-04-30","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2020-04-30: Converted to regular approval. <i>(No supporting studies are cited)</i>","2022-09-05"
"Pembrolizumab","FDA","2020-06-16","High tumor mutation burden malignancy",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+","FALSE","","progression","","","","","",TRUE,"KEYNOTE-158_TMB-H","2020-06-16: Accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic <a href=""/wiki/TMB-H"" class=""mw-redirect"" title=""TMB-H"">tumor mutational burden-high (TMB H)</a> [at least 10 mutations/megabase (mut/Mb)] <a href=""/wiki/Malignant_solid_neoplasm,_TMB-H"" title=""Malignant solid neoplasm, TMB-H"">solid tumors</a>, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(New disease-agnostic indication; based on KEYNOTE-158_TMB-H)</i>","2023-01-03"
"Pembrolizumab","FDA","2020-06-24","Cutaneous squamous cell carcinoma",FALSE,FALSE,FALSE,"","","(Recurrent OR Metastatic) AND not curable by surgery or radiation","","","","",NA,"","","","","","","",TRUE,"KEYNOTE-629","2020-06-24: Approved for patients with recurrent or metastatic <a href=""/wiki/Cutaneous_squamous_cell_carcinoma"" title=""Cutaneous squamous cell carcinoma"">cutaneous squamous cell carcinoma (cSCC)</a> that is not curable by surgery or radiation. <i>(New disease indication; based on KEYNOTE-629)</i>","2022-09-05"
"Pembrolizumab","FDA","2020-06-29","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","0","FALSE","","","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-177","2020-06-29: Approved for the first-line treatment of patients with unresectable or metastatic <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>. <i>(Expanded to first-line setting; based on KEYNOTE-177)</i>","2022-09-05"
"Pembrolizumab","FDA","2020-10-14","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2020-10-14: Converted to regular approval. <i>(No supporting studies are cited)</i>","2022-09-05"
"Pembrolizumab","FDA","2020-10-15","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",TRUE,"KEYNOTE-204","2020-10-15: Approved for the treatment of pediatric patients with refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a>. <i>(Prior treatment criteria relaxed; based on KEYNOTE-204)</i>","2023-05-08"
"Pembrolizumab","FDA","2020-10-15","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","pediatric","","2+","FALSE","","relapsed","","","","","",TRUE,"KEYNOTE-204","2020-10-15: Approved for the treatment of pediatric patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a> that has relapsed after 2 or more lines of therapy. <i>(Approval extended to third-line pediatric setting; based on KEYNOTE-204)</i>","2023-05-08"
"Pembrolizumab","FDA","2020-10-15","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","Refractory","","","pediatric","","",NA,"","","","","","","",TRUE,"KEYNOTE-204","2020-10-15: Approved for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin lymphoma (cHL)</a>. <i>(Prior treatment criteria relaxed; based on KEYNOTE-204)</i>","2023-05-08"
"Pembrolizumab","FDA","2020-11-13","Breast cancer",TRUE,FALSE,FALSE,"","","Locally recurrent unresectable OR Metastatic","","","","",NA,"","","","","Chemotherapy","TNBC|PD-L1 CPS at least 10%","FALSE",TRUE,"KEYNOTE-355","2020-11-13: Accelerated approval in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (TNBC) whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (CPS at least 10) as determined by an FDA approved test. <i>(New disease indication; based on KEYNOTE-355)</i>","2023-01-03"
"Pembrolizumab","FDA","2021-03-22","Esophageal cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","Not candidate for surgical resection or definitive chemoradiation","",NA,"","","","","Platinum AND Fluoropyrimidine","","",TRUE,"KEYNOTE-590","2021-03-22: Approved in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal</a> or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation. <i>(Histology-specific restriction removed; protein expression requirement removed; prior therapy requirement removed; surgery and radiation eligibility restriction added; drug combination requirement added; based on KEYNOTE-590)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-03-30","Small cell lung cancer",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"KEYNOTE-604","2021-03-30: Accelerated approval for patients with metastatic <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer (SCLC)</a> with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a> and at least one other prior line of therapy withdrawn. <i>(Based on KEYNOTE-604)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-05-05","Gastric cancer",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","","","0","FALSE","","","","","Trastuzumab AND Platinum agent AND Fluoropyrimidine","HER2+","FALSE",TRUE,"KEYNOTE-811","2021-05-05: Granted accelerated approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (GEJ) adenocarcinoma. <i>(Based on KEYNOTE-811)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-07-21","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced","","","Not candidate for potentially curative surgery and/or radiation therapy","1+ SACT","FALSE","Any","progression","","","Lenvatinib","Not MSI-H or dMMR","TRUE",TRUE,"KEYNOTE-775","2021-07-21: Full approval in combination with <a href=""/wiki/Lenvatinib_(Lenvima)"" title=""Lenvatinib (Lenvima)"">Lenvatinib (Lenvima)</a> for patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. <i>(Based on KEYNOTE-775)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-07-26","Breast cancer",FALSE,FALSE,FALSE,"","Perioperative","Early","high-risk","","","",NA,"","","","","Chemotherapy","TNBC","FALSE",TRUE,"KEYNOTE-522","2021-07-26: Regular approval for high-risk, early-stage, triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. <i>(Based on KEYNOTE-522)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-07-26","Breast cancer",FALSE,FALSE,FALSE,"","","Locally recurrent unresectable OR Metastatic","","","","",NA,"","","","","Chemotherapy","TNBC|PD-L1 CPS at least 10%","FALSE",TRUE,"KEYNOTE-522","2021-07-26: Regular approval in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (TNBC) whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (Combined Positive Score [CPS] at least 10) as determined by an FDA approved test. <i>(Based on KEYNOTE-522)</i>","2023-01-03"
"Pembrolizumab","FDA","2021-08-10","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","0","FALSE","","","","","Lenvatinib","","",TRUE,"CLEAR","2021-08-10: Approved in combination with <a href=""/wiki/Lenvatinib_(Lenvima)"" title=""Lenvatinib (Lenvima)"">Lenvatinib (Lenvima)</a> for first-line treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on CLEAR)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-08-31","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"KEYNOTE-361","2021-08-31: Converted to regular approval. <i>(Based on KEYNOTE-361)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-10-13","Cervical cancer",FALSE,FALSE,FALSE,"","","Persistent OR Recurrent OR Metastatic","","","","",NA,"","","","","Chemotherapy AND Optional Bevacizumab","PD-L1 CPS at least 1%","FALSE",TRUE,"KEYNOTE-826","2021-10-13: Full approval in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> (CPS at least 1) <i>(Based on KEYNOTE-826)</i>","2023-01-03"
"Pembrolizumab","FDA","2021-11-17","Renal cell carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","Intermediate-risk OR High-risk","","","Nephrectomy OR (Nephrectomy AND Metastatectomy)","FALSE","","","","","","","",TRUE,"KEYNOTE-564","2021-11-17: Approved for the adjuvant treatment of patients with <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. <i>(Based on KEYNOTE-564)</i>","2022-09-05"
"Pembrolizumab","FDA","2021-12-03","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage IIB or IIC","","adults AND pediatric patients 12 years and older","","Surgical resection","FALSE","","complete resection","","","","","",TRUE,"KEYNOTE-716","2021-12-03: Approved for the adjuvant treatment of adult and pediatric (12 years of age or older) patients with stage IIB or IIC <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> following complete resection. <i>(Based on KEYNOTE-716)</i>","2023-01-03"
"Pembrolizumab","FDA","2022-02-04","Gastric cancer",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2022-02-04: Accelerated approval for patients with recurrent locally advanced or metastatic, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction adenocarcinoma whose tumors <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">express</a> <a href=""/wiki/Biomarkers#PD-L1"" title=""Biomarkers"">PD-L1</a> as determined by an FDA-approved test. Patients must have had disease progression on or after two or more prior systemic therapies, including <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a> and <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-containing chemotherapy</a> and, if appropriate, HER2/neu-targeted therapy withdrawn by manufacturer.","2024-06-03"
"Pembrolizumab","FDA","2022-03-21","Endometrial cancer",FALSE,FALSE,FALSE,"","","Advanced","","","Not candidate for potentially curative surgery and/or radiation therapy","1+ SACT","FALSE","Any","progression","","","0","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-158_endometrial","2022-03-21: Approved as a single agent for patients with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a>, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. <i>(Based on KEYNOTE-158_endometrial)</i>","2022-09-05"
"Pembrolizumab","FDA","2023-01-26","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Adjuvant","Stage IB or Stage II or Stage IIIA","","","","Resection AND Platinum-based chemotherapy","FALSE","","","","","","","",TRUE,"PEARLS","2023-01-26: Approved for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a at least 4 cm), II, or IIIA <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Approval expanded to the maintenance setting; Based on PEARLS)</i>","2023-03-15"
"Pembrolizumab","FDA","2023-03-28","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+",NA,"","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-164","2023-03-28: Converted to regular approval for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(Based on KEYNOTE-164, KEYNOTE-158, and KEYNOTE-051)</i>","2024-06-03"
"Pembrolizumab","FDA","2023-03-28","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+",NA,"","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-158","2023-03-28: Converted to regular approval for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(Based on KEYNOTE-164, KEYNOTE-158, and KEYNOTE-051)</i>","2024-06-03"
"Pembrolizumab","FDA","2023-03-28","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults and pediatric","","1+",NA,"","progression","","","","MSI-H|dMMR","FALSE",TRUE,"KEYNOTE-051","2023-03-28: Converted to regular approval for adult and pediatric patients with unresectable or metastatic, <a href=""/wiki/Biomarkers#MSI-H"" title=""Biomarkers"">microsatellite instability-high (MSI-H)</a> or <a href=""/wiki/Biomarkers#dMMR"" title=""Biomarkers"">mismatch repair deficient (dMMR)</a> <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed following prior treatment and who have no satisfactory alternative treatment options. <i>(Based on KEYNOTE-164, KEYNOTE-158, and KEYNOTE-051)</i>","2024-06-03"
"Pembrolizumab","FDA","2023-03-28","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","","","","","","","","","",NA,"","2023-03-28: Converted to regular approval.","2024-12-02"
"Pembrolizumab","FDA","2023-10-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Resectable","","","","",NA,"","","","","Platinum-containing chemotherapy","","",TRUE,"KEYNOTE-671","2023-10-16: Approved with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors â‰¥4 cm or node positive) <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on KEYNOTE-671)</i>","2023-11-07"
"Pembrolizumab","FDA","2023-10-31","Biliary tract cancer",FALSE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","","","",NA,"","","","","Cisplatin AND Gemcitabine","","",TRUE,"KEYNOTE-966","2023-10-31: Approved in combination with gemcitabine and cisplatin for locally advanced unresectable or metastatic <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer (BTC)</a>. <i>(Based on KEYNOTE-966)</i>","2023-11-07"
"Pembrolizumab","FDA","2023-11-07","Gastric cancer",TRUE,FALSE,FALSE,"","First-line","Locally advanced unresectable OR Metastatic","","","","",NA,"","","","","Trastuzumab AND Platinum agent AND Fluoropyrimidine","HER2+ AND PD-L1+ (CPS at least 1)","",TRUE,"KEYNOTE-811","2023-11-07: Accelerated approval revised in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (GEJ) adenocarcinoma with tumors that express PD-L1 (CPS at least 1). <i>(New biomarker restriction; based on KEYNOTE-811)</i>","2024-01-06"
"Pembrolizumab","FDA","2023-11-16","Gastric cancer",FALSE,FALSE,FALSE,"","First-line","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","Platinum agent AND Fluoropyrimidine","HER2","TRUE",TRUE,"KEYNOTE-859","2023-11-16: Approved with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (GEJ) adenocarcinoma. <i>(Based on KEYNOTE-859)</i>","2024-01-06"
"Pembrolizumab","FDA","2023-12-15","Merkel cell carcinoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"KEYNOTE-913","2023-12-15: Converted to full approval for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma</a>. <i>(Based on KEYNOTE-913)</i>","2024-12-02"
"Pembrolizumab","FDA","2024-01-12","Cervical cancer",FALSE,FALSE,FALSE,"","","FIGO 2014 Stage III-IVA","","","","",NA,"","","","","Chemoradiation","","",TRUE,"KEYNOTE-A18","2024-01-12: Approved with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>. <i>(Based on KEYNOTE-A18)</i>","2024-02-01"
"Pembrolizumab","FDA","2024-01-25","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"KEYNOTE-394","2024-01-25: Regular approval for patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with <a href=""/wiki/Sorafenib_(Nexavar)"" title=""Sorafenib (Nexavar)"">sorafenib</a>. <i>(Based on KEYNOTE-394)</i>","2024-12-02"
"Pembrolizumab","FDA","2024-06-17","Endometrial cancer",FALSE,FALSE,FALSE,"","","Primary advanced OR Recurrent","","adults","","",NA,"","","","","Carboplatin AND Paclitaxel","","",TRUE,"NRG GY018","2024-06-17: Approved with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a>. <i>(Based on NRG GY018)</i>","2024-09-06"
"Pembrolizumab","FDA","2024-09-17","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"KEYNOTE-483","2024-09-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural"">FDA approved</a> with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma (MPM)</a>. <i>(Based on KEYNOTE-483)</i>","2024-12-02"
"Pembrolizumab","HC","2018-09-21","Primary mediastinal B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","","",NA,"","","","","","","",NA,"","2018-09-21: Notice of compliance with conditions for adult and pediatric patients with relapsed or refractory <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">Primary Mediastinal B-cell Lymphoma</a> (rrPMBCL).","2023-05-08"
"Pembrolizumab","HC","2019-04-11","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","ineligible for cisplatin-containing chemotherapy","",NA,"","","","","0","PD-L1 CPS at least 10%","FALSE",NA,"","2019-04-11: Notice of compliance with conditions for the treatment of patients with locally advanced unresectable or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a>, as monotherapy, in adults who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) at least 10] as determined by a validated test.","2023-05-08"
"Pembrolizumab","HC","2019-04-11","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","ineligible for platinum-containing chemotherapy","",NA,"","","","","0","","",NA,"","2019-04-11: Notice of compliance with conditions for the treatment of patients with locally advanced unresectable or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma</a>, as monotherapy, in adults who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.","2023-05-08"
"Pembrolizumab","HC","2019-04-18","Endometrial cancer",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","","","adults","","1+","FALSE","","progression","","","","MSI-H|dMMR","FALSE",NA,"","2019-04-18: Notice of compliance with conditions for the treatment of adults with MSI-H or dMMR <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial cancer</a> that has progressed following prior therapy and who have no satisfactory alternative treatment options.","2023-05-08"
"Pembrolizumab","HC","2019-04-18","Colorectal cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen","FALSE","","progression","","","","MSI-H|dMMR","FALSE",NA,"","2019-04-18: Notice of compliance with conditions for the treatment of adults with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.","2023-05-08"
"Pembrolizumab","HC","2019-09-20","Endometrial cancer",TRUE,FALSE,FALSE,"","","Advanced","","adults","not candidates for curative surgery or radiation","Platinum-based regimen","FALSE","","progression","","","Lenvatinib","Not MSI-H or dMMR","TRUE",NA,"","2019-09-20: Notice of compliance with conditions for the treatment of adults patients, in combination with lenvatinib, with advanced <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy and are not candidates for curative surgery or radiation.","2023-05-08"
"Pembrolizumab","HC","2021-02-03","Classical Hodgkin lymphoma",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2021-02-03: Indication as a monotherapy, for the treatment for adult patients with refractory or relapsed <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin Lymphoma (cHL)</a> who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV withdrawn.","2023-05-08"
"Pembrolizumab","HC","2021-02-05","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","","Autologous HSCT","FALSE","","failure","","","","","",NA,"","2021-02-05: Notice of compliance with conditions for the treatment of adult and pediatric patients with refractory or relapsed <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin Lymphoma (cHL)</a> who have failed autologous stem cell transplant (ASCT).","2023-07-31"
"Pembrolizumab","HC","2021-02-05","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults and pediatric","not candidates for multi-agent salvage chemotherapy and HSCT","",NA,"","","","","","","",NA,"","2021-02-05: Notice of compliance with conditions for the treatment of adult and pediatric patients with refractory or relapsed <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin Lymphoma (cHL)</a> who are not candidates for multi-agent salvage chemotherapy and ASCT.","2023-07-31"
"Pembrolizumab","NMPA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Pembrolizumab","PMDA","2016-09-28","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2016-09-28: New approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Pembrolizumab","PMDA","2016-12-19","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","PD-L1+","FALSE",NA,"","2016-12-19: New additional indication and a new dosage for the treatment of patients with PD-L1-positive, unresectable, recurrent or advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2017-11-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-11-30: New additional indication for the treatment of relapsed or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin's lymphoma</a>.","2023-06-16"
"Pembrolizumab","PMDA","2017-12-25","Urothelial carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2017-12-25: New additional indication for the treatment of unresectable <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> which progressed after cancer chemotherapy.","2023-06-16"
"Pembrolizumab","PMDA","2018-12-21","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","","Advanced OR Recurrent","","","Refractory or intolerant to standard therapies","Chemotherapy","FALSE","","progression","","","","MSI-H","FALSE",NA,"","2018-12-21: Conditional new indication for advanced or recurrent microsatellite instability-high (MSI-High) <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies)","2023-06-16"
"Pembrolizumab","PMDA","2018-12-21","Melanoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-12-21: New indication for <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Pembrolizumab","PMDA","2018-12-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2018-12-21: New indication for unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2019-12-20","Head and neck cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","",NA,"","","","","","","",NA,"","2019-12-20: New indication for the treatment of recurrent or metastatic <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2019-12-20","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2019-12-20: New indication and a new dosage for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Pembrolizumab","PMDA","2020-08-21","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","PD-L1+","FALSE",NA,"","2020-08-21: New indication and a new dosage for the treatment of unresectable advanced or recurrent PD-L1-positive <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">esophageal squamous cell carcinoma</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Pembrolizumab","PMDA","2021-08-25","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","MSI-H","FALSE",NA,"","2021-08-25: New indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2021-08-25","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","PD-L1+ AND HR- AND HER2-","FALSE",NA,"","2021-08-25: New indication and a new dosage for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2021-11-25","Esophageal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2021-11-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2021-12-24","Endometrial cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2021-12-24: New indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Endometrial_cancer"" title=""Endometrial cancer"">endometrial carcinoma</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Pembrolizumab","PMDA","2022-02-25","High tumor mutation burden malignancy",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","Refractory or intolerant to standard therapies","Chemotherapy","FALSE","","progression","","","","TMB-H","FALSE",NA,"","2022-02-25: New indication for the treatment of advanced or recurrent <a href=""/wiki/Malignant_solid_neoplasm,_TMB-H"" title=""Malignant solid neoplasm, TMB-H"">solid tumors</a> with tumor mutation burden-high (TMB-high) that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies).","2023-06-16"
"Pembrolizumab","PMDA","2022-08-24","Renal cell carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2022-08-24: New indication and a new dosage for postoperative adjuvant treatment for <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Pembrolizumab","PMDA","2022-09-26","Breast cancer",FALSE,FALSE,FALSE,"","Perioperative","","High-risk for recurrence","","","",NA,"","","","","","HR- AND HER2-","TRUE AND TRUE",NA,"","2022-09-26: New indication and a new dosage for the preoperative and postoperative adjuvant treatment of hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with a high risk of recurrence.","2023-06-16"
"Pembrolizumab","PMDA","2022-09-26","Cervical cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2022-09-26: New indication for the treatment of advanced or recurrent <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>.","2023-06-16"
"Pembrolizumab","PMDA","2023-06-26","Primary mediastinal B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2023-06-26: New indication for the treatment of relapsed or refractory <a href=""/wiki/Primary_mediastinal_B-cell_lymphoma"" title=""Primary mediastinal B-cell lymphoma"">primary mediastinal large B-cell lymphoma</a>.","2024-06-03"
"Pemetrexed","EMA","2004-09-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-09-20: Initial marketing authorization as Alimta.","2023-05-08"
"Pemetrexed","FDA","2004-02-04","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","Unresectable OR not candidate for curative surgery","","","","",NA,"","","","","Cisplatin","","",TRUE,"EMPHACIS","2004-02-04: Initial approval in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a> is indicated for the treatment of patients with <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a> whose disease is either unresectable or who are otherwise not candidates for curative surgery. <i>(Based on EMPHACIS)</i>","2022-09-05"
"Pemetrexed","FDA","2004-08-19","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Chemotherapy","FALSE","","","","","0","","",TRUE,"JMEI","2004-08-19: Accelerated approval as a single-agent for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> after prior chemotherapy. <i>(New disease entity; based on JMEI)</i>","2022-09-05"
"Pemetrexed","FDA","2008-09-26","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Cisplatin","","",TRUE,"EMPHACIS","2008-09-26: Indication revised for <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">mesothelioma</a> in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a>. <i>(Based on EMPHACIS)</i>","2022-09-05"
"Pemetrexed","FDA","2008-09-26","Non-small cell lung cancer nonsquamous",TRUE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Cisplatin","","",TRUE,"JMDB","2008-09-26: Accelerated approval for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer</a> initial treatment in combination with <a href=""/wiki/Cisplatin_(Platinol)"" title=""Cisplatin (Platinol)""> cisplatin</a>. <i>(Based on JMDB)</i>","2022-09-05"
"Pemetrexed","FDA","2008-09-26","Non-small cell lung cancer nonsquamous",TRUE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","","","","0","","",TRUE,"JMEI","2008-09-26: Accelerated approval for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer</a> as a single-agent after prior chemotherapy. <i>(Based on JMEI)</i>","2022-09-05"
"Pemetrexed","FDA","2009-07-02","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","Platinum-based regimen","FALSE","","no progression","","","","","",TRUE,"JMEN","2009-07-02: Converted to regular approval and additional indication for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer</a>: Maintenance treatment of patients whose disease has not progressed after four cycles of <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based</a> first-line chemotherapy. <i>(Based on JMEN and PARAMOUNT)</i>","2022-09-05"
"Pemetrexed","FDA","2009-07-02","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line maintenance","","","","","Platinum-based regimen","FALSE","","no progression","","","","","",TRUE,"PARAMOUNT","2009-07-02: Converted to regular approval and additional indication for <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer</a>: Maintenance treatment of patients whose disease has not progressed after four cycles of <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based</a> first-line chemotherapy. <i>(Based on JMEN and PARAMOUNT)</i>","2022-09-05"
"Pemetrexed","FDA","2018-06-04","Non-small cell lung cancer nonsquamous",TRUE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Carboplatin AND Pembrolizumab","","",TRUE,"KEYNOTE-189","2018-06-04: Accelerated approval in combination with pembrolizumab and carboplatin for first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous NSCLC</a>. <i>(Based on KEYNOTE-189)</i>","2022-09-05"
"Pemetrexed","FDA","2019-01-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-01-30: Converted to regular approval","2023-05-08"
"Pemetrexed","HC","2004-05-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2004-05-21: Initial notice of compliance (details unavailable)","2023-05-20"
"Pemetrexed","HC","2007-01-11","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Chemotherapy","FALSE","","","","","0","","",NA,"","2007-01-11: New indication as monotherapy for patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> after prior chemotherapy.","2023-05-20"
"Pemetrexed","HC","2008-09-02","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","good performance status","","0","FALSE","","","","","Cisplatin","","",NA,"","2008-09-02: New indication in combination with cisplatin therapy for the initial treatment of good performance status patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-small cell lung cancer other than predominantly squamous cell histology</a>.","2023-05-20"
"Pemetrexed","HC","2010-05-11","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line maintenance","Locally advanced OR Metastatic","","good performance status","","Platinum-doublet excluding pemetrexed x 4","FALSE","First-line","no progression","","","","","",NA,"","2010-05-11: New indication as mintenance treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous non-small cell lung cancer</a>, in a good performance status patients without disease progression immediately following four cycles of first-line platinum doublet chemotherapy, excluding pemetrexed.","2023-05-20"
"Pemetrexed","HC","2013-05-09","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line maintenance","Advanced","","","","Pemetrexed-containing platinum doublet","FALSE","First-line","","immediately prior","","0","","",NA,"","2013-05-09: Revised monotherapy indication to permit continuous Alimta maintenance treatment in patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">nonsquamous NSCLC</a>, immediately following Alimta-containing first-line platinum doublet chemotherapy.","2023-05-20"
"Pemetrexed","PMDA","2007-01-04","Malignant pleural mesothelioma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Cisplatin","","",NA,"","2007-01-04: Initial approval for use to treat <a href=""/wiki/Malignant_pleural_mesothelioma"" title=""Malignant pleural mesothelioma"">malignant pleural mesothelioma</a> in combination with cisplatin.","2023-06-16"
"Pemetrexed","PMDA","2009-05-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2009-05-20: New additional indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Pemigatinib","EMA","2021-03-26","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-03-26: Initial conditional authorization as Pemazyre.","2023-05-08"
"Pemigatinib","FDA","2020-04-17","Cholangiocarcinoma",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","1+","FALSE","","","","","","FGFR2 rearrangement","FALSE",TRUE,"FIGHT-202","2020-04-17: Granted accelerated approval for the treatment of adults with previously treated, unresectable locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with a <a href=""/wiki/Biomarkers#FGFR2"" title=""Biomarkers"">fibroblast growth factor receptor 2 (FGFR2)</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion</a> or other <a href=""/wiki/Biomarkers#Rearrangement"" title=""Biomarkers"">rearrangement</a>. <i>(Based on FIGHT-202)</i>","2022-09-05"
"Pemigatinib","FDA","2022-08-26","Malignant hematologic neoplasm",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","FGFR1 rearrangement","FALSE",TRUE,"FIGHT-203","2022-08-26: Approved for adults with relapsed or refractory <a href=""/wiki/Category:Malignant_hematologic_neoplasm"" title=""Category:Malignant hematologic neoplasm"">myeloid/lymphoid neoplasms (MLNs)</a> with <a href=""/wiki/Biomarkers#FGFR1"" title=""Biomarkers"">fibroblast growth factor receptor 1 (FGFR1)</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">rearrangement</a>. <i>(Based on FIGHT-203)</i>","2022-09-05"
"Pemigatinib","HC","2021-09-17","Cholangiocarcinoma",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","1+","FALSE","","","","","","FGFR2 rearrangement","FALSE",NA,"","2021-09-17: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic <a href=""/wiki/Cholangiocarcinoma"" title=""Cholangiocarcinoma"">cholangiocarcinoma</a> with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.","2023-05-08"
"Pemigatinib","PMDA","2021-03-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-03-21: Newly indicated for the treatment of unresectable FGFR2 fusion gene-positive <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Penicillin V","","","",FALSE,FALSE,TRUE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Penpulimab","NMPA","2021-08-05","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT","FALSE","","","","","","","",NA,"","2021-08-05: Initial approval for treatment of patients with relapsed or refractory (""r/r"") <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classic Hodgkin's lymphoma (""cHL"")</a> after at least second-line systemic chemotherapy treatment.","2023-05-08"
"Penpulimab","NMPA","2023-01-15","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","First-line","Locally advanced OR Metastatic","","","","",NA,"","","","","Chemotherapy","","",TRUE,"AK105-302","2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer (sq-NSCLC)</a>. <i>(Based on AK105-302)</i>","2023-07-31"
"Pentamidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pentostatin","FDA","1991-10-11","Hairy cell leukemia",FALSE,FALSE,FALSE,"","Refractory","","","adults","","Alfa interferon","FALSE","","","","","","","",TRUE,"SWOG 8691","1991-10-11: Initial approval for treatment for adult patients with alpha-interferon-refractory <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a>. <i>(Based on SWOG 8691)</i>","2022-09-05"
"Pertuzumab","EMA","2013-03-04","Breast cancer",FALSE,FALSE,FALSE,"","","Locally recurrent unresectable OR Metastatic","","adults","","anti-HER2 therapy OR chemotherapy","TRUE","","","","","Trastuzumab AND Docetaxel","HER2+","FALSE",TRUE,"CLEOPATRA","2013-03-04: Initial marketing authorization as Perjeta. Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. <i>(Based on CLEOPATRA)</i>","2023-11-07"
"Pertuzumab","EMA","2015-07-28","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Locally advanced OR Inflammatory OR Early stage","","adults","","",NA,"","","","","Trastuzumab AND Chemotherapy","HER2+","FALSE",NA,"","2015-07-28: Extension of indication to include the use of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence.","2023-11-07"
"Pertuzumab","EMA","2018-05-31","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","adults","","",NA,"","","","","Trastuzumab AND Chemotherapy","HER2+","FALSE",TRUE,"APHINITY","2018-05-31: Extension of indication for Perjeta, in combination with trastuzumab and chemotherapy, for the adjuvant treatment of adult patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on APHINITY)</i>","2023-11-07"
"Pertuzumab","FDA","2012-06-08","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","anti-HER2 therapy OR chemotherapy","TRUE","Metastatic","","","","Trastuzumab AND Docetaxel","HER2+","FALSE",TRUE,"CLEOPATRA","2012-06-08: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm307592.htm"">FDA approved</a> for use in combination with <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)"">trastuzumab</a> and <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> for the treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have <b>not received</b> prior anti-HER2 therapy or chemotherapy for metastatic disease. <i>(Based on CLEOPATRA)</i>","2022-09-05"
"Pertuzumab","FDA","2013-09-30","Breast cancer",TRUE,FALSE,FALSE,"","Neoadjuvant","Locally advanced OR Inflammatory OR (Early greater than 2 cm in diameter or node positive)","","","","",NA,"","","","","Trastuzumab AND Docetaxel","HER2+","FALSE",TRUE,"BERENICE","2013-09-30: Granted accelerated approval for use in combination with <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)"">trastuzumab</a> and <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> for the neoadjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a>, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Approval extended to the neoadjuvant setting; based on NeoSphere, TRYPHAENA, BERENICE)</i>","2022-09-05"
"Pertuzumab","FDA","2013-09-30","Breast cancer",TRUE,FALSE,FALSE,"","Neoadjuvant","Locally advanced OR Inflammatory OR (Early greater than 2 cm in diameter or node positive)","","","","",NA,"","","","","Trastuzumab AND Docetaxel","HER2+","FALSE",TRUE,"NeoSphere","2013-09-30: Granted accelerated approval for use in combination with <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)"">trastuzumab</a> and <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> for the neoadjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a>, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Approval extended to the neoadjuvant setting; based on NeoSphere, TRYPHAENA, BERENICE)</i>","2022-09-05"
"Pertuzumab","FDA","2013-09-30","Breast cancer",TRUE,FALSE,FALSE,"","Neoadjuvant","Locally advanced OR Inflammatory OR (Early greater than 2 cm in diameter or node positive)","","","","",NA,"","","","","Trastuzumab AND Docetaxel","HER2+","FALSE",TRUE,"TRYPHAENA","2013-09-30: Granted accelerated approval for use in combination with <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)"">trastuzumab</a> and <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> for the neoadjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a>, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Approval extended to the neoadjuvant setting; based on NeoSphere, TRYPHAENA, BERENICE)</i>","2022-09-05"
"Pertuzumab","FDA","2017-12-20","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","Surgery","FALSE","","","","","Trastuzumab AND Chemotherapy","HER2+","FALSE",TRUE,"APHINITY","2017-12-20: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer"">Regular FDA approval</a> for use in combination with <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)"">trastuzumab</a> and chemotherapy as adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Granted regular approval; Approval extended to the adjuvant setting; based on APHINITY)</i>","2022-09-05"
"Pertuzumab","HC","2012-08-31","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","anti-HER2 therapy OR chemotherapy","TRUE","Metastatic","","","","","HER2+","FALSE",NA,"","2012-08-31: Initial notice of compliance for the treatment of patients with HER2-positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.","2023-05-20"
"Pertuzumab","PMDA","2013-06-28","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2013-06-28: Initial approval for the treatment of unresectable or recurrent HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Pertuzumab","PMDA","2018-10-10","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2018-10-10: New indication for the treatment of HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Pertuzumab","PMDA","2022-03-28","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","HER2+","FALSE",NA,"","2022-03-28: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colon or rectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Pertuzumab and Trastuzumab hyaluronidase","EMA","2020-12-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-12-21: Initial authorization","2023-09-09"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Localled advanced OR Inflammatory OR Early stage","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"APHINITY","2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"APHINITY","2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Localled advanced OR Inflammatory OR Early stage","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"BERENICE","2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"BERENICE","2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","anti-HER2 therapy or chemotherapy","TRUE","Metastatic","","","","Docetaxel","HER2+","FALSE",TRUE,"CLEOPATRA","2020-06-29: Initial approval in combination with docetaxel for treatment of patients with HER2 positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. <i>(Based on CLEOPATRA and FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","anti-HER2 therapy or chemotherapy","TRUE","Metastatic","","","","Docetaxel","HER2+","FALSE",TRUE,"FeDeriCa","2020-06-29: Initial approval in combination with docetaxel for treatment of patients with HER2 positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. <i>(Based on CLEOPATRA and FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Localled advanced OR Inflammatory OR Early stage","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"FeDeriCa","2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"FeDeriCa","2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Localled advanced OR Inflammatory OR Early stage","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"NeoSphere","2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"NeoSphere","2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant","Localled advanced OR Inflammatory OR Early stage","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"TRYPHAENA","2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","FDA","2020-06-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","High-risk for recurrence","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",TRUE,"TRYPHAENA","2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)</i>","2023-07-31"
"Pertuzumab and Trastuzumab hyaluronidase","PMDA","2023-09-25","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2023-09-25: New combination drugs with a new active ingredient indicated for the treatment of HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2024-06-03"
"Pertuzumab and Trastuzumab hyaluronidase","PMDA","2023-09-25","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","HER2+","FALSE",NA,"","2023-09-25: New combination drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent HER2-positive <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colon or rectal cancer</a> that has progressed after cancer chemotherapy.","2024-06-03"
"Pexidartinib","FDA","2019-08-02","Tenosynovial giant cell tumor",FALSE,FALSE,FALSE,"","","Symptomatic associated with severe morbidity or functional limitations","","adults","","Surgery","FALSE","","not responsive","","","","","",TRUE,"ENLIVEN","2019-08-02: Approved for the treatment of adult patients with symptomatic <a href=""/wiki/Tenosynovial_giant_cell_tumor"" title=""Tenosynovial giant cell tumor"">tenosynovial giant cell tumor (TGCT)</a> associated with severe morbidity or functional limitations and not responsive to improvement with surgery. <i>(Based on ENLIVEN)</i>","2022-09-05"
"Phenytoin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Phytonadione","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pimitespib","PMDA","2022-06-20","Gastrointestinal stromal tumor",FALSE,FALSE,TRUE,"","","","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2022-06-20: A drug with a new active ingredient indicated for the treatment of <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Pipobroman","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pirarubicin","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pirtobrutinib","EMA","2023-04-26","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","BTK inhibitor","FALSE","","","","","0","","",NA,"","2023-04-26: CHMP recommends conditional authorization as Jaypirca. Jaypirca as monotherapy would be indicated for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.","2023-11-07"
"Pirtobrutinib","FDA","2023-01-27","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+ SACT, including BTK inhibitor","FALSE","","","","","","","",TRUE,"BRUIN_MCL","2023-01-27: Granted accelerated approval for relapsed or refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> after at least two lines of systemic therapy, including a BTK inhibitor. <i>(Based on BRUIN_MCL)</i>","2023-03-15"
"Pirtobrutinib","FDA","2023-12-01","Chronic lymphocytic leukemia",TRUE,FALSE,FALSE,"","","","","adults","","2+ SACT, including BTK inhibitor AND BCL-2 inhibitor",NA,"","","","","","","",TRUE,"BRUIN_CLL","2023-12-01: Granted accelerated approval for adults with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)</a> who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. <i>(Based on BRUIN_CLL)</i>","2024-01-06"
"Pixantrone","EMA","2012-05-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-05-10: Initial authorization as Pixuvri","2023-05-08"
"Pixantrone","EMA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+","FALSE","","","","","0","","",NA,"","Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory <a href=""/wiki/Category:Aggressive_non-Hodgkin_lymphomas"" title=""Category:Aggressive non-Hodgkin lymphomas"">aggressive non-Hodgkin B-cell lymphomas (NHL)</a>. The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.","2023-05-20"
"Plerixafor","EMA","2009-07-30","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-07-30: Initial authorization","2023-05-08"
"Plerixafor","PMDA","2016-12-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-12-19: Initial approval for the enhancement of mobilization of hematopoietic stem cells to the peripheral blood for autologous peripheral blood stem cell transplantation.","2023-06-16"
"Plicamycin","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"",NA,"2023-05-08"
"Plicamycin","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Polatuzumab vedotin","EMA","2020-01-16","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-01-16: Initial conditional approval","2023-05-08"
"Polatuzumab vedotin","FDA","2019-06-10","Diffuse large B-cell lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","2+","FALSE","","","","","Bendamustine AND Rituximab","","",TRUE,"GO29365","2019-06-10: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL), not otherwise specified</a>, after at least two prior therapies. <i>(Based on GO29365)</i>","2022-09-05"
"Polatuzumab vedotin","FDA","2023-04-19","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","IPI 2+","adults","","0","FALSE","","","","","R-CHP","","",TRUE,"POLARIX","2023-04-19: Approved with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)</a>, or <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a> and who have an International Prognostic Index (IPI) score of 2 or greater. <i>(Based on POLARIX)</i>","2023-05-08"
"Polatuzumab vedotin","FDA","2023-04-19","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","","IPI 2+","adults","","0","FALSE","","","","","R-CHP","","",TRUE,"POLARIX","2023-04-19: Approved with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)</a>, or <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma (HGBL)</a> and who have an International Prognostic Index (IPI) score of 2 or greater. <i>(Based on POLARIX)</i>","2023-05-08"
"Polatuzumab vedotin","HC","2020-07-09","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-07-09: Initial notice of compliance with conditions","2023-05-08"
"Polatuzumab vedotin","HC","2023-01-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-01-20: Conditions were met","2023-05-08"
"Polatuzumab vedotin","PMDA","2021-03-21","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-03-21: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>.","2023-06-16"
"Polatuzumab vedotin","PMDA","2022-08-24","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2022-08-24: New indication and a new dosage for the treatment of <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma</a>.","2023-06-16"
"Pomalidomide","EMA","2013-08-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-08-05: Initial marketing authorisation","2023-07-31"
"Pomalidomide","FDA","2013-02-08","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","","","2+, including Bortezomib AND Lenalidomide","FALSE","","progression","within 60 days of completion of last therapy","","","","",TRUE,"CC-4047-MM-002","2013-02-08: Accelerated approval for treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> in patients who received at least two previous therapies including <a href=""/wiki/Lenalidomide_(Revlimid)"" title=""Lenalidomide (Revlimid)"">Lenalidomide (Revlimid)</a> and <a href=""/wiki/Bortezomib_(Velcade)"" title=""Bortezomib (Velcade)"">Bortezomib (Velcade)</a> who have progressive disease within 60 days of the completion of the last therapy. <i>(Based on CC-4047-MM-002)</i>","2022-09-05"
"Pomalidomide","FDA","2015-04-23","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","2+, including Proteasome inhibitor AND Lenalidomide","FALSE","","progression","within 60 days of completion of last therapy","","Dexamethasone","","",TRUE,"NIMBUS","2015-04-23: Converted to regular approval for use in combination with low-dose dexamethasone, for the treatment of patients with relapsed and/or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least 2 previous lines of therapy, including lenalidomide and a proteasome inhibitor, and whose disease progressed during or within 60 days of completing the last therapy. <i>(Based on NIMBUS)</i>","2022-09-05"
"Pomalidomide","FDA","2020-05-14","Kaposi sarcoma",TRUE,FALSE,FALSE,"","","","","adults","","HAART","FALSE","","failure","","","","","",TRUE,"NCI 12-C-0047","2020-05-14: Accelerated approval for adult patients with AIDS-related <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">Kaposi sarcoma</a> after failure of highly active antiretroviral therapy. <i>(New disease entity with prior treatment requirement; based on NCI 12-C-0047)</i>","2022-09-05"
"Pomalidomide","FDA","2020-05-14","Kaposi sarcoma",TRUE,FALSE,FALSE,"","","","","adults","HIV-negative","",NA,"","","","","","","",TRUE,"NCI 12-C-0047","2020-05-14: Accelerated approval for <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">Kaposi sarcoma</a> in adult patients who are HIV-negative. <i>(New disease entity; based on NCI 12-C-0047)</i>","2022-09-05"
"Pomalidomide","HC","2014-01-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-01-20: Initial notice of compliance","2023-07-31"
"Pomalidomide","PMDA","2015-03-26","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2015-03-26: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Ponatinib","EMA","2013-07-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-07-01: Initial authorization","2023-05-08"
"Ponatinib","FDA","2012-12-14","Chronic myeloid leukemia",TRUE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","Tyrosine kinase inhibitor therapy","FALSE","","Resistance OR intolerance","","","","","",TRUE,"OPTIC","2012-12-14: Accelerated approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myeloid leukemia (CML)</a> that is resistant or intolerant to prior <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitor therapy</a> <i>(Based on OPTIC)</i>","2022-09-21"
"Ponatinib","FDA","2012-12-14","Acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","","","adults","","Tyrosine kinase inhibitor therapy","FALSE","","Resistance OR intolerance","","","","BCR-ABL1","FALSE",TRUE,"PACE","2012-12-14: Accelerated approval for the treatment of adult patients with <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a> (Ph+ ALL) that is resistant or intolerant to prior <a href=""/wiki/Regimen_classes#Tyrosine_kinase_inhibitor_therapy"" title=""Regimen classes"">tyrosine kinase inhibitor therapy</a>. <i>(Based on PACE)</i>","2022-09-05"
"Ponatinib","FDA","2016-11-29","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","no other TKI is indicated","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"PACE","2016-11-29: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia (CML)</a> or <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia (ALL)</a> for whom no other tyrosine kinase inhibitor therapy is indicated. <i>(Based on PACE)</i>","2023-01-03"
"Ponatinib","FDA","2016-11-29","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","no other TKI is indicated","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","",NA,"","","","","","BCR-ABL1","FALSE",TRUE,"PACE","2016-11-29: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia""> chronic myeloid leukemia (CML)</a> or <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias""> acute lymphoblastic leukemia (ALL)</a> for whom no other tyrosine kinase inhibitor therapy is indicated. <i>(Based on PACE)</i>","2023-01-03"
"Ponatinib","FDA","2016-11-29","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","",NA,"","","","","","BCR-ABL1 p.T315I","FALSE",TRUE,"PACE","2016-11-29: Granted full approval for the treatment of adult patients with <a href=""/wiki/Biomarkers#T315I"" title=""Biomarkers"">T315I</a>Â­-positive, <a href=""/wiki/Biomarkers#BCR-ABL1"" title=""Biomarkers"">Philadelphia chromosome-positive</a> <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">ALL</a>. <i>(Based on PACE)</i>","2023-01-03"
"Ponatinib","FDA","2016-11-29","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","Chronic phase OR Accelerated phase OR Blast crisis","","adults","","",NA,"","","","","","BCR-ABL1 p.T315I","FALSE",TRUE,"PACE","2016-11-29: Granted full approval for the treatment of adult patients with <a href=""/wiki/Biomarkers#T315I"" title=""Biomarkers"">T315I</a>Â­-positive <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">CML</a> (chronic phase, accelerated phase, or blast phase). <i>(Based on PACE)</i>","2023-03-10"
"Ponatinib","FDA","2024-03-19","Acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","","","adults","","0",NA,"","","","","Chemotherapy","Ph+","",TRUE,"PhALLCON","2024-03-19: Granted accelerated approval in combination with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a> (Ph+ ALL). <i>(Based on PhALLCON)</i>","2024-06-03"
"Ponatinib","HC","2015-04-02","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-04-02: Initial notice of compliance with conditions","2023-05-08"
"Ponatinib","HC","2022-10-03","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-10-03: Conditions were met","2023-05-08"
"Ponatinib","PMDA","2016-09-28","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","Ph+","FALSE",NA,"","2016-09-28: New approval for the treatment of recurrent or refractory Philadelphia chromosome-positive <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>.","2023-06-16"
"Ponatinib","PMDA","2016-09-28","Chronic myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","SACT","FALSE","","Resistance OR intolerance","","","","","",NA,"","2016-09-28: New approval for the treatment of <a href=""/wiki/Chronic_myeloid_leukemia"" title=""Chronic myeloid leukemia"">chronic myelogenous leukemia</a> with resistance or intolerance to prior drug therapies.","2023-06-16"
"Porfimer","EMA","1993-04-19","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1993-04-19: EURD","2023-07-31"
"Pralatrexate","FDA","2009-09-24","Peripheral T-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"PROPEL","2009-09-24: Accelerated approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma (PTCL)</a>. <i>(Based on PROPEL)</i>","2022-09-05"
"Pralatrexate","HC","2018-10-26","Peripheral T-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2018-10-26: Initial notice of compliance with conditions for the treatment of patients with relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma (PTCL)</a>.","2023-05-08"
"Pralatrexate","PMDA","2017-07-03","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-07-03: New approval for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>.","2023-06-16"
"Pralsetinib","EMA","2021-11-18","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-11-18: Initial conditional authorization","2023-05-08"
"Pralsetinib","FDA","2020-09-04","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","RET fusion","FALSE",TRUE,"ARROW_RET-NSCLC","2020-09-04: Accelerated approval for adult patients with metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion-positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on ARROW_RET-NSCLC)</i>","2022-09-05"
"Pralsetinib","FDA","2020-12-01","Thyroid cancer",TRUE,FALSE,FALSE,"","","","","adults AND pediatric patients 12 years and older","","Iodine-131, if appropriate","FALSE","","refractory","","","","RET fusion","FALSE",TRUE,"ARROW_RET-thyroid","2020-12-01: Accelerated approval for adult and pediatric patients 12 years of age and older with <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion-positive</a> <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a> who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). <i>(Based on ARROW_RET-thyroid)</i>","2022-09-05"
"Pralsetinib","FDA","2020-12-01","Thyroid cancer medullary",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","RET mutation","FALSE",TRUE,"ARROW_RET-thyroid","2020-12-01: Accelerated approval for adult and pediatric patients 12 years of age and older with advanced or metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutant</a> <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a> (MTC) who require systemic therapy. <i>(Based on ARROW_RET-thyroid)</i>","2022-09-05"
"Pralsetinib","FDA","2023-07-20","Thyroid cancer medullary",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-07-20: Accelerated approval for adult and pediatric patients 12 years of age and older with advanced or metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutant</a> <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a> (MTC) who require systemic therapy withdrawn.","2024-06-03"
"Pralsetinib","FDA","2023-08-09","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","RET fusion","FALSE",TRUE,"ARROW_RET-NSCLC","2023-08-09: Granted regular approval for adult patients with metastatic rearranged during transfection (RET) fusion-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> as detected by an FDA-approved test. <i>(Based on ARROW_RET-NSCLC)</i>","2023-09-09"
"Pralsetinib","HC","2021-06-30","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","","RET fusion","FALSE",NA,"","2021-06-30: Initial notice of compliance with conditions for the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>","2023-05-08"
"Prasugrel","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Pravastatin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Prednimustine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Prednisolone","EMA","1956-07-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1956-07-13: EURD","2023-07-31"
"Prednisolone","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Prednisolone","PMDA","2011-09-16","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-09-16: New indication for the treatment of <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Prednisolone","PMDA","2015-06-26","Lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-06-26: revised indications and a new dosage for the treatment of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> and similar diseases (closely-related diseases).","2023-06-16"
"Prednisone","EMA","1955-05-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1955-05-18: EURD","2023-07-31"
"Procarbazine","EMA","1966-10-07","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1966-10-07: EURD","2023-07-31"
"Procarbazine","FDA","1969-07-22","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1969-07-22: Initial FDA approval","2022-09-05"
"Procarbazine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Stage III or IV","","","","",NA,"","","","","Nitrogen mustard AND Vincristine AND Prednisone","","",TRUE,"Kolygin 1976","Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. <i>(Based on Young et al. 1973a, Kolygin 1976, possibly others)</i>","2022-09-05"
"Procarbazine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Stage III or IV","","","","",NA,"","","","","Nitrogen mustard AND Vincristine AND Prednisone","","",TRUE,"Young et al. 1973a","Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. <i>(Based on Young et al. 1973a, Kolygin 1976, possibly others)</i>","2022-09-05"
"Prochlorperazine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Promethazine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Protamine sulfate","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Protein C human","EMA","2001-07-16","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-07-16: Initial authorization as Ceprotin","2023-05-08"
"Protein C human","EMA","Uncertain date","Purpura fulminans",FALSE,FALSE,NA,"","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.","2023-05-20"
"Prothrombin Complex Concentrate human","FDA","2013-04-29","VKA toxicity",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2013-04-29: <b>Kcentra</b> approved for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding.","2022-09-05"
"Prothrombin Complex Concentrate human","FDA","2023-07-25","VKA toxicity",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"LEX-209","2023-07-25: <b>Balfaxar</b> approved for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. <i>(Based on LEX-209)</i>","2023-07-31"
"Pyrotinib","NMPA","2018-08-22","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-08-22: Initial conditional authorization","2023-05-08"
"Quinine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Quizartinib","EMA","2023-09-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-09-14: CHMP recommended marketing authorization at Vanflyta. Vanflyta would be indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.","2023-11-07"
"Quizartinib","FDA","2023-07-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Induction","","","adults","","0","FALSE","","","","","Cytarabine AND Anthracycline","FLT3-ITD","FALSE",TRUE,"QuANTUM-First","2023-07-20: Approved with standard cytarabine and anthracycline induction for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. <i>(Based on QuANTUM-First)</i>","2023-07-31"
"Quizartinib","FDA","2023-07-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Consolidation","","","adults","","",NA,"","","","","Cytarabine","FLT3-ITD","FALSE",TRUE,"QuANTUM-First","2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. <i>(Based on QuANTUM-First)</i>","2023-07-31"
"Quizartinib","FDA","2023-07-20","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","Maintenance","","","adults","","",NA,"","","","","0","FLT3-ITD","FALSE",TRUE,"QuANTUM-First","2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. <i>(Based on QuANTUM-First)</i>","2023-07-31"
"Quizartinib","PMDA","2019-06-18","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","FLT3-ITD","FALSE",NA,"","2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Quizartinib","PMDA","2023-05-25","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","0",NA,"","","","","","FLT3-ITD","",NA,"","2023-05-25: New indication and a new dosage for the treatment of newly diagnosed FLT3-ITD mutation-positive <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2024-06-03"
"Rabeprazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Radium-223","EMA","2013-11-13","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","symptomatic bone metastases and no known visceral metastatic disease","","adults","","",NA,"","","","","","","",TRUE,"ALSYMPCA","2013-11-13: Initial marketing authorization as Xofigo. Xofigo is indicated for the treatment of adults with castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>, symptomatic bone metastases and no known visceral metastases. <i>(Based on ALSYMPCA)</i>","2023-09-17"
"Radium-223","FDA","2013-05-15","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","symptomatic bone metastases and no known visceral metastatic disease","","","","",NA,"","","","","","","",TRUE,"ALSYMPCA","2013-05-15: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352393.htm"">FDA approved</a> for the treatment of patients with castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>, symptomatic bone metastases and no known visceral metastatic disease. <i>(Based on ALSYMPCA)</i>","2022-09-05"
"Radium-223","HC","2013-12-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-12-12: Initial notice of compliance (details unavailable)","2023-05-20"
"Radium-223","PMDA","2016-03-28","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic to bone","","","","",NA,"","","","","","","",NA,"","2016-03-28: Initial approval for the treatment of castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> with bone metastases.","2023-06-16"
"Radotinib","KFDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Raloxifene","EMA","1998-08-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-08-05: EURD","2023-07-31"
"Raltitrexed","EMA","1995-11-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-11-08: EURD","2023-07-31"
"Raltitrexed","HC","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Ramosetron","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ramucirumab","EMA","2014-12-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-12-16: Initial marketing authorization as Cyramza.","2023-05-08"
"Ramucirumab","FDA","2014-04-21","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Fluoropyrimidine-based regimen OR Platinum-based regimen","FALSE","","progression","","","","","",TRUE,"REGARD","2014-04-21: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm"">Initial approval</a> for the treatment of patients with advanced or metastatic, <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric or gastroesophageal junction (GEJ) adenocarcinoma</a> with disease progression on or after prior treatment with <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a> or <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-</a> containing chemotherapy. <i>(Based on REGARD)</i>","2022-09-05"
"Ramucirumab","FDA","2014-11-05","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","Paclitaxel","","",TRUE,"RAINBOW","2014-11-05: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm421930.htm"">Approval and indication expanded</a> for use in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> for the treatment of patients with advanced <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer""> gastric or gastroesophageal junction (GEJ) adenocarcinoma</a>. <i>(Requirement for prior lines of treatment removed; based on RAINBOW)</i>","2022-09-05"
"Ramucirumab","FDA","2014-12-12","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Platinum-based regimen","FALSE","","progression","","","Docetaxel","","",TRUE,"REVEL","2014-12-12: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm"">Approved</a> for use in combination with <a href=""/wiki/Docetaxel_(Taxotere)"" title=""Docetaxel (Taxotere)"">docetaxel</a> for the treatment of patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> with disease progression on or after <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(New disease entity; based on REVEL)</i>","2022-09-05"
"Ramucirumab","FDA","2015-04-24","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine AND Oxaliplatin AND Bevacizumab","FALSE","","progression","","","FOLFIRI","","",TRUE,"RAISE","2015-04-24: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm"">Approved</a> in combination with <a href=""/wiki/Colorectal_cancer#FOLFIRI_&_Ramucirumab"" title=""Colorectal cancer"">FOLFIRI</a>, for the treatment of metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> with disease progression on or after prior therapy with <a href=""/wiki/Bevacizumab_(Avastin)"" title=""Bevacizumab (Avastin)"">bevacizumab</a>, <a href=""/wiki/Oxaliplatin_(Eloxatin)"" title=""Oxaliplatin (Eloxatin)"">oxaliplatin</a>, and a fluoropyrimidine. <i>(New disease entity; based on RAISE)</i>","2022-09-05"
"Ramucirumab","FDA","2019-05-10","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","0","AFP at least 400 ng/mL","FALSE",TRUE,"REACH-2","2019-05-10: Approved as a single agent for <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> in patients who have an <a href=""/wiki/Biomarkers#AFP"" title=""Biomarkers"">alpha fetoprotein (AFP)</a> of at least 400 ng/mL and have been previously treated with sorafenib. <i>(New disease entity; based on REACH-2)</i>","2022-09-05"
"Ramucirumab","FDA","2020-05-29","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Erlotinib","EGFR exon 19 deletion|EGFR p.L858R","FALSE",TRUE,"RELAY","2020-05-29: Approved in combination with erlotinib for first-line treatment of metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer""> non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#EGFR"" title=""Biomarkers"">epidermal growth factor receptor (EGFR)</a> <a href=""/wiki/Biomarkers#Exon_19"" title=""Biomarkers"">exon 19</a> <a href=""#Biomarkers_Structural_Variant"">deletions</a> or <a href=""/wiki/Biomarkers#L858R"" title=""Biomarkers"">exon 21 (L858R) mutations</a>. <i>(Approval expanded to first-line setting in EGFR+ NSCLC; based on RELAY)</i>","2022-09-05"
"Ramucirumab","HC","2015-07-16","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Fluoropyrimidine AND Platinum-based regimen","FALSE","","progression","","","0","","",NA,"","2015-07-16: Initial notice of compliance as a single agent for the treatment of patients with advanced or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.","2023-05-20"
"Ramucirumab","HC","2015-07-16","Gastric cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","","","Fluoropyrimidine AND Platinum-based regimen","FALSE","","progression","","","Paclitaxel","","",NA,"","2015-07-16: Initial notice of compliance in combination with paclitaxel for the treatment of patients with advanced or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.","2023-05-20"
"Ramucirumab","PMDA","2015-03-26","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2015-03-26: Initial approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>.","2023-06-16"
"Ramucirumab","PMDA","2016-05-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2016-05-23: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Ramucirumab","PMDA","2016-06-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2016-06-20: New additional indication and a new dosage for the treatment of unresectable advanced/relapsed <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Ramucirumab","PMDA","2019-06-18","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","AFP greater than 400 ng/mL","",NA,"","2019-06-18: New indication for the treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy.","2023-06-16"
"Ranimustine","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Ranitidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Rasburicase","EMA","2001-02-23","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2001-02-23: Initial authorization as Fasturtec","2023-05-08"
"Rasburicase","FDA","2002-07-12","Hyperuricemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2002-07-12: Approved for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.","2022-09-05"
"Rasburicase","PMDA","2009-10-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-10-16: Initial approval for the treatment of hyperuricemia in patients receiving cancer chemotherapy.","2023-06-16"
"Ravulizumab","EMA","2019-07-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-07-02: Initial authorization","2023-05-08"
"Ravulizumab","FDA","2018-12-21","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"CHAMPION 301","2018-12-21: Initial approval for adult patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on CHAMPION 301 and CHAMPION 302)</i>","2023-11-07"
"Ravulizumab","FDA","2018-12-21","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"CHAMPION 302","2018-12-21: Initial approval for adult patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on CHAMPION 301 and CHAMPION 302)</i>","2023-11-07"
"Ravulizumab","FDA","2018-12-21","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"ALXN1210-PNH-301","2018-12-21: Initial approval for adult patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on ALXN1210-PNH-301 and ALXN1210-PNH-302)</i>","2022-09-05"
"Ravulizumab","FDA","2018-12-21","Paroxysmal nocturnal hemoglobinuria",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"ALXN1210-PNH-302","2018-12-21: Initial approval for adult patients with <a href=""/wiki/Paroxysmal_nocturnal_hemoglobinuria"" title=""Paroxysmal nocturnal hemoglobinuria"">paroxysmal nocturnal hemoglobinuria (PNH)</a>. <i>(Based on ALXN1210-PNH-301 and ALXN1210-PNH-302)</i>","2022-09-05"
"Realgar-Indigo naturalis formulation","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Regorafenib","EMA","2013-08-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-08-26: Initial marketing authorization as Stivarga.","2023-05-08"
"Regorafenib","FDA","2012-09-27","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen AND VEGFR inhibitor therapy","FALSE","","","","If KRAS WT, EGFR TKI therapy","","","",TRUE,"CORRECT","2012-09-27: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm321378.htm"">Approved</a> for patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) who have been previously treated with <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes"">oxaliplatin-</a>, and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes"">irinotecan-based</a> chemotherapy, an <a href=""/wiki/Regimen_classes#VEGFR_inhibitor_therapy"" title=""Regimen classes"">anti-VEGF therapy</a>, and, if KRAS wild type, an <a href=""/wiki/Regimen_classes#EGFR_TKI_therapy"" title=""Regimen classes"">anti-EGFR therapy</a>. <i>(Based on CORRECT)</i>","2022-09-05"
"Regorafenib","FDA","2013-02-25","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","Advanced unresectable","","","","All other FDA-approved treatments","FALSE","","","","","","","",TRUE,"GRID","2013-02-25: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340958.htm"">Approved</a> for patients with advanced <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumors (GIST)</a> that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. <i>(Based on GRID)</i>","2022-09-05"
"Regorafenib","FDA","2017-04-27","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","Sorafenib","FALSE","","","","","","","",TRUE,"RESORCE","2017-04-27: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555548.htm"">Approved</a> for the treatment of patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with <a href=""/wiki/Sorafenib_(Nexavar)"" title=""Sorafenib (Nexavar)"">sorafenib</a>. <i>(Based on RESORCE)</i>","2022-09-05"
"Regorafenib","HC","2013-03-11","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen AND VEGFR inhibitor therapy","FALSE","","","","If KRAS WT, EGFR TKI therapy","","","",NA,"","2013-03-11: Initial notice of compliance for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-vascular endothelial growth factor (anti-VEGF) therapy, and, if KRAS wild type, an anti-epidermal growth factor receptor (anti-EGFR) therapy.","2023-05-20"
"Regorafenib","HC","2013-10-14","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Imatinib AND Sunitinib","FALSE","","progression OR intolerance","","","","","",NA,"","2013-10-14: New indication for adult patients with metastatic and/or unresectable <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">GIST</a> who have had disease progression on or intolerance to imatinib mesylate and sunitinib malate treatment.","2023-05-20"
"Regorafenib","HC","2017-08-29","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen AND VEGFR inhibitor therapy","FALSE","","","","If RAS WT, EGFR TKI therapy","","","",NA,"","2017-08-29: Indication revised for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer (CRC)</a> who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-vascular endothelial growth factor (anti-VEGF) therapy, and, if RAS wild type, an anti-epidermal growth factor receptor (anti-EGFR) therapy.","2023-05-20"
"Regorafenib","HC","2017-09-18","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","1 SACT","FALSE","","","","","","","",NA,"","2017-09-18: New indication for use in the treatment of patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have been previously treated with one systemic therapy.","2023-05-20"
"Regorafenib","PMDA","2013-03-25","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2013-03-25: Initial approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Regorafenib","PMDA","2013-08-20","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2013-08-20: New additional indication for the treatment of <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Regorafenib","PMDA","2017-06-26","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2017-06-26: New additional indication for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Relugolix","EMA","2022-04-29","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-sensitive","Advanced","","adults","","",NA,"","","","","","","",TRUE,"HERO","2022-04-29: Initial authorization as Orgovyx. Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on HERO)</i>","2023-09-17"
"Relugolix","FDA","2020-12-18","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"","","","","","","",TRUE,"HERO","2020-12-18: Approved for adult patients with advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on HERO)</i>","2022-09-05"
"Relugolix","PMDA","2019-01-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-01-08: Initial approval for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids.","2023-06-16"
"Repotrectinib","FDA","2023-11-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","",NA,"","","","","","ROS1","FALSE",TRUE,"TRIDENT-1","2023-11-15: Approved for locally advanced or metastatic ROS1-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on TRIDENT-1)</i>","2024-01-06"
"Repotrectinib","FDA","2024-06-13","Malignant solid neoplasm NTRK-mutated",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic OR Surgical resection is likely to result in severe morbidity","","adults AND pediatric patients 12 years and older","","1+ OR no satisfactory alternative therapy",NA,"","progression","","","","NTRK","FALSE",TRUE,"TRIDENT-1","2024-06-13: Granted accelerated approval for adult and pediatric patients 12 years and older with <a href=""/wiki/Malignant_solid_neoplasm,_NTRK-mutated"" title=""Malignant solid neoplasm, NTRK-mutated"">solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion</a>, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. <i>(Based on TRIDENT-1)</i>","2024-09-06"
"Retifanlimab","FDA","2023-03-22","Merkel cell carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","",NA,"","","","","","","",TRUE,"POD1UM-201","2023-03-22: Granted accelerated approval for adult patients with metastatic or recurrent locally advanced <a href=""/wiki/Merkel_cell_carcinoma"" title=""Merkel cell carcinoma"">Merkel cell carcinoma (MCC)</a>. <i>(Based on POD1UM-201)</i>","2023-03-29"
"Revumenib","FDA","2024-11-15","Acute leukemia",FALSE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"AUGMENT-101","2024-11-15: Approved for relapsed or refractory <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a> with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. <i>(Based on AUGMENT-101)</i>","2024-12-02"
"Rho(D) immune globulin","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Ribociclib","EMA","2017-08-22","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-08-22: Initial authorization","2023-05-08"
"Ribociclib","FDA","2017-03-13","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","Endocrine therapy","TRUE","","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONALEESA-2","2017-03-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.htm"">Initial FDA approval</a> in combination with an <a href=""/wiki/Category:Aromatase_inhibitors"" title=""Category:Aromatase inhibitors"">aromatase inhibitor</a> as initial endocrine-based therapy for the treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on MONALEESA-2 and MONALEESA-3)</i>","2022-09-05"
"Ribociclib","FDA","2017-03-13","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","Endocrine therapy","TRUE","","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONALEESA-3","2017-03-13: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.htm"">Initial FDA approval</a> in combination with an <a href=""/wiki/Category:Aromatase_inhibitors"" title=""Category:Aromatase inhibitors"">aromatase inhibitor</a> as initial endocrine-based therapy for the treatment of postmenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">hormone receptor (HR)</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 (HER2)</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on MONALEESA-2 and MONALEESA-3)</i>","2022-09-05"
"Ribociclib","FDA","2018-07-18","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","pre/perimenopausal women","","Endocrine therapy","TRUE","","","","","Aromatase inhibitor","HR+ and HER2-","FALSE AND TRUE",TRUE,"MONALEESA-7","2018-07-18: FDA approval expanded in combination with an <a href=""/wiki/Category:Aromatase_inhibitors"" title=""Category:Aromatase inhibitors"">aromatase inhibitor</a> for pre/perimenopausal women with <a href=""/wiki/Biomarkers#HR"" title=""Biomarkers"">HR</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Normal_expression"" title=""Biomarkers"">negative</a> advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, as initial endocrine-based therapy. <i>(No longer limited to postmenopausal women; based on MONALEESA-7)</i>","2022-09-05"
"Ribociclib","FDA","2024-09-17","Breast cancer",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"NATALEE","2024-09-17: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ribociclib-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-early-high-risk-0"">FDA approved</a> with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> at high risk of recurrence. <i>(Based on NATALEE)</i>","2024-12-02"
"Ribociclib","HC","2018-06-18","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","postmenopausal women","","Endocrine therapy","TRUE","","","","","Letrozole","HR+ and HER2-","",NA,"","2018-06-18: Initial notice of compliance in combination with letrozole for treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as an initial endocrine-based therapy.","2023-05-20"
"Ribociclib","HC","2020-02-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-02-07: Expanded indication (details unavailable)","2023-05-20"
"Ribociclib","HC","2023-02-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-02-10: Expanded indication (details unavailable)","2023-05-20"
"Ripretinib","EMA","2021-11-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-11-18: Initial authorization","2023-05-08"
"Ripretinib","FDA","2020-05-15","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","adults","","3+ TKIs, including Imatinib","FALSE","","","","","","","",TRUE,"INVICTUS","2020-05-15: Approved for adult patients with advanced <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor (GIST)</a> who have received prior treatment with 3 or more kinase inhibitors, including imatinib. <i>(Based on INVICTUS)</i>","2022-09-05"
"Risedronate","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Rituximab","EMA","1998-06-02","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-06-02: Initial marketing authorization as MabThera.","2023-05-08"
"Rituximab","FDA","1997-11-26","Follicular lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",TRUE,"Maloney et al. 1997a","1997-11-26: Initial FDA approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin's lymphoma. <i>(Based on Maloney et al. 1997a and McLaughlin et al. 1998)</i>","2022-09-05"
"Rituximab","FDA","1997-11-26","Indolent lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",TRUE,"Maloney et al. 1997a","1997-11-26: Initial FDA approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin's lymphoma. <i>(Based on Maloney et al. 1997a and McLaughlin et al. 1998)</i>","2022-09-21"
"Rituximab","FDA","1997-11-26","Follicular lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",TRUE,"McLaughlin et al. 1998","1997-11-26: Initial FDA approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin's lymphoma. <i>(Based on Maloney et al. 1997a and McLaughlin et al. 1998)</i>","2022-09-05"
"Rituximab","FDA","1997-11-26","Indolent lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","CD20+","FALSE",TRUE,"McLaughlin et al. 1998","1997-11-26: Initial FDA approval for the treatment of patients with relapsed or refractory <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low-grade</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin's lymphoma. <i>(Based on Maloney et al. 1997a and McLaughlin et al. 1998)</i>","2022-09-21"
"Rituximab","FDA","2006-02-10","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","CHOP OR Anthracycline-based regimen","CD20+","FALSE",TRUE,"ECOG E4494","2006-02-10: Approved for use in the first-line treatment of patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens. <i>(new disease entity added; scope expanded to first-line treatment; combination therapy required; based on ECOG E4494, LNH 98-5, NCIC-CTG LY.9)</i>","2023-01-03"
"Rituximab","FDA","2006-02-10","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","CHOP OR Anthracycline-based regimen","CD20+","FALSE",TRUE,"LNH 98-5","2006-02-10: Approved for use in the first-line treatment of patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens. <i>(new disease entity added; scope expanded to first-line treatment; combination therapy required; based on ECOG E4494, LNH 98-5, NCIC-CTG LY.9)</i>","2023-01-03"
"Rituximab","FDA","2006-02-10","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","CHOP OR Anthracycline-based regimen","CD20+","FALSE",TRUE,"NCIC-CTG LY.9","2006-02-10: Approved for use in the first-line treatment of patients with <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens. <i>(new disease entity added; scope expanded to first-line treatment; combination therapy required; based on ECOG E4494, LNH 98-5, NCIC-CTG LY.9)</i>","2023-01-03"
"Rituximab","FDA","2006-09-29","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","","CD20+","FALSE",TRUE,"M39021","2006-09-29: Approved for the first-line treatment of patients with <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell non-Hodgkin's lymphoma. <i>(scope expanded to first-line treatment; based on M39021)</i>","2022-09-05"
"Rituximab","FDA","2006-09-29","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","","CD20+","FALSE",TRUE,"M39021","2006-09-29: Approved for the first-line treatment of patients with <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low grade</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell non-Hodgkin's lymphoma. <i>(scope expanded to first-line treatment; based on M39021)</i>","2022-09-21"
"Rituximab","FDA","2010-02-18","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fludarabine AND Cyclophosphamide","","",TRUE,"GCLLSG CLL8","2010-02-18: Approved in combination with fludarabine and cyclophosphamide (FC), for the treatment of previously untreated and previously treated patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(New disease entity; based on GCLLSG CLL8 and REACH)</i>","2022-09-05"
"Rituximab","FDA","2010-02-18","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fludarabine AND Cyclophosphamide","","",TRUE,"REACH","2010-02-18: Approved in combination with fludarabine and cyclophosphamide (FC), for the treatment of previously untreated and previously treated patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a>. <i>(New disease entity; based on GCLLSG CLL8 and REACH)</i>","2022-09-05"
"Rituximab","FDA","2011-01-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","Maintenance","","","","","Rituximab AND Chemotherapy","FALSE","","CR or PR","","","","CD20+","FALSE",TRUE,"ECOG E1496","2011-01-28: Approved for maintenance therapy for patients with previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD-20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin lymphoma who achieve a response to rituximab in combination with chemotherapy. <i>(Approval extended to maintenance setting; based on ECOG E1496 and PRIMA_FL)</i>","2022-09-05"
"Rituximab","FDA","2011-01-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","Maintenance","","","","","Rituximab AND Chemotherapy","FALSE","","CR or PR","","","","CD20+","FALSE",TRUE,"PRIMA_FL","2011-01-28: Approved for maintenance therapy for patients with previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD-20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell non-Hodgkin lymphoma who achieve a response to rituximab in combination with chemotherapy. <i>(Approval extended to maintenance setting; based on ECOG E1496 and PRIMA_FL)</i>","2022-09-05"
"Rituximab","FDA","2021-12-02","Non-Hodgkin lymphoma pediatric",FALSE,FALSE,FALSE,"","","Advanced","","pediatric patients 6 months and older","","0","FALSE","","","","","","CD20+","FALSE",TRUE,"Inter-B-NHL Ritux 2010","2021-12-02: Approved in combination with chemotherapy for pediatric patients (at least 6 months to less than 18 years) with previously untreated, advanced stage, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Non-Hodgkin_lymphoma,_pediatric"" title=""Non-Hodgkin lymphoma, pediatric"">diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL)</a>. <i>(Based on Inter-B-NHL Ritux 2010)</i>","2023-01-03"
"Rituximab","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Rituximab","PMDA","2013-06-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-06-14: New additional indication and a new dosage for the treatment of CD 20-positive B-cell lymphoproliferative disorders in immunocompromised patients.","2023-06-16"
"Rituximab","PMDA","2017-06-26","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-06-26: New additional indication and a new dosage for the treatment of chronic <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">idiopathic thrombocytopenic purpura</a>.","2023-06-16"
"Rituximab","PMDA","2019-03-26","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2019-03-26: New additional indication and a new dosage for the treatment of CD20-positive <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia</a>.","2023-06-16"
"Rituximab","PMDA","2020-02-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-02-21: New indication and a new dosage for the treatment of <a href=""/wiki/Acquired_thrombotic_thrombocytopenic_purpura"" title=""Acquired thrombotic thrombocytopenic purpura"">acquired thrombotic thrombocytopenic purpura</a>.","2023-06-16"
"Rituximab and hyaluronidase human","FDA","2017-06-22","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","CHOP OR Anthracycline-based regimen","","",TRUE,"MabEase","2017-06-22: Approved for previously untreated <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a> in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. <i>(Based on MabEase)</i>","2022-09-05"
"Rituximab and hyaluronidase human","FDA","2017-06-22","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Chemotherapy","","",TRUE,"SABRINA","2017-06-22: Approved for previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">FL</a> in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. <i>(Based on SABRINA)</i>","2022-09-05"
"Rituximab and hyaluronidase human","FDA","2017-06-22","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fludarabine AND Cyclophosphamide","","",TRUE,"SAWYER","2017-06-22: Approved for previously untreated and previously treated <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">CLL</a> in combination with fludarabine and cyclophosphamide (FC). <i>(Based on SAWYER)</i>","2022-09-05"
"Rituximab and hyaluronidase human","FDA","2017-06-22","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","CVP","FALSE","","non-progressing","","","0","","",FALSE,"","2017-06-22: Approved for non-progressing (including stable disease), <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">FL</a> as a single agent after first-line <a href=""/wiki/Follicular_lymphoma#CVP"" title=""Follicular lymphoma"">cyclophosphamide, vincristine, and prednisone (CVP)</a> chemotherapy. <i>(No supporting studies are cited)</i>","2022-09-05"
"Rituximab and hyaluronidase human","FDA","2017-06-22","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","0","","",FALSE,"","2017-06-22: Approved for relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> as a single agent. <i>(No supporting studies are cited)</i>","2022-09-05"
"Rituximab-abbs","FDA","2018-11-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","First-line","","","adults","","0","FALSE","","","","","Chemotherapy","CD20+","FALSE",NA,"","2018-11-28: Initial approval for the treatment of adult patients with previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell NHL in combination with first line chemotherapy.","2023-07-31"
"Rituximab-abbs","FDA","2018-11-28","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","CVP","FALSE","SD or better","","","","0","CD20+","FALSE",NA,"","2018-11-28: Initial approval for the treatment of adult patients with non-progressing (including stable disease), <a href=""/wiki/Category:Indolent_lymphomas"" title=""Category:Indolent lymphomas"">low-grade</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.","2023-05-20"
"Rituximab-abbs","FDA","2018-11-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","0","CD20+","FALSE",NA,"","2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, <a href=""/wiki/Category:Indolent_lymphomas"" title=""Category:Indolent lymphomas"">low grade</a> or <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell NHL as a single agent.","2023-05-20"
"Rituximab-abbs","FDA","2018-11-28","Indolent lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","0","CD20+","FALSE",NA,"","2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, <a href=""/wiki/Category:Indolent_lymphomas"" title=""Category:Indolent lymphomas"">low grade</a> or <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell NHL as a single agent.","2023-05-20"
"Rituximab-abbs","FDA","2018-11-28","Follicular lymphoma",FALSE,FALSE,FALSE,"","Maintenance","","","adults","","Rituximab AND Chemotherapy","FALSE","","CR or PR","","","0","","",NA,"","2018-11-28: Initial approval as single-agent maintenance therapy for the treatment of adult patients with <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell NHL achieving a complete or partial response to a rituximab product in combination with chemotherapy.","2023-07-31"
"Rituximab-arrx","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Rituximab-pvvr","FDA","2019-07-23","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","CHOP OR Anthracycline-based regimen","CD20+","FALSE",NA,"","2019-07-23: Approved for previously untreated <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.","2023-01-03"
"Rituximab-pvvr","FDA","2019-07-23","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","CVP","FALSE","","non-progressing","","","0","CD20+","FALSE",NA,"","2019-07-23: Approved for non-progressing (including stable disease), <a href=""/wiki/Category:Indolent_lymphomas"" title=""Category:Indolent lymphomas"">low-grade</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.","2023-01-03"
"Rituximab-pvvr","FDA","2019-07-23","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Fludarabine AND Cyclophosphamide","CD20+","FALSE",NA,"","2019-07-23: Approved for previously untreated and previously treated <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">CLL</a> in combination with fludarabine and cyclophosphamide (FC).","2023-01-03"
"Rituximab-pvvr","FDA","2019-07-23","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","0","CD20+","FALSE",TRUE,"REFLECTIONS B328-06","2019-07-23: Approved for <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell NHL as a single agent. <i>(Based on REFLECTIONS B328-06)</i>","2023-01-03"
"Rituximab-pvvr","FDA","2019-07-23","Follicular lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","CD20+","FALSE",NA,"","2019-07-23: Approved for previously untreated <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a>, <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy","2023-01-03"
"Rituximab-pvvr","FDA","2019-07-23","Indolent lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","0","CD20+","FALSE",NA,"","2019-07-23: Approved for <a href=""/wiki/Category:Indolent_lymphomas"" title=""Category:Indolent lymphomas"">low grade</a> <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a>-<a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> B-cell NHL as a single agent.","2023-01-03"
"Rivaroxaban","EMA","2008-09-30","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-09-30: Initial authorization","2023-05-08"
"Rivaroxaban","FDA","2011-07-01","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-07-01: Approved for the prophylaxis of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">DVT</a>, which may lead to PE in patients undergoing knee or hip replacement surgery.","2022-09-05"
"Rivaroxaban","FDA","2011-11-04","Atrial fibrillation",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-11-04: Approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. <i>(Non-hematologic indication)</i>","2022-09-05"
"Rivaroxaban","FDA","2012-11-02","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-11-02: Approved for the treatment of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis (DVT), pulmonary embolism (PE)</a>, and for the reduction in the risk of recurrence of DVT and of PE.","2022-09-05"
"Rivaroxaban","PMDA","2015-09-24","Venous thromboembolism",FALSE,FALSE,FALSE,"","Treatment|Prevention","","","","","",NA,"","","","","","","",NA,"","2015-09-24: New additional indication and a new dosage for the treatment and prevention of recurrence of <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis and pulmonary thromboembolism</a>.","2023-06-16"
"Rivaroxaban","PMDA","2021-01-22","Venous thromboembolism",FALSE,FALSE,FALSE,"","Treatment|Prevention","","","pediatric","","",NA,"","","","","","","",NA,"","2021-01-22: New indication and a new additional pediatric dosage for the treatment and prevention of recurrent <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">venous thromboembolism</a>.","2023-06-16"
"Rolapitant","EMA","2010-01-23","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2020-01-23: Withdrawn at the manufacturer's request, for commercial reasons","2023-05-08"
"Rolapitant","EMA","2017-04-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-04-20: Initial authorization as Varuby","2023-05-08"
"Rolapitant","FDA","2015-09-01","Nausea and vomiting",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-09-01: Initial FDA approval ""in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.""","2022-09-05"
"Rolapitant","FDA","2017-10-25","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2017-10-25: IV formulation FDA approved","2022-09-05"
"Romidepsin","FDA","2009-11-05","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","","","","","","",TRUE,"GPI-04-0001","2009-11-05: Initial FDA approval for treatment of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma (CTCL)</a> in patients who have received at least one prior systemic therapy. <i>(Based on NIH 01-C-0049_CTCL and GPI-04-0001)</i>","2022-09-05"
"Romidepsin","FDA","2009-11-05","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","","","","","","",TRUE,"NIH 01-C-0049_CTCL","2009-11-05: Initial FDA approval for treatment of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma (CTCL)</a> in patients who have received at least one prior systemic therapy. <i>(Based on NIH 01-C-0049_CTCL and GPI-04-0001)</i>","2022-09-05"
"Romidepsin","FDA","2011-06-16","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","1+ SACT","FALSE","","","","","","","",TRUE,"GPI-06-0002","2011-06-16: Additional indication for treatment of <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma""> peripheral T-cell lymphoma (PTCL)</a> in patients who have received at least one prior therapy. <i>(Based on GPI-06-0002)</i>","2022-09-05"
"Romidepsin","FDA","2021-07-30","Peripheral T-cell lymphoma",FALSE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"LYSA Ro-CHOP","2021-07-30: Approval for treatment of <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma""> peripheral T-cell lymphoma (PTCL)</a> in patients who have received at least one prior therapy withdrawn. <i>(Based on LYSA Ro-CHOP)</i>","2022-09-21"
"Romidepsin","HC","2013-10-16","Peripheral T-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","not eligible for transplant","1+ SACT","FALSE","","","","","","","",NA,"","2013-10-16: Initial notice of compliance with conditions for the treatment of patients with relapsed/refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma (PTCL)</a> who are not eligible for transplant and have received at least one prior systemic therapy.","2023-05-08"
"Romidepsin","PMDA","2017-07-03","Peripheral T-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2017-07-03: New approval for the treatment of relapsed or refractory <a href=""/wiki/Peripheral_T-cell_lymphoma"" title=""Peripheral T-cell lymphoma"">peripheral T-cell lymphoma</a>.","2023-06-16"
"Romiplostim","EMA","2009-02-04","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-02-04: Initial authorization","2023-05-08"
"Romiplostim","FDA","2008-08-22","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-08-22: Initial approval","2022-09-05"
"Romiplostim","FDA","2018-12-14","Immune thrombocytopenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2018-12-14: Approved for pediatric patients 1 year of age and older with <a href=""/wiki/Immune_thrombocytopenia"" title=""Immune thrombocytopenia"">immune thrombocytopenia (ITP)</a> for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","2022-09-05"
"Romiplostim","PMDA","2019-06-18","Aplastic anemia",FALSE,FALSE,FALSE,"","","","","","","Conventional treatment","FALSE","","Inadequate response","","","","","",NA,"","2019-06-18: New indication and a new dosage for the treatment of <a href=""/wiki/Aplastic_anemia"" title=""Aplastic anemia"">aplastic anemia</a> in patients who have not responded sufficiently to conventional treatments.","2023-06-16"
"Ropeginterferon alfa-2b","EMA","2019-02-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-02-15: Initial authorization","2023-05-08"
"Ropeginterferon alfa-2b","FDA","2021-11-12","Polycythemia vera",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"PEGINVERA","2021-11-12: Initial approval for adults with <a href=""/wiki/Polycythemia_vera"" title=""Polycythemia vera"">polycythemia vera</a>. <i>(Based on PEGINVERA)</i>","2023-07-31"
"Ropeginterferon alfa-2b","PMDA","2023-03-27","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-03-27: Initial approval","2023-07-31"
"Rucaparib","EMA","2018-05-23","Ovarian cancer",FALSE,FALSE,FALSE,"","","Platinum-sensitive relapsed or progressive","","adults","unable to tolerate further platinum chemotherapy","2+ platinum-based chemotherapy",NA,"","","","","0","BRCAm","",NA,"","2018-05-23: Rubraca is indicated as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.","2023-09-17"
"Rucaparib","EMA","2023-04-24","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-04-24: Indication withdrawn","2023-07-31"
"Rucaparib","EMA","2023-10-12","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Advanced (FIGO stages III and IV)","","adults","","Platinum-based regimen",NA,"First-line","PR or CR","","","0","","",NA,"","2023-10-12: CHMP approved new indication as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","2023-11-07"
"Rucaparib","EMA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Platinum-sensitive relapsed","","adults","","Platinum-based regimen","FALSE","","CR or PR","","","0","","",NA,"","Uncertain date: Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in response (complete or partial) to platinum-based chemotherapy.","2023-07-31"
"Rucaparib","EMA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","Platinum-sensitive relapsed or progressive","","adults","unable to tolerate further platinum chemotherapy","2+ platinum-based chemotherapy","FALSE","","","","","0","BRCAm","FALSE",NA,"","Uncertain date: Rubraca is indicated as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer</a>, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.","2023-07-31"
"Rucaparib","FDA","2016-12-19","Ovarian cancer",TRUE,FALSE,FALSE,"","","","","","","2+ chemotherapy","FALSE","","","","","","gBRCAm|sBRCAm","FALSE",TRUE,"ARIEL2","2016-12-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm"">Granted accelerated approval</a> for treatment of patients with deleterious <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a> <a href=""/wiki/Biomarkers#Mutation"" title=""Biomarkers"">mutation</a> (<a href=""/wiki/Biomarkers#germline"" title=""Biomarkers"">germline</a> and/or <a href=""/wiki/Biomarkers#Somatic"" title=""Biomarkers"">somatic</a>) associated advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> who have been treated with two or more chemotherapies. <i>(Based on Study 10 and ARIEL2)</i>","2022-09-05"
"Rucaparib","FDA","2016-12-19","Ovarian cancer",TRUE,FALSE,FALSE,"","","","","","","2+ chemotherapy","FALSE","","","","","","gBRCAm|sBRCAm","FALSE",TRUE,"Study 10","2016-12-19: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm"">Granted accelerated approval</a> for treatment of patients with deleterious <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a> <a href=""/wiki/Biomarkers#Mutation"" title=""Biomarkers"">mutation</a> (<a href=""/wiki/Biomarkers#germline"" title=""Biomarkers"">germline</a> and/or <a href=""/wiki/Biomarkers#Somatic"" title=""Biomarkers"">somatic</a>) associated advanced <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> who have been treated with two or more chemotherapies. <i>(Based on Study 10 and ARIEL2)</i>","2022-09-05"
"Rucaparib","FDA","2018-04-06","Ovarian cancer",FALSE,FALSE,FALSE,"","Maintenance","Recurrent","","","","Platinum-based regimen","FALSE","","CR or PR","","","","","",TRUE,"ARIEL3","2018-04-06: Full approval for the maintenance treatment of recurrent <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">epithelial ovarian, fallopian tube, or primary peritoneal cancer</a> who are in a complete or partial response to <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum-based chemotherapy</a>. <i>(Indication expanded to maintenance therapy; based on ARIEL3)</i>","2022-09-05"
"Rucaparib","FDA","2020-05-15","Prostate cancer",TRUE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","Androgen receptor-directed therapy AND Taxane-based regimen","FALSE","","","","","","gBRCAm|sBRCAm","FALSE",TRUE,"TRITON2","2020-05-15: Granted accelerated approval for patients with <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a> <a href=""/wiki/Biomarkers#Mutation"" title=""Biomarkers"">mutation</a> (<a href=""/wiki/Biomarkers#germline"" title=""Biomarkers"">germline</a> and/or <a href=""/wiki/Biomarkers#Somatic"" title=""Biomarkers"">somatic</a>)-associated metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) who have been treated with <a href=""/wiki/Regimen_classes#Androgen_receptor-directed_therapy"" title=""Regimen classes"">androgen receptor-directed therapy</a> and a <a href=""/wiki/Regimen_classes#Taxane-based_regimen"" title=""Regimen classes"">taxane-based chemotherapy</a>. <i>(New disease entity; based on TRITON2)</i>","2022-09-05"
"Rucaparib","FDA","2022-06-10","Ovarian cancer",TRUE,TRUE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"ARIEL4","2022-06-10: Manufacturer has requested withdrawal of accelerated approval. <i>(Based on ARIEL4)</i>","2022-09-05"
"Ruxolitinib","EMA","2012-08-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-08-23: Initial authorization","2023-05-08"
"Ruxolitinib","FDA","2011-11-16","Myelofibrosis",FALSE,FALSE,TRUE,"","","","Intermediate-risk OR High-risk","","","",NA,"","","","","","","",TRUE,"COMFORT-I","2011-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm"">Initial FDA approval</a> for treatment of patients with intermediate or high-risk <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis""> myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis</a>. <i>(Based on COMFORT-I and COMFORT-II)</i>","2022-09-05"
"Ruxolitinib","FDA","2011-11-16","Myelofibrosis",FALSE,FALSE,TRUE,"","","","Intermediate-risk OR High-risk","","","",NA,"","","","","","","",TRUE,"COMFORT-II","2011-11-16: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm"">Initial FDA approval</a> for treatment of patients with intermediate or high-risk <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis""> myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis</a>. <i>(Based on COMFORT-I and COMFORT-II)</i>","2022-09-05"
"Ruxolitinib","FDA","2014-12-04","Polycythemia vera",FALSE,FALSE,FALSE,"","","","","","","Hydroxyurea","FALSE","","Inadequate response OR intolerance","","","","","",TRUE,"RESPONSE","2014-12-04: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm"">Indication expanded</a> for the treatment of patients with <a href=""/wiki/Polycythemia_vera"" title=""Polycythemia vera"">polycythemia vera (PV)</a> who have had an inadequate response to or are intolerant of <a href=""/wiki/Hydroxyurea_(Hydrea)"" title=""Hydroxyurea (Hydrea)"">hydroxyurea (HU)</a>. <i>(New disease entity; based on RESPONSE)</i>","2022-09-05"
"Ruxolitinib","FDA","2019-05-24","Graft versus host disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"REACH1","2019-05-24: Indication expanded for steroid-refractory acute <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">graft-versus-host disease (GVHD)</a> in adult and pediatric patients 12 years and older. <i>(New condition; based on REACH1)</i>","2022-09-05"
"Ruxolitinib","FDA","2021-09-21","Graft versus host disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"REACH3","2021-09-21: Approved for chronic <a href=""/wiki/Graft_versus_host_disease"" title=""Graft versus host disease"">graft-versus-host disease (cGVHD)</a> after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. <i>(Based on REACH3)</i>","2022-09-05"
"Ruxolitinib","HC","2012-06-19","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-06-19: Initial notice of compliance","2023-07-31"
"Ruxolitinib","PMDA","2014-07-04","Myelofibrosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-07-04: Initial approval for the treatment of <a href=""/wiki/Myelofibrosis"" title=""Myelofibrosis"">myelofibrosis</a>.","2023-06-16"
"Ruxolitinib","PMDA","2015-09-24","Polycythemia vera",FALSE,FALSE,FALSE,"","","","","","","Conventional treatment","FALSE","","Inadequate response|Inappropriate","","","","","",NA,"","2015-09-24: New additional indication and a new dosage for the treatment of <a href=""/wiki/Polycythemia_vera"" title=""Polycythemia vera"">polycythemia vera</a> (use only when conventional therapies are not sufficiently effective or inappropriate).","2023-06-16"
"Sacituzumab govitecan","EMA","2021-11-22","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","2+ SACT, including 1+ in the advanced setting","FALSE","","","","","0","TNBC","FALSE",TRUE,"ASCENT","2021-11-22: Initial marketing authorization as Trodelvy. Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease. <i>(Based on ASCENT)</i>","2023-09-17"
"Sacituzumab govitecan","EMA","2023-07-26","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Endocrine-based therapy AND 2+ SACT in the advanced setting","FALSE","","","","","","HR+ and HER2-","FALSE AND TRUE",TRUE,"TROPiCS-02","2023-07-26: Extension of indication to include treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. <i>(Based on TROPiCS-02)</i>","2023-09-17"
"Sacituzumab govitecan","FDA","2020-04-22","Breast cancer",TRUE,FALSE,TRUE,"","","Metastatic","","adults","","2+","FALSE","","","","","","TNBC","FALSE",TRUE,"IMMU-132-01","2020-04-22: Granted accelerated approval for adult patients with metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who received at least two prior therapies for metastatic disease. <i>(Based on IMMU-132-01)</i>","2022-09-05"
"Sacituzumab govitecan","FDA","2021-04-07","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","","","2+ SACT, including 1+ in the metastatic setting","FALSE","","","","","","TNBC","FALSE",TRUE,"ASCENT","2021-04-07: Granted regular approval for patients with unresectable locally advanced or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. <i>(Based on ASCENT)</i>","2022-09-05"
"Sacituzumab govitecan","FDA","2021-04-13","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-based regimen AND (anti-PD-1 antibody OR anti-PD-L1 antibody)","FALSE","","","","","","","",TRUE,"TROPHY-U-01","2021-04-13: Granted accelerated approval for patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial cancer</a> (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. <i>(Based on TROPHY-U-01)</i>","2022-09-05"
"Sacituzumab govitecan","FDA","2023-02-03","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","","","Endocrine-based therapy AND 2+ SACT","FALSE","Metastatic","","","","","HR+ and HER2-","FALSE AND TRUE",TRUE,"TROPiCS-02","2023-02-03: Approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. <i>(Based on TROPiCS-02)</i>","2023-03-15"
"Sacituzumab govitecan","HC","2021-09-24","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","2+, including 1+ in the metastatic setting","FALSE","","","","","","TNBC","FALSE",NA,"","2021-09-24: Initial notice of compliance for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease.","2023-05-20"
"Samarium-153","EMA","1998-02-04","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1998-02-04: Initial authorization","2023-05-08"
"Samarium-153","FDA","1997-03-28","Skeletal metastases from solid tumors",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1997-03-28: Initial approval for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.","2022-09-05"
"Sargramostim","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Scopolamine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Selinexor","EMA","2021-03-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-03-26: Initial authorization as Nexpovio","2023-05-08"
"Selinexor","FDA","2019-07-03","Multiple myeloma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","4+, including 2+ Proteasome inhibitor, 2+ Immunomodulators, and anti-CD38 antibody","FALSE","","","","","Dexamethasone","","",TRUE,"STORM","2019-07-03: Granted accelerated approval in combination with dexamethasone for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. <i>(Based on STORM)</i>","2022-09-05"
"Selinexor","FDA","2020-06-22","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"SADAL","2020-06-22: Granted accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL), not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>, after at least 2 lines of systemic therapy. <i>(New disease entity; based on SADAL)</i>","2022-09-05"
"Selinexor","FDA","2020-06-22","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"SADAL","2020-06-22: Granted accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL), not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>, after at least 2 lines of systemic therapy. <i>(New disease entity; based on SADAL)</i>","2022-09-05"
"Selinexor","FDA","2020-12-18","Multiple myeloma",FALSE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","Bortezomib AND Dexamethasone","","",TRUE,"BOSTON","2020-12-18: Full approval in combination with bortezomib and dexamethasone for the treatment of adult patients with <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least one prior therapy. <i>(Based on BOSTON)</i>","2022-09-05"
"Selpercatinib","EMA","2021-02-11","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-02-11: Initial conditional authorization as Retsevmo.","2023-05-08"
"Selpercatinib","FDA","2020-05-08","Non-small cell lung cancer",TRUE,FALSE,TRUE,"","","Metastatic","","adults","","",NA,"","","","","","RET fusion","FALSE",TRUE,"LIBRETTO-001_NSCLC","2020-05-08: Granted accelerated approval for adult patients with metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion-positive</a> <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on LIBRETTO-001_NSCLC)</i>","2022-09-05"
"Selpercatinib","FDA","2020-05-08","Thyroid cancer",TRUE,FALSE,TRUE,"","","Advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","Iodine-131, if appropriate","FALSE","","","","","","RET fusion","FALSE",TRUE,"LIBRETTO-001_thyroid","2020-05-08: Granted accelerated approval for adult and pediatric patients at least 12 years of age with advanced or metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion-positive</a> <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a> who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). <i>(Based on LIBRETTO-001_thyroid)</i>","2023-01-03"
"Selpercatinib","FDA","2020-05-08","Thyroid cancer",TRUE,FALSE,TRUE,"","","Advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","RET mutation","FALSE",TRUE,"LIBRETTO-001_thyroid","2020-05-08: Granted accelerated approval for adult and pediatric patients at least 12 years of age with advanced or metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutant</a> <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a> (MTC) who require systemic therapy. <i>(Based on LIBRETTO-001_thyroid)</i>","2023-01-03"
"Selpercatinib","FDA","2022-09-21","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","",NA,"","","","","","RET fusion","FALSE",TRUE,"LIBRETTO-001_NSCLC","2022-09-21: Granted regular approval for adult patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">rearranged during transfection (RET) gene</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion</a>. <i>(Based on LIBRETTO-001_NSCLC)</i>","2022-11-03"
"Selpercatinib","FDA","2022-09-21","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","1+ SACT OR no satisfactory treatment options","FALSE","","progression","","","","RET fusion","FALSE",TRUE,"LIBRETTO-001_RET","2022-09-21: Granted accelerated approval for adult patients with locally advanced or metastatic <a href=""/wiki/Malignant_solid_neoplasm,_RET-mutated"" title=""Malignant solid neoplasm, RET-mutated"">solid tumors with a rearranged during transfection (RET) gene fusion</a> that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. <i>(Based on LIBRETTO-001_RET)</i>","2022-11-03"
"Selpercatinib","FDA","2023-06-12","Thyroid cancer",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults AND pediatric patients 2 years and older","","Radioactive iodine if appropriate",NA,"","refractory","","","","RET fusion","FALSE",TRUE,"LIBRETTO-001_thyroid","2023-06-12: Regular approval for adult and pediatric patients 2 years of age and older with advanced or metastatic <a href=""/wiki/Biomarkers#RET"" title=""Biomarkers"">RET</a> <a href=""/wiki/Biomarkers#fusion"" title=""Biomarkers"">fusion-positive</a> <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a> who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). <i>(Based on LIBRETTO-001_thyroid)</i>","2024-09-06"
"Selpercatinib","FDA","2024-05-29","Malignant solid neoplasm RET-mutated",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","pediatric patients 2 years or older","","1+ SACT OR no satisfactory treatment options",NA,"","progression","","","","RET fusion","",TRUE,"LIBRETTO-121","2024-05-29: Granted accelerated approval for pediatric patients two years of age and older with locally advanced or metastatic <a href=""/wiki/Malignant_solid_neoplasm,_RET-mutated"" title=""Malignant solid neoplasm, RET-mutated"">solid tumors with a RET gene fusion</a>, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. <i>(Based on LIBRETTO-121)</i>","2024-06-03"
"Selpercatinib","FDA","2024-05-29","Thyroid cancer medullary",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","pediatric patients 2 years or older","","",NA,"","","","","","RET mutation","",TRUE,"LIBRETTO-121","2024-05-29: Granted accelerated approval for pediatric patients two years of age and older with advanced or metastatic <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer (MTC)</a> with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. <i>(Based on LIBRETTO-121)</i>","2024-06-03"
"Selpercatinib","FDA","2024-05-29","Thyroid cancer",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","pediatric patients 2 years or older","","I-131 (if appropriate)",NA,"","refractory","","","","RET fusion","",TRUE,"LIBRETTO-121","2024-05-29: Granted accelerated approval for pediatric patients two years of age and older with advanced or metastatic <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a> with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). <i>(Based on LIBRETTO-121)</i>","2024-06-03"
"Selpercatinib","FDA","2024-09-27","Thyroid cancer medullary",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"LIBRETTO-531","2024-09-27: Granted regular approval for adult and pediatric patients 2 years of age and older with advanced or metastatic <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer (MTC)</a> with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. <i>(Based on LIBRETTO-531)</i>","2024-12-02"
"Selpercatinib","HC","2021-06-15","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","0","RET fusion","FALSE",NA,"","2021-06-15: Initial notice of compliance with conditions as monotherapy for the treatment of metastatic RET fusion-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> in adult patients.","2023-05-08"
"Selpercatinib","HC","2021-06-15","Thyroid cancer differentiated",TRUE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","Sorafenib OR Lenvatinib","FALSE","","","","","0","RET fusion","FALSE",NA,"","2021-06-15: Initial notice of compliance with conditions as monotherapy for the treatment of RET fusion-positive <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated thyroid carcinoma</a> in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.","2023-05-08"
"Selpercatinib","HC","2021-06-15","Thyroid cancer medullary",TRUE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults AND pediatric patients 12 years and older","","",NA,"","","","","0","RET mutation","FALSE",NA,"","2021-06-15: Initial notice of compliance with conditions as monotherapy for the treatment of RET-mutant <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer (MTC)</a> in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.","2023-05-08"
"Selpercatinib","PMDA","2021-09-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","RET fusion","FALSE",NA,"","2021-09-27: Newly indicated for the treatment of RET fusion gene-positive unresectable advanced or recurrent <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Selpercatinib","PMDA","2022-02-25","Thyroid cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","RET fusion","FALSE",NA,"","2022-02-25: New indication and a new dosage for the treatment of RET fusion gene-positive unresectable <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a>.","2023-06-16"
"Selpercatinib","PMDA","2022-02-25","Thyroid cancer medullary",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","RET mutation","FALSE",NA,"","2022-02-25: New indication and a new dosage for the treatment of RET gene mutation-positive unresectable <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a>.","2023-06-16"
"Selumetinib","EMA","2020-04-10","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-04-10: Initial marketing authorisation.","2023-07-31"
"Selumetinib","FDA","2020-04-10","Plexiform neurofibroma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2020-04-10: Approved for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable <a href=""/w/index.php?title=Plexiform_neurofibromaandaction=editandredlink=1"" class=""new"" title=""Plexiform neurofibroma (page does not exist)"">plexiform neurofibromas (PN)</a>.","2022-09-05"
"Selumetinib","PMDA","2022-09-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-09-26: Drugs with a new active ingredient indicated for the treatment of <a href=""/w/index.php?title=Plexiform_neurofibromaandaction=editandredlink=1"" class=""new"" title=""Plexiform neurofibroma (page does not exist)"">plexiform neurofibroma</a> in patients with neurofibromatosis type 1.","2023-06-16"
"Semustine","","","",FALSE,FALSE,FALSE,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Sennosides","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Serplulimab","NMPA","2022-03-25","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","Advanced unresectable OR Metastatic","","adults","","Standard therapies",NA,"","failure","","","","MSI-H","",TRUE,"HLX10-010-MSI201","2022-03-25: Initial approval for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> that have failed to respond to previous standard treatments. <i>(Based on HLX10-010-MSI201)</i>","2023-05-08"
"Serplulimab","NMPA","2022-11-01","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","First-line","Unresectable locally advanced OR Metastatic","","","","",NA,"","","","","Carboplatin AND nab-Paclitaxel","","",TRUE,"ASTRUM-004","2022-11-01: Approved in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer (sqNSCLC)</a>. <i>(Based on ASTRUM-004)</i>","2023-07-31"
"Serplulimab","NMPA","2023-01-18","Small cell lung cancer",FALSE,FALSE,FALSE,"","","Extensive stage","","","","",NA,"","","","","Carboplatin AND Etoposide","","",TRUE,"ASTRUM-005","2023-01-18: Approved for ES-<a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">SCLC</a> in combination with carboplatin and etoposide. <i>(Based on ASTRUM-005)</i>","2023-07-31"
"Siltuximab","FDA","2014-04-23","Castleman disease",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",TRUE,"CR016705","2014-04-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm"">FDA approved</a> for the treatment of patients with <a href=""/wiki/Castleman_disease"" title=""Castleman disease""> multicentric Castleman's disease (MCD)</a> who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. <i>(Based on CR016705)</i>","2022-09-05"
"Sintilimab","NMPA","2018-12-24","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-12-24: Initial approval","2023-09-09"
"Sipuleucel-T","EMA","2013-09-06","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Non-visceral metastatic","","men with asymptomatic or minimally symptomatic","chemotherapy is not yet clinically indicated","",NA,"","","","","","","",NA,"","2013-09-06: Initial authorization for treating men with asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> in whom chemotherapy is not yet clinically indicated.","2023-05-08"
"Sipuleucel-T","EMA","2015-05-06","NONE",FALSE,TRUE,FALSE,"No linked condition","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",NA,"","2015-05-06: Authorization withdrawn at the request of the manufacturer, for commercial reasons","2023-05-08"
"Sipuleucel-T","FDA","2010-04-29","Prostate cancer",FALSE,FALSE,TRUE,"","Castrate-resistant","Metastatic","","asymptomatic or minimally symptomatic","","",NA,"","","","","","","",TRUE,"D9901","2010-04-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm"">Initial FDA approval</a> for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on D9901 and IMPACT_prostate)</i>","2022-09-05"
"Sipuleucel-T","FDA","2010-04-29","Prostate cancer",FALSE,FALSE,TRUE,"","Castrate-resistant","Metastatic","","asymptomatic or minimally symptomatic","","",NA,"","","","","","","",TRUE,"IMPACT_prostate","2010-04-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm"">Initial FDA approval</a> for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>. <i>(Based on D9901 and IMPACT_prostate)</i>","2022-09-05"
"Sirolimus","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Sirolimus protein-bound particles","FDA","2021-11-22","PEComa",FALSE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","","","",TRUE,"AMPECT","2021-11-22: Approved for adult patients with locally advanced unresectable or metastatic malignant <a href=""/wiki/PEComa"" title=""PEComa"">perivascular epithelioid cell tumor (PEComa)</a>. <i>(Based on AMPECT)</i>","2022-09-05"
"Sonidegib","EMA","2015-08-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-08-14: Initial authorization","2023-05-08"
"Sonidegib","EMA","Uncertain date","Cutaneous basal cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","adults","not amenable to curative surgery or radiation therapy","",NA,"","","","","","","",NA,"","Uncertain date: Odomzo is indicated for the treatment of adult patients with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma (BCC)</a> who are not amenable to curative surgery or radiation therapy.","2023-05-20"
"Sonidegib","FDA","2015-07-24","Cutaneous basal cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","","not candidate for surgery or radiation therapy","",NA,"","","","","","","",TRUE,"BOLT","2015-07-24: Initial approval for the treatment of patients with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma (BCC)</a> who are not candidates for surgery or radiation therapy. <i>(Based on BOLT)</i>","2023-03-10"
"Sonidegib","FDA","2015-07-24","Cutaneous basal cell carcinoma",FALSE,FALSE,FALSE,"","","Locally advanced","","","","Surgery or Radiation therapy","FALSE","","recurrence","","","","","",TRUE,"BOLT","2015-07-24: Initial approval for the treatment of patients with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma (BCC)</a> that has recurred following surgery or radiation therapy. <i>(Based on BOLT)</i>","2023-03-10"
"Sorafenib","EMA","2006-07-19","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2006-07-19: Initial marketing authorization as Nexavar. Nexavar is indicated for the treatment of <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a>.","2023-09-17"
"Sorafenib","EMA","2006-07-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","(Interferon alfa|Interleukin-2) OR considered unsuitable for such therapy",NA,"","","","","","","",NA,"","2006-07-19: Initial marketing authorization as Nexavar. Nexavar is indicated for the treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.","2023-09-17"
"Sorafenib","EMA","2014-05-23","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Radioactive iodine",NA,"","refractory","","","","","",NA,"","2014-05-23: Extension of the indication for the treatment of progressive, locally advanced or metastatic, <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma</a>, refractory to radioactive iodine.","2023-09-17"
"Sorafenib","FDA","2005-12-20","Renal cell carcinoma",FALSE,FALSE,TRUE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"TARGET_RCC","2005-12-20: Approved for the treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma (RCC)</a>. <i>(Based on TARGET_RCC)</i>","2022-09-05"
"Sorafenib","FDA","2007-11-16","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",TRUE,"SHARP","2007-11-16: Approved for the treatment of patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma""> hepatocellular carcinoma (HCC)</a>. <i>(Based on SHARP)</i>","2022-09-05"
"Sorafenib","FDA","2013-11-22","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","","Locally recurrent OR Metastatic","","","","Iodine-131","FALSE","","refractory","","","","","",TRUE,"DECISION","2013-11-22: Approved for the treatment of locally recurrent or metastatic, progressive, <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated""> differentiated thyroid carcinoma (DTC)</a> refractory to radioactive iodine treatment. <i>(Based on DECISION)</i>","2022-09-05"
"Sorafenib","HC","2006-07-28","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-07-28: Initial notice of compliance with conditions","2023-05-08"
"Sorafenib","HC","2009-06-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-06-12: Conditions were met","2023-05-08"
"Sorafenib","PMDA","2008-01-25","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2008-01-25: Initial approval for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Sorafenib","PMDA","2009-05-20","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2009-05-20: New additional indication for the treatment of unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a>.","2023-06-16"
"Sorafenib","PMDA","2014-06-20","Thyroid cancer differentiated",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2014-06-20: New additional indication for the treatment of unresectable <a href=""/wiki/Thyroid_cancer,_differentiated"" title=""Thyroid cancer, differentiated"">differentiated thyroid carcinoma</a>.","2023-06-16"
"Sorafenib","PMDA","2016-02-29","Thyroid cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2016-02-29: Revised indication for the treatment of unresectable <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">thyroid cancer</a>.","2023-06-16"
"Sotorasib","EMA","2022-01-06","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-01-06: Initial conditional authorization as Lumykras.","2023-05-08"
"Sotorasib","FDA","2021-05-28","Non-small cell lung cancer",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT","FALSE","","","","","","KRAS p.G12C","FALSE",TRUE,"CodeBreaK100_NSCLC","2021-05-28: Accelerated approval for adult patients with <a href=""/wiki/Biomarkers#KRAS"" title=""Biomarkers"">KRAS</a> <a href=""/wiki/Biomarkers#G12C"" title=""Biomarkers"">G12C-mutated</a> locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>, as determined by an FDA-approved test, who have received at least one prior systemic therapy. <i>(Based on CodeBreaK100_NSCLC)</i>","2023-01-03"
"Sotorasib","HC","2021-09-10","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","1+ SACT","FALSE","","","","","","KRAS p.G12C","FALSE",NA,"","2021-09-10: Initial notice of compliance with conditions for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> who have received at least one prior systemic therapy.","2023-05-08"
"Sotorasib","PMDA","2022-01-20","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","KRAS p.G12C","FALSE",NA,"","2022-01-20: Newly indicated for the treatment of unresectable advanced or recurrent KRAS G12C mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Stilbamidine","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Streptozocin","EMA","1982-05-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1982-05-07: EURD","2023-07-31"
"Streptozocin","FDA","1982-05-07","Pancreatic NET",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","","",FALSE,"","1982-05-07: Initial FDA approval for the treatment of metastatic <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">islet cell carcinoma of the pancreas</a>. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease. <i>(No supporting studies are cited)</i>","2022-09-05"
"Streptozocin","PMDA","2014-09-26","Pancreatic NET",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2014-09-26: Initial approval for the treatment of <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">neuroendocrine tumors of the pancreas</a> and gastrointestinal tract.","2023-06-16"
"Strontium-89","FDA","1993-06-18","Skeletal metastases from solid tumors",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases.","2022-09-05"
"Strontium-89","PMDA","2007-07-31","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-07-31: Initial approval for pain relief in bone scintigraphy-positive metastatic lesions in patients with solid cancers.","2023-06-16"
"Sugemalimab","NMPA","2022-06-06","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable stage III","","","","Platinum-based chemoradiotherapy","FALSE","","no progression","","","","","",TRUE,"GEMSTONE-301","2022-06-06: Approved for the treatment of patients with unresectable stage III <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. <i>(Based on GEMSTONE-301)</i>","2023-05-08"
"Sunitinib","EMA","2006-07-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced OR Metastatic","","adults","","",NA,"","","","","","","",NA,"","2006-07-19: Initial authorization as Sutent. Sutent is indicated for the treatment of advanced/metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> (MRCC) in adults.","2023-09-17"
"Sunitinib","EMA","Uncertain date","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Imatinib","FALSE","","Resistance OR intolerance","","","","","",NA,"","Uncertain date: Sutent is indicated for the treatment of unresectable and/or metastatic malignant <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumour (GIST)</a> in adults after failure of imatinib mesilate treatment due to resistance or intolerance.","2023-09-17"
"Sunitinib","EMA","Uncertain date","Pancreatic NET",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","well-differentiated","","","",NA,"","progression","","","","","",NA,"","Uncertain date: Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumours</a> with disease progression in adults.","2023-09-17"
"Sunitinib","FDA","2006-01-26","Renal cell carcinoma",TRUE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"A618-1006","2006-01-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021968lbl.pdf"">Initial accelerated approval</a> for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a>. <i>(Based on RTKC-0511-014 and A618-1006)</i>","2022-09-05"
"Sunitinib","FDA","2006-01-26","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","","","Imatinib","FALSE","","progression OR intolerance","","","","","",TRUE,"A6181004","2006-01-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021968lbl.pdf"">Initial FDA approval</a> for the treatment of <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumor</a> after disease progression on or intolerance to <a href=""/wiki/Imatinib_(Gleevec)"" title=""Imatinib (Gleevec)""> imatinib mesylate</a>. <i>(Based on A6181004)</i>","2022-09-05"
"Sunitinib","FDA","2006-01-26","Renal cell carcinoma",TRUE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"RTKC-0511-014","2006-01-26: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021968lbl.pdf"">Initial accelerated approval</a> for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a>. <i>(Based on RTKC-0511-014 and A618-1006)</i>","2022-09-05"
"Sunitinib","FDA","2007-02-02","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"A618-1034","2007-02-02: Granted regular approval for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>. <i>(Converted to regular approval; based on A618-1034)</i>","2022-09-05"
"Sunitinib","FDA","2011-05-20","Pancreatic NET",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","","","",NA,"","","","","","","",TRUE,"A6181111","2011-05-20: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm256499.htm"">FDA approved</a> for treatment of progressive, well-differentiated <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumors (pNET)</a> in patients with unresectable locally advanced or metastatic disease. <i>(Based on A6181111)</i>","2022-09-05"
"Sunitinib","FDA","2017-11-16","Renal cell carcinoma",FALSE,FALSE,FALSE,"","Adjuvant","","High-risk for recurrence","adults","","Nephrectomy","FALSE","","","","","","","",TRUE,"S-TRAC","2017-11-16: Approved for the adjuvant treatment of adult patients at high risk of recurrent <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a> following nephrectomy. <i>(Approval expanded to the adjuvant setting; based on S-TRAC)</i>","2022-09-05"
"Sunitinib","HC","2006-08-17","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-08-17: Initial notice of compliance with conditions","2023-05-08"
"Sunitinib","HC","2010-04-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-04-23: Conditions were met","2023-05-08"
"Sunitinib","PMDA","2008-04-16","Gastrointestinal stromal tumor",FALSE,FALSE,FALSE,"","","","","","","Imatinib","FALSE","","resistance","","","","","",NA,"","2008-04-16: Initial approval for the treatment of imatinib-resistant <a href=""/wiki/Gastrointestinal_stromal_tumor"" title=""Gastrointestinal stromal tumor"">gastrointestinal stromal tumors</a>.","2023-06-16"
"Sunitinib","PMDA","2008-04-16","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2008-04-16: Initial approval for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinomas</a>.","2023-06-16"
"Sunitinib","PMDA","2012-08-10","Pancreatic NET",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-08-10: New additional indication and a new dosage for <a href=""/wiki/Pancreatic_NET"" title=""Pancreatic NET"">pancreatic neuroendocrine tumour</a>.","2023-06-16"
"Suramin","","","",FALSE,FALSE,NA,"No month/year information","","","","","","",NA,"","","","","","","",NA,"",NA,"2023-05-08"
"Suramin","","","",FALSE,FALSE,NA,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Sutimlimab","EMA","2022-11-15","Cold agglutinin disease",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",NA,"","2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with <a href=""/wiki/Cold_agglutinin_disease"" title=""Cold agglutinin disease"">cold agglutinin disease (CAD)</a>.","2023-05-08"
"Sutimlimab","FDA","2022-02-04","Cold agglutinin disease",FALSE,FALSE,TRUE,"","","","","adults","","",NA,"","","","","","","",TRUE,"CARDINAL","2022-02-04: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with <a href=""/wiki/Cold_agglutinin_disease"" title=""Cold agglutinin disease"">cold agglutinin disease (CAD)</a>. <i>(Based on CARDINAL)</i>","2022-11-22"
"Sutimlimab","PMDA","2022-06-20","Cold agglutinin disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2022-06-20: A drug with a new active ingredient indicated for the treatment of <a href=""/wiki/Cold_agglutinin_disease"" title=""Cold agglutinin disease"">cold agglutinin disease</a>.","2023-06-16"
"Tabelecleucel","EMA","2022-12-16","Post-transplant lymphoproliferative disorder",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","adults AND pediatric patients 2 years and older","","",NA,"1+","","","","0","EBV+","FALSE",NA,"","2022-12-16: Initial authorization as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive <a href=""/wiki/Post-transplant_lymphoproliferative_disorder"" title=""Post-transplant lymphoproliferative disorder"">post-transplant lymphoproliferative disease</a> (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.","2023-05-08"
"Tacrolimus","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Tafasitamab","EMA","2021-08-26","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-08-26: Initial conditional approval as Minjuvi","2023-05-08"
"Tafasitamab","FDA","2020-07-31","Diffuse large B-cell lymphoma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","not eligible for autologous HSCT","",NA,"","","","","Lenalidomide","","",TRUE,"L-MIND","2020-07-31: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, and who are not eligible for autologous stem cell transplant. <i>(Based on L-MIND)</i>","2022-09-05"
"Tafasitamab","FDA","2020-07-31","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","not eligible for autologous HSCT","",NA,"","","","","Lenalidomide","","",TRUE,"L-MIND","2020-07-31: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, and who are not eligible for autologous stem cell transplant. <i>(Based on L-MIND)</i>","2022-09-05"
"Tafasitamab","HC","2021-08-19","Diffuse large B-cell lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","not eligible for autologous HSCT","",NA,"","","","","Lenalidomide","","",NA,"","2021-08-19: Initial notice of compliance with conditions in combination with lenalidomide for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, who are not eligible for autologous stem cell transplant (ASCT)","2023-05-08"
"Tafasitamab","HC","2021-08-19","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","not eligible for autologous HSCT","",NA,"","","","","Lenalidomide","","",NA,"","2021-08-19: Initial notice of compliance with conditions in combination with lenalidomide for the treatment of adult patients with relapsed or refractory <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, including <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from low grade lymphoma</a>, who are not eligible for autologous stem cell transplant (ASCT)","2023-05-08"
"Tagraxofusp","EMA","2021-01-07","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-01-07: Initial authorization as Elzonris","2023-05-08"
"Tagraxofusp","FDA","2018-12-21","Blastic plasmacytoid dendritic cell neoplasm",FALSE,FALSE,TRUE,"","","","","adults AND pediatric patients 2 years and older","","",NA,"","","","","","","",TRUE,"STML-401-0114","2018-12-21: Initial approval for <a href=""/wiki/Blastic_plasmacytoid_dendritic_cell_neoplasm"" title=""Blastic plasmacytoid dendritic cell neoplasm"">blastic plasmacytoid dendritic cell neoplasm (BPDCN)</a> in adults and in pediatric patients 2 years and older. <i>(Based on STML-401-0114)</i>","2022-09-05"
"Talazoparib","EMA","2019-06-20","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Anthracycline AND Taxane unless not suitable","FALSE","(neo)adjuvant|Locally advanced|Metastatic","","","HR-positive: endocrine therapy or be considered unsuitable for endocrine-based therapy","0","gBRCAm and HER2-","FALSE",TRUE,"EMBRACA","2019-06-20: Initial authorization as Talzenna. Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. <i>(Based on EMBRACA)</i>","2023-09-17"
"Talazoparib","EMA","2023-11-09","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","adults","chemotherapy is not clinically indicated","",NA,"","","","","Enzalutamide","","",NA,"","2023-11-09: CHMP recommends new marketing authorisation - Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC) in whom chemotherapy is not clinically indicated.","2024-01-06"
"Talazoparib","EMA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy",NA,"","","","","0","gBRCAm and HER2-","",NA,"","Uncertain date: Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.","2023-05-08"
"Talazoparib","FDA","2018-10-16","Breast cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","",NA,"","","","","","gBRCAm and HER2-","FALSE",TRUE,"EMBRACA","2018-10-16: Initial approval for patients with deleterious or suspected deleterious <a href=""/wiki/Biomarkers#Germline"" title=""Biomarkers"">germline</a> <a href=""/wiki/Biomarkers#BRCA"" title=""Biomarkers"">BRCA</a>-<a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutated</a> (gBRCAm), <a href=""/wiki/Biomarkers#ERBB2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#negative"" title=""Biomarkers"">negative</a> locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on EMBRACA)</i>","2022-09-05"
"Talazoparib","FDA","2023-06-20","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","","","","","",NA,"","","","","Enzalutamide","HRR mutation","FALSE",TRUE,"TALAPRO-2","2023-06-20: Approved with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a> (mCRPC). <i>(Based on TALAPRO-2)</i>","2023-07-31"
"Talazoparib","PMDA","2024-01-18","Prostate cancer",FALSE,FALSE,FALSE,"","Castrate-resistant","Metastatic","","","","",NA,"","","","","","BRCAm","",NA,"","2024-01-18: Newly indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer"">prostate cancer</a>.","2024-06-03"
"Talazoparib","PMDA","2024-01-18","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","Chemotherapy",NA,"","","","","","BRCAm AND HER2-","",NA,"","2024-01-18: Newly indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in patients who have previously been treated with chemotherapy.","2024-06-03"
"Talimogene laherparepvec","EMA","2015-12-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2015-12-16: Initial authorization","2023-05-08"
"Talimogene laherparepvec","FDA","2015-10-27","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable","","","","Surgery","FALSE","","recurrence","","","","","",TRUE,"OPTiM","2015-10-27: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm"">FDA approved</a> for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> recurrent after initial surgery. <i>(Based on OPTiM)</i>","2022-09-05"
"Taloporfin","PMDA","2013-09-20","CNS cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","","",NA,"","2013-09-20: New additional indication and a new dosage for the treatment of <a href=""/wiki/Category:CNS_cancers"" title=""Category:CNS cancers"">primary malignant brain tumor</a> (only for the case where surgical excision of tumor is performed).","2023-07-31"
"Taloporfin","PMDA","2015-05-26","Esophageal cancer",FALSE,FALSE,FALSE,"","","Recurrent","","","","Radiotherapy OR Chemoradiotherapy","FALSE","","persistence","","","","","",NA,"","2015-05-26: New additional indication for the treatment of recurrent <a href=""/wiki/Esophageal_cancer"" title=""Esophageal cancer"">esophageal cancer</a> associated with local persistence after chemoradiotherapy or radiotherapy.","2023-07-31"
"Talquetamab","FDA","2023-08-09","Multiple myeloma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","4+ SACT, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody","FALSE","","","","","","","",TRUE,"MonumenTAL-1","<b>2023-08-09:</b> Granted accelerated approval for adults with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. <i>(Based on MonumenTAL-1)</i>","2023-09-09"
"Tamibarotene","PMDA","2005-04-11","Acute promyelocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2005-04-11: Initial approval for the treatment of <a href=""/wiki/Acute_promyelocytic_leukemia"" title=""Acute promyelocytic leukemia"">Acute promyelocytic leukemia</a>.","2023-06-16"
"Tamoxifen","EMA","1974-04-29","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1974-04-29: EURD","2023-07-31"
"Tamoxifen","FDA","1977-12-30","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1977-12-30: Initial FDA approval","2022-09-05"
"Tamoxifen","FDA","1989-03-16","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","premenopausal women","","",NA,"","","","","","","",TRUE,"Buchanan et al. 1986","1989-03-16: Approved for use in premenopausal women with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as an alternative to oophorectomy or ovarian radiation. <i>(Based on Buchanan et al. 1986, Crump et al. 1997, Ingle et al. 1986a)</i>","2022-09-05"
"Tamoxifen","FDA","1989-03-16","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","premenopausal women","","",NA,"","","","","","","",TRUE,"Crump et al. 1997","1989-03-16: Approved for use in premenopausal women with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as an alternative to oophorectomy or ovarian radiation. <i>(Based on Buchanan et al. 1986, Crump et al. 1997, Ingle et al. 1986a)</i>","2022-09-05"
"Tamoxifen","FDA","1989-03-16","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","premenopausal women","","",NA,"","","","","","","",TRUE,"Ingle et al. 1986a","1989-03-16: Approved for use in premenopausal women with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as an alternative to oophorectomy or ovarian radiation. <i>(Based on Buchanan et al. 1986, Crump et al. 1997, Ingle et al. 1986a)</i>","2022-09-05"
"Tamoxifen","FDA","1998-10-29","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1998-10-29: Approved to reduce the occurrence of contralateral breast cancer in patients receiving adjuvant Nolvadex therapy for <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2022-09-05"
"Tamoxifen","FDA","1998-10-29","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1998-10-29: Approved to reduce the incidence of breast cancer in women at high risk for breast cancer.","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"ECOG 1178","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"Hubay et al. 1980","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"NATO","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"NCIC-CTG MA.4","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"NSABP B-09","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","postmenopausal women","","Total mastectomy OR Segmental mastectomy, axillary dissection, and breast irradiation","FALSE","","","","","","","",TRUE,"NSABP B-14","Uncertain date: Approved for the treatment of node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. <i>(Based on ECOG 1178, Hubay et al. 1980, NATO, NCIC-CTG MA.4, NSABP B-09, NSABP B-14)</i>","2022-09-05"
"Tamoxifen","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","ER+","FALSE",TRUE,"Crump et al. 1997","Uncertain date: Approved for the treatment of metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in women and men. Available evidence indicates that patients whose tumors are <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> are more likely to benefit from NOLVADEX therapy. <i>(Based on Crump et al. 1997)</i>","2022-09-05"
"Tarlatamab","FDA","2024-05-16","Small cell lung cancer",TRUE,FALSE,TRUE,"","","Extensive stage","","","","Platinum-containing chemotherapy",NA,"","progression","","","","","",TRUE,"DeLLphi-301","2024-05-16: Granted accelerated approval for extensive stage <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer"">small cell lung cancer</a> (ES-SCLC) with disease progression on or after platinum-based chemotherapy. <i>(Based on DeLLphi-301)</i>","2024-06-03"
"Tazemetostat","FDA","2020-01-23","Epithelioid sarcoma",TRUE,FALSE,TRUE,"","","Locally advanced OR Metastatic","","adults AND pediatric patients 16 years and older","not eligible for complete resection","",NA,"","","","","","","",TRUE,"EZH-202","2020-01-23: Granted accelerated approval for adults and pediatric patients aged 16 years and older with metastatic or locally advanced <a href=""/wiki/Epithelioid_sarcoma"" title=""Epithelioid sarcoma"">epithelioid sarcoma</a> not eligible for complete resection. <i>(Based on EZH-202)</i>","2022-09-05"
"Tazemetostat","FDA","2020-06-17","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","EZH2 mutation","FALSE",TRUE,"E7438-G000-101","2020-06-17: Granted accelerated approval for adult patients with relapsed or refractory (R/R) <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> whose tumors are positive for an <a href=""/wiki/Biomarkers#EZH2"" title=""Biomarkers"">EZH2</a> <a href=""/wiki/Biomarkers#Alterations"" title=""Biomarkers"">mutation</a> as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. <i>(Based on E7438-G000-101)</i>","2022-09-05"
"Tazemetostat","FDA","2020-06-17","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","no satisfactory alternative treatment options","",NA,"","","","","","","",TRUE,"E7438-G000-101","2020-06-17: Granted accelerated approval for adult patients with R/R <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">FL</a> who have no satisfactory alternative treatment options. <i>(Based on E7438-G000-101)</i>","2022-09-05"
"Tazemetostat","PMDA","2021-06-23","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","Standard therapies","FALSE","","refractory or intolerant","","","","EZH2 mutation","FALSE",NA,"","2021-06-23: Newly indicated for the treatment of relapsed or refractory EZH2 gene mutation-positive <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma</a> (for use only if refractory or intolerant to standard therapies).","2023-06-16"
"Tbo-filgrastim","FDA","2012-08-29","Neutropenia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2012-08-29: Initial approval for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.","2022-09-05"
"Tebentafusp","EMA","2022-04-01","Uveal melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","0","HLA-A*02:01 positive","FALSE",NA,"","2022-04-01: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic <a href=""/wiki/Uveal_melanoma"" title=""Uveal melanoma"">uveal melanoma</a>.","2023-05-08"
"Tebentafusp","FDA","2022-01-25","Uveal melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","","HLA-A*02:01 positive","FALSE",TRUE,"IMCgp100-202","2022-01-25: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic <a href=""/wiki/Uveal_melanoma"" title=""Uveal melanoma"">uveal melanoma</a>. <i>(Based on IMCgp100-202)</i>","2022-09-05"
"Teclistamab","EMA","2022-08-23","Multiple myeloma",TRUE,FALSE,TRUE,"","","Relapsed or refractory","","adults","","3+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","progression","","","0","","",NA,"","2022-08-23: Initial conditional approval as monotherapy for the treatment of adult patients with relapsed and refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.","2023-05-08"
"Teclistamab","FDA","2022-10-25","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","4+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","","","","","","",TRUE,"MajesTEC-1 Phase 1","2022-10-25: Approved for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. <i>(Based on MajesTEC-1 Phase 1 and MajesTEC-1 Phase 2)</i>","2022-11-22"
"Teclistamab","FDA","2022-10-25","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","4+, including Proteasome inhibitor AND Immunomodulator AND anti-CD38 antibody","FALSE","","","","","","","",TRUE,"MajesTEC-1 Phase 2","2022-10-25: Approved for adult patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. <i>(Based on MajesTEC-1 Phase 1 and MajesTEC-1 Phase 2)</i>","2022-11-22"
"Teclistamab","FDA","2024-02-20","Multiple myeloma",FALSE,FALSE,FALSE,"","Relapsed or refractory","","","","","",NA,"","CR or better for at least 6 months","","","","","",TRUE,"MajesTEC-1 Phase 1","2024-02-20: Approved for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have achieved and maintained a complete response or better for a minimum of 6 months. <i>(Based on MajesTEC-1 Phase 1 and MajesTEC-1 Phase 2)</i>","2024-06-03"
"Teclistamab","FDA","2024-02-20","Multiple myeloma",FALSE,FALSE,FALSE,"","Relapsed or refractory","","","","","",NA,"","CR or better for at least 6 months","","","","","",TRUE,"MajesTEC-1 Phase 2","2024-02-20: Approved for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a> who have achieved and maintained a complete response or better for a minimum of 6 months. <i>(Based on MajesTEC-1 Phase 1 and MajesTEC-1 Phase 2)</i>","2024-06-03"
"Tegafur and uracil","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Tegafur gimeracil oteracil","EMA","2011-03-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2011-03-14: Initial marketing authorization as Teysuno.","2023-05-08"
"Tegafur gimeracil oteracil","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Tegafur gimeracil oteracil","PMDA","2005-11-14","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2005-11-14: New indication for the treatment of inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2006-08-10","Pancreatic cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2006-08-10: New indication for <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of inoperable or relapsed <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Colorectal cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a> in addition to <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>, <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>, and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a> in addition to <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>, <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>, and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Head and neck cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a> in addition to <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>, <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>, and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a> in addition to <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>, <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>, and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2007-08-23","Pancreatic cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2007-08-23: New indication for the treatment of <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary cancer</a> in addition to <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a>, <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>, <a href=""/wiki/Head_and_neck_cancer"" title=""Head and neck cancer"">head and neck cancer</a>, <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>, and <a href=""/wiki/Pancreatic_cancer"" title=""Pancreatic cancer"">pancreatic cancer</a>.","2023-06-16"
"Tegafur gimeracil oteracil","PMDA","2022-11-24","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","High-risk for recurrence","","","Surgery","FALSE","","","","","","HR+ and HER2-","FALSE AND TRUE",NA,"","2022-11-24: New indication and a new dosage for the postoperative adjuvant treatment of hormone receptor(HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with a high risk of recurrence.","2023-06-16"
"Telotristat","FDA","2017-02-28","Neuroendocrine tumor",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2017-02-28: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544035.htm"">Initial FDA approval</a> to be used in combination with <a href=""/wiki/Category:Somatostatin_analogs"" title=""Category:Somatostatin analogs"">somatostatin analog (SSA) therapy</a> for the treatment of adults with <a href=""/wiki/Neuroendocrine_tumor"" title=""Neuroendocrine tumor"">carcinoid</a> syndrome diarrhea that SSA therapy alone has inadequately controlled.","2022-09-05"
"Temozolomide","EMA","1999-01-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1999-01-26: Initial marketing authorization as Temodal.","2023-05-08"
"Temozolomide","FDA","1999-08-11","Anaplastic glioma",TRUE,FALSE,FALSE,"","First relapse","Refractory","","adults","","Nitrosourea AND Procarbazine","FALSE","","progression","","","","","",TRUE,"MK-7365-006","1999-08-11: Initial accelerated approval for treatment of adult patients with refractory <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">anaplastic astrocytoma</a>, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine. <i>(Based on MK-7365-006)</i>","2022-09-05"
"Temozolomide","FDA","2005-03-15","Glioblastoma",FALSE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Radiotherapy","","",TRUE,"EORTC 22981/26981; NCIC-CTG CE.3","2005-03-15: Regular approval for newly diagnosed <a href=""/wiki/Glioblastoma"" title=""Glioblastoma"">glioblastoma multiforme (GBM)</a> concomitantly with radiotherapy and then as maintenance treatment. <i>(Based on EORTC 22981/26981; NCIC-CTG CE.3)</i>","2022-09-05"
"Temozolomide","FDA","2005-03-15","Anaplastic glioma",FALSE,FALSE,FALSE,"","","Refractory","","","","Nitrosourea AND Procarbazine","FALSE","","","","","","","",TRUE,"MK-7365-006","2005-03-15: Regular approval for refractory <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">anaplastic astrocytoma</a> patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. <i>(Based on MK-7365-006)</i>","2022-09-05"
"Temozolomide","FDA","2023-09-14","Anaplastic glioma",FALSE,FALSE,FALSE,"","Adjuvant","","","adults","","Surgery","FALSE","","","","","","","",TRUE,"CATNON","2023-09-14: Project Renewal revised indication for adjuvant treatment of adults with newly diagnosed <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">anaplastic astrocytoma</a>. <i>(Based on CATNON)</i>","2023-11-07"
"Temozolomide","FDA","2023-09-14","Anaplastic glioma",FALSE,FALSE,FALSE,"","","Refractory","","adults","","",NA,"","","","","","","",TRUE,"MK-7365-006","2023-09-14: Project Renewal revised indication for treatment of adults with refractory <a href=""/wiki/Anaplastic_glioma"" title=""Anaplastic glioma"">anaplastic astrocytoma</a>. <i>(Based on MK-7365-006)</i>","2023-11-07"
"Temozolomide","PMDA","2006-07-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2006-07-26: Initial approval for treatment of <a href=""/wiki/Category:Malignant_gliomas"" title=""Category:Malignant gliomas"">malignant glioma</a>.","2023-06-16"
"Temozolomide","PMDA","2019-02-21","Ewing sarcoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2019-02-21: New additional indication and a new dosage for the treatment of relapsed or refractory <a href=""/wiki/Ewing_sarcoma"" title=""Ewing sarcoma"">Ewing's sarcoma</a>.","2023-06-16"
"Temsirolimus","EMA","2007-11-19","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","at least three of six prognostic risk factors","","","",NA,"","","","","","","",TRUE,"ARCC","2007-11-19: Initial authorization as Torisel. Torisel is indicated for the first-line treatment of patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> who have at least three of six prognostic risk factors. <i>(Based on ARCC)</i>","2023-09-17"
"Temsirolimus","EMA","2009-10-14","Mantle cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","",NA,"","","","","","","",NA,"","2009-10-14: Extension of Indication to add treatment of adult patients with relapsed and/or refractory <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a>.","2023-09-17"
"Temsirolimus","FDA","2007-05-30","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"ARCC","2007-05-30: Initial FDA approval for the treatment of advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma""> renal cell carcinoma</a>. <i>(Based on ARCC)</i>","2022-09-05"
"Temsirolimus","HC","2007-12-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-12-21: Initial notice of compliance","2023-07-31"
"Temsirolimus","PMDA","2010-07-23","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","","",NA,"","2010-07-23: Initial approval for the treatment of unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma</a>.","2023-06-16"
"Teniposide","EMA","1976-04-05","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1976-04-05: EURD","2023-07-31"
"Teniposide","FDA","1992-07-14","Acute lymphoblastic leukemia",FALSE,FALSE,FALSE,"","Induction","Refractory","","","","",NA,"","","","","","","",NA,"","1992-07-14: Initial approval for induction therapy in patients with refractory childhood <a href=""/wiki/Category:Acute_lymphoblastic_leukemias"" title=""Category:Acute lymphoblastic leukemias"">acute lymphoblastic leukemia</a>","2022-09-05"
"Tepotinib","EMA","2022-02-16","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Require systemic therapy","Advanced","","adults","","Immunotherapy OR Platinum-based regimen","FALSE","","","","","0","MET exon 14 skipping alteration","FALSE",NA,"","2022-02-16: Initial authorization as monotherapy is indicated for the treatment of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","2023-05-08"
"Tepotinib","FDA","2021-02-03","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",TRUE,"VISION_NSCLC","2021-02-03: Granted accelerated approval for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harboring <a href=""/wiki/Biomarkers#MET"" title=""Biomarkers"">mesenchymal-epithelial transition (MET)</a> <a href=""/wiki/Biomarkers#Exon_14"" title=""Biomarkers"">exon 14</a> skipping alterations. <i>(Based on VISION_NSCLC)</i>","2022-09-05"
"Tepotinib","FDA","2024-02-15","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","","MET exon 14 skipping alteration","",TRUE,"VISION_NSCLC","2024-02-15: Granted full approval for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harboring <a href=""/wiki/Biomarkers#MET"" title=""Biomarkers"">mesenchymal-epithelial transition (MET)</a> <a href=""/wiki/Biomarkers#Exon_14"" title=""Biomarkers"">exon 14</a> skipping alterations. <i>(Based on VISION_NSCLC)</i>","2024-06-03"
"Tepotinib","HC","2021-05-27","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Locally advanced unresectable OR Metastatic","","adults","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",NA,"","2021-05-27: Initial notice of compliance with conditions for the treatment of adult patients with locally advanced unresectable or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.","2023-05-08"
"Tepotinib","PMDA","2020-03-25","Non-small cell lung cancer",FALSE,FALSE,TRUE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","MET exon 14 skipping alteration","FALSE",NA,"","2020-03-25: Newly indicated for the treatment of unresectable advanced or recurrent MET exon 14 (METex14) skipping mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Tetracycline","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Thalidomide","EMA","2008-04-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2008-04-16: EURD","2023-07-31"
"Thalidomide","FDA","2006-05-25","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Dexamethasone","","",TRUE,"ECOG E1A00","2006-05-25: First cancer-specific FDA indication: Accelerated approval in combination with <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)""> dexamethasone</a> for the treatment of patients with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma""> multiple myeloma</a>. <i>(Based on ECOG E1A00 and THAL-MM-003)</i>","2022-09-05"
"Thalidomide","FDA","2006-05-25","Multiple myeloma",TRUE,FALSE,FALSE,"","","","","","","0","FALSE","","","","","Dexamethasone","","",TRUE,"THAL-MM-003","2006-05-25: First cancer-specific FDA indication: Accelerated approval in combination with <a href=""/wiki/Dexamethasone_(Decadron)"" title=""Dexamethasone (Decadron)""> dexamethasone</a> for the treatment of patients with newly diagnosed <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma""> multiple myeloma</a>. <i>(Based on ECOG E1A00 and THAL-MM-003)</i>","2022-09-05"
"Thalidomide","FDA","2014-06-19","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2014-06-19: Converted to regular approval. <i>(No supporting studies are cited)</i>","2022-09-05"
"Thalidomide","HC","2010-08-04","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-08-04: Initial notice of compliance","2023-07-31"
"Thalidomide","PMDA","2008-10-16","Multiple myeloma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2008-10-16: Initial approval for the treatment of relapsed or refractory <a href=""/wiki/Multiple_myeloma"" title=""Multiple myeloma"">multiple myeloma</a>.","2023-06-16"
"Thioguanine","EMA","1966-01-18","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1966-01-18: EURD","2023-07-31"
"Thioguanine","FDA","1966-01-18","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1966-01-18: Initial approval","2022-09-05"
"Thiotepa","EMA","1959-03-09","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1959-03-09: EURD","2023-07-31"
"Thiotepa","EMA","2010-03-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-03-15: Initial authorization as Tepadina","2023-05-08"
"Thiotepa","FDA","1959-03-09","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1959-03-09: Initial FDA approval","2022-09-05"
"Thiotepa","FDA","Uncertain date","Beta thalassemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Approved to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with <a href=""/wiki/Beta_thalassemia"" title=""Beta thalassemia"">class 3 beta-thalassemia</a>.","2022-09-05"
"Thiotepa","FDA","Uncertain date","Bladder cancer",FALSE,FALSE,FALSE,"","","Superficial","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for treatment of superficial <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer"">papillary carcinoma of the urinary bladder</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Thiotepa","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for treatment of adenocarcinoma of the <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast</a> or <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovary</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Thiotepa","FDA","Uncertain date","Malignant neoplasm",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for controlling intracavitary effusions secondary to diffuse or localized <a href=""/wiki/Category:Malignant_neoplasm"" title=""Category:Malignant neoplasm"">neoplastic diseases</a> of various serosal cavities. <i>(No supporting studies are cited)</i>","2022-09-05"
"Thiotepa","FDA","Uncertain date","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for treatment of adenocarcinoma of the <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast</a> or <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovary</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Thiotepa","HC","2017-03-29","CNS lymphoma",TRUE,FALSE,FALSE,"","Consolidation","","","adults","","",NA,"","","","","High-dose chemotherapy","","",NA,"","2017-03-29: Notice of compliance with conditions in combination with other chemotherapeutic products as part of a high-dose chemotherapy (HDCT) consolidation regimen followed by autologous stem cell transplantation (ASCT) for adult patients with <a href=""/wiki/CNS_lymphoma"" title=""CNS lymphoma"">central nervous system (CNS) lymphoma</a>.","2023-05-08"
"Thiotepa","PMDA","2019-03-26","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","prior to auto HSCT","","pediatric","","",NA,"","","","","","","",NA,"","2019-03-26: Newly approved for the conditioning treatment of <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a> in pediatric patients prior to autologous hematopoietic stem-cell transplantation.","2023-06-16"
"Thiotepa","PMDA","2020-03-25","Lymphoma",FALSE,FALSE,FALSE,"","Conditioning","","","","","",NA,"","","","","","","",NA,"","2020-03-25: New indication and a new dosage for the conditioning treatment of <a href=""/wiki/Category:Lymphomas"" title=""Category:Lymphomas"">malignant lymphoma</a> in patients prior to autologous hematopoietic stem-cell transplantation.","2023-06-16"
"Ticagrelor","FDA","2011-07-20","Acute coronary syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).","2022-09-05"
"Ticagrelor","FDA","2015-09-03","Acute coronary syndrome",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).","2022-09-05"
"Ticlopidine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Tinzaparin","FDA","2000-07-14","Venous thromboembolism",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2000-07-14: Initial FDA approval: treatment of acute symptomatic <a href=""/wiki/Venous_thromboembolism"" title=""Venous thromboembolism"">deep vein thrombosis with or without pulmonary embolism</a> when administered in conjunction with <a href=""/wiki/Warfarin_(Coumadin)"" title=""Warfarin (Coumadin)"">Warfarin (Coumadin)</a>","2022-09-05"
"Tinzaparin","FDA","2011-02-10","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-02-10: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.leo-pharma.us/Files/Billeder/LEO_local_images/LEO-Pharma.US/10%20Feb%202011_Firm_Press_Release_LEO_Pharma_Inc.pdf"">Voluntary recall</a> as a voluntary measure after a dialogue with the FDA following an inspection at the production facility in Ballerup, Denmark. The dialogue concerned the production process and more specifically, the theoretical risk of presence of particulate matter in the released vials.","2022-09-05"
"Tirabrutinib","PMDA","2020-03-25","CNS lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2020-03-25: Newly indicated for the treatment of relapsed or refractory primary <a href=""/wiki/CNS_lymphoma"" title=""CNS lymphoma"">central nervous system (CNS) lymphoma</a>.","2023-07-31"
"Tirabrutinib","PMDA","2020-08-21","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2020-08-21: New indications for the treatment of <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinemia</a> and lymphoplasmacytic lymphoma.","2023-07-31"
"Tirofiban","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Tisagenlecleucel","EMA","2017-08-30","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2017-08-30: Initial marketing authorisation","2023-07-31"
"Tisagenlecleucel","FDA","2017-08-30","B-cell acute lymphoblastic leukemia",FALSE,FALSE,TRUE,"","Refractory or in second or later relapse","","","Up to 25 years old","","",NA,"","","","","","","",TRUE,"ELIANA","2017-08-30: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574154.htm"">FDA regular approval</a> for the treatment of patients up to age 25 years with <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">B-cell precursor acute lymphoblastic leukemia (ALL)</a> that is refractory or in second or later relapse. <i>(Based on ELIANA)</i>","2022-09-05"
"Tisagenlecleucel","FDA","2018-05-01","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"JULIET","2018-05-01: FDA approval expanded for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. <i>(Based on JULIET)</i>","2022-09-05"
"Tisagenlecleucel","FDA","2018-05-01","High-grade B-cell lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"JULIET","2018-05-01: FDA approval expanded for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. <i>(Based on JULIET)</i>","2023-03-15"
"Tisagenlecleucel","FDA","2018-05-01","Transformed lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"JULIET","2018-05-01: FDA approval expanded for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL) not otherwise specified</a>, <a href=""/wiki/High-grade_B-cell_lymphoma"" title=""High-grade B-cell lymphoma"">high-grade B-cell lymphoma</a> and <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">DLBCL arising from follicular lymphoma</a>. <i>(Based on JULIET)</i>","2022-09-05"
"Tisagenlecleucel","FDA","2022-05-27","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"ELARA","2022-05-27: Granted accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> after two or more lines of systemic therapy. <i>(Based on ELARA)</i>","2022-09-05"
"Tisagenlecleucel","HC","2018-09-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-09-05: Initial notice of compliance","2023-07-31"
"Tisagenlecleucel","HC","2022-12-19","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT","FALSE","","","","","","","",NA,"","2022-12-19: Notice of compliance with conditions for adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">1, 2, 3a follicular lymphoma (FL)</a> after two or more lines of systemic therapy.","2023-05-08"
"Tislelizumab","EMA","2023-09-19","Esophageal squamous cell carcinoma",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","Platinum-containing chemotherapy",NA,"","","","","0","","",NA,"","2023-09-19: Initial marketing authorization as Tevimbra. Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic <a href=""/wiki/Esophageal_squamous_cell_carcinoma"" title=""Esophageal squamous cell carcinoma"">oesophageal squamous cell carcinoma</a> after prior platinum-based chemotherapy.","2023-11-07"
"Tislelizumab","NMPA","2019-12-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2019-12-26: Initial approval","2023-09-09"
"Tislelizumab","NMPA","Uncertain date","Classical Hodgkin lymphoma",TRUE,FALSE,FALSE,"","","","","","","2+",NA,"","","","","","","",NA,"","Uncertain date: Conditional approval for the treatment of patients with <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin's lymphoma (cHL)</a> who received at least two prior therapies","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Hepatocellular carcinoma",TRUE,FALSE,FALSE,"","","","","","","1+ SACT",NA,"","","","","","","",NA,"","Uncertain date: Conditional approval for the treatment of patients with <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a> who have received at least one systemic therapy","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Malignant solid neoplasm",TRUE,FALSE,FALSE,"","","Advanced unresectable OR Metastatic","","","","",NA,"","","","","","dMMR|MSI-H","",NA,"","Uncertain date: Conditional approval for the treatment of patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">solid tumors</a>.","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","Second-line|Third-line","Locally advanced OR Metastatic","","","","Platinum-containing chemotherapy",NA,"","progression","","","","","",NA,"","Uncertain date: Full approval for second- or third-line treatment of patients with locally advanced or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">NSCLC</a> who progressed on prior platinum-based chemotherapy.","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Non-small cell lung cancer nonsquamous",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Chemotherapy","","",NA,"","Uncertain date: Full approval for first-line treatment of patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer,_nonsquamous"" title=""Non-small cell lung cancer, nonsquamous"">non-squamous NSCLC</a> in combination with chemotherapy.","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Non-small cell lung cancer squamous",FALSE,FALSE,FALSE,"","First-line","Advanced","","","","",NA,"","","","","Chemotherapy","","",NA,"","Uncertain date: Full approval for first-line treatment of patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer,_squamous"" title=""Non-small cell lung cancer, squamous"">squamous non-small cell lung cancer (NSCLC)</a> in combination with chemotherapy.","2023-11-07"
"Tislelizumab","NMPA","Uncertain date","Urothelial carcinoma",TRUE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","","","Platinum-containing chemotherapy",NA,"","progression","during or following OR within 12 months of neoadjuvant or adjuvant treatment","","","PD-L1 high","",NA,"","Uncertain date: Conditional approval for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Urothelial_carcinoma"" title=""Urothelial carcinoma"">urothelial carcinoma (UC)</a> with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy","2023-11-07"
"Tisotumab vedotin","FDA","2021-09-20","Cervical cancer",TRUE,FALSE,TRUE,"","","Recurrent OR Metastatic","","adults","","Chemotherapy","FALSE","","progression","","","","","",TRUE,"innovaTV 204","2021-09-20: Granted accelerated approval for adult patients with recurrent or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> with disease progression on or after chemotherapy. <i>(Based on innovaTV 204)</i>","2022-09-05"
"Tisotumab vedotin","FDA","2024-04-24","Cervical cancer",FALSE,FALSE,FALSE,"","","Recurrent OR Metastatic","","","","Chemotherapy",NA,"","progression","","","","","",TRUE,"innovaTV 301","2024-04-24: Granted regular approval for recurrent or metastatic <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a> with disease progression on or after chemotherapy. <i>(Based on innovaTV 301)</i>","2024-06-03"
"Tivozanib","EMA","2017-08-24","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced","","adults","","",NA,"","","","","","","",TRUE,"TIVO-1","2017-08-24: Initial authorization for first line treatment of adult patients with advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on TIVO-1)</i>","2023-09-17"
"Tivozanib","EMA","2017-08-24","Renal cell carcinoma",FALSE,FALSE,FALSE,"","","Advanced","","adults","","VEGFR inhibitor AND mTOR pathway inhibitor AND cytokine therapy","FALSE AND FALSE AND TRUE","","","","","","","",TRUE,"TIVO-1","2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">RCC</a>. <i>(Based on TIVO-1)</i>","2023-09-17"
"Tivozanib","FDA","2021-03-10","Renal cell carcinoma",FALSE,FALSE,FALSE,"","Relapsed or refractory","Advanced","","adults","","2+ SACT","FALSE","","","","","","","",TRUE,"TIVO-3","2021-03-10: Approved for adult patients with relapsed or refractory advanced <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a> following two or more prior systemic therapies. <i>(Based on TIVO-3)</i>","2022-09-05"
"Tocilizumab","FDA","2010-01-08","Rheumatoid arthritis",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","2010-01-08: Initial FDA approval for rheumatoid arthritis","2022-09-05"
"Tofacitinib","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Topotecan","EMA","1996-11-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-11-12: Initial marketing authorization as Hycamtin.","2023-05-08"
"Topotecan","FDA","1996-05-28","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1+ Chemotherapy","FALSE","","failure","","","","","",TRUE,"Bookman et al. 1996","1996-05-28: Initial FDA approval for metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a> after failure of initial or subsequent chemotherapy. <i>(Based on Bookman et al. 1996 and ten Bokkel Huinink et al. 1997)</i>","2022-09-05"
"Topotecan","FDA","1996-05-28","Ovarian cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","1+ Chemotherapy","FALSE","","failure","","","","","",TRUE,"ten Bokkel Huinink et al. 1997","1996-05-28: Initial FDA approval for metastatic <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer""> carcinoma of the ovary</a> after failure of initial or subsequent chemotherapy. <i>(Based on Bookman et al. 1996 and ten Bokkel Huinink et al. 1997)</i>","2022-09-05"
"Topotecan","FDA","1998-11-30","Small cell lung cancer",FALSE,FALSE,FALSE,"","","Sensitive disease defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy","","","","1 Chemothearpy","FALSE","","failure","","","","","",TRUE,"von Pawel et al. 1999","1998-11-30: Indication expanded to include <a href=""/wiki/Small_cell_lung_cancer"" title=""Small cell lung cancer""> small cell lung cancer</a> sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy. <i>(Based on von Pawel et al. 1999)</i>","2022-09-05"
"Topotecan","FDA","2006-06-14","Cervical cancer",FALSE,FALSE,FALSE,"","","(Stage IV-B OR recurrent OR persistent) AND not amenable to curative treatment with surgery and/or radiation therapy","","","","",NA,"","","","","","","",TRUE,"GOG 179","2006-06-14: Indication expanded to include stage IV-B, recurrent, or persistent <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer""> carcinoma of the cervix</a> which is not amenable to curative treatment with surgery and/or radiation therapy. <i>(Based on GOG 179)</i>","2022-09-05"
"Topotecan","PMDA","2011-02-23","Ovarian cancer",FALSE,FALSE,FALSE,"","","","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2011-02-23: New additional indication and a new dosage for the treatment of <a href=""/wiki/Ovarian_cancer"" title=""Ovarian cancer"">ovarian cancer</a> which has progressed after cancer chemotherapy.","2023-06-16"
"Topotecan","PMDA","2013-06-14","Malignant solid neoplasm",FALSE,FALSE,FALSE,"","","","","pediatric","","",NA,"","","","","","","",NA,"","2013-06-14: New additional indication and a new dosage for the treatment of pediatric <a href=""/wiki/Category:Malignant_solid_neoplasm"" title=""Category:Malignant solid neoplasm"">malignant solid tumors</a>.","2023-06-16"
"Topotecan","PMDA","2015-11-20","Cervical cancer",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2015-11-20: New additional indication and a new dosage for the treatment of advanced or recurrent <a href=""/wiki/Cervical_cancer"" title=""Cervical cancer"">cervical cancer</a>.","2023-06-16"
"Toremifene","EMA","1996-02-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1996-02-14: Initial authorization","2023-05-08"
"Toremifene","FDA","1997-05-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","postmenopausal women","","",NA,"","","","","","ER+|ER unknown","FALSE",TRUE,"Gershanovich et al. 1997","1997-05-29: Initial approval for the treatment of metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen-receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> tumors. <i>(Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhoenen et al. 1997)</i>","2022-09-05"
"Toremifene","FDA","1997-05-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","postmenopausal women","","",NA,"","","","","","ER+|ER unknown","FALSE",TRUE,"Hayes et al. 1995","1997-05-29: Initial approval for the treatment of metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen-receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> tumors. <i>(Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhoenen et al. 1997)</i>","2022-09-05"
"Toremifene","FDA","1997-05-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","postmenopausal women","","",NA,"","","","","","ER+|ER unknown","FALSE",TRUE,"Pyrhoenen et al. 1997","1997-05-29: Initial approval for the treatment of metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in postmenopausal women with <a href=""/wiki/Biomarkers#ER"" title=""Biomarkers"">estrogen-receptor</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> or <a href=""/wiki/Biomarkers#Unknown"" title=""Biomarkers"">unknown</a> tumors. <i>(Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhoenen et al. 1997)</i>","2022-09-05"
"Toripalimab","FDA","2023-10-27","Nasopharyngeal carcinoma",FALSE,FALSE,FALSE,"","First-line","Recurrent locally advanced OR Metastatic","","adults","","0","FALSE","","","","","Cisplatin AND Gemcitabine","","",TRUE,"JUPITER-02","2023-10-27: Approved with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced <a href=""/wiki/Nasopharyngeal_carcinoma"" title=""Nasopharyngeal carcinoma"">nasopharyngeal carcinoma (NPC)</a>. <i>(Based on JUPITER-02)</i>","2023-11-07"
"Toripalimab","FDA","2023-10-27","Nasopharyngeal carcinoma",FALSE,FALSE,FALSE,"","","Recurrent unresectable|Metastatic","","adults","","Platinum-containing chemotherapy","FALSE","","progression","","","0","","",TRUE,"POLARIS-02","2023-10-27: Approved as a single agent for adults with recurrent unresectable or metastatic <a href=""/wiki/Nasopharyngeal_carcinoma"" title=""Nasopharyngeal carcinoma"">NPC</a> with disease progression on or after a platinum-containing chemotherapy. <i>(Based on POLARIS-02)</i>","2023-11-07"
"Toripalimab","NMPA","2018-12-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-12-17: Initial approval","2023-09-09"
"Toripalimab","NMPA","2024-04-11","Renal cell carcinoma",FALSE,FALSE,FALSE,"","First-line","Unresectable OR Metastatic","Medium-risk|High-risk","","","",NA,"","","","","Axitinib","","",TRUE,"RENOTORCH","2024-04-11: Approved in combination with axitinib for the first-line treatment of patients with medium- to high-risk unresectable or metastatic <a href=""/wiki/Renal_cell_carcinoma"" title=""Renal cell carcinoma"">renal cell carcinoma (RCC)</a>. <i>(Based on RENOTORCH)</i>","2024-06-03"
"Tositumomab and I-131","FDA","2003-06-27","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab AND Chemotherapy","FALSE","","relapsed","","","","CD20+","FALSE",TRUE,"CP-97-012","2003-06-27: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular, non-Hodgkin's lymphoma</a>, with and without transformation, whose disease is refractory to <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">Rituximab (Rituxan)</a> and has relapsed following chemotherapy. <i>(Based on CP-97-012 and RIT-II-004)</i>","2022-09-05"
"Tositumomab and I-131","FDA","2003-06-27","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab AND Chemotherapy","FALSE","","relapsed","","","","CD20+","FALSE",TRUE,"RIT-II-004","2003-06-27: Granted accelerated approval for the treatment of patients with <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular, non-Hodgkin's lymphoma</a>, with and without transformation, whose disease is refractory to <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">Rituximab (Rituxan)</a> and has relapsed following chemotherapy. <i>(Based on CP-97-012 and RIT-II-004)</i>","2022-09-05"
"Tositumomab and I-131","FDA","2004-12-22","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab","TRUE","","","","","","CD20+","FALSE",FALSE,"","2004-12-22: Accelerated approval for patients with relapsed or refractory, <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a> or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> non-Hodgkin's lymphoma who have not received <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">Rituximab (Rituxan)</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Tositumomab and I-131","FDA","2004-12-22","Indolent lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab","TRUE","","","","","","CD20+","FALSE",FALSE,"","2004-12-22: Accelerated approval for patients with relapsed or refractory, <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a> or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> non-Hodgkin's lymphoma who have not received <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">Rituximab (Rituxan)</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Tositumomab and I-131","FDA","2004-12-22","Transformed lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","","","Rituximab","TRUE","","","","","","CD20+","FALSE",FALSE,"","2004-12-22: Accelerated approval for patients with relapsed or refractory, <a href=""/wiki/Indolent_lymphoma"" title=""Indolent lymphoma"">low grade</a>, <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular</a> or <a href=""/wiki/Transformed_lymphoma"" title=""Transformed lymphoma"">transformed</a> <a href=""/wiki/Biomarkers#CD20"" title=""Biomarkers"">CD20</a> <a href=""/wiki/Biomarkers#Expression"" title=""Biomarkers"">positive</a> non-Hodgkin's lymphoma who have not received <a href=""/wiki/Rituximab_(Rituxan)"" title=""Rituximab (Rituxan)"">Rituximab (Rituxan)</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Tositumomab and I-131","FDA","2013-10-23","NONE",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",FALSE,"","2013-10-23: Accelerated approval for rituximab-naive patients withdrawn. <i>(failure to complete confirmatory study)</i>","2022-09-05"
"Tovorafenib","FDA","2024-04-23","Low-grade glioma pediatric",TRUE,FALSE,FALSE,"","Relapsed or refractory","","","pediatric patients 6 months and older","","",NA,"","","","","","BRAF fusion|BRAF p.V600","",TRUE,"FIREFLY-1","2024-04-23: Granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">pediatric low-grade glioma (LGG)</a> harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. <i>(Based on FIREFLY-1)</i>","2024-06-03"
"Trabectedin","EMA","2007-09-17","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2007-09-17: Initial authorization","2023-05-08"
"Trabectedin","FDA","2015-10-23","Leiomyosarcoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","Anthracycline-based regimen","FALSE","","","","","","","",TRUE,"ET743-SAR-3007","2015-10-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://pubmed.ncbi.nlm.nih.gov/28774898/"">Approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Liposarcoma"" title=""Liposarcoma"">liposarcoma</a> or <a href=""/wiki/Leiomyosarcoma"" title=""Leiomyosarcoma"">leiomyosarcoma</a> who have received a prior <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing regimen</a>. <i>(Based on ET743-SAR-3007)</i>","2022-09-05"
"Trabectedin","FDA","2015-10-23","Liposarcoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","Anthracycline-based regimen","FALSE","","","","","","","",TRUE,"ET743-SAR-3007","2015-10-23: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://pubmed.ncbi.nlm.nih.gov/28774898/"">Approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Liposarcoma"" title=""Liposarcoma"">liposarcoma</a> or <a href=""/wiki/Leiomyosarcoma"" title=""Leiomyosarcoma"">leiomyosarcoma</a> who have received a prior <a href=""/wiki/Regimen_classes#Anthracycline-based_regimen"" title=""Regimen classes"">anthracycline-containing regimen</a>. <i>(Based on ET743-SAR-3007)</i>","2022-09-05"
"Trabectedin","HC","2010-05-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-05-13: Initial notice of compliance","2023-07-31"
"Trabectedin","PMDA","2015-09-28","Soft tissue sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-09-28: Initial approval for the treatment of patients with <a href=""/wiki/Soft_tissue_sarcoma"" title=""Soft tissue sarcoma"">soft tissue sarcoma</a>.","2023-06-16"
"Trametinib","EMA","2014-06-30","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","","BRAF p.V600","",TRUE,"METRIC","2014-06-30: Initial marketing authorization as Mekinist. Mekinist is indicated for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation. <i>(Based on METRIC)</i>","2023-11-07"
"Trametinib","EMA","2015-08-25","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","Dabrafenib AND Trametinib","BRAF p.V600","",NA,"","2015-08-25: Extension of indication to add a new therapeutic indication for the use in combination of trametinib and dabrafenib for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation.","2023-11-07"
"Trametinib","EMA","2017-03-27","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Advanced","","adults","","",NA,"","","","","Dabrafenib","BRAF p.V600","",NA,"","2017-03-27: Extension of indication to include the combination treatment with trametinib and dabrafenib of adult patients with advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with a BRAF V600 mutation.","2023-11-07"
"Trametinib","EMA","2018-08-27","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Stage III","","adults","","Surgery",NA,"","Complete resection","","","Dabrafenib AND Trametinib","BRAF p.V600","",NA,"","2018-08-27: Extension of indication to include the combination adjuvant treatment with trametinib and dabrafenib of adult patients with stage III <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with a BRAF V600 mutation, following complete resection.","2023-11-07"
"Trametinib","EMA","2023-11-09","High-grade glioma pediatric",FALSE,FALSE,FALSE,"","","","","pediatric patients 1 year and older","","1+ radiation|1+ chemotherapy",NA,"","","","","Dabrafenib","BRAF p.V600E","",NA,"","2023-11-09: CHMP recommended marketing authorisation as Spexotras - Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/High-grade_glioma,_pediatric"" title=""High-grade glioma, pediatric"">high-grade glioma (HGG)</a> with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.","2024-01-06"
"Trametinib","EMA","2023-11-09","Low-grade glioma pediatric",FALSE,FALSE,FALSE,"","","","","pediatric patients 1 year and older","do not require systemic therapy","",NA,"","","","","Dabrafenib","BRAF p.V600E","",NA,"","2023-11-09: CHMP recommended marketing authorisation as Spexotras - Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">low-grade glioma (LGG)</a> with a BRAF V600E mutation who require systemic therapy.","2024-01-06"
"Trametinib","FDA","2013-05-29","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"METRIC","2013-05-29: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm"">FDA approved</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on METRIC)</i>","2022-09-05"
"Trametinib","FDA","2014-01-10","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Dabrafenib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-d","2014-01-10: Accelerated approval in combination with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on COMBI-d and COMBI-MB)</i>","2022-09-05"
"Trametinib","FDA","2014-01-10","Melanoma",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","Dabrafenib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-MB","2014-01-10: Accelerated approval in combination with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a> as detected by an FDA-approved test. <i>(Based on COMBI-d and COMBI-MB)</i>","2022-09-05"
"Trametinib","FDA","2017-06-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Dabrafenib","BRAF p.V600E","FALSE",TRUE,"BRF113928 previously treated","2017-06-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm"">FDA approved</a> in combination with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BRF113928 previously treated and BRF113928 untreated)</i>","2022-09-05"
"Trametinib","FDA","2017-06-22","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","Dabrafenib","BRAF p.V600E","FALSE",TRUE,"BRF113928 untreated","2017-06-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm"">FDA approved</a> in combination with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> for patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> as detected by an FDA-approved test. <i>(Based on BRF113928 previously treated and BRF113928 untreated)</i>","2022-09-05"
"Trametinib","FDA","2018-04-30","Melanoma",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","Surgical resection","FALSE","","Complete resection","","","Dabrafenib","BRAF p.V600E|BRAF p.V600K","FALSE",TRUE,"COMBI-AD","2018-04-30: Regular FDA approval with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> in combination for the adjuvant treatment of patients with <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E</a> or <a href=""/wiki/Biomarkers#V600K"" title=""Biomarkers"">V600K mutations</a>, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. <i>(Based on COMBI-AD)</i>","2022-09-05"
"Trametinib","FDA","2018-05-04","Thyroid cancer",FALSE,FALSE,FALSE,"","no satisfactory locoregional treatment options","Locally advanced OR Metastatic","","","","",NA,"","","","","Dabrafenib","BRAF p.V600E","FALSE",TRUE,"ROAR","2018-05-04: FDA approval with <a href=""/wiki/Dabrafenib_(Tafinlar)"" title=""Dabrafenib (Tafinlar)"">Dabrafenib (Tafinlar)</a> in combination for the treatment of patients with locally advanced or metastatic <a href=""/wiki/Thyroid_cancer"" title=""Thyroid cancer"">anaplastic thyroid cancer (ATC)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> and with no satisfactory locoregional treatment options. <i>(Based on ROAR)</i>","2022-09-05"
"Trametinib","FDA","2023-03-16","Low-grade glioma pediatric",FALSE,FALSE,FALSE,"","Require systemic therapy","","","pediatric patients 1 year and older","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"TADPOLE","2023-03-16: FDA approved for pediatric patients 1 year of age and older with <a href=""/wiki/Low-grade_glioma,_pediatric"" title=""Low-grade glioma, pediatric"">low-grade glioma (LGG)</a> with a <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a> who require systemic therapy. <i>(Based on TADPOLE)</i>","2023-03-29"
"Trametinib","HC","2016-03-11","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-03-11: Initial notice of compliance with conditions","2023-05-08"
"Trametinib","HC","2016-05-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-05-13: Conditions were met","2023-05-08"
"Trametinib","PMDA","2016-03-28","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2016-03-28: Initial approval for the treatment of unresectable <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with BRAF mutation.","2023-06-16"
"Trametinib","PMDA","2018-03-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2018-03-23: New additional indication for the treatment of unresectable advanced or recurrent BRAF mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a>.","2023-06-16"
"Trametinib","PMDA","2018-07-02","Melanoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2018-07-02: New additional indication and a new dosage indicated for the treatment of BRAF mutation-positive <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-06-16"
"Trametinib","PMDA","2023-11-24","Malignant solid neoplasm BRAF-mutated",FALSE,FALSE,FALSE,"","","Advanced OR Recurrent","","","","Standard therapies",NA,"","refractory or intolerant","","","","BRAF mutation","",NA,"","2023-11-24: New indication and a new dosage for the treatment of advanced or recurrent <a href=""/wiki/Malignant_solid_neoplasm,_BRAF-mutated"" title=""Malignant solid neoplasm, BRAF-mutated"">BRAF mutation-positive solid tumor</a> (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies.","2024-06-03"
"Trametinib","PMDA","2023-11-24","Hairy cell leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","BRAF mutation","",NA,"","2023-11-24: New indication and a new dosage for the treatment of relapsed or refractory BRAF mutation-positive <a href=""/wiki/Hairy_cell_leukemia"" title=""Hairy cell leukemia"">hairy cell leukemia</a>.","2024-06-03"
"Tranexamic acid","FDA","1986-12-30","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1986-12-30: Initial FDA approval","2022-09-05"
"Tranexamic acid","FDA","Uncertain date","Hemophilia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2008-12-22 (oldest label available at Drugs @ FDA): Indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.","2023-05-20"
"Trastuzumab","EMA","2000-08-28","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","Anthracycline is not suitable","0","FALSE","Metastatic","","","","Paclitaxel","HER2+","FALSE",NA,"","2000-08-28: Initial market authorization as Herceptin. Herceptin is indicated for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> whose tumours overexpress HER2: in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.","2023-11-07"
"Trastuzumab","EMA","2000-08-28","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","2+ SACT, including Anthracycline-based regimen AND Taxane-based regimen unless unsuitable","FALSE","Metastatic","","","HR-positive: endocrine therapy or be considered unsuitable for endocrine-based therapy","0","HER2+","FALSE",NA,"","2000-08-28: Herceptin is indicated for the treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> whose tumours overexpress HER2: as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.","2023-11-07"
"Trastuzumab","EMA","2006-05-22","Breast cancer",FALSE,FALSE,FALSE,"","","Early","","","","",NA,"","","","","","HER2+","",NA,"","2006-05-22: Extension of indication for use in patients with HER2-positive with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-11-07"
"Trastuzumab","EMA","2010-01-19","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0 SACT",NA,"Metastatic","","","","Capecitabine|5-FU AND Cisplatin","HER2+","",NA,"","2010-01-19: Extension of indication for use in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of patients with HER2-positive metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">adenocarcinoma of the stomach</a> or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.","2023-11-07"
"Trastuzumab","EMA","2011-04-20","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","","","",NA,"","","","","AC-T|AC-D|TC","HER2+","",NA,"","2011-04-20: Extension of indication to include concurrent use of Herceptin with chemotherapy in the adjuvant treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> as part of a treatment regimen consisting of doxorubicin and cyclophosphamide followed by combination with paclitaxel or docetaxel, or as part of a treatment regimen in combination with docetaxel and carboplatin.","2023-11-07"
"Trastuzumab","EMA","2011-12-19","Breast cancer",FALSE,FALSE,FALSE,"","Neoadjuvant AND Adjuvant","Locally advanced|Tumors greater than 2cm in diameter","","","","",NA,"","","","","Chemotherapy","HER2+","FALSE",NA,"","2011-12-19: Extension of indication to include treatment of patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in combination with neoadjuvant chemotherapy, followed by adjuvant trastuzumab monotherapy, for locally advanced (including inflammatory) breast cancer or tumours greater than 2 cm in diameter.","2023-11-07"
"Trastuzumab","FDA","1998-09-25","Breast cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","1+ Chemotherapy","FALSE","","","","","0","HER2+","FALSE",TRUE,"Cobleigh et al. 1999","1998-09-25: Initial FDA approval as a single agent for treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> whose tumors <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpress</a> the <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2 protein</a> and who have received one or more chemotherapy regimens for their metastatic disease. <i>(Based on Cobleigh et al. 1999)</i>","2022-09-05"
"Trastuzumab","FDA","2002-08-28","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Chemotherapy","TRUE","Metastatic","","","","Paclitaxel","HER2+","FALSE",TRUE,"Slamon et al. 2001","2002-08-28: Approved in combination with <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> for treatment of patients with metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> whose tumors <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpress</a> the <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2 protein</a> and who have not received chemotherapy for their metastatic disease. <i>(Approval extended to first-line metastatic setting; based on Slamon et al. 2001)</i>","2022-09-05"
"Trastuzumab","FDA","2006-11-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","",NA,"","","","","Doxorubicin AND Cyclophosphamide AND Paclitaxel","HER2+","FALSE",TRUE,"BCIRG 006","2006-11-16: Label revised: trastuzumab as part of a treatment regimen containing <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a>, <a href=""/wiki/Cyclophosphamide_(Cytoxan)"" title=""Cyclophosphamide (Cytoxan)""> cyclophosphamide</a>, and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> is indicated for the adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a>, node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Approval extended to adjuvant setting; based on BCIRG 006, HERA, NCCTG N9831, NSABP B-31)</i>","2022-09-05"
"Trastuzumab","FDA","2006-11-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","",NA,"","","","","Doxorubicin AND Cyclophosphamide AND Paclitaxel","HER2+","FALSE",TRUE,"HERA","2006-11-16: Label revised: trastuzumab as part of a treatment regimen containing <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a>, <a href=""/wiki/Cyclophosphamide_(Cytoxan)"" title=""Cyclophosphamide (Cytoxan)""> cyclophosphamide</a>, and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> is indicated for the adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a>, node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Approval extended to adjuvant setting; based on BCIRG 006, HERA, NCCTG N9831, NSABP B-31)</i>","2022-09-05"
"Trastuzumab","FDA","2006-11-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","",NA,"","","","","Doxorubicin AND Cyclophosphamide AND Paclitaxel","HER2+","FALSE",TRUE,"NCCTG N9831","2006-11-16: Label revised: trastuzumab as part of a treatment regimen containing <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a>, <a href=""/wiki/Cyclophosphamide_(Cytoxan)"" title=""Cyclophosphamide (Cytoxan)""> cyclophosphamide</a>, and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> is indicated for the adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a>, node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Approval extended to adjuvant setting; based on BCIRG 006, HERA, NCCTG N9831, NSABP B-31)</i>","2022-09-05"
"Trastuzumab","FDA","2006-11-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Node-positive","","","","",NA,"","","","","Doxorubicin AND Cyclophosphamide AND Paclitaxel","HER2+","FALSE",TRUE,"NSABP B-31","2006-11-16: Label revised: trastuzumab as part of a treatment regimen containing <a href=""/wiki/Doxorubicin_(Adriamycin)"" title=""Doxorubicin (Adriamycin)""> doxorubicin</a>, <a href=""/wiki/Cyclophosphamide_(Cytoxan)"" title=""Cyclophosphamide (Cytoxan)""> cyclophosphamide</a>, and <a href=""/wiki/Paclitaxel_(Taxol)"" title=""Paclitaxel (Taxol)""> paclitaxel</a> is indicated for the adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a>, node-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Approval extended to adjuvant setting; based on BCIRG 006, HERA, NCCTG N9831, NSABP B-31)</i>","2022-09-05"
"Trastuzumab","FDA","2008-01-18","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2008-01-18: Labeling simplified: indicated for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Approval extended to all settings)</i>","2022-09-05"
"Trastuzumab","FDA","2010-10-20","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","0","FALSE","","","","","Cisplatin AND Fluoropyrimidine","HER2+","FALSE",TRUE,"ToGA","2010-10-20: Approved in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil), for the treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal (GE) junction adenocarcinoma</a>, who have not received prior treatment for metastatic disease. <i>(New disease entity; based on ToGA)</i>","2022-09-05"
"Trastuzumab","PMDA","2008-02-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","HER2+","FALSE",NA,"","2008-02-29: New indication and dosage for use as a postoperative adjuvant chemotherapy in patients with HER2-overexpressing <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Trastuzumab","PMDA","2011-03-10","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2011-03-10: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> with HER2 overexpression.","2023-06-16"
"Trastuzumab","PMDA","2011-11-25","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2011-11-25: New additional indication and a new dosage for the treatment of <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> with HER2 overexpression.","2023-06-16"
"Trastuzumab","PMDA","2021-11-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-11-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive <a href=""/w/index.php?title=Salivary_gland_tumorsandaction=editandredlink=1"" class=""new"" title=""Salivary gland tumors (page does not exist)"">salivary gland tumors</a>.","2023-06-16"
"Trastuzumab","PMDA","2022-03-28","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","HER2+","FALSE",NA,"","2022-03-28: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colon or rectal cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Trastuzumab and hyaluronidase","FDA","2019-02-28","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",TRUE,"HannaH","2019-02-28: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on HannaH)</i>","2022-09-05"
"Trastuzumab deruxtecan","EMA","2021-01-18","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-01-18: Initial conditional authorization","2023-05-08"
"Trastuzumab deruxtecan","EMA","2023-02-16","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Chemotherapy","FALSE","Metastatic","","","","0","HER2 low","FALSE",NA,"","2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received prior chemotherapy in the metastatic setting.","2023-07-31"
"Trastuzumab deruxtecan","EMA","2023-02-16","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Chemotherapy","FALSE","Adjuvant","recurrence","during or within 6 months of completion","","0","HER2 low","FALSE",NA,"","2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.","2023-07-31"
"Trastuzumab deruxtecan","EMA","2023-02-16","Gastric cancer",TRUE,FALSE,FALSE,"","","","","adults","","Trastuzumab-based regimen","FALSE","","","","","0","HER2+","FALSE",NA,"","2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with advanced HER2-positive <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction (GEJ) adenocarcinoma</a> who have received a prior trastuzumab-based regimen.","2023-05-08"
"Trastuzumab deruxtecan","EMA","Uncertain date","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","1+ anti-HER2-based regimen","FALSE","","","","","0","HER2+","FALSE",NA,"","Uncertain date: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received one or more prior anti HER2 based regimens.","2023-05-08"
"Trastuzumab deruxtecan","FDA","2019-12-20","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","2+ anti-HER2-based regimen","FALSE","Metastatic","","","","","HER2+","FALSE",TRUE,"DESTINY-Breast01","2019-12-20: Granted accelerated approval for patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received two or more prior anti-HER2-based regimens in the metastatic setting. <i>(Based on DESTINY-Breast01)</i>","2022-09-05"
"Trastuzumab deruxtecan","FDA","2021-01-15","Gastric cancer",FALSE,FALSE,FALSE,"","","Locally advanced OR Metastatic","","adults","","Trastuzumab-based regimen","FALSE","","","","","","HER2+","FALSE",TRUE,"DESTINY-Gastric01","2021-01-15: Approved for adult patients with locally advanced or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal (GEJ) adenocarcinoma</a> who have received a prior trastuzumab-based regimen. <i>(Based on DESTINY-Gastric01)</i>","2022-09-05"
"Trastuzumab deruxtecan","FDA","2022-05-04","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","anti-HER2-based regimen","FALSE","Metastatic","","","","","HER2+","FALSE",TRUE,"DESTINY-Breast03","2022-05-04: Regular approval for adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received a prior anti-HER2-based regimen in the metastatic setting. <i>(Converted to full approval; Based on DESTINY-Breast03)</i>","2023-03-10"
"Trastuzumab deruxtecan","FDA","2022-05-04","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","anti-HER2-based regimen","FALSE","Neoadjuvant or Adjuvant","recurrence","6 months of completing therapy","","","HER2+","FALSE",TRUE,"DESTINY-Breast03","2022-05-04: Regular approval for adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received a prior anti-HER2-based regimen in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. <i>(Converted to full approval; Based on DESTINY-Breast03)</i>","2023-03-10"
"Trastuzumab deruxtecan","FDA","2022-08-05","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Chemotherapy","FALSE","Metastatic","","","","","HER2 low","FALSE",TRUE,"DESTINY-Breast04","2022-08-05: Approved for adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Low"" title=""Biomarkers"">low (IHC 1+ or IHC 2+/ISH-)</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received a prior chemotherapy in the metastatic setting. <i>(Based on DESTINY-Breast04)</i>","2023-03-10"
"Trastuzumab deruxtecan","FDA","2022-08-05","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Chemotherapy","FALSE","Adjuvant","recurrence","6 months of completing therapy","","","HER2 low","FALSE",TRUE,"DESTINY-Breast04","2022-08-05: Approved for adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Low"" title=""Biomarkers"">low (IHC 1+ or IHC 2+/ISH-)</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have developed disease recurrence during or within six months of completing adjuvant chemotherapy. <i>(Based on DESTINY-Breast04)</i>","2023-03-10"
"Trastuzumab deruxtecan","FDA","2022-08-11","Non-small cell lung cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","1+ SACT","FALSE","","","","","","HER2 mutation","FALSE",TRUE,"DESTINY-Lung02","2022-08-11: Granted accelerated approval for adult patients with unresectable or metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> whose tumors have activating <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">human epidermal growth factor receptor 2 HER2 (ERBB2)</a> mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. <i>(Based on DESTINY-Lung02)</i>","2022-09-05"
"Trastuzumab deruxtecan","FDA","2024-04-05","Malignant solid neoplasm ERBB2-mutated",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults","","1+ SACT",NA,"","","","","","HER2+","",TRUE,"DESTINY-PanTumor02","2024-04-05: Granted accelerated approval for adult patients with unresectable or metastatic <a href=""/wiki/Malignant_solid_neoplasm,_ERBB2-mutated"" title=""Malignant solid neoplasm, ERBB2-mutated"">HER2-positive (IHC3+) solid tumors</a> who have received prior systemic treatment and have no satisfactory alternative treatment options. <i>(Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02)</i>","2024-06-03"
"Trastuzumab deruxtecan","FDA","2024-04-05","Malignant solid neoplasm ERBB2-mutated",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults","","1+ SACT",NA,"","","","","","HER2+","",TRUE,"DESTINY-Lung01","2024-04-05: Granted accelerated approval for adult patients with unresectable or metastatic <a href=""/wiki/Malignant_solid_neoplasm,_ERBB2-mutated"" title=""Malignant solid neoplasm, ERBB2-mutated"">HER2-positive (IHC3+) solid tumors</a> who have received prior systemic treatment and have no satisfactory alternative treatment options. <i>(Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02)</i>","2024-06-03"
"Trastuzumab deruxtecan","FDA","2024-04-05","Malignant solid neoplasm ERBB2-mutated",TRUE,FALSE,FALSE,"","no satisfactory alternative treatment options","Unresectable OR Metastatic","","adults","","1+ SACT",NA,"","","","","","HER2+","",TRUE,"DESTINY-CRC02","2024-04-05: Granted accelerated approval for adult patients with unresectable or metastatic <a href=""/wiki/Malignant_solid_neoplasm,_ERBB2-mutated"" title=""Malignant solid neoplasm, ERBB2-mutated"">HER2-positive (IHC3+) solid tumors</a> who have received prior systemic treatment and have no satisfactory alternative treatment options. <i>(Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02)</i>","2024-06-03"
"Trastuzumab deruxtecan","HC","2021-04-15","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","Trastuzumab emtansine","FALSE","","","","","","HER2+","FALSE",NA,"","2021-04-15: Initial notice of compliance with conditions for the treatment of adult patients with unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have received prior treatment with trastuzumab emtansine (T-DM1).","2023-05-08"
"Trastuzumab deruxtecan","PMDA","2020-03-25","Breast cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","Chemotherapy","FALSE","","refractory or intolerant","","","","HER2+","FALSE",NA,"","2020-03-25: Conditional new approval for the treatment of unresectable or recurrent HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).","2023-06-16"
"Trastuzumab deruxtecan","PMDA","2020-03-25","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","Chemotherapy","FALSE","","refractory or intolerant","","","","HER2+","FALSE",NA,"","2020-03-25: Newly indicated for the treatment of unresectable or recurrent HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).","2023-06-16"
"Trastuzumab deruxtecan","PMDA","2020-09-25","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","HER2+","FALSE",NA,"","2020-09-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> that has progressed after cancer chemotherapy.","2023-06-16"
"Trastuzumab deruxtecan","PMDA","2022-11-24","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","Chemotherapy","FALSE","","","","","","HER2+","FALSE",NA,"","2022-11-24: New indication for the treatment of unresectable or recurrent HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> in patients who have previously been treated with chemotherapy.","2023-06-16"
"Trastuzumab deruxtecan","PMDA","2023-08-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy",NA,"","progression","","","","HER2+","",NA,"","2023-08-23: New indication for the treatment of unresectable advanced or recurrent HER2 (ERBB2) mutation-positive <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer</a> that has progressed after cancer chemotherapy.","2024-06-03"
"Trastuzumab emtansine","EMA","2013-11-15","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","Trastuzumab AND Taxane",NA,"","","","","0","HER2+","",NA,"","2013-11-15: Initial marketing authorization as Kadcyla. Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who previously received trastuzumab and a taxane, separately or in combination. Patients should have received prior therapy for locally advanced or metastatic disease.","2023-11-07"
"Trastuzumab emtansine","EMA","2013-11-15","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable locally advanced OR Metastatic","","adults","","Trastuzumab AND Taxane",NA,"Adjuvant","recurrence","within 6 months of completion","","0","HER2+","",NA,"","2013-11-15: Initial marketing authorization as Kadcyla. Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who previously received trastuzumab and a taxane, separately or in combination. Patients should have developed disease recurrence during or within six months of completing adjuvant therapy.","2023-11-07"
"Trastuzumab emtansine","EMA","2019-12-16","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","adults","","Taxane and trastuzumab-based regimen AND Surgery",NA,"Neoadjuvant","invasive residual disease in the breast and/or lymph nodes","","","0","HER2+","",NA,"","2019-12-16: Extension of indication to include the use of Kadcyla as a single agent for the adjuvant treatment of adult patients with HER2-positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who have invasive residual disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.","2023-11-07"
"Trastuzumab emtansine","FDA","2013-02-22","Breast cancer",FALSE,FALSE,TRUE,"","","Metastatic","","","","Trastuzumab AND Taxane","FALSE","","","","","","HER2+","FALSE",TRUE,"EMILIA","2013-02-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm"">Initial approval</a> for patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a>, metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> who previously received <a href=""/wiki/Trastuzumab_(Herceptin)"" title=""Trastuzumab (Herceptin)""> trastuzumab</a> and a <a href=""/wiki/Category:Taxanes"" title=""Category:Taxanes"">taxane</a>, separately or in combination. <i>(Based on EMILIA)</i>","2022-09-05"
"Trastuzumab emtansine","FDA","2019-05-03","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Taxane and trastuzumab-based regimen AND Surgery","FALSE","Neoadjuvant","residual invasive disease","","","","HER2+","FALSE",TRUE,"KATHERINE","2019-05-03: Approval expanded for the adjuvant treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. <i>(Indication extended to the adjuvant setting; based on KATHERINE)</i>","2022-09-05"
"Trastuzumab emtansine","HC","2013-09-11","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Trastuzumab AND Taxane","FALSE","Metastatic","","","","0","HER2+","FALSE",NA,"","2013-09-11: Initial notice of compliance as monotherapy for the treatment of HER2-positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> patients who received both prior treatment with trastuzumab and a taxane, separately or in combination. Patients should have received prior therapy for metastatic disease.","2023-09-09"
"Trastuzumab emtansine","HC","2013-09-11","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Trastuzumab AND Taxane","FALSE","Adjuvant","","within 6 months of completion","","0","HER2+","FALSE",NA,"","2013-09-11: Initial notice of compliance as monotherapy for the treatment of HER2-positive metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> patients who received both prior treatment with trastuzumab and a taxane, separately or in combination. Patients should have developed disease recurrence during or within 6 months of completing adjuvant therapy.","2023-09-09"
"Trastuzumab emtansine","HC","2019-11-25","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","Early","","","","Trastuzumab AND Taxane","FALSE","Neoadjuvant","residual invasive disease","","","0","HER2+","FALSE",NA,"","2019-11-25: New indication as monotherapy for the adjuvant treatment of HER-2 positive early <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a> patients who have residual invasive disease following neoadjuvant taxine and trastuzumab based treatment.","2023-07-31"
"Trastuzumab emtansine","PMDA","2013-09-20","Breast cancer",FALSE,FALSE,FALSE,"","","Unresectable OR Recurrent","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2013-09-20: Initial approval for the treatment of unresectable or recurrent HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Trastuzumab emtansine","PMDA","2020-08-21","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","Surgery","FALSE","","","","","","HER2+","FALSE",NA,"","2020-08-21: New indication and a new dosage for the postoperative adjuvant treatment for HER2-positive <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Trastuzumab-anns","FDA","2019-06-13","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-06-13: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2022-09-05"
"Trastuzumab-anns","FDA","2019-06-13","Gastric cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-06-13: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction adenocarcinoma</a>.","2022-09-05"
"Trastuzumab-dkst","FDA","2017-12-01","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",TRUE,"HERITAGE","2017-12-01: Initial approval for the treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast</a> or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">stomach cancer (gastric or gastroesophageal junction adenocarcinoma)</a>. <i>(Based on HERITAGE)</i>","2022-09-05"
"Trastuzumab-dkst","FDA","2017-12-01","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HER2+","FALSE",TRUE,"HERITAGE","2017-12-01: Initial approval for the treatment of patients with <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast</a> or metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">stomach cancer (gastric or gastroesophageal junction adenocarcinoma)</a>. <i>(Based on HERITAGE)</i>","2022-09-05"
"Trastuzumab-dttb","FDA","2019-01-18","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-01-18: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2022-09-05"
"Trastuzumab-dttb","FDA","2019-01-18","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-01-18: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction adenocarcinoma</a>.","2022-09-05"
"Trastuzumab-pkrb","FDA","2018-12-14","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2018-12-14: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2022-09-05"
"Trastuzumab-qyyp","FDA","2019-03-11","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-03-11: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2022-09-05"
"Trastuzumab-qyyp","FDA","2019-03-11","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HER2+","FALSE",NA,"","2019-03-11: Initial approval for the treatment of <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a> <a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">overexpressing</a> metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction adenocarcinoma</a>.","2022-09-05"
"Trastuzumab-strf","FDA","2024-04-29","Breast cancer",FALSE,FALSE,FALSE,"","Adjuvant","","","","","",NA,"","","","","","HER2+","",NA,"","2024-04-29: Initial approval for adjuvant treatment of HER2-overexpressing <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2024-06-03"
"Trastuzumab-strf","FDA","2024-04-29","Breast cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HER2+","",TRUE,"HLX02-BC01","2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>. <i>(Based on HLX02-BC01)</i>","2024-06-03"
"Trastuzumab-strf","FDA","2024-04-29","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","",NA,"","","","","","HER2+","",NA,"","2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction adenocarcinoma</a>.","2024-06-03"
"Tremelimumab","EMA","2023-02-20","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","First-line","Advanced OR Unresectable","","","","",NA,"","","","","Durvalumab","","",TRUE,"HIMALAYA","2023-02-20: Initial authorisation as Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma (HCC)</a>. <i>(Based on HIMALAYA)</i>","2023-05-08"
"Tremelimumab","EMA","2023-04-04","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","First-line","Metastatic","","","","",NA,"","","","","Durvalumab AND Platinum-based chemotherapy","No EGFR mutations AND No ALK mutations","TRUE",TRUE,"POSEIDON","2023-04-04: Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with no sensitising EGFR mutations or ALK positive mutations. <i>(Based on POSEIDON)</i>","2023-07-31"
"Tremelimumab","FDA","2022-10-21","Hepatocellular carcinoma",FALSE,FALSE,FALSE,"","","Unresectable","","adults","","",NA,"","","","","Durvalumab","","",TRUE,"HIMALAYA","2022-10-21: Approved in combination with durvalumab for adult patients with unresectable <a href=""/wiki/Hepatocellular_carcinoma"" title=""Hepatocellular carcinoma"">hepatocellular carcinoma</a> (uHCC). <i>(Based on HIMALAYA)</i>","2022-11-22"
"Tremelimumab","FDA","2022-11-10","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","",NA,"","","","","Durvalumab AND Platinum agent","No EGFR mutations AND No ALK mutations","TRUE",TRUE,"POSEIDON","2022-11-10: Approved in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a> with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <i>(Based on POSEIDON)</i>","2022-11-22"
"Tremelimumab","PMDA","2022-12-23","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-12-23: Initial approval","2023-11-07"
"Treosulfan","EMA","2019-06-20","Allogeneic HSCT",FALSE,FALSE,FALSE,"","","","","adults|pediatric patients older than 1 month","none|non-malignant disease","",NA,"","","","","Fludarabine","","",NA,"","2019-06-20: Initial authorization as Trecondi. Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to <a href=""/wiki/Allogeneic_HSCT"" title=""Allogeneic HSCT"">allogeneic haematopoietic stem cell transplantation (alloHSCT)</a> in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.","2023-11-07"
"Treosulfan","EMA","2023-03-06","Allogeneic HSCT",FALSE,FALSE,FALSE,"","","","","adults AND pediatric patients older than 1 month","","",NA,"","","","","Fludarabine","","",NA,"","2023-03-06: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to <a href=""/wiki/Allogeneic_HSCT"" title=""Allogeneic HSCT"">allogeneic haematopoietic stem cell transplantation (alloHSCT)</a> in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.","2023-11-07"
"Treosulfan","EMA","2023-08-08","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2023-08-08: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.","2023-09-17"
"Treosulfan","EMA","Uncertain date","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","Uncertain date: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.","2023-05-20"
"Trifluridine and tipiracil","EMA","2016-04-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-04-25: Initial authorization","2023-05-08"
"Trifluridine and tipiracil","FDA","2015-09-22","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based regimen AND Oxaliplatin-based regimen AND Irinotecan-based regimen AND VEGFR inhibitor therapy","FALSE","","","","","","","",TRUE,"RECOURSE","2015-09-22: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm463743.htm"">Approved</a> for the treatment of patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> who have been previously treated with <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine-</a>, <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes""> oxaliplatin-</a> and <a href=""/wiki/Regimen_classes#Irinotecan-based_regimen"" title=""Regimen classes""> irinotecan-based</a> chemotherapy, an <a href=""/wiki/Regimen_classes#Anti-VEGF_biologic_therapy"" title=""Regimen classes"">anti-VEGF biological therapy</a>, and if RAS wild-type, an <a href=""/wiki/Category:EGFR_inhibitors"" title=""Category:EGFR inhibitors"">anti-EGFR therapy</a>. <i>(Based on RECOURSE)</i>","2022-09-05"
"Trifluridine and tipiracil","FDA","2019-02-22","Gastric cancer",FALSE,FALSE,FALSE,"","","Metastatic","","adults","","2+ Chemotherapy, including Fluoropyrimidine-based regimen AND Platinum-based regimen AND (Taxane OR Irinotecan) AND anti-HER2-based regimen, if appropriate","FALSE","","","","","","","",TRUE,"TAGS","2019-02-22: Approved for adult patients with metastatic <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric or gastroesophageal junction (GEJ) adenocarcinoma</a> previously treated with at least two prior lines of chemotherapy that included a <a href=""/wiki/Regimen_classes#Fluoropyrimidine-based_regimen"" title=""Regimen classes"">fluoropyrimidine</a>, a <a href=""/wiki/Regimen_classes#Platinum-based_regimen"" title=""Regimen classes"">platinum</a>, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. <i>(New disease entity; based on TAGS)</i>","2022-09-05"
"Trifluridine and tipiracil","FDA","2023-08-02","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Fluoropyrimidine-based chemotherapy AND oxaliplatin-based chemotherapy AND irinotecan-based chemotherapy AND anti-VEGF biological therapy","FALSE","","","","if RAS wild-type, an anti-EGFR therapy","Bevacizumab","","",TRUE,"SUNLIGHT","2023-08-02: Approved in combination with bevacizumab, for metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. <i>(Based on SUNLIGHT)</i>","2023-09-09"
"Trifluridine and tipiracil","HC","2018-01-25","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2018-01-25: Initial notice of compliance","2023-06-15"
"Trifluridine and tipiracil","PMDA","2014-03-24","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Standard therapies","FALSE","","refractory or intolerant","","","","","",NA,"","2014-03-24: Initial approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (for use only if refractory or intolerant to standard therapies).","2023-06-16"
"Trifluridine and tipiracil","PMDA","2015-03-20","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2015-03-20: Revised indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Trifluridine and tipiracil","PMDA","2019-08-22","Gastric cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","Chemotherapy","FALSE","","progression","","","","","",NA,"","2019-08-22: New indication for the treatment of unresectable advanced or recurrent <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric cancer</a> that have progressed after chemotherapy.","2023-06-16"
"Trimethoprim-Sulfamethoxazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Trimetrexate","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Tripotassium dicitratobismuthate","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Triptorelin","EMA","1986-03-05","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1986-03-05: EURD","2023-07-31"
"Triptorelin","FDA","2000-06-15","Prostate cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Heyns et al. 2003","2000-06-15: Initial FDA approval in the palliative treatment of advanced <a href=""/wiki/Prostate_cancer"" title=""Prostate cancer""> prostate cancer</a>. <i>(Based on Heyns et al. 2003)</i>","2022-09-05"
"Tropisetron","KFDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Tropisetron","PMDA","","NONE",NA,NA,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2023-06-26"
"Tucatinib","EMA","2021-02-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2021-02-11: Initial marketing authorization as Tukysa.","2023-05-08"
"Tucatinib","FDA","2020-04-17","Breast cancer",FALSE,FALSE,FALSE,"","","Advanced unresectable OR Metastatic","","adults","","1+ anti-HER-based regimen","FALSE","Metastatic","","","","Trastuzumab AND Capecitabine","HER2+","FALSE",TRUE,"HER2CLIMB","2020-04-17: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. <i>(Based on HER2CLIMB)</i>","2022-09-05"
"Tucatinib","FDA","2023-01-19","Colorectal cancer",TRUE,FALSE,FALSE,"","","Unresectable OR Metastatic","","","","fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy","FALSE","","progression","","","trastuzumab","RAS and HER2+","TRUE AND FALSE",TRUE,"MOUNTAINEER","2023-01-19: Granted accelerated approval in combination with trastuzumab for <a href=""/wiki/Biomarkers#RAS"" title=""Biomarkers"">RAS</a> wild-type <a href=""/wiki/Biomarkers#HER2"" title=""Biomarkers"">HER2</a>-<a href=""/wiki/Biomarkers#Overexpression"" title=""Biomarkers"">positive</a> unresectable or metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. <i>(Based on MOUNTAINEER)</i>","2023-03-15"
"Ublituximab","FDA","2023-01-06","Multiple sclerosis",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2023-01-06: Approved for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.","2023-07-31"
"Umbralisib","FDA","2021-02-05","Marginal zone lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1+ Anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"UNITY-NHL","2021-02-05: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who have received at least one prior <a href=""/wiki/Regimen_classes#Anti-CD20-based_regimen"" title=""Regimen classes"">anti-CD20-based regimen</a>. <i>(Based on UNITY-NHL)</i>","2022-09-05"
"Umbralisib","FDA","2021-02-05","Follicular lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","3+ SACT","FALSE","","","","","","","",TRUE,"UNITY-NHL","2021-02-05: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> who have received at least three prior lines of systemic therapy. <i>(Based on UNITY-NHL)</i>","2022-09-05"
"Umbralisib","FDA","2022-06-01","NONE",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"UNITY-CLL","2022-06-01: Accelerated approval withdrawn due to safety concerns. <i>(Based on UNITY-CLL)</i>","2022-09-21"
"Unfractionated heparin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Uracil mustard","FDA","1962-09-13","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1962-09-13: Initial FDA approval","2022-09-05"
"Urethane","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Uridine triacetate","FDA","2015-12-11","Fluoropyrimidine toxicity",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-12-11: Approved for patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms","2023-05-20"
"Uridine triacetate","FDA","2015-12-11","Fluoropyrimidine toxicity",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2015-12-11: Approved for patients who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or earlyonset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.","2023-05-20"
"Valacyclovir","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Valemetostat","PMDA","2022-09-26","Adult T-cell leukemia-lymphoma",FALSE,FALSE,TRUE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",TRUE,"DS3201-A-J201","2022-09-26: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Adult_T-cell_leukemia-lymphoma"" title=""Adult T-cell leukemia-lymphoma"">adult T-cell leukemia/lymphoma</a>. <i>(Based on DS3201-A-J201)</i>","2023-07-31"
"Valganciclovir","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Valproate","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Valrubicin","FDA","1998-09-25","Bladder cancer",FALSE,FALSE,FALSE,"","","","","","patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality","",NA,"BCG","refractory","","","","","",TRUE,"Steinberg et al. 2000","1998-09-25: Initial FDA approval for intravesical therapy of <a href=""/wiki/BCG_vaccine"" title=""BCG vaccine""> BCG</a>-refractory <a href=""/wiki/Bladder_cancer"" title=""Bladder cancer""> carcinoma <i>in situ</i> (CIS) of the urinary bladder</a> in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. <i>(Based on Steinberg et al. 2000)</i>","2022-11-22"
"Vandetanib","EMA","2012-02-16","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-02-16: Initial marketing authorization as Caprelsa.","2023-05-08"
"Vandetanib","FDA","2011-04-06","Thyroid cancer medullary",FALSE,FALSE,FALSE,"","Symptomatic or progressive","Unresectable locally advanced OR Metastatic","","","","",NA,"","","","","","","",TRUE,"ZETA","2011-04-06: Initial approval for the treatment of symptomatic or progressive <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a> in patients with unresectable locally advanced or metastatic disease. <i>(Based on ZETA)</i>","2022-09-05"
"Vandetanib","HC","2012-01-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-01-12: Initial notice of compliance","2023-07-31"
"Vandetanib","PMDA","2015-09-28","Thyroid cancer medullary",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","","",NA,"","2015-09-28: Initial approval for the treatment of unresectable <a href=""/wiki/Thyroid_cancer,_medullary"" title=""Thyroid cancer, medullary"">medullary thyroid cancer</a>.","2023-06-16"
"Vemurafenib","EMA","2012-02-17","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","0","BRAF p.V600","",TRUE,"BRIM-3","2012-02-17: Initial authorization as Zelboraf. Zelboraf is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>. <i>(Based on BRIM-3)</i>","2023-11-07"
"Vemurafenib","EMA","Uncertain date","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable OR Metastatic","","adults","","",NA,"","","","","0","BRAF p.V600","",NA,"","Uncertain date: Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a>.","2023-05-08"
"Vemurafenib","FDA","2011-08-17","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"BRIM-3","2011-08-17: Initial FDA approval for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a>. <i>(Based on BRIM2, BRIM-3, and MO25743)</i>","2022-09-05"
"Vemurafenib","FDA","2011-08-17","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"BRIM2","2011-08-17: Initial FDA approval for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a>. <i>(Based on BRIM2, BRIM-3, and MO25743)</i>","2022-09-05"
"Vemurafenib","FDA","2011-08-17","Melanoma",FALSE,FALSE,TRUE,"","","Unresectable OR Metastatic","","","","",NA,"","","","","","BRAF p.V600E","FALSE",TRUE,"MO25743","2011-08-17: Initial FDA approval for the treatment of patients with unresectable or metastatic <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600E"" title=""Biomarkers"">V600E mutation</a>. <i>(Based on BRIM2, BRIM-3, and MO25743)</i>","2022-09-05"
"Vemurafenib","FDA","2017-11-06","Erdheim-Chester disease",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","BRAF p.V600","FALSE",TRUE,"VE-BASKET","2017-11-06: Granted regular FDA approval for the treatment of patients with <a href=""/wiki/Erdheim-Chester_disease"" title=""Erdheim-Chester disease"">Erdheim-Chester Disease (ECD)</a> with <a href=""/wiki/Biomarkers#BRAF"" title=""Biomarkers"">BRAF</a> <a href=""/wiki/Biomarkers#V600"" title=""Biomarkers"">V600 mutation</a>. <i>(Based on VE-BASKET)</i>","2022-09-05"
"Vemurafenib","HC","2012-02-15","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2012-02-15: Initial notice of compliance","2023-07-31"
"Vemurafenib","PMDA","2014-12-26","Melanoma",FALSE,FALSE,FALSE,"","","Unresectable","","","","",NA,"","","","","","BRAF mutation","FALSE",NA,"","2014-12-26: Initial approval for the treatment of unresectable malignant <a href=""/wiki/Melanoma"" title=""Melanoma"">melanoma</a> with BRAF mutation.","2023-06-16"
"Venetoclax","EMA","2016-12-04","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-12-04: Initial authorization as Venclyxto","2023-05-08"
"Venetoclax","FDA","2016-04-11","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","1+","FALSE","","","","","","del17p","FALSE",TRUE,"M12-175","<b>2016-04-11: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm"">Initial accelerated approval</a></b> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a> with <a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>, as detected by an FDA-approved test, who have received at least one prior therapy. <i>(Based on M12-175, M13-982, M14-032 ibrutinib cohort, and M14-032 idelalisib cohort)</i>","2022-09-05"
"Venetoclax","FDA","2016-04-11","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","1+","FALSE","","","","","","del17p","FALSE",TRUE,"M13-982","<b>2016-04-11: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm"">Initial accelerated approval</a></b> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a> with <a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>, as detected by an FDA-approved test, who have received at least one prior therapy. <i>(Based on M12-175, M13-982, M14-032 ibrutinib cohort, and M14-032 idelalisib cohort)</i>","2022-09-05"
"Venetoclax","FDA","2016-04-11","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","1+","FALSE","","","","","","del17p","FALSE",TRUE,"M14-032 ibrutinib cohort","<b>2016-04-11: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm"">Initial accelerated approval</a></b> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a> with <a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>, as detected by an FDA-approved test, who have received at least one prior therapy. <i>(Based on M12-175, M13-982, M14-032 ibrutinib cohort, and M14-032 idelalisib cohort)</i>","2022-09-05"
"Venetoclax","FDA","2016-04-11","Chronic lymphocytic leukemia",TRUE,FALSE,TRUE,"","","","","","","1+","FALSE","","","","","","del17p","FALSE",TRUE,"M14-032 idelalisib cohort","<b>2016-04-11: <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm"">Initial accelerated approval</a></b> for the treatment of patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL)</a> with <a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a> <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>, as detected by an FDA-approved test, who have received at least one prior therapy. <i>(Based on M12-175, M13-982, M14-032 ibrutinib cohort, and M14-032 idelalisib cohort)</i>","2022-09-05"
"Venetoclax","FDA","2018-06-08","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","1+","FALSE","","","","","","del17p","FALSE",TRUE,"MURANO","2018-06-08: Granted regular approval for patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>, with or without <a href=""/wiki/Biomarkers#17p"" title=""Biomarkers"">17p</a>  <a href=""/wiki/Biomarkers#Deletion"" title=""Biomarkers"">deletion</a>, who have received at least one prior therapy. <i>(Regular approval; Biomarker-specific indication relaxed; based on MURANO)</i>","2022-09-05"
"Venetoclax","FDA","2018-11-21","Acute myeloid leukemia",TRUE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","Azacitidine OR Decitabine OR LoDAC","","",TRUE,"M14-358","2018-11-21: Accelerated approval for use in combination with <a href=""/wiki/Azacitidine_(Vidaza)"" title=""Azacitidine (Vidaza)"">azacitidine</a> or <a href=""/wiki/Decitabine_(Dacogen)"" title=""Decitabine (Dacogen)"">decitabine</a> or low-dose <a href=""/wiki/Cytarabine_(Ara-C)"" title=""Cytarabine (Ara-C)"">cytarabine</a> for the treatment of newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. <i>(New disease entity; based on M14-358 and M14-387)</i>","2022-09-05"
"Venetoclax","FDA","2018-11-21","Acute myeloid leukemia",TRUE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","Azacitidine OR Decitabine OR LoDAC","","",TRUE,"M14-387","2018-11-21: Accelerated approval for use in combination with <a href=""/wiki/Azacitidine_(Vidaza)"" title=""Azacitidine (Vidaza)"">azacitidine</a> or <a href=""/wiki/Decitabine_(Dacogen)"" title=""Decitabine (Dacogen)"">decitabine</a> or low-dose <a href=""/wiki/Cytarabine_(Ara-C)"" title=""Cytarabine (Ara-C)"">cytarabine</a> for the treatment of newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. <i>(New disease entity; based on M14-358 and M14-387)</i>","2022-09-05"
"Venetoclax","FDA","2019-05-15","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"GCLLSG CLL14","2019-05-15: Approved for adult patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>. <i>(Prior treatment exposure requirement removed; based on GCLLSG CLL14)</i>","2022-09-05"
"Venetoclax","FDA","2020-10-16","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","Azacitidine OR Decitabine OR LoDAC","","",TRUE,"VIALE-A","2020-10-16: Regular approval in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. <i>(Converted to regular approval; based on VIALE-A and VIALE-C)</i>","2022-09-05"
"Venetoclax","FDA","2020-10-16","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","adults 75 years or older OR have comorbidities that preclude intensive induction chemotherapy","","0","FALSE","","","","","Azacitidine OR Decitabine OR LoDAC","","",TRUE,"VIALE-C","2020-10-16: Regular approval in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia (AML)</a> in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. <i>(Converted to regular approval; based on VIALE-A and VIALE-C)</i>","2022-09-05"
"Venetoclax","HC","2016-09-30","NONE",TRUE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2016-09-30: Initial notice of compliance with conditions","2023-05-08"
"Venetoclax","HC","2020-01-13","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2020-01-13: Conditions were met","2023-05-08"
"Venetoclax","PMDA","2019-09-20","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2019-09-20: Newly indicated for the treatment of relapsed or refractory <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia/small lymphocytic lymphoma</a>.","2023-06-16"
"Venetoclax","PMDA","2021-03-23","Acute myeloid leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2021-03-23: New indication and a new dosage for the treatment of <a href=""/wiki/Acute_myeloid_leukemia"" title=""Acute myeloid leukemia"">acute myeloid leukemia</a>.","2023-06-16"
"Vinblastine","FDA","1965-11-25","NONE",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","1965-11-25: Initial approval as Velban","2022-09-05"
"Vinblastine","FDA","Uncertain date","Testicular cancer",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",TRUE,"Loehrer et al. 1988","Uncertain date: Approved for <a href=""/wiki/Testicular_cancer"" title=""Testicular cancer"">advanced carcinoma of the testis</a>. <i>(Based on Loehrer et al. 1988)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Breast cancer",FALSE,FALSE,FALSE,"","","","","","","Appropriate endocrine surgery and hormonal therapy","FALSE","","Unresponsive","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Gestational trophoblastic neoplasia",FALSE,FALSE,FALSE,"","","","","","","Other chemotherapy","FALSE","","Resistant","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Gestational_trophoblastic_neoplasia"" title=""Gestational trophoblastic neoplasia"">choriocarcinoma resistant to other chemotherapeutic agents</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Stage III or IV","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for generalized <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a> (Stages III and IV, Ann Arbor modification of Rye staging system). <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","Advanced","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">mycosis fungoides</a> (advanced stages). <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">histiocytic lymphoma</a>. <i>(No supporting studies are cited)</i>","2023-07-31"
"Vinblastine","FDA","Uncertain date","Histiocytic lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for histiocytic lymphoma. <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Histiocytosis X",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Kaposi sarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Kaposi_sarcoma"" title=""Kaposi sarcoma"">Kaposi's sarcoma</a>. <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). <i>(No supporting studies are cited)</i>","2022-09-05"
"Vinblastine","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","Uncertain date: Approved for <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)</a>. <i>(No supporting studies are cited)</i>","2023-07-31"
"Vincristine","EMA","1995-04-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1995-04-12: EURD","2023-07-31"
"Vincristine","FDA","1963-07-10","NONE",FALSE,FALSE,TRUE,"","","","","","","",NA,"","","","","","","",NA,"","1963-07-10: Initial FDA approval","2022-09-05"
"Vincristine","FDA","Uncertain date","Acute leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","FDA","Uncertain date","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","FDA","Uncertain date","Neuroblastoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","FDA","Uncertain date","Non-Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","FDA","Uncertain date","Rhabdomyosarcoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","FDA","Uncertain date","Wilms tumor",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","Chemotherapy","","",FALSE,"","2014-08-05 (oldest label available at Drugs @ FDA): Indicated in <a href=""/wiki/Category:Acute_leukemias"" title=""Category:Acute leukemias"">acute leukemia</a>. It has also been shown to be useful in combination with other oncolytic agents in <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">Hodgkin's disease</a>, <a href=""/wiki/Category:Non-Hodgkin_lymphomas"" title=""Category:Non-Hodgkin lymphomas"">non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)</a>, <a href=""/wiki/Rhabdomyosarcoma"" title=""Rhabdomyosarcoma"">rhabdomyosarcoma</a>, <a href=""/wiki/Neuroblastoma"" title=""Neuroblastoma"">neuroblastoma</a>, and <a href=""/wiki/Wilms_tumor"" title=""Wilms tumor"">Wilms' tumor</a>. <i>(No supporting studies are cited)</i>","2023-05-08"
"Vincristine","PMDA","2013-03-25","Pheochromocytoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2013-03-25: New additional indication and a new dosage for the treatment of <a href=""/wiki/Pheochromocytoma"" title=""Pheochromocytoma"">pheochromocytoma</a>.","2023-06-16"
"Vincristine liposomal","FDA","2012-08-09","B-cell acute lymphoblastic leukemia",TRUE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"RALLY","2012-08-09: Accelerated approval for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">acute lymphoblastic leukemia (ALL)</a> in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. <i>(Based on RALLY)</i>","2022-09-05"
"Vincristine liposomal","FDA","2022-05-02","B-cell acute lymphoblastic leukemia",TRUE,TRUE,FALSE,"","not applicable","not applicable","not applicable","not applicable","","not applicable","FALSE","not applicable","not applicable","not applicable","not applicable","not applicable","not applicable","",TRUE,"Hallmarq","2022-05-02: Accelerated approval for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) <a href=""/wiki/B-cell_acute_lymphoblastic_leukemia"" title=""B-cell acute lymphoblastic leukemia"">acute lymphoblastic leukemia (ALL)</a> in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies withdrawn at request of manufacturer <i>(Based on Hallmarq)</i>","2022-09-21"
"Vindesine","EMA","1979-04-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1979-04-11: EURD","2023-07-31"
"Vinflunine","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"",NA,"2023-05-08"
"Vinflunine","","","",FALSE,FALSE,FALSE,"No month/year information","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Vinflunine","EMA","2009-09-21","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-09-21: Initial marketing authorization at Javlor.","2023-05-08"
"Vinorelbine","EMA","1989-04-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","1989-04-11: EURD","2023-07-31"
"Vinorelbine","FDA","1994-12-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Crawford et al. 1996","1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)</i>","2022-09-05"
"Vinorelbine","FDA","1994-12-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"Le Chevalier et al. 1994","1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)</i>","2022-09-05"
"Vinorelbine","FDA","1994-12-23","Non-small cell lung cancer",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"SWOG S9308","1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced <a href=""/wiki/Non-small_cell_lung_cancer"" title=""Non-small cell lung cancer"">non-small cell lung cancer (NSCLC)</a>. <i>(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)</i>","2022-09-05"
"Vinorelbine","PMDA","2005-05-31","Breast cancer",FALSE,FALSE,FALSE,"","","Inoperable OR Recurrent","","","","",NA,"","","","","","","",NA,"","2005-05-31: New indication for the treatment of inoperable or recurrent <a href=""/wiki/Breast_cancer"" title=""Breast cancer"">breast cancer</a>.","2023-06-16"
"Vismodegib","EMA","2013-04-26","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-04-26: Initial authorization","2023-05-08"
"Vismodegib","FDA","2012-01-30","Cutaneous basal cell carcinoma",FALSE,FALSE,TRUE,"","","Locally advanced","","adults","","Surgical resection","FALSE","","recurrence","","","","","",TRUE,"ERIVANCE BCC","2012-01-30: Initial FDA approval for the treatment of adults with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma</a> that has recurred following surgery. <i>(Based on ERIVANCE BCC)</i>","2023-03-10"
"Vismodegib","FDA","2012-01-30","Cutaneous basal cell carcinoma",FALSE,FALSE,TRUE,"","not candidates for surgery or radiation","Locally advanced","","adults","","",NA,"","","","","","","",TRUE,"ERIVANCE BCC","2012-01-30: Initial FDA approval for the treatment of adults with locally advanced <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma</a> who are not candidates for surgery, and who are not candidates for radiation. <i>(Based on ERIVANCE BCC)</i>","2023-03-10"
"Vismodegib","FDA","2012-01-30","Cutaneous basal cell carcinoma",FALSE,FALSE,TRUE,"","","Metastatic","","adults","","",NA,"","","","","","","",TRUE,"ERIVANCE BCC","2012-01-30: Initial FDA approval for the treatment of adults with metastatic <a href=""/wiki/Cutaneous_basal_cell_carcinoma"" title=""Cutaneous basal cell carcinoma"">basal cell carcinoma</a>. <i>(Based on ERIVANCE BCC)</i>","2023-03-10"
"Vismodegib","HC","2013-07-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-07-12: Initial notice of compliance","2023-07-31"
"Von Willebrand factor and factor VIII complex human","","","",FALSE,FALSE,NA,"No record of FDA approval","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Vonoprazan","PMDA","2014-12-26","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-12-26: Initial approval for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer.","2023-07-31"
"Vorapaxar","FDA","2023-05-14","NONE",FALSE,FALSE,TRUE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-05: Initial approval for the reduction of thrombotic cardiovascular events in patients with prior MI or with PAD.","2023-07-31"
"Vorasidenib","FDA","2024-08-06","Low-grade glioma",FALSE,FALSE,TRUE,"","","","","adults AND pediatric patients 12 years and older","","Surgical resection OR Biopsy",NA,"","","","","","IDH1 mutation OR IDH2 mutation","FALSE|FALSE",TRUE,"INDIGO","2024-08-06: Approved for adult and pediatric patients 12 years and older with <a href=""/wiki/Low-grade_glioma"" title=""Low-grade glioma"">Grade 2 astrocytoma or oligodendroglioma</a> with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. <i>(Based on INDIGO)</i>","2024-09-06"
"Voriconazole","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Vorinostat","EMA","2010-09-20","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2010-09-20: Orphan designation for the treatment of malignant mesothelioma.","2023-07-31"
"Vorinostat","EMA","2013-03-12","NONE",FALSE,TRUE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-03-12: Orphan designation withdrawn.","2023-07-31"
"Vorinostat","FDA","2006-10-06","Cutaneous T-cell lymphoma",FALSE,FALSE,TRUE,"","","","","","","2+ SACT","FALSE","","progression OR persistence OR recurrence","","","","","",TRUE,"Duvic et al. 2006","2006-10-06: Initial FDA approval: treatment of cutaneous manifestations in patients with <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma</a> who have progressive, persistent or recurrent disease on or following two systemic therapies. <i>(Based on Duvic et al. 2006 and Merck 0683-001)</i>","2022-09-05"
"Vorinostat","FDA","2006-10-06","Cutaneous T-cell lymphoma",FALSE,FALSE,TRUE,"","","","","","","2+ SACT","FALSE","","progression OR persistence OR recurrence","","","","","",TRUE,"Merck 0683-001","2006-10-06: Initial FDA approval: treatment of cutaneous manifestations in patients with <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma""> cutaneous T-cell lymphoma</a> who have progressive, persistent or recurrent disease on or following two systemic therapies. <i>(Based on Duvic et al. 2006 and Merck 0683-001)</i>","2022-09-05"
"Vorinostat","HC","2009-06-11","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2009-06-11: Initial notice of compliance","2023-07-31"
"Vorinostat","PMDA","2011-07-01","Cutaneous T-cell lymphoma",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",NA,"","2011-07-01: Initial approval for the treatment of <a href=""/wiki/Cutaneous_T-cell_lymphoma"" title=""Cutaneous T-cell lymphoma"">cutaneous T-cell lymphoma</a>.","2023-06-16"
"Voxelotor","EMA","2022-02-14","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2022-02-14: Initial EMA authorization","2023-05-08"
"Voxelotor","FDA","2019-11-25","Sickle cell anemia",TRUE,FALSE,TRUE,"","","","","adults AND pediatric patients 12 years and older","","",NA,"","","","","","","",NA,"","2019-11-25: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-target-abnormality-sickle-cell-disease"">FDA accelerated approval</a> ""for the treatment of <a href=""/wiki/Sickle_cell_anemia"" title=""Sickle cell anemia"">sickle cell disease (SCD)</a> in adults and pediatric patients 12 years of age and older."" in adults and pediatric patients 12 years of age and older.","2022-09-05"
"Voxelotor","FDA","2021-12-17","Sickle cell anemia",TRUE,FALSE,FALSE,"","","","","pediatric patients 4 up to 11 years","","",NA,"","","","","","","",NA,"","2021-12-17: Granted <a target=""_blank"" rel=""noreferrer noopener"" class=""external text"" href=""https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years"">FDA accelerated approval</a> ""to treat sickle cell disease in pediatric patients aged four up to 11 years"" in addition to previous accelerated approval for Oxbryta for patients aged 12 years and older with sickle cell disease.","2024-09-06"
"Warfarin","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Zanidatamab","FDA","2024-11-20","Biliary tract cancer",TRUE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"HERIZON-BTC-01","2024-11-20: Granted accelerated approval for previously treated, unresectable or metastatic HER2-positive (IHC 3+) <a href=""/wiki/Category:Biliary_tract_cancers"" title=""Category:Biliary tract cancers"">biliary tract cancer (BTC)</a>, as detected by an FDA-approved test. <i>(Based on HERIZON-BTC-01)</i>","2024-12-02"
"Zanubrutinib","EMA","2021-11-22","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","adults","","1+",NA,"","","","","0","","",TRUE,"ASPEN","2021-11-22: Initial authorization as monotherapy for the treatment of adult patients with <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinaemia (WM)</a> who have received at least one prior therapy. <i>(Based on ASPEN)</i>","2023-11-07"
"Zanubrutinib","EMA","2021-11-22","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","","unsuitable for chemo-immunotherapy","0","","","","","","0","","",TRUE,"ASPEN","2021-11-22: Initial authorization as monotherapy for the treatment of adult patients with <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinaemia (WM)</a> in first line treatment for patients unsuitable for chemo-immunotherapy. <i>(Based on ASPEN)</i>","2024-12-02"
"Zanubrutinib","EMA","2022-10-28","Marginal zone lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","1+ anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"BGB-3111-AU-003","2022-10-28: Extension of indication to include treatment of adult patients with <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who have received at least one-prior anti-CD20-based therapy. <i>(Based on BGB-3111-AU-003 and MAGNOLIA)</i>","2023-11-07"
"Zanubrutinib","EMA","2022-10-28","Marginal zone lymphoma",FALSE,FALSE,FALSE,"","","","","adults","","1+ anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"MAGNOLIA","2022-10-28: Extension of indication to include treatment of adult patients with <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who have received at least one-prior anti-CD20-based therapy. <i>(Based on BGB-3111-AU-003 and MAGNOLIA)</i>","2023-11-07"
"Zanubrutinib","EMA","2022-11-15","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ALPINE","2022-11-15: Extension of indication to include treatment of adult patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a>. <i>(Based on SEQUOIA_CLL and ALPINE)</i>","2023-11-07"
"Zanubrutinib","EMA","2022-11-15","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"SEQUOIA_CLL","2022-11-15: Extension of indication to include treatment of adult patients with <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukaemia (CLL)</a>. <i>(Based on SEQUOIA_CLL and ALPINE)</i>","2023-11-07"
"Zanubrutinib","EMA","2023-10-12","Follicular lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","2+ SACT",NA,"","","","","Obinutuzumab","","",NA,"","2023-10-12: CHMP approved new indication in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> who have received at least two prior systemic therapies.","2023-11-07"
"Zanubrutinib","FDA","2019-11-14","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","","","",TRUE,"BGB-3111-206","2019-11-14: Accelerated approval for adult patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> who have received at least one prior therapy. <i>(Based on BGB-3111-AU-003 and BGB-3111-206)</i>","2022-09-05"
"Zanubrutinib","FDA","2019-11-14","Mantle cell lymphoma",TRUE,FALSE,FALSE,"","","","","adults","","1+","FALSE","","","","","","","",TRUE,"BGB-3111-AU-003","2019-11-14: Accelerated approval for adult patients with <a href=""/wiki/Mantle_cell_lymphoma"" title=""Mantle cell lymphoma"">mantle cell lymphoma (MCL)</a> who have received at least one prior therapy. <i>(Based on BGB-3111-AU-003 and BGB-3111-206)</i>","2022-09-05"
"Zanubrutinib","FDA","2021-08-31","Waldenstroem macroglobulinemia",FALSE,FALSE,FALSE,"","","","","adults","","",NA,"","","","","","","",TRUE,"ASPEN","2021-08-31: Approved for adult patients with <a href=""/wiki/Waldenstr%C3%B6m_macroglobulinemia"" title=""Waldenstroem macroglobulinemia"">Waldenstroem's macroglobulinemia (WM)</a>. <i>(Based on ASPEN)</i>","2022-11-22"
"Zanubrutinib","FDA","2021-09-14","Marginal zone lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1+ Anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"BGB-3111-AU-003","2021-09-14: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who have received at least one <a href=""/wiki/Regimen_classes#Anti-CD20-based_regimen"" title=""Regimen classes"">anti-CD20-based regimen</a>. <i>(Based on MAGNOLIA and BGB-3111-AU-003)</i>","2022-09-05"
"Zanubrutinib","FDA","2021-09-14","Marginal zone lymphoma",TRUE,FALSE,FALSE,"","","Relapsed or refractory","","adults","","1+ Anti-CD20-based regimen","FALSE","","","","","","","",TRUE,"MAGNOLIA","2021-09-14: Accelerated approval for adult patients with relapsed or refractory <a href=""/wiki/Marginal_zone_lymphoma"" title=""Marginal zone lymphoma"">marginal zone lymphoma (MZL)</a> who have received at least one <a href=""/wiki/Regimen_classes#Anti-CD20-based_regimen"" title=""Regimen classes"">anti-CD20-based regimen</a>. <i>(Based on MAGNOLIA and BGB-3111-AU-003)</i>","2022-09-05"
"Zanubrutinib","FDA","2023-01-19","Chronic lymphocytic leukemia",FALSE,FALSE,FALSE,"","","","","","","",NA,"","","","","","","",TRUE,"SEQUOIA_CLL","2023-01-19: Approved for <a href=""/wiki/Chronic_lymphocytic_leukemia"" title=""Chronic lymphocytic leukemia"">chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</a>. <i>(Based on SEQUOIA_CLL)</i>","2023-03-15"
"Zanubrutinib","FDA","2024-03-07","Follicular lymphoma",TRUE,FALSE,FALSE,"","Relapsed or refractory","","","","","2+ SACT",NA,"","","","","","","",TRUE,"ROSEWOOD","2024-03-07: Granted accelerated approval with obinutuzumab for relapsed or refractory <a href=""/wiki/Follicular_lymphoma"" title=""Follicular lymphoma"">follicular lymphoma (FL)</a> after two or more lines of systemic therapy. <i>(Based on ROSEWOOD)</i>","2024-06-03"
"Zidovudine","","","",FALSE,FALSE,NA,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Zimberelimab","NMPA","2021-08-30","Classical Hodgkin lymphoma",FALSE,FALSE,FALSE,"","","Relapsed or refractory","","","","",NA,"","","","","","","",NA,"","2021-08-30: Approved for the treatment of recurrent or refractory <a href=""/wiki/Classical_Hodgkin_lymphoma"" title=""Classical Hodgkin lymphoma"">classical Hodgkin's lymphoma (cHL)</a>.","2023-05-08"
"Ziv-aflibercept","EMA","2013-02-01","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2013-02-01: Initial marketing authorization as Zaltrap.","2023-05-08"
"Ziv-aflibercept","FDA","2012-08-31","Colorectal cancer",FALSE,FALSE,FALSE,"","","Metastatic","","","","Oxaliplatin-based regimen","FALSE","","progression OR resistance","","","FOLFIRI","","",TRUE,"VELOUR","2012-08-31: Initial FDA approval in combination with <a href=""/wiki/Fluorouracil_(5-FU)"" title=""Fluorouracil (5-FU)""> 5-fluorouracil</a>, <a href=""/wiki/Leucovorin_(Folinic_acid)"" title=""Leucovorin (Folinic acid)""> leucovorin</a>, <a href=""/wiki/Irinotecan_(Camptosar)"" title=""Irinotecan (Camptosar)""> irinotecan</a> - (<a href=""/wiki/Colorectal_cancer#FOLFIRI_&_Ziv-aflibercept"" title=""Colorectal cancer""> FOLFIRI</a>), is indicated for patients with metastatic <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a> (mCRC) that is resistant to or has progressed following an <a href=""/wiki/Regimen_classes#Oxaliplatin-based_regimen"" title=""Regimen classes""> oxaliplatin-containing regimen</a>. <i>(Based on VELOUR)</i>","2022-09-05"
"Ziv-aflibercept","HC","2014-02-12","NONE",FALSE,FALSE,FALSE,"No linked condition","","","","","","",NA,"","","","","","","",NA,"","2014-02-12: Initial notice of compliance","2023-07-31"
"Ziv-aflibercept","PMDA","2017-03-30","Colorectal cancer",FALSE,FALSE,FALSE,"","","Unresectable advanced OR Recurrent","","","","",NA,"","","","","","","",NA,"","2017-03-30: Initial approval for the treatment of unresectable advanced or recurrent <a href=""/wiki/Colorectal_cancer"" title=""Colorectal cancer"">colorectal cancer</a>.","2023-06-16"
"Zolbetuximab","FDA","2024-10-18","Gastric cancer",FALSE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"GLOW_gastric","2024-10-18: Approved with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test. <i>(Based on GLOW_gastric and SPOTLIGHT)</i>","2024-12-02"
"Zolbetuximab","FDA","2024-10-18","Gastric cancer",FALSE,FALSE,TRUE,"To be dissected","","","","","","","","","","","","","","",TRUE,"SPOTLIGHT","2024-10-18: Approved with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative <a href=""/wiki/Gastric_cancer"" title=""Gastric cancer"">gastric</a> or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test. <i>(Based on GLOW_gastric and SPOTLIGHT)</i>","2024-12-02"
"Zoledronic acid","","","",FALSE,FALSE,FALSE,"No changes in FDA indication section","","","","","","",NA,"","","","","","","",NA,"","","2022-09-05"
"Zuberitamab","NMPA","2023-09-13","Diffuse large B-cell lymphoma",FALSE,FALSE,FALSE,"To be dissected","","","","","","","","","","","","","","",TRUE,"Li et al. 2024","2023-09-13: Initial approval for the treatment of CD20-positive <a href=""/wiki/Diffuse_large_B-cell_lymphoma"" title=""Diffuse large B-cell lymphoma"">diffuse large B-cell lymphoma (DLBCL)</a>. <i>(Based on Li et al. 2024)</i>","2024-12-02"
